0001144204-17-045100.txt : 20170825 0001144204-17-045100.hdr.sgml : 20170825 20170825110210 ACCESSION NUMBER: 0001144204-17-045100 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 117 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170825 DATE AS OF CHANGE: 20170825 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACETO CORP CENTRAL INDEX KEY: 0000002034 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 111720520 STATE OF INCORPORATION: NY FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-04217 FILM NUMBER: 171050831 BUSINESS ADDRESS: STREET 1: 4 TRI HARBOR COURT CITY: PORT WASHINGTON STATE: NY ZIP: 11050 BUSINESS PHONE: 5166276000 MAIL ADDRESS: STREET 1: 4 TRI HARBOR COURT CITY: PORT WASHINGTON STATE: NY ZIP: 11050 FORMER COMPANY: FORMER CONFORMED NAME: ACETO CHEMICAL CO INC DATE OF NAME CHANGE: 19851203 10-K 1 v472462_10k.htm FORM 10-K

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-K

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended June 30, 2017

Commission file number 000-04217

 

ACETO CORPORATION

(Exact name of registrant as specified in its charter)

 

  New York       11-1720520  

(State or other jurisdiction of
incorporation or organization)		   (I.R.S. Employer Identification
Number)

 

  4 Tri Harbor Court, Port Washington, NY 11050  
  (Address of principal executive offices)  

 

(516) 627-6000

(Registrant's telephone number, including area code)

 

Securities registered pursuant to Section 12 (b) of the Act:

 

  Common Stock, par value $.01 per share       The NASDAQ Global Select Market  
(Title of Class)   (Name of each exchange on which registered)

 

Securities registered pursuant to Section 12 (g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ¨ No x

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 of Section 15(d) of the Act.

Yes ¨ No x

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every interactive data file required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer x Accelerated filer ¨
   
Non-accelerated filer ¨ (Do not check if a smaller reporting company) Smaller reporting company ¨
   
Emerging growth company ¨  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No x

 

The aggregate market value of the voting stock of the Company held by non-affiliates of the Company based on the closing price of the common stock on December 31, 2016 as reported on the NASDAQ Global Select Market was approximately $564,677,707.

 

The Registrant has 30,109,417 shares of common stock outstanding as of August 21, 2017.

 

Documents incorporated by reference: The information required in response to Part III of this Annual Report on Form 10-K is hereby incorporated by reference to the specified portions of the Registrant’s definitive proxy statement for the annual meeting of shareholders.

 

 

 

   

 

 

ACETO CORPORATION AND SUBSIDIARIES

FORM 10-K

FOR THE FISCAL YEAR ENDED JUNE 30, 2017

 

TABLE OF CONTENTS

 

PART I 3
   
Item 1. Business 3
Item 1A. Risk Factors 9
Item 1B. Unresolved Staff Comments 23
Item 2. Properties 23
Item 3. Legal Proceedings 24
Item 4. Mine Safety Disclosures 24
   
PART II 25
   
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 25
Item 6. Selected Financial Data 27
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 27
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 45
Item 8. Financial Statements and Supplementary Data 46
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 46
Item 9A. Controls and Procedures 46
Item 9B. Other Information 49
   
PART III 49
   
Item 10. Directors, Executive Officers and Corporate Governance 49
Item 11. Executive Compensation 49
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 49
Item 13. Certain Relationships and Related Transactions and Director Independence 49
Item 14. Principal Accounting Fees and Services 49
   
PART IV 49
   
Item 15. Exhibits, Financial Statement Schedules 49
Item 16. Form 10-K Summary 55
   
SIGNATURES 96

 

 2 

 

 

PART I

 

CAUTIONARY STATEMENT RELATING TO THE SAFE HARBOR PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

 

This Annual Report on Form 10-K contains forward-looking statements as that term is defined in the federal securities laws. The events described in forward-looking statements contained in this Annual Report on Form 10-K may not occur. Generally, these statements relate to our business plans or strategies, projected or anticipated benefits or other consequences of our plans or strategies, financing plans, projected or anticipated benefits from acquisitions that we may make, or projections involving anticipated revenues, earnings or other aspects of our operating results or financial position, and the outcome of any contingencies. Any such forward-looking statements are based on current expectations, estimates and projections of management. We intend for these forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements. Words such as “may,” “will,” “expect,” “believe,” “anticipate,” “project,” “plan,” “intend,” “estimate,” and “continue,” and their opposites and similar expressions are intended to identify forward-looking statements. We caution you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of which are beyond our control, that may influence the accuracy of the statements and the projections upon which the statements are based. Factors that may affect our results include, but are not limited to, the risks and uncertainties discussed in Item 1A of this Annual Report on Form 10-K.

 

Any one or more of these uncertainties, risks and other influences could materially affect our results of operations and whether forward-looking statements made by us ultimately prove to be accurate. Our actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.

 

NOTE REGARDING DOLLAR AMOUNTS

 

In this Annual Report on Form 10-K, all dollar amounts are expressed in thousands, except share prices and per-share amounts.

 

Item 1. Business

 

General

 

Aceto Corporation, together with its consolidated subsidiaries, are referred to herein collectively as “Aceto”, “the Company”, “we”, “us”, and “our”, unless the context indicates otherwise. Aceto was incorporated in 1947 in the State of New York. We are an international company engaged in the development, marketing, sales and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, specialty performance chemicals inclusive of agricultural intermediates and agricultural protection products. Our business is organized along product lines into three principal segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals.

 

We believe our main business strengths are sourcing, regulatory support, quality assurance and marketing and distribution. Aceto functions as a virtual manufacturing company, distributing more than 1,100 chemical compounds used principally as finished products or raw materials in the pharmaceutical, nutraceutical, agricultural, coatings and industrial chemical industries. With business operations in ten countries, we believe that our global reach is distinctive in the industry, enabling us to source and supply quality products on a worldwide basis. Leveraging local professionals, we source more than two-thirds of our products from Asia, buying from approximately 500 companies in China and 200 in India. One supplier accounted for 16% of purchases in fiscal 2017 and 0% in 2016.

 

Strategic relationships with manufacturers of pharmaceutical, nutraceutical, agricultural and specialty chemical products in the United States and internationally serve as a valuable resource to Aceto customers, enabling them to procure vital chemical based products necessary for their diverse and complex applications. A strong global technical network differentiates Aceto from commodity distribution companies. With regional managers in the United States, Europe and Asia, we provide regulatory support and quality assurance for customers and suppliers worldwide. Our regulatory network ensures that all products we distribute are produced to applicable required standards and conform to customer specifications for their intended end use.

 

Our presence in China, Germany, France, The Netherlands, Singapore, India, Hong Kong, Philippines, the United Kingdom and the United States, along with strategically located warehouses worldwide, enable us to respond quickly to demands from customers worldwide, assuring that a consistent, high-quality supply of pharmaceutical, nutraceutical, specialty chemicals and agricultural protection products are readily accessible. We are able to offer our customers competitive pricing, continuity of supply, and quality control. Highly experienced staff, approximately one-third of whom are technically trained, enable Aceto to meet individual customer needs. Our marketing, sales, regulatory and technical professionals possess an intimate knowledge of worldwide sources of supply and product applications, as well as statutory and technical requirements. Many of our professionals are respected leaders in their industry, bringing 25 or more years of experience to customer applications. This longevity has fostered confidence and loyalty among customers and suppliers.

 

 3 

 

 

Aceto partners with customers during the product development process, creating new applications for existing products, as well as new product sourcing opportunities. We offer solutions for product and production challenges, while assisting with quality assurance, government approvals and compliance. All of these value-added services allow Aceto’s customers to be more responsive to their end use customers and more competitive in the global marketplace. We believe our 70 years of experience, our reputation for reliability and stability, and our long-term relationships with suppliers have fostered loyalty among our customers.

 

We remain confident about our business prospects. We anticipate organic growth through our plans to introduce new products for finished dosage form generic drugs, the further globalization of our nutraceutical business, the continued globalization of our Performance Chemicals business, the expansion of our agricultural protection products by investing in product lines and intellectual property, the continued enhancement of our sourcing operations in China and India, and the steady improvement of our quality assurance and regulatory capabilities.

 

We believe our track record of continuous product introductions demonstrates our commitment to be recognized by the worldwide generic pharmaceutical industry as an important, reliable supplier. Our plans involve seeking strategic acquisitions that enhance our earnings and forming alliances with partners that add to our capabilities, when possible.

 

Other than product rights and license agreements for certain of our finished dosage form generic products which are part of our Human Health business and U.S. Environmental Protection Agency (EPA) registrations for our Performance Chemicals, we hold no patents, franchises or concessions that we consider material to our operations.

 

Information concerning revenue and gross profit attributable to each of our reportable segments and geographic information is found in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, and in Note 19 to the Consolidated Financial Statements, Part II, Item 8, “Financial Statements and Supplementary Data.”

 

Human Health

 

Products that fall within the Human Health segment include finished dosage form generic drugs and nutraceutical products. Aceto sells generic prescription products and over-the-counter pharmaceutical products to leading wholesalers, chain drug stores, distributors and mass merchandisers. On December 21, 2016, Aceto’s Rising Pharmaceuticals subsidiary (“Rising”) completed the acquisition of certain generic products and related assets of entities formerly known as Citron Pharma LLC (“Citron”), and its affiliate Lucid Pharma LLC (“Lucid”). Rising formed two subsidiaries to consummate the product acquisition – Rising Health, LLC (which acquired certain products and related assets of Citron) and Acetris Health, LLC (which acquired certain products and related assets of Lucid). Citron is a privately-held New Jersey-based pharmaceutical company focused on developing and marketing generic pharmaceutical products in partnership with leading generic pharmaceutical manufacturers based in India and the U.S. Lucid is a privately-held New Jersey-based generic pharmaceutical distributor specializing in providing cost-effective products to various agencies of the U.S. Federal Government including the Veterans Administration and the Defense Logistics Agency. Lucid services 18 national contracts with the Federal Government, nearly all of which have 5-year terms.

 

Aceto and Rising Health possess complementary asset-light business models, drug development and manufacturing partnerships and product portfolios. We believe that, consistent with our strategy of expanding Rising’s portfolio of finished dosage form generic products through product development partnerships and acquisitions of late stage assets, abbreviated new drug applications (“ANDAs”) and complementary generic drug businesses, this product acquisition significantly expanded our roster of commercialized products and pipeline of products under development. In addition, we believe that this transaction greatly enhanced our size and stature within the generic pharmaceutical industry, expanded our partnership network and offers us opportunities to realize meaningful cost and tax efficiencies, as well as representing an integral component of Aceto's continued strategy to become a Human Health oriented company.

 

According to a QuintilesIMS press release on May 5, 2017, growth in U.S. spending on prescription medicines fell in 2016 as competition intensified among manufacturers, and payers ramped up efforts to limit price increases. According to the QuintilesIMS Institute study, “Drug spending grew at a 4.8 percent pace in 2016 to $323 billion, less than half the rate of the previous two years, after adjusting for off-invoice discounts and rebates. The surge of innovative medicine introductions paused in 2016, with fewer than half as many new drugs launched than in 2014 and 2015. While the total use of medicines continued to climb—with total prescriptions dispensed reaching 6.1 billion, up 3.3 percent over 2015 levels—the spike in new patients being treated for hepatitis C ebbed, which contributed to the decline in spend. Net price increases—reflecting rebates and other price breaks from manufacturers—averaged 3.5 percent last year, up from 2.5 percent in 2015.”

 

 4 

 

 

Aceto supplies the raw materials used in the production of nutritional and packaged dietary supplements, including vitamins, amino acids, iron compounds and biochemicals used in pharmaceutical and nutritional preparations.

 

Pharmaceutical Ingredients

 

The Pharmaceutical Ingredients segment has two product groups: Active Pharmaceutical Ingredients (APIs) and Pharmaceutical Intermediates.

 

We supply APIs to many of the major generic drug companies, who we believe view Aceto as a valued partner in their effort to develop and market generic drugs. The process of introducing a new API from pipeline to market spans a number of years and begins with Aceto partnering with a generic pharmaceutical manufacturer and jointly selecting an API, several years before the expiration of a composition of matter patent, for future genericizing. We then identify the appropriate supplier, and concurrently utilizing our global technical network, work to ensure they meet standards of quality to comply with regulations. Our client, the generic pharmaceutical company, will submit the ANDA for U.S. Food and Drug Administration (“FDA”) approval or European-equivalent approval. The introduction of the API to market occurs after all the development testing has been completed and the ANDA or European-equivalent is approved and the patent expires or is deemed invalid. Aceto, at all times, has a pipeline of APIs at various stages of development both in the United States and Europe. Additionally, as the pressure to lower the overall cost of healthcare increases, Aceto has focused on, and works very closely with our customers to develop new API opportunities to provide alternative, more economical, second-source options for existing generic drugs. By leveraging our worldwide sourcing, regulatory and quality assurance capabilities, we provide to generic drug manufacturers an alternative, economical source for existing API products.

 

Aceto has long been a supplier of pharmaceutical intermediates, the complex chemical compounds that are the building blocks used in producing APIs. These are the critical components of all drugs, whether they are already on the market or currently undergoing clinical trials. Faced with significant economic pressures as well as ever-increasing regulatory barriers, the innovative drug companies look to Aceto as a source for high quality intermediates.

 

Aceto employs, on occasion, the same second source strategy for our pharmaceutical intermediates business that we use in our API business. Historically, pharmaceutical manufacturers have had one source for the intermediates needed to produce their products. Utilizing our global sourcing, regulatory support and quality assurance network, Aceto works with the large, global pharmaceutical companies, sourcing lower cost, quality pharmaceutical intermediates that will meet the same high level standards that their current commercial products adhere to.

 

According to a QuintilesIMS press release on December 6, 2016, “total spending on medicines is forecast to reach $1.5 trillion by 2021, up 33 percent from 2016 levels, even as annual growth moderates from the record pace set in 2014 and 2015, according to new research released by the QuintilesIMS Institute. While historically large numbers of high-quality new medicines will emerge from the R&D pipeline in the next five years, pricing and market access pressures, lower volume growth in pharmerging markets and greater savings from patent expiries will contribute to the lower rate of growth. The report, Outlook for Global Medicines Through 2021: Balancing Cost and Value, found that medicine spending will grow at a 4-7 percent compound annual rate during the next five years, down from the nearly 9 percent growth level seen in 2014 and 2015. The total global spend for pharmaceuticals through 2021 will increase by $367 billion on a constant-dollar basis. Spending is measured at the ex-manufacturer level before adjusting for rebates, discounts, taxes and other adjustments that affect net sales received by manufacturers. The impact of these factors is estimated to reduce growth by $127 billion, or approximately 35 percent of the growth forecast through 2021.”

 

Performance Chemicals

 

The Performance Chemicals segment includes specialty chemicals and agricultural protection products.

 

Aceto is a major supplier to many different industrial segments providing chemicals used in the manufacture of plastics, surface coatings, cosmetics and personal care, textiles, fuels and lubricants. The paint and coatings industry produces products that bring color, texture, and protection to houses, furniture, packaging, paper, and durable goods. Many of today's coatings are eco-friendly, by allowing inks and coatings to be cured by ultraviolet light instead of solvents, or allowing power coatings to be cured without solvents. These growing technologies are critical in protecting and enhancing the world's ecology and Aceto is focused on supplying the specialty additives that make modern coating techniques possible.

 

 5 

 

 

The chemistry that makes much of the modern world possible is often done by building up simple molecules to sophisticated compounds in step-by-step chemical processes. The products that are incorporated in each step are known as intermediates and they can be as varied as the end uses they serve, such as crop protection products, dyes and pigments, textiles, fuel additives, electronics - essentially all things chemical.

 

Aceto provides various specialty chemicals for the food, flavor, fragrance, paper and film industries. Aceto’s raw materials are also used in sophisticated technology products, such as high-end electronic parts used for photo tooling, circuit boards, production of computer chips, and in the production of many of today's modern gadgets.

 

According to a July 14, 2017 Federal Reserve Statistical Release, in the second quarter of calendar year 2017, the index for consumer durables, which impacts the Specialty Chemicals business of the Performance Chemicals segment, is expected to increase at an annual rate of 1.3%.

 

Aceto’s agricultural protection products include herbicides, fungicides and insecticides, which control weed growth as well as the spread of insects and microorganisms that can severely damage plant growth. One of Aceto's most widely used agricultural protection products is a sprout inhibitor that extends the storage life of potatoes. Utilizing our global sourcing and regulatory capabilities, we identify and qualify manufacturers either producing the product or with knowledge of the chemistry necessary to produce the product, and then file an application with the U.S. EPA for a product registration. Aceto has an ongoing working relationship with manufacturers in China and India to determine which of the non-patented or generic, agricultural protection products they produce can be effectively marketed in the Western world. We have successfully brought numerous products to market. We have a strong pipeline, which includes future additions to our product portfolio. The combination of our global sourcing and regulatory capabilities makes the generic agricultural market a niche for us and we will continue to offer new product additions in this market. In the National Agricultural Statistics Services release dated June 30, 2017, the total crop acreage planted in the United States in 2017 decreased by .3% to 318 million acres from 319 million acres in 2016. The number of peanut acres planted in 2017 increased 8.8% from 2016 levels while sugarcane acreage harvested decreased 3.4% from 2016. In addition, the potato acreage harvested in 2017 increased approximately ..7% from the 2016 level.

 

Research and Development Expenses

 

Research and development expenses (R&D) represent investment in our generic finished dosage form product pipeline. R&D expenses during fiscal years 2017, 2016 and 2015 were $7,898, $7,937 and $5,942 respectively.

 

Long-lived Assets

 

Long-lived assets, excluding property held for sale, by geographic region as of June 30, 2017, 2016 and 2015 were as follows:

 

   Long-lived assets 
   2017   2016   2015 
United States  $528,359   $152,701   $152,886 
Europe   2,538    2,504    2,544 
Asia-Pacific   1,582    1,781    1,893 
Total  $532,479   $156,986   $157,323 

 

Suppliers and Customers

 

We will only purchase products from specifically approved plants that meet strict guidelines for quality. We regularly visit our suppliers to evaluate them not only on the basis of ability to deliver satisfactory products on a timely and cost efficient basis, but also on quality system, facilities and equipment system, materials system, production system, packaging and labeling system, and laboratory control system. During the fiscal years ended June 30, 2017 and 2016 approximately 62% and 56%, respectively, of our purchases were from Asia and approximately 17% and 22%, respectively, were from Europe.

 

Our customers are primarily located throughout the United States, Europe and Asia. We will continue our program of regular visits to our suppliers' plants, and will continue to educate them on the quality of product and service required by our customers. Aceto is uniquely able to do this, as many of our sales representatives are technically trained (chemists, chemical engineers, biologists, pharmacologists, etc.) most with in-plant or industrial laboratory experience that allows them to effectively communicate customer requirements to sourcing teams. Our customers include a wide range of companies in the industrial chemical, agricultural, and human health and pharmaceutical industries, and range from small trading companies to Fortune 500 companies. During fiscal years 2017, 2016 and 2015, sales made to customers in the United States totaled $465,879, $380,533 and $369,663, respectively. Sales made to customers outside the United States during fiscal years 2017, 2016 and 2015 totaled $172,439, $177,991 and $177,288, respectively, of which, approximately 56%, 56% and 62%, respectively, were to customers located in Europe. One customer (AmerisourceBergen Corporation) accounted for 12% of net sales in fiscal 2017, 14% of net sales in 2016 and 13% of net sales in fiscal 2015. Another customer (McKesson Corporation) accounted for 11% of net sales in fiscal 2017, 7% of net sales in 2016 and 6% of net sales in 2015. No single product accounted for as much as 10% of net sales in fiscal 2017, 2016 or 2015.

 

 6 

 

 

Competition

 

The Company operates in a highly competitive business environment. We compete by offering high-quality products produced around the world by both large and small manufacturers at attractive prices. Because of our long standing relationships with many suppliers as well as our sourcing operations in both China and India, we are able to ensure that any given product is manufactured at a facility that can meet the regulatory requirements for that product. For the most part, we store our inventory of chemical-based products in public warehouses strategically located throughout the United States, Europe, and Asia, and we can therefore fill our customer orders on a timely basis. We have developed ready access to key purchasing, research, and technical executives of our customers and suppliers. This allows us to ensure that when necessary, sourcing decisions can be made quickly. We will also continue to search for new products, as well as for new sources for products where we feel our existing sources have lapsed in either product or delivery quality, and/or have failed to meet the needs of our customers or markets.

 

Environmental and Regulatory

 

We are subject to extensive regulation by federal, state and local agencies in the countries in which we do business. Of particular importance is the FDA in the U.S. It has jurisdiction over testing, safety, effectiveness, manufacturing, labeling, marketing, advertising and post-marketing surveillance of our Human Health products.

 

Certain of our products involve the use, storage and transportation of toxic and hazardous materials. The Company's operations are subject to extensive laws and regulations relating to the storage, handling, transportation and discharge of materials into the environment and the maintenance of safe working conditions. We have designed safety procedures to comply with the standards prescribed by federal, state and local regulations. We promote the use of environmentally friendly recyclable packaging by our suppliers. We endeavor to meet our customers' packaging requirements. We only use warehouses and carriers approved to handle chemicals and that have appropriate permits and licenses. We will endeavor to ensure that each package of each shipment has correct labels and supplier lot numbers, and is in compliance with safety and environmental laws.

 

Our global quality assurance network, with regional managers in the U.S., Europe and Asia, seeks to ensure that the quality of a product meets both its specifications and intended use. Our technical network performs a service that allows Aceto to source and qualify APIs, pharmaceutical intermediates, finished dosage form generics, agricultural products, specialty chemicals, and nutraceutical products from around the world. It also provides substantial regulatory support and technical assistance to manufacturers worldwide, enabling them to meet the stringent regulatory guidelines that govern the pharmaceutical, nutraceutical, specialty chemicals and agricultural protection industries.

 

A subsidiary of the Company markets certain agricultural protection products which are subject to the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA). FIFRA requires that test data be provided to the EPA to register, obtain and maintain approved labels for pesticide products. The EPA requires that follow-on registrants of these products compensate the initial registrant for the cost of producing the necessary test data on a basis prescribed in the FIFRA regulations. Follow-on registrants do not themselves generate or contract for the data. However, when FIFRA requirements mandate that new test data be generated to enable all registrants to continue marketing a pesticide product, often both the initial and follow-on registrants establish a task force to jointly undertake the testing effort. The Company is presently a member of several such task force groups, which requires payments for such memberships.

 

In connection with the 2016 acquisition of certain products and related assets by Aceto from Lucid, the government contracting business of Citron, Aceto acquired through the government’s novation process Lucid’s government contracts.  The U.S. government has advised Lucid that it is reviewing whether Lucid’s supply of certain products under its government contracts complied with the contracts’ country-of-origin clauses as mandated by the federal Trade Agreements Act (“TAA”).  Aceto is not named in this matter.  If the products are found to not have complied with the country-of-origin clauses, then the government could exercise remedies, including termination of one or more of the subject contracts or other statutory damages.  By virtue of Aceto’s assumption of these contracts, Aceto could be liable for some of these damages.  Aceto is entitled to indemnification under the terms of the product purchase agreement governing that transaction from the sellers for damages it may suffer as a result.  In order to protect its position and without commenting on the merits of the U.S. government’s claim, Aceto has submitted an indemnification claim to the sellers under the product purchase agreement, covering damages that Aceto may suffer as a result of this matter. Aceto has offset rights under the product purchase agreement with respect to future payment obligations that, in Aceto’s view, substantially exceed any damages that Aceto may suffer as a result of this matter.

 

 7 

 

 

Employees

 

At June 30, 2017, we had 286 employees, none of whom were covered by a collective bargaining agreement.

 

Available information

 

We file annual, quarterly, and current reports, proxy statements, and other information with the U.S. Securities and Exchange Commission (“SEC”). You may read and copy any document we file at the SEC’s public reference room at 100 F Street, NE, Washington, D.C. 20549.

 

You may call the SEC at 1-800-SEC-0330 for information on the public reference room. The SEC maintains a website that contains annual, quarterly, and current reports, proxy statements, and other information that issuers (including Aceto) file electronically with the SEC. The SEC’s website is www.sec.gov.

 

Our website is www.aceto.com. We make available free of charge through our Internet site, via a link to the SEC’s website at www.sec.gov, our annual reports on Form 10-K; quarterly reports on Form 10-Q; current reports on Form 8-K; Forms 3, 4 and 5 filed on behalf of our directors and executive officers; and any amendments to those reports and forms. We make these filings available as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information on our website is not incorporated by reference into this Annual Report on Form 10-K.

 

 8 

 

 

Item 1A. Risk factors

 

You should carefully consider the following risk factors and other information included in this Annual Report on Form 10-K. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we currently deem immaterial could also impair our business operations. If any of the following risk factors occur, our reputation, business, financial condition, operating results and cash flows could be materially adversely affected.

 

If we are unable to compete effectively with our competitors, many of which have greater market presence and resources than us, our reputation, business, financial condition, operating results and cash flows could be materially adversely affected.

 

Our financial condition and operating results are directly related to our ability to compete in the intensely competitive global pharmaceutical and chemical markets. We face intense competition from global and regional distributors of pharmaceutical and chemical products, many of which are large pharmaceutical and chemical manufacturers as well as distributors. Many of these companies have substantially greater resources than us, including, among other things, greater financial, marketing and distribution resources. We cannot assure you that we will be able to compete successfully with any of these companies. In addition, increased competition could result in price reductions, reduced margins and loss of market share for our products, all of which could materially adversely affect our reputation, business, financial condition, operating results and cash flows.

 

Our distribution operations of finished dosage form generic drugs and APIs are subject to the risks of the generic pharmaceutical industry.

 

The ability of our business to provide consistent, sequential quarterly growth is affected, in large part, by our participation in the launch of new products by generic manufacturers and the subsequent advent and extent of competition encountered by these products. Revenues and gross profit derived from the sales of generic pharmaceutical products tend to follow a pattern based on certain regulatory and competitive factors. This competition can result in significant and rapid declines in pricing with a corresponding decrease in net sales. Net selling prices of generic drugs typically decline over time, sometimes dramatically, as additional generic pharmaceutical companies receive approvals and enter the market for a given generic product and competition intensifies. When additional versions of one of our generic products enter the market, we generally lose market share and our selling prices and margins on that product decline.

 

The approval process for generic pharmaceutical products often results in the FDA granting final approval simultaneously or within close proximity to a number of generic pharmaceutical products at the time a patent claim for a corresponding branded product or other market exclusivity expires. This often forces a generic firm to face immediate competition when it introduces a generic product into the market. Additionally, further generic approvals often continue to be granted for a given product subsequent to the initial launch of the generic product. These circumstances generally result in significantly lower prices, as well as reduced margins, for generic products compared to branded products. New generic market entrants generally cause continued price and margin erosion over the generic product life cycle. As a result, we could be unable to grow or maintain market share with respect to our generic pharmaceutical products, which could materially adversely affect our reputation, business, financial condition, operating results and cash flows.

 

We may experience declines in sales volumes or prices of certain of our products as the result of the concentration of sales to wholesalers and the continuing trend towards consolidation of such wholesalers and other customer groups which could have a material adverse impact on our business, financial condition, operating results and cash flows.

 

Wholesalers and retail drug chains have undergone, and are continuing to undergo, significant consolidation. This consolidation may result in these groups gaining additional purchasing leverage and consequently increasing the product pricing pressures facing our finished dosage form generic business. The result of these developments could have a material adverse effect on our business, financial position, results of operations and cash flows.

 

Our pipeline of products in development may be subject to regulatory delays at the FDA. Delays in key products could have material adverse effects on our reputation, business, financial condition, operating results and cash flows.

 

Our future revenue growth and profitability are partially dependent upon our ability to introduce new products on a timely basis in relation to our competitors’ product introductions. Our failure to do so successfully could materially adversely affect our reputation, business, financial condition, operating results and cash flows. Many products require FDA approval or the equivalent regulatory approvals in our overseas markets prior to being marketed. The process of obtaining FDA/regulatory approval to market new and generic pharmaceutical products is rigorous, time-consuming, costly and often unpredictable. We may be unable to obtain requisite FDA approvals on a timely basis for new generic products.

 

 9 

 

 

Pharmaceutical product quality standards are steadily increasing and all products, including those already approved, may need to meet current standards. If our products are not able to meet these standards, we may be required to discontinue marketing and/or recall such products from the market.

 

Steadily increasing quality standards are applicable to pharmaceutical products still under development and those already approved and on the market. These standards result from product quality initiatives implemented by the FDA, and updated U.S. Pharmacopeial Convention (“USP”) Reference Standards. The USP is a scientific nonprofit organization that sets standards for the identity, strength, quality, and purity of medicines, food ingredients, and dietary supplements manufactured, distributed, and consumed worldwide. Pharmaceutical products approved prior to the implementation of new quality standards may not meet these standards, which could require us to discontinue marketing and/or recall such products from the market, either of which could have a material adverse effect on our business, financial position, results of operations and cash flows.

 

If brand pharmaceutical companies are successful in limiting the use of generics through their legislative and regulatory efforts, our sales of generic products may suffer.

 

Many brand pharmaceutical companies increasingly have used state and federal legislative and regulatory means to delay generic competition. These efforts have included:

 

·pursuing new patents for existing products which may be granted just before the expiration of one patent which could extend patent protection for additional years or otherwise delay the launch of generics;
·using the Citizen Petition process to request amendments to FDA standards;
·seeking changes to U.S. Pharmacopoeia, an organization which publishes industry recognized compendia of drug standards;
·attaching patent extension amendments to non-related federal legislation;
·engaging in state-by-state initiatives to enact legislation that restricts the substitution of some generic drugs, which could have an impact on products that we are developing;
·persuading regulatory bodies to withdraw the approval of brand name drugs for which the patents are about to expire and converting the market to another product of the brand company on which longer patent protection exists;
·entering into agreements whereby other generic companies will begin to market an authorized generic, a generic equivalent of a branded product, at the same time or after generic competition initially enters the market;
·filing suits for patent infringement and other claims that may delay or prevent regulatory approval, manufacture, and/or sale of generic products; and,
·introducing “next-generation” products prior to the expiration of market exclusivity for the reference product, which often materially reduces the demand for the generic or the reference product for which we seek regulatory approval.

 

In the U.S., some companies have lobbied Congress for amendments to the Hatch-Waxman Act that would give them additional advantages over generic competitors. For example, although the term of a company’s drug patent can be extended to reflect a portion of the time an NDA is under regulatory review, some companies have proposed extending the patent term by a full year for each year spent in clinical trials rather than the one-half year that is currently permitted.

 

If proposals like these were to become effective, or if any other actions by our competitors and other third parties to prevent or delay activities necessary to the approval, manufacture, or distribution of our products are successful, our entry into the market and our ability to generate revenues associated with new products may be delayed, reduced, or eliminated, which could have material adverse effects on our reputation, business, financial condition, operating results and cash flows.

 

A proposed FDA rule allowing generic companies to distribute revised labels that differ from the corresponding reference listed drug (“RLD”) could have an adverse effect on our operations because of a potential increase in litigation exposure.

 

On November 13, 2013, the FDA issued a proposed rule (Docket No. FDA-2013-N-0500) titled "Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products." Pursuant to the rule, the FDA will change existing regulations to allow generic drug application holders, in advance of the FDA’s review, to distribute revised labeling, to reflect safety-related changes based on newly acquired information. Currently, the labels of generic drugs must conform to those of the corresponding RLD and any failure-to-warn claims against generic companies are preempted under U.S. Federal law. Once this rule is released, we could be found liable under such failure-to-warn claims if we do not revise our labeling to reflect safety-related changes promptly upon receipt of applicable safety information. While we proactively conduct surveillance for reported safety issues with our products, we cannot guarantee that this will prevent us from being found liable under a failure-to-warn claim. When this proposed regulatory change is adopted, it could increase our potential liability with respect to failure-to-warn claims, which, even if successfully defended, could have material adverse effects on our reputation, business, financial condition, operating results and cash flows.

 

 10 

 

 

Our policies regarding returns, allowances, rebates and chargebacks, and marketing programs adopted by wholesalers may reduce our revenues in future fiscal periods.

 

Based on industry practice, generic drug manufacturers have liberal return policies and have been willing to give customers post-sale inventory allowances. Under these arrangements, from time to time we give our customers credits on our generic products that our customers already hold in inventory after we have decreased the market prices of the same generic products due to competitive pricing. Therefore, if new competitors enter the marketplace and significantly lower the prices of any of their competing products, we could reduce the price of our product. As a result, we would be obligated to provide credits to our customers who are then holding inventories of such products, which could reduce sales revenue and gross margin for the period the credit is provided. Like our competitors, we also give credits for chargebacks to wholesalers that have contracts with us for their sales to hospitals, group purchasing organizations, pharmacies or other customers.

 

A chargeback is the difference between the price the wholesaler pays and the price that the wholesaler’s end-customer pays for a product. Although we establish reserves based on our prior experience and our best estimates of the impact that these policies may have in subsequent periods, we cannot ensure that our reserves are adequate or that actual product returns, allowances, rebates, chargebacks and partnered product liabilities will not exceed our estimates.

 

The regulatory approval process outside the U.S. varies depending on foreign regulatory requirements, and failure to obtain regulatory approval in foreign jurisdictions would prevent the marketing of our products in those jurisdictions.

 

We have certain worldwide intellectual property rights to market some of our products and product candidates. We intend to seek approval to market certain of our products outside of the U.S. To market our products in the European Union and other foreign jurisdictions, we must obtain separate regulatory authorization and comply with numerous and varying regulatory requirements. Approval of a product by the comparable regulatory authorities of foreign countries must be obtained prior to marketing that product in those countries. The approval procedure varies among countries and can involve additional testing, and the time required to obtain approval may differ from that required to obtain FDA approval. The foreign regulatory approval process includes all of the risks associated with obtaining FDA approval set forth herein and approval by the FDA does not ensure approval by the regulatory authorities of any other country, nor does the approval by foreign regulatory authorities in one country ensure approval by regulatory authorities in other foreign countries or the FDA. If we fail to comply with these regulatory requirements or obtain and maintain required approvals, our target market will be reduced and our ability to generate revenue from abroad will be adversely affected.

 

We have entered into collaborative arrangements that may not result in marketable products.

 

We regularly enter into collaborative arrangements to develop generic products for us to market in the U.S. We can offer no assurances that these arrangements will result in additional approved products, or that we will be able to market the products at a profit. In addition, any expenses related to trials, or additional studies required by the FDA, that we may incur in connection with these collaborative arrangements may negatively affect our business, financial condition, operating results and cash flows. Specifically:

 

  · trials could be more costly than we anticipate;
  · formulation development could take longer and be more costly than we expect; and
  · we may be required to obtain specialized equipment in order to manufacture products on a commercial scale.

 

Any of these events could have a material adverse effect on our business, financial condition, operating results and cash flows.

 

Our growth and development will depend on developing, commercializing and marketing new products, including both our own products and those developed with our collaboration partners. If we do not do so successfully, our growth and development will be impaired.

 

Our future revenues and profitability will depend, to a significant extent, upon our ability to successfully commercialize new generic pharmaceutical products in a timely manner. As a result, we must continually develop and test new products, and these new products must meet regulatory standards and receive requisite regulatory approvals. Products we are currently developing may or may not achieve the technology success or receive the regulatory approvals or clearances necessary for us to market them. Furthermore, the development and commercialization process is time-consuming and costly, and we cannot assure you that any of our products, if and when developed and approved, can be successfully commercialized. Some of our collaboration partners may decide to make substantial changes to a product’s formulation or design, may experience financial difficulties or have limited financial resources, any of which may delay the development, commercialization and/or marketing of new products. In addition, if a co-developer on a new product terminates our collaboration agreement or does not perform under the agreement, we may experience delays and, possibly, additional costs in developing and marketing that product.

 

 11 

 

 

The time necessary to develop generic drugs may adversely affect whether, and the extent to which, we receive a return on our capital.

 

We generally begin our development activities for a new generic drug product several years in advance of the patent expiration date of the brand-name drug equivalent. The development process, including drug formulation, testing, and FDA review and approval, often takes three or more years. This process requires that we expend considerable capital to pursue activities that do not yield an immediate or near-term return. Also, because of the significant time necessary to develop a product, the actual market for a product at the time it is available for sale may be significantly less than the originally projected market for the product, including the possibility that the product has become eligible for OTC sales. If this were to occur, our potential return on our investment in developing the product, if approved for marketing by the FDA, would be adversely affected and we may never receive a return on our investment in the product.

 

If we experience product recalls, we may incur significant and unexpected costs, and our business reputation could be adversely affected.

 

We may be exposed to product recalls and adverse public relations if our products are alleged to cause injury or illness, or if we are alleged to have violated governmental regulations. A product recall could result in substantial and unexpected expenditures, which would reduce operating profit and cash flow. In addition, a product recall may require significant management attention. Product recalls may hurt the value of our brands and lead to decreased demand for our products. Product recalls also may lead to increased scrutiny by federal, state or international regulatory agencies of our operations and increased litigation and could have a material adverse effect on our reputation, business, financial condition, operating results and cash flows.

 

Dependence on a limited number of suppliers of Human Health and Pharmaceutical Ingredients products could lead to delays, lost revenue or increased costs.

 

Our future operating results may depend substantially on our suppliers’ ability to timely provide Human Health and Pharmaceutical Ingredients products in connection with ANDAs and such suppliers’ ability to supply us with these ingredients or materials in sufficient volumes to meet our production requirements. A number of the ingredients or materials that we use are available from only a single or limited number of qualified suppliers, and may be used across multiple product lines. If there is a significant increase in demand for an ingredient or other material resulting in an inability to meet demand, if an ingredient or material is otherwise in short supply or becomes wholly unavailable, or if a supplier has a quality issue, we may experience delays or increased costs in obtaining that ingredient or material. If we are unable to obtain sufficient quantities of ingredients or other necessary materials, we may experience production delays in our supply.

 

Each of the following could also interrupt the supply of, or increase the cost of, ingredients or other materials:

 

• an unwillingness of a supplier to supply ingredients or other materials to us;

• consolidation of key suppliers;

• failure of a key supplier’s business process;

• a key supplier’s inability to access credit necessary to operate its business; or

• failure of a key supplier to remain in business, to remain an independent supplier, or to adjust to market conditions.

 

Any interruption in the supply or increase in the cost of ingredients or other materials provided by single or limited source suppliers could have a material adverse effect on our reputation, business, financial condition, operating results and cash flows.

 

Our success in our Human Health segment is linked to the size and growth rate of the generic pharmaceutical, vitamin, mineral and supplement markets and an adverse change in the size or growth rate of these markets could have a material adverse effect on us.

 

An adverse change in size or growth rate of the generic pharmaceutical, vitamin, mineral and supplement markets could have a material adverse effect on us. Underlying market conditions are subject to change based on economic conditions, consumer preferences and other factors that are beyond our control, including media attention and scientific research, which may be positive or negative.

 

 12 

 

 

Healthcare reform and a reduction in the reimbursement levels by governmental authorities, HMOs, MCOs or other third-party payors could materially adversely affect our business, financial condition, operating results and cash flows.

 

Third party payors increasingly challenge pricing of pharmaceutical products. The trend toward managed healthcare, the growth of organizations such as HMOs and MCOs and legislative proposals to reform healthcare and government insurance programs could significantly influence the purchase of pharmaceutical products, resulting in lower prices and a reduction in product demand. Such cost containment measures and healthcare reform could affect our ability to sell our products and could have a material adverse effect on our business, results of operations, financial condition and cash flows.

 

Any failure to comply with the complex reporting and payment obligations under Medicare, Medicaid and other government programs may result in litigation or sanctions.

 

We are subject to various federal and state laws pertaining to healthcare fraud and abuse, including anti-kickback, false claims, marketing and pricing laws. We are also subject to Medicaid and other government reporting and payment obligations that are highly complex and somewhat ambiguous. Violations of these laws and reporting obligations are punishable by criminal and/or civil sanctions and exclusion from participation in federal and state healthcare programs such as Medicare and Medicaid. The recent healthcare reform legislation made several changes to the federal anti-kickback statute, false claims laws, and health care fraud statute such as increasing penalties and making it easier for the government to bring sanctions against pharmaceutical companies. If our past, present or future operations are found to be in violation of any of the laws described above or other similar governmental regulations, we may be subject to the applicable penalty associated with the violation which could adversely affect our ability to operate our business and negatively impact our financial results. Further, if there is a change in laws, regulations or administrative or judicial interpretations, we may have to change our business practices or our existing business practices could be challenged as unlawful, which could have a material adverse effect on our business, results of operations, financial condition and cash flows.

 

Our future results could be materially affected by a number of public health issues whether occurring in the United States or abroad.

 

Public health issues, whether occurring in the United States or abroad, could disrupt our operations, disrupt the operations of suppliers or customers, or have a broader adverse impact on consumer spending and confidence levels that would negatively affect our suppliers and customers. We may be required to suspend operations in some or all of our locations, which could have a material adverse effect on our business, results of operations, financial condition and cash flows.

 

Our revenue stream and related gross profit is difficult to predict.

 

Our revenue stream is difficult to predict because it is primarily generated as customers place orders and customers can change their requirements or cancel orders. Many of our sales orders are short-term and could be cancelled at any time. As a result, much of our revenue is not recurring from period to period, which contributes to the variability of our results from period to period. In addition, certain of our products carry a higher gross margin than other products, particularly in the Human Health and Pharmaceutical Ingredients segments. Reduced sales of these higher margin products could have a material adverse effect on our operating results. We believe that quarter-to-quarter comparisons of our operating results are not a good indication of our future performance.

 

From time to time we may need to rely on licenses to proprietary technologies, which may be difficult or expensive to obtain.

 

We may need to obtain licenses to patents and other proprietary rights held by third parties to develop, manufacture and market products. If we are unable to timely obtain these licenses on commercially reasonable terms, our ability to commercially market our products may be inhibited or prevented, which could have a material adverse effect on our business, financial condition, operating results and cash flows.

 

Changes to the industries and markets that Aceto serves could have a material adverse effect on our business, financial condition, operating results and cash flows.

 

The business environment in which we operate remains challenging. Portions of our operations are subject to the same business cycles as those experienced by automobile, housing, and durable goods manufacturers. Our demand is largely derived from the demand for our customers’ products, which subjects us to uncertainties related to downturns in our customers’ business and unanticipated customer production shutdowns or curtailments. A material downturn in sales or gross profit due to weak end-user markets and loss of customers could have a material adverse effect on our business, financial condition, operating results and cash flows.

 

 13 

 

 

Our operating results could fluctuate in future quarters, which could adversely affect the trading price of our common stock.

 

Our operating results could fluctuate on a quarterly basis as a result of a number of factors, including, among other things, the timing of contracts, orders, the delay or cancellation of a contract, and changes in government regulations. Any one of these factors could have a significant impact on our quarterly results. In some quarters, our revenue and operating results could fall below the expectations of securities analysts and investors, which would likely cause the trading price of our common stock to decline.

 

We have significant inventories on hand.

 

The Company maintains significant inventories. Any significant unanticipated changes in future product demand or market conditions, including, among other things, the current uncertainty in the global market, could materially adversely affect the value of inventory and our business, financial condition, operating results and cash flows.

 

Failure to obtain products from outside manufacturers could adversely affect our ability to fulfill sales orders to our customers.

 

We rely on outside manufacturers to supply products for resale to our customers. Manufacturing problems, including, among other things, manufacturing delays caused by plant shutdowns, regulatory issues, damage or disruption to raw material supplies due to weather, including, among other things, any potential effects of climate change, natural disaster or fire, could occur. If such problems occur, we cannot assure you that we will be able to deliver our products to our customers profitably or on time.

 

Increases in the cost of shipping with our third-party shippers could have a material adverse effect on our business, financial condition, operating results and cash flows.

 

Shipping is a significant expense in the operation of our business. Accordingly, any significant increase in shipping rates could have an adverse effect on our operating results. Similarly, strikes or other service interruptions by those shippers could cause our operating expenses to rise and adversely affect our ability to deliver products on a timely basis.

 

We could incur significant uninsured environmental and other liabilities inherent in the chemical/pharmaceutical distribution industry that could materially adversely affect our business, financial condition, operating results and cash flows.

 

The business of distributing chemicals and pharmaceuticals is subject to regulation by numerous federal, state, local, and foreign governmental authorities. These regulations impose liability for loss of life, damage to property and equipment, pollution and other environmental damage that could occur in our business. Many of these regulations provide for substantial fines and remediation costs in the event of chemical spills, explosions and pollution. While we believe that we are in substantial compliance with all current laws and regulations, we can give no assurance that we will not incur material liabilities that are not covered by insurance or exceed our insurance coverage or that such insurance will remain available on terms and at rates acceptable to us. Additionally, if existing environmental and other regulations are changed, or additional laws or regulations are passed, the cost of complying with those laws could be substantial, thereby materially adversely affecting our business, financial condition, operating results and cash flows.

 

In fiscal years 2011, 2009, 2008 and 2007, the Company received letters from the Pulvair Site Group, a group of potentially responsible parties (PRP Group) who are working with the State of Tennessee (the State) to remediate a contaminated property in Tennessee called the Pulvair site. The PRP Group has alleged that Aceto shipped hazardous substances to the site which were released into the environment. The State had begun administrative proceedings against the members of the PRP Group and Aceto with respect to the cleanup of the Pulvair site and the PRP Group has begun to undertake cleanup. The PRP Group is seeking a settlement of approximately $1,700 from the Company for its share to remediate the site contamination. Although the Company acknowledges that it shipped materials to the site for formulation over twenty years ago, the Company believes that the evidence does not show that the hazardous materials sent by Aceto to the site have significantly contributed to the contamination of the environment and thus believes that, at most, it is a de minimis contributor to the site contamination. Accordingly, the Company believes that the settlement offer is unreasonable. Management believes that the ultimate outcome of this matter will not have a material adverse effect on the Company's financial condition or liquidity.

 

Our subsidiary, Arsynco, has environmental remediation obligations in connection with its former manufacturing facility in Carlstadt, New Jersey. Estimates of how much it would cost to remediate environmental contamination at this site have increased since the facility was closed in 1993. If the actual costs are significantly greater than estimated, it could have a material adverse effect on our financial condition, operating results and cash flows.

 

 14 

 

 

In March 2006, Arsynco received notice from the EPA of its status as a PRP under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) for a site described as the Berry’s Creek Study Area (“BCSA”). Arsynco is one of over 150 PRPs which have potential liability for the required investigation and remediation of the site. The estimate of the potential liability is not quantifiable for a number of reasons, including the difficulty in determining the extent of contamination and the length of time remediation may require. In addition, any estimate of liability must also consider the number of other PRPs and their financial strength. In July 2014, Arsynco received notice from the U.S. Department of Interior (“USDOI”) regarding the USDOI’s intent to perform a Natural Resource Damage (NRD) Assessment at the BCSA. Arsynco has to date declined to participate in the development and performance of the NRD assessment process. Based on prior practice in similar situations, it is possible that the State may assert a claim for natural resource damages with respect to the Arsynco site itself, and either the federal government or the State (or both) may assert claims against Arsynco for natural resource damages in connection with Berry's Creek; any such claim with respect to Berry's Creek could also be asserted against the approximately 150 PRPs which the EPA has identified in connection with that site. Any claim for natural resource damages with respect to the Arsynco site itself may also be asserted against BASF, the former owners of the Arsynco property. In September 2012, Arsynco entered into an agreement with three of the other PRPs that had previously been impleaded into New Jersey Department of Environmental Protection, et al. v. Occidental Chemical Corporation, et al., Docket No. ESX-L-9868-05 (the "NJDEP Litigation") and were considering impleading Arsynco into the same proceeding. Arsynco entered into an agreement to avoid impleader. Pursuant to the agreement, Arsynco agreed to (1) a tolling period that would not be included when computing the running of any statute of limitations that might provide a defense to the NJDEP Litigation; (2) the waiver of certain issue preclusion defenses in the NJDEP Litigation; and (3) arbitration of certain potential future liability allocation claims if the other parties to the agreement are barred by a court of competent jurisdiction from proceeding against Arsynco. In July 2015, Arsynco was contacted by an allocation consultant retained by a group of the named PRPs, inviting Arsynco to participate in the allocation among the PRPs’ investigation and remediation costs relating to the BCSA. Arsynco declined that invitation. Since an amount of the liability cannot be reasonably estimated at this time, no accrual is recorded for these potential future costs. The impact of the resolution of this matter on the Company’s results of operations in a particular reporting period is not currently known.

 

The distribution and sale of some of our products are subject to prior governmental approvals and thereafter ongoing governmental regulation.

 

Our products are subject to laws administered by federal, state and foreign governments, including the Toxic Substances Control Act as well as regulations requiring registration and approval of many of our products. More stringent restrictions could make our products less desirable, which would adversely affect our revenues and profitability. Some of our products are subject to the EPA registration and re-registration requirements, and are registered in accordance with FIFRA. Such registration requirements are based, among other things, on data demonstrating that the product will not cause unreasonable adverse effects on human health or the environment when used according to approved label directions. Governmental regulatory authorities have required, and may require in the future, that certain scientific data requirements be performed on our products and this may require us, on our behalf or in joint efforts with other registrants, to perform additional testing. Responding to such requirements may cause delays in or the cessation of the sales of one or more of our products which would adversely affect our profitability. We can provide no assurance that any testing approvals or registrations will be granted on a timely basis, if at all, or that our resources will be adequate to meet the costs of regulatory compliance or that the economic benefit of complying with the requirement will exceed our cost.

 

Incidents related to hazardous materials could materially adversely affect our reputation, business, financial condition, operating results and cash flows.

 

Portions of our operations require the controlled use of hazardous materials. Although we are diligent in designing and implementing safety procedures to comply with the standards prescribed by federal, state, and local regulations, the risk of accidental contamination of property or injury to individuals from these materials cannot be completely eliminated. In the event of such an incident, we could be liable for any damages that result, which could materially adversely affect our reputation, business, financial condition, operating results and cash flows.

 

We are also continuing to expand our business in China and India, where environmental, health and safety regulations are still early in their development. As a result, we cannot determine how these laws will be implemented and the impact of such regulation on the Company.

 

 15 

 

 

Violations of cGMP and other government regulations could have a material adverse effect on our reputation, business, financial condition and results of operations.

 

All facilities and manufacturing techniques used to manufacture pharmaceutical products for clinical use or for commercial sale in the United States and other Aceto markets must be operated in conformity with current Good Manufacturing Practices ("cGMP") regulations as required by the FDA and other regulatory bodies. Our suppliers’ facilities are subject to scheduled periodic regulatory and customer inspections to ensure compliance with cGMP and other requirements applicable to such products. A finding that we or one or more of our suppliers had materially violated these requirements could result in one or more regulatory sanctions, loss of a customer contract, disqualification of data for client submissions to regulatory authorities and a mandated closing of our suppliers’ facilities, which in turn could have a material adverse effect on our reputation, business, financial condition, operating results and cash flows.

 

Our business could give rise to product liability claims that are not covered by insurance or indemnity agreements or exceed insurance policy or indemnity agreement limitations.


The marketing, distribution and use of pharmaceutical and chemical products involve substantial risk of product liability claims. We could be held liable if any product we or our partners develop or distribute causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. A successful product liability claim that we have not insured against, that exceeds our levels of insurance or for which we are not indemnified, may require us to pay a substantial amount of damages. In the event that we are forced to pay such damages, this payment could have a material adverse effect on our reputation, business, financial condition, operating results and cash flows.

 

Rising insurance costs, as well as the inability to obtain certain insurance coverage for risks faced by us, could negatively impact profitability.

 

The cost of insurance, including workers compensation, product liability and general liability insurance, has risen in recent years and may increase in the future. In response, we may increase deductibles and/or decrease certain coverage to mitigate these costs. These increases and our increased risk due to increased deductibles and reduced coverage could materially adversely affect our business, financial condition, operating results and cash flows. Additionally, certain insurance coverage may not be available to us for risks faced by us. Sometimes the coverage we obtain for certain risks may not be adequate to fully reimburse the amount of damage that we could possibly sustain. Should either of these events occur, the lack of insurance to cover our entire loss could materially adversely affect our business, financial condition, operating results and cash flows.

 

We source many of our products in China and changes in the political and economic policies of China’s government could have a significant impact upon the business we may be able to conduct in China and our financial condition, operating results and cash flows.

 

Our business operations could be materially adversely affected by the current and future political environment in China. China has operated as a socialist state since the mid-1900s and is controlled by the Communist Party of China. The Chinese government exerts substantial influence and control over the manner in which companies, such as ours, must conduct business activities in China. China has only permitted provincial and local economic autonomy and private economic activities since 1988. The government of China has exercised and continues to exercise substantial control over virtually every sector of the Chinese economy, through regulation and state ownership. Our ability to conduct business in China could be adversely affected by changes in Chinese laws and regulations, including, among others, those relating to taxation, import and export tariffs, raw materials, environmental regulations, land use rights, property and other matters. Under its current leadership, the government of China has been pursuing economic reform policies that encourage private economic activity and greater economic decentralization. There is no assurance, however, that the government of China will continue to pursue these policies, or that it will not significantly alter these policies from time to time without notice.

 

China’s laws and regulations governing our current business operations in China are sometimes vague and uncertain. Any changes in such laws and regulations could materially adversely affect our business, financial condition, operating results and cash flows.

 

China’s legal system is a civil law system based on written statutes, in which system decided legal cases have little value as precedents unlike the common law system prevalent in the United States. There are substantial uncertainties regarding the interpretation and application of China’s laws and regulations, including among others, the laws and regulations governing the conduct of business in China, or the enforcement and performance of arrangements with customers and suppliers in the event of the imposition of statutory liens, death, bankruptcy and criminal proceedings. The Chinese government has been developing a comprehensive system of commercial laws, and considerable progress has been made in introducing laws and regulations dealing with economic matters such as foreign investment, corporate organization and governance, commerce, taxation and trade. However, because these laws and regulations are relatively new, and because of the limited volume of published cases and judicial interpretation and their lack of force as precedents, interpretation and enforcement of these laws and regulations involve significant uncertainties. New laws and regulations that affect existing and proposed future businesses may also be applied retroactively. We cannot predict what effect the interpretation of existing or new laws or regulations may have on our business in China. If the relevant authorities find that we are in violation of China’s laws or regulations, they would have broad discretion in dealing with such a violation, including, among other things: (i) levying fines and (ii) requiring that we discontinue any portion or all of our business in China.

 

 16 

 

 

The promulgation of new laws, changes to existing laws and the pre-emption of local regulations by national laws may adversely affect foreign businesses conducting business in China. While the trend of legislation over the last 20 plus years has significantly enhanced the protection of foreign businesses in China, there can be no assurance that a change in leadership, social or political disruption, or unforeseen circumstances affecting China’s political, economic or social life, will not affect China’s government’s ability to continue to support and pursue these reforms. Such a shift could have a material adverse effect on our business and prospects.

 

Our ability to compete in certain markets we serve is dependent on our ability to continue to expand our capacity in certain offshore locations. However, as our presence in these locations increases, we are exposed to risks inherent to these locations which could materially adversely affect our business, financial condition, operating results and cash flows.

 

A significant portion of our outsourcing has been shifted to India. As such, we are exposed to the risks inherent to operating in India including, among others, (1) a highly competitive labor market for skilled workers which may result in significant increases in labor costs as well as shortages of qualified workers in the future, and (2) the possibility that the U.S. federal government or the European Union may enact legislation which may disincentivize customers from producing in their local countries which would reduce the demand for the services we provide in India and could materially adversely affect our business, financial condition, operating results and cash flows.

 

Fluctuations in foreign currency exchange rates could materially adversely affect our business, financial condition, operating results and cash flows.

 

A substantial portion of our revenue is denominated in currencies other than the U.S. dollar because certain of our foreign subsidiaries operate in their local currencies. Our business, financial condition, operating results and cash flows therefore could be materially adversely affected by fluctuations in the exchange rate between foreign currencies and the U.S. dollar.

 

Failure to comply with U.S. or non-U.S. laws regulating trade, such as the U.S. Foreign Corrupt Practices Act, could result in adverse consequences, including fines, criminal sanctions, or loss of access to markets.

 

We are subject to the U.S. Foreign Corrupt Practices Act (“FCPA”), which, among other things, prohibits corporations and individuals from paying, offering to pay, or authorizing the payment of anything of value to any foreign government official, government staff member, political party, or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect their transactions and to devise and maintain an adequate system of internal accounting controls. While our employees and agents are required to comply with these laws, we cannot assure you that our internal policies and procedures will always protect us from violations of these laws, despite our commitment to legal compliance and corporate ethics. The occurrence or allegation of these types of events could materially adversely affect our reputation, business, financial condition, operating results and cash flows.

 

Tax legislation and assessments by various tax authorities could be materially different than the amounts we have provided for in our consolidated financial statements.

 

We are regularly audited by federal, state, and foreign tax authorities. From time to time, these audits could result in proposed assessments. While we believe that we have adequately provided for any such assessments, future settlements could be materially different than we have provided for and thereby materially adversely affect our earnings and cash flows.

 

We operate in various tax jurisdictions, and although we believe that we have provided for income and other taxes in accordance with the relevant regulations, if the applicable regulations were ultimately interpreted differently by a taxing authority, we could be exposed to additional tax liabilities. Our effective tax rate is based on our expected geographic mix of earnings, statutory rates, intercompany transfer pricing, and enacted tax rules. Significant judgment is required in determining our effective tax rate and in evaluating our tax positions on a worldwide basis. We believe our tax positions, including, among others, intercompany transfer pricing policies, are consistent with the tax laws in the jurisdictions in which we conduct our business. It is possible that these positions may be challenged by jurisdictional tax authorities and could have a significant impact on our effective tax rate. In addition, from time to time, various legislative initiatives could be proposed that could adversely affect our tax positions. There can be no assurance that our effective tax rate will not be adversely affected by these initiatives. In connection with the Organization for Economic Cooperation and Development Base Erosion and Profit Shifting (BEPS) project, starting in 2017, companies may be required to disclose more information to tax authorities on operations around the world. The Company regularly assesses the likely outcomes of its tax audits to determine the appropriateness of its tax reserves. However, any tax authority could take a position on tax treatment that is contrary to the Company’s expectations, which could result in tax liabilities in excess of reserves.

 

 17 

 

 

The U.S. Congress and Trump administration may make substantial changes to fiscal, tax, regulation and other federal policies that may adversely affect our business, financial condition, operating results and cash flows.

 

The Trump administration has called for substantial changes to U.S. fiscal and tax policies, which may include comprehensive corporate and individual tax reform. In addition, the Trump administration has called for significant changes to U.S. trade, healthcare, immigration, foreign, and government regulatory policy. To the extent the U.S. Congress or Trump administration implements changes to U.S. policy, those changes may impact, among other things, the U.S. and global economy, international trade and relations, unemployment, immigration, corporate taxes, healthcare, the U.S. regulatory environment, inflation and other areas. Although we cannot predict the impact, if any, of these changes to our business, they could adversely affect our business, financial condition, operating results and cash flows. Until we know what policy changes are made and how those changes impact our business and the business of our competitors over the long term, we will not know if, overall, we will benefit from them or be negatively affected by them.

 

Our business is subject to a number of global economic risks.

 

From time to time, financial markets in the United States, Europe and Asia have and could experience extreme disruption, including, among other things, extreme volatility in security prices, severely diminished liquidity and credit availability, rating downgrades of certain investments and declining valuations of others. Governments have taken unprecedented actions intending to address extreme market conditions that include severely restricted credit and declines in values of certain assets.

 

An economic downturn in the businesses or geographic areas in which we sell our products could reduce demand for our products and result in a decrease in revenue that could have a negative impact on our results of operations. Continued volatility and disruption of financial markets in the United States, Europe and Asia could limit our customers’ ability to obtain adequate financing or credit to purchase our products or to pay for outstanding invoices owed to us or to maintain operations, and result in a decrease in revenue or cash collections that could have a material adverse effect on our business, financial condition, operating results and cash flows.

 

We have a significant amount of bank loans.

 

At June 30, 2017, we have $90,000 of revolving bank loans outstanding and $142,500 outstanding in a bank term loan. If we are unable to generate sufficient cash flow or otherwise obtain funds necessary to make required payments on the credit facility, it will be in default. This current debt arrangement requires us to comply with several financial covenants. Our ability to comply with these covenants may be affected by events beyond our control and could result in a default under our credit facility, which could have a material adverse effect on our business, financial condition, operating results and cash flows.

 

Even if we are able to meet our debt service obligations, the amount of debt we have could adversely affect us by limiting our ability to obtain any necessary financing in the future for working capital, dividend payments, capital expenditures, debt service requirements, or other purposes. It also places us at a disadvantage relative to our competitors who have lower levels of debt, while making us more vulnerable to a downturn in our business or the economy in general. It also requires us to use a substantial portion of our cash to pay principal and interest on our debt, instead of investing those funds in the business.

 

Making interest and principal payments on our Convertible Senior Notes due 2020 (the “Notes”), which were issued in November 2015, requires and will continue to require a significant amount of cash, and we may not have sufficient cash flows from our business to make future interest and principal payments.

 

Our ability to continue to make scheduled interest payments and to make future principal payments on the Notes depends on our future performance, which is subject to economic, financial, competitive, and other factors beyond our control. Our business may not continue to generate cash flows from operations sufficient to service our debt. If we are unable to generate such cash flows, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt, or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations, including the Notes, which could have a material adverse effect on our business, financial condition, operating results and cash flows.

 

 18 

 

 

We may not have the ability to raise the funds necessary to settle conversions of the Notes that we issued in November 2015 or to repurchase such Notes upon a fundamental change, and our senior secured credit facility contains, and our future debt may contain, limitations on our ability to pay cash upon conversion or repurchase of such Notes.

 

Holders of our Notes have the right to require us to repurchase their notes upon the occurrence of certain fundamental events (each, a “fundamental change”) at a fundamental change repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any. In addition, upon conversion of the Notes, unless we elect to deliver solely shares of our common stock to settle such conversion (other than paying cash in lieu of delivering any fractional shares), we will be required to make cash payments in respect of the Notes being converted. However, we may not have enough available cash or be able to obtain financing at the time we are required to make repurchases of notes surrendered therefor or pay cash upon conversions of notes being converted. In addition, our ability to repurchase the Notes or to pay cash upon conversions of the Notes is limited by agreements governing our existing senior secured credit facility, and may be further limited by law, by regulatory authority or by agreements governing our future indebtedness. Our failure to repurchase notes at a time when the repurchase is required by the indenture governing the Notes or to pay any cash payable on future conversions of the Notes as required by the indenture would constitute a default under the indenture. A default under the indenture or the fundamental change itself could, if not cured within applicable time periods, lead to a default under agreements governing our existing senior secured credit facility, and could also lead to a default under agreements governing our future indebtedness. If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the Notes or make cash payments upon conversions thereof.

 

Our senior secured credit facility limits our ability to pay any cash amount upon the conversion or repurchase of the Notes.

 

Our existing senior secured credit facility prohibits us from making any cash payments on the conversion or repurchase of the Notes if an event of default exists under that facility or if, after giving effect to such conversion or repurchase (and any additional indebtedness incurred in connection with such conversion or a repurchase), we would not be in pro forma compliance with our financial covenants under that facility. Any new credit facility that we may enter into in the future may have similar restrictions. Our failure to make cash payments upon the conversion or repurchase of the Notes as required under the terms of the Notes would permit holders of the Notes to accelerate our obligations under the Notes.

 

The conditional conversion feature of the Notes, if triggered, may adversely affect our financial condition and operating results.

 

In the event the conditional conversion feature of the Notes is triggered, holders of notes will be entitled to convert the Notes at any time during specified periods at their option. If one or more holders elect to convert their notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation through the payment of cash, which could adversely affect our liquidity. In addition, even if holders do not elect to convert their notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the Notes as a current rather than long-term liability, which would result in a material reduction of our net working capital.

 

The accounting method for convertible debt securities that may be settled in cash, such as the Notes, could have a material effect on our reported financial results.

 

In May 2008, the Financial Accounting Standards Board (“FASB”) issued FASB Staff Position No. APB 14-1, Accounting for Convertible Debt Instruments That May Be Settled in Cash Upon Conversion (Including Partial Cash Settlement), which has subsequently been codified as Accounting Standards Codification 470-20, Debt with Conversion and Other Options (“ASC 470-20”). Under ASC 470-20, an entity must separately account for the liability and equity components of the convertible debt instruments (such as the Notes) that may be settled entirely or partially in cash upon conversion in a manner that reflects the issuer’s economic interest cost. The effect of ASC 470-20 on the accounting for the Notes is that the equity component is required to be included in the capital in excess of par value section of shareholders’ equity on our consolidated balance sheet, and the value of the equity component would be treated as original issue discount for purposes of accounting for the debt component of the Notes. As a result, we will be required to record a greater amount of non-cash interest expense in current periods presented as a result of the amortization of the discounted carrying value of the Notes to their face amount over the term of the Notes. We will report lower net income in our financial results because ASC 470-20 will require interest to include both the current period’s amortization of the debt discount and the instrument’s coupon interest, which could adversely affect our reported or future financial results, the trading price of our common stock and the trading price of the Notes.

 

 19 

 

 

In addition, under certain circumstances, convertible debt instruments (such as the Notes) that may be settled entirely or partly in cash are currently accounted for utilizing the treasury stock method, the effect of which is that the shares issuable upon conversion of the Notes are not included in the calculation of diluted earnings per share except to the extent that the conversion value of the Notes exceeds their principal amount. Under the treasury stock method, for diluted earnings per share purposes, the transaction is accounted for as if the number of shares of common stock that would be necessary to settle such excess are issued (which is the policy we intend to follow for settling such excess). If we are unable to use the treasury stock method in the future for the shares issuable upon conversion of the Notes, then our diluted earnings per share would be adversely affected.

 

We may need to raise additional capital to fund larger acquisitions and investments in the future which may not be available on acceptable terms or at all.

 

Acquisitions and investments in new products are an important component of our growth strategy. Larger acquisitions and investments will require us to raise additional capital. We may consider issuing additional debt or equity securities in the future to fund potential acquisitions or investments. If we issue equity or convertible debt securities to raise additional funds, our existing stockholders may experience dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of our existing shareholders. If we incur additional debt, it may increase our leverage relative to our earnings or to our equity capitalization, requiring us to pay additional interest expense and potentially lowering our credit ratings. We may not be able to market such issuances on favorable terms, or at all, in which case, we may not be able to develop or enhance our products, execute our business plan, take advantage of future opportunities, or respond to competitive pressures or unanticipated customer requirements.

 

Our acquisition strategy is subject to a number of inherent risks, including, among other things, the risk that our acquisitions may not be successful.

 

We continually seek to expand our business through acquisitions of other companies that complement our own and through joint ventures, licensing agreements and other arrangements. Any decision regarding strategic alternatives would be subject to inherent risks, and we cannot guarantee that we will be able to identify the appropriate opportunities, successfully negotiate economically beneficial terms, successfully integrate any acquired business, retain key employees, or achieve the anticipated synergies or benefits of the strategic alternative selected. Acquisitions can require significant capital resources and divert our management’s attention from our existing business. Additionally, we may issue additional shares in connection with a strategic transaction, thereby diluting the holdings of our existing common shareholders, incur debt or assume liabilities, become subject to litigation, or consume cash, thereby reducing the amount of cash available for other purposes.

 

If we are unable to manage our growth, our business, financial condition, operating results and cash flows could be materially adversely affected.

 

We have experienced rapid growth in the past several years, including the acquisition of membership interests of PACK Pharmaceuticals, LLC in fiscal 2014 and the acquisition of certain generic products and related assets of entities formerly known as Citron Pharma LLC and its affiliate Lucid Pharma in fiscal 2017. This growth has required us to expand, upgrade, and improve our administrative, operational, and management systems, internal controls and resources. Failing to manage growth effectively could have a material adverse effect on our business, financial condition, operating results and cash flows.

 

Any acquisition that we make could result in a substantial charge to our earnings.

 

We have previously incurred charges to our earnings in connection with acquisitions, and may continue to experience charges to our earnings for any acquisitions that we make, including, among other things, contingent consideration and impairment charges. These costs may also include substantial severance and other closure costs associated with eliminating duplicate or discontinued products, employees, operations and facilities. These charges could have a material adverse effect on our results of operations and they could have a material adverse effect on the market price of our common stock.

 

We have significant goodwill and other intangible assets. Consequently, potential impairment of goodwill and other intangibles may significantly impact our profitability.

 

Under U.S. generally accepted accounting principles (“GAAP”), we are required to evaluate goodwill for impairment at least annually. If we determine that the fair value is less than the carrying value, an impairment loss will be recorded in our statement of income. The determination of fair value is a highly subjective exercise and can produce significantly different results based on the assumptions used and methodologies employed. If our projected long-term sales growth rate, profit margins or terminal rate are considerably lower and/or the assumed weighted average cost of capital is considerably higher, future testing may indicate impairment and we would have to record a non-cash goodwill impairment loss in our statement of income.

 

 20 

 

 

Our information technology systems could fail to perform adequately or we may fail to adequately protect such information technology systems against data corruption, cyber-based attacks, or network security breaches.

 

We rely on information technology networks and systems, including the Internet, to process, transmit, and store electronic information. In particular, we depend on our information technology infrastructure to effectively manage its business data, supply chain, logistics, accounting, and other business processes and electronic communications between our personnel and our customers and suppliers. If we do not allocate and effectively manage the resources necessary to build and sustain an appropriate technology infrastructure, our business, financial condition, operating results and cash flows therefore could be materially adversely affected. In addition, security breaches or system failures of this infrastructure can create system disruptions, shutdowns, or unauthorized disclosure of confidential information. If we are unable to prevent such breaches or failures, our operations could be disrupted, or we may suffer financial damage or loss because of lost or misappropriated information.

 

Our business may be adversely affected if we encounter complications in connection with the upgrade and implementation of our enterprise resource planning (“ERP”) system, our information technology systems and infrastructure. Upgrading and integrating our business systems could result in implementation issues and business disruptions.

 

In recent years, we have implemented or planned implementations of a new ERP system at all of our global locations. We also are planning to implement a new ERP system at our Rising subsidiary, which would include recently acquired assets during fiscal 2017. In general, the process of planning and preparing for these types of implementations is extremely complex and we are required to address a number of challenges including data conversion, system cutover and user training. Problems in any of these areas could cause operational problems during implementation including delayed shipments, missed sales, billing and accounting errors and other operational issues. While we have invested significantly in the operation and protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions, or identify breaches in our systems. Prolonged interruptions or significant breaches could materially adversely affect our business, financial condition, operating results and cash flows.

 

Our potential liability arising from our commitment to indemnify our directors, officers and employees could materially adversely affect our business, financial condition, operating results and cash flows.

 

We have committed in our bylaws to indemnify our directors, officers and employees against the reasonable expenses incurred by these persons in connection with any action brought against them in such capacity, except in matters as to which they are adjudged to have breached a duty to us. The maximum potential amount of future payments we could be required to make under this provision is unlimited. While we have ”directors and officers” insurance policies that should cover all or some of this potential exposure, we could be adversely affected if we are required to pay damages or incur legal costs in connection with a claim above our insurance limits.

 

Our business could be materially adversely affected by terrorist activities.

 

Our business depends on the free flow of products and services through the channels of commerce worldwide. Instability due to military, terrorist, political and economic actions in other countries could materially disrupt our overseas operations and export sales. In fiscal years 2017 and 2016, approximately 27% and 32%, respectively of our revenues were attributable to operations conducted abroad and to sales generated from the United States to foreign countries. In addition, in fiscal year 2017, approximately 62% and 17% of our purchases came from Asia and Europe, respectively. In addition, in certain countries where we currently operate or export, intend to operate or export, or intend to expand our operations, we could be subject to other political, military and economic uncertainties, including, among other things, labor unrest, restrictions on transfers of funds and unexpected changes in regulatory environments.

 

We rely heavily on key executives for our financial performance.

 

Our financial performance is highly dependent upon the efforts and abilities of our key executives. The loss of the services of any of our key executives could therefore have a material adverse effect upon our financial position and operating results. We do not maintain “key-man” insurance on any of our key executives.

 

Shortage of qualified and technical personnel in a competitive marketplace may prevent us from growing our business.

 

We may be unable to hire or retain qualified and technical employees and there is substantial competition for highly skilled employees. If we fail to attract and retain key employees, our business could be adversely impacted.

 

 21 

 

 

Litigation could harm our business and our management and financial resources.

 

Substantial, complex or extended litigation could cause us to incur large expenditures and could distract our management. For example, lawsuits by employees, stockholders, collaborators, distributors, customers, or end-users of our products or services could be very costly and substantially disrupt our business. Disputes from time to time with such companies or individuals are not uncommon, and we cannot assure you that we will always be able to resolve such disputes out of court or on favorable terms.

 

The market price of our stock could be volatile.

 

The market price of our common stock has been subject to volatility and may continue to be volatile in the future, due to a variety of factors, including, among other things:

 

·quarterly fluctuations in our operating income and earnings per share results
·technological innovations or new product introductions by us or our competitors
·economic conditions
·tariffs, duties and other trade barriers including, among other things, anti-dumping duties
·disputes concerning patents or proprietary rights
·changes in earnings estimates and market growth rate projections by market research analysts
·any future issuances of our common stock, which may include primary offerings for cash, stock splits, issuances in connection with business acquisitions, restricted stock/units and the grant or exercise of stock options from time to time
·sales of common stock by existing security holders
·loss of key personnel
·securities class actions or other litigation

 

The market price for our common stock may also be affected by our ability to meet analysts' expectations. Any failure to meet such expectations, even slightly, could have an adverse effect on the market price of our common stock. In addition, the stock market is subject to extreme price and volume fluctuations. This volatility has had a significant effect on the market prices of securities issued by many companies for reasons unrelated to the operating performance of these companies.

 

Our stock repurchase program could affect the price of our common stock and increase volatility. The repurchase program may be suspended or terminated at any time, which could result in a decrease in the trading price of our common stock.

 

In May 2017, the Board of Directors of the Company authorized the continuation of the Company’s stock repurchase program, expiring in May 2020. Under the stock repurchase program, the Company is authorized, but not obligated, to purchase up to 5,000 shares of common stock in open market or private transactions, at prices not to exceed the market value of the common stock at the time of such purchase. Repurchases pursuant to our stock repurchase program could affect our stock price and increase the volatility of our common stock. The existence of a stock repurchase program could also potentially reduce the market liquidity for our stock. Although the stock repurchase program is intended to enhance long-term stockholder value, we cannot provide assurance that this will occur. The stock repurchase program may be suspended or terminated at any time, and we have no obligation to repurchase any amount of our common stock under the program.

 

There are inherent uncertainties involved in estimates, judgments and assumptions used in preparing financial statements in accordance with U.S. generally accepted accounting principles. Any changes in the estimates, judgments and assumptions we use could have a material adverse effect on our business, financial condition, operating results and cash flows.

 

The consolidated financial statements included in the periodic reports we file with the SEC are prepared in accordance with GAAP. Preparing financial statements in accordance with GAAP involves making estimates, judgments and assumptions, including accruals for chargebacks, rebates, returns, partnered products and other allowances, that affect reported amounts of assets, liabilities, revenues, expenses and income. Estimates, judgments and assumptions are inherently subject to change, and any such changes could result in corresponding changes to the reported amounts.

 

Changes in accounting standards issued by the Financial Accounting Standards Board (“FASB”) or other standard-setting bodies may adversely affect our financial statements.

 

Our financial statements are subject to the application of U.S. GAAP, which is periodically revised and/or expanded. Accordingly, from time-to-time we are required to adopt new or revised accounting standards issued by recognized authoritative bodies, including the FASB and the SEC. It is possible that future accounting standards we are required to adopt could change the current accounting treatment that we apply to our consolidated financial statements and that such changes could have a material adverse effect on our results of operations and financial condition.

 

 22 

 

 

Failure to maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act could have material adverse effect on our business and stock price.

 

Section 404 of the Sarbanes-Oxley Act requires us to evaluate annually the effectiveness of our internal controls over financial reporting as of the end of each fiscal year and to include a management report assessing the effectiveness of our internal controls over financial reporting in our Annual Report on Form 10-K . Section 404 also requires our independent registered public accounting firm to report on our internal controls over financial reporting. If we fail to maintain the adequacy of our internal controls, we cannot assure you that we will be able to conclude in the future that we have effective internal controls over financial reporting. If we fail to maintain effective internal controls, we might be subject to sanctions or investigation by regulatory authorities, such as the Securities and Exchange Commission or NASDAQ. Any such action could adversely affect our financial results and the market price of our common stock and may also result in delayed filings with the Securities and Exchange Commission.

 

Compliance with changing regulation of corporate governance and public disclosure could result in additional expenses.

 

Complying with changing laws, regulations and standards relating to corporate governance and public disclosure, including, among others, the Sarbanes-Oxley Act of 2002 and new SEC regulations, will require the Company to expend additional resources. We are committed to maintaining the highest standards of corporate governance and public disclosure. As a result, we may be required to continue to invest necessary resources to comply with evolving laws, regulations and standards, and this investment could result in increased expenses and a diversion of management time and attention from revenue-generating activities.

 

The expansion of social media platforms present new risks and challenges, which could have a material adverse effect on our reputation, business, financial condition, operating results and cash flows.

 

The inappropriate use of certain media vehicles could cause brand damage or information leakage or could lead to legal implications from the improper collection and/or dissemination of personally identifiable information. In addition, negative posts or comments about us on any social networking website could seriously damage our reputation. Further, the disclosure of non-public company sensitive information through external media channels could lead to information loss as there might not be structured processes in place to secure and protect information. If our non-public sensitive information is disclosed or if our reputation is seriously damaged through social media, it could have a material adverse effect on our business, financial condition, operating results and cash flows.

 

Item 1B. Unresolved Staff Comments

 

None.

 

Item 2. Properties

 

In March 2010, we purchased a building in Port Washington, New York, which is the site of our global headquarters. We moved our corporate offices into this building in April 2011. Our global headquarters consists of approximately 48,000 gross square feet and is subject to a mortgage, which at June 30, 2017, had an outstanding balance of $2,763.

 

The Company leases approximately 41,000 gross square feet of office and warehouse space in Allendale, New Jersey for its Rising subsidiary. This lease expires in October 2017. At that time, Rising will be relocating to newly leased property in Saddle Brook, New Jersey and leasing approximately 30,000 gross square feet of office space. In addition, in the first quarter of fiscal year 2018, Rising will commence leasing approximately 125,000 gross square feet of warehouse space in Somerset, New Jersey. This building is owned by the former owners of Citron and Lucid. The lease was entered into contemporaneously with the execution of our product purchase agreement with Citron and Lucid.

 

In November 2007, we purchased approximately 2,300 gross square meters of land along with 12,000 gross square feet of office space in Mumbai, India.

 

Arsynco owns a 12-acre parcel in Carlstadt, New Jersey.

 

In November 2004, we purchased approximately 1,300 gross square meters of office space located in Shanghai, China for our sales offices and investment purposes.

 

 23 

 

 

We also lease office space in Hamburg, Germany; Düsseldorf, Germany; Heemskerk, The Netherlands; Paris, France; Lyon, France, Singapore and the Philippines. These offices are used for sales and administrative purposes.

 

We believe that our properties are generally well maintained, in good condition and adequate for our present needs.

 

Item 3. Legal Proceedings

 

We are subject to various claims that have arisen in the normal course of business. We do not know what impact the final resolution of these matters will have on our results of operations in a particular reporting period.

 

In fiscal years 2011, 2009, 2008 and 2007, the Company received letters from the Pulvair Site Group, a group of potentially responsible parties (PRP Group) who are working with the State of Tennessee (the State) to remediate a contaminated property in Tennessee called the Pulvair site. The PRP Group has alleged that Aceto shipped hazardous substances to the site which were released into the environment. The State had begun administrative proceedings against the members of the PRP Group and Aceto with respect to the cleanup of the Pulvair site and the PRP Group has begun to undertake cleanup. The PRP Group is seeking a settlement of approximately $1,700 from the Company for its share to remediate the site contamination. Although the Company acknowledges that it shipped materials to the site for formulation over twenty years ago, the Company believes that the evidence does not show that the hazardous materials sent by Aceto to the site have significantly contributed to the contamination of the environment and thus believes that, at most, it is a de minimis contributor to the site contamination. Accordingly, the Company believes that the settlement offer is unreasonable. Management believes that the ultimate outcome of this matter will not have a material adverse effect on the Company's financial condition or liquidity.

 

In March 2006, Arsynco received notice from the EPA of its status as a PRP under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) for a site described as the Berry’s Creek Study Area (“BCSA”). Arsynco is one of over 150 PRPs which have potential liability for the required investigation and remediation of the site. The estimate of the potential liability is not quantifiable for a number of reasons, including the difficulty in determining the extent of contamination and the length of time remediation may require. In addition, any estimate of liability must also consider the number of other PRPs and their financial strength. In July 2014, Arsynco received notice from the U.S. Department of Interior (“USDOI”) regarding the USDOI’s intent to perform a Natural Resource Damage (NRD) Assessment at the BCSA. Arsynco has to date declined to participate in the development and performance of the NRD assessment process. Based on prior practice in similar situations, it is possible that the State may assert a claim for natural resource damages with respect to the Arsynco site itself, and either the federal government or the State (or both) may assert claims against Arsynco for natural resource damages in connection with Berry's Creek; any such claim with respect to Berry's Creek could also be asserted against the approximately 150 PRPs which the EPA has identified in connection with that site. Any claim for natural resource damages with respect to the Arsynco site itself may also be asserted against BASF, the former owners of the Arsynco property. In September 2012, Arsynco entered into an agreement with three of the other PRPs that had previously been impleaded into New Jersey Department of Environmental Protection, et al. v. Occidental Chemical Corporation, et al., Docket No. ESX-L-9868-05 (the "NJDEP Litigation") and were considering impleading Arsynco into the same proceeding. Arsynco entered into an agreement to avoid impleader. Pursuant to the agreement, Arsynco agreed to (1) a tolling period that would not be included when computing the running of any statute of limitations that might provide a defense to the NJDEP Litigation; (2) the waiver of certain issue preclusion defenses in the NJDEP Litigation; and (3) arbitration of certain potential future liability allocation claims if the other parties to the agreement are barred by a court of competent jurisdiction from proceeding against Arsynco. In July 2015, Arsynco was contacted by an allocation consultant retained by a group of the named PRPs, inviting Arsynco to participate in the allocation among the PRPs’ investigation and remediation costs relating to the BCSA. Arsynco declined that invitation. Since a liability amount cannot be reasonably estimated at this time, no accrual is recorded for these potential future costs. The impact of the resolution of this matter on the Company’s results of operations in a particular reporting period is not currently known.

 

Item 4. Mine Safety Disclosures

 

Not Applicable.

 

 24 

 

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Our common stock is traded on the NASDAQ Global Select Market using the symbol “ACET.” The following table states the fiscal year 2016 and 2017 high and low sales prices of our common stock as reported by the NASDAQ Global Select Market for the periods indicated.

 

   HIGH   LOW 
         
FISCAL YEAR 2016          
First Quarter  $31.75   $21.21 
Second Quarter   32.20    24.27 
Third Quarter   26.90    19.20 
Fourth Quarter   24.84    20.00 
           
FISCAL YEAR 2017          
First Quarter  $25.98   $18.25 
Second Quarter   22.46    15.69 
Third Quarter   22.43    14.32 
Fourth Quarter   16.30    13.50 

 

Cash dividends of $0.065 per common share were paid in September, December, March and June of fiscal year 2017. Cash dividends of $0.06 per common share were paid in September, December, March and June of fiscal years 2016 and 2015.

 

As of August 21, 2017, there were 226 holders of record of our common stock.

 

29,365,771 shares of our common stock were held by the nominee of the Depository Trust Company, the country's principal central depository. For purposes of determining the number of owners of our common stock, those shares are considered to be owned by one holder. Additional individual holdings in street name result in a sizable number of beneficial owners being represented on our records as owned by various banks and stockbrokers.

 

 25 

 

 

Performance Graph

 

The following graph compares on a cumulative basis the yearly percentage change, assuming dividend reinvestment, over the last five fiscal years in (a) the total shareholder return on our common stock with (b) the total return on the Standard & Poor’s 500 Index, (c) the total return of our Prior Peer Group and (d) total return of our Current Peer Group. We have decided to change our peer group comparison to a new Peer Group (Current Peer Group) consisting of 15 companies selected by us to reflect our current business strategy of focusing more on the end market pharmaceutical space. The Current Peer group companies included: Akorn, Albany Molecular Research, Inc., American Vanguard Corporation, Amphastar Pharmaceuticals, ANI Pharmaceuticals, Cambrex Corporation, Depomed, Impax Laboratories, Inc., Innophos Holdings, Inc., Lannett Company, Inc., Lawson Products, Inc., Prestige Brand Holdings, Inc., Quaker Chemical Corporation, Sagent Pharmaceuticals, Inc. and Usana Health Sciences, Inc. We believe that the companies included in the Current Peer Group are more comparable to Aceto and reflect Aceto’s business strategy, placing greater emphasis on companies whose primary business is tied to health care. Going forward, we expect to include the Current Peer Group and not the Prior Peer Group.

 

The following graph assumes that $100 had been invested in each of the Company, the Standard & Poor’s 500 Index, the Prior Peer Group and the Current Peer Group on June 30, 2012. The stock price performance included in this graph is not necessarily indicative of future stock price performance.

 

 

ASSUMES $100 INVESTED ON JUNE 30, 2012

ASSUMES DIVIDEND REINVESTMENT

FISCAL YEAR ENDING JUNE 30, 2017

 

  Aceto Corporation  S&P 500 Index  Prior Peer Group  Current Peer Group
June 30, 2012 100  100  100  100
June 30, 2013 157  121  131  119
June 30, 2014 208  150  166  184
June 30, 2015 285  161  205  250
June 30, 2016 256  168  182  198
June 30, 2017 183  198  203  206

 

 26 

 

 

Item 6. Selected Financial Data

(In thousands, except per-share amounts)

 

Fiscal years ended June 30,  2017   2016   2015   2014   2013 
                     
Net sales  $638,318   $558,524   $546,951   $510,179   $499,690 
Operating income   30,554    58,028    56,333    44,272    34,416 
Net income   11,376    34,766    33,483    29,000    22,328 
                          
At year end                         
                          
Working capital  $251,355   $253,755   $185,310   $157,831   $128,393 
Total assets   1,040,790    540,778    489,774    467,984    323,430 
Long-term liabilities (including long-term debt)   410,313    137,430    110,563    115,877    38,883 
Shareholders’ equity   407,672    304,442    254,211    233,584    194,640 
                          
Income per common share                         
                          
Basic income per common share from net income  $0.35   $1.19   $1.17   $1.04   $0.83 
Diluted income per common share from net income  $0.35   $1.18   $1.14   $1.02   $0.81 
Cash dividends per common share  $0.26   $0.24   $0.24   $0.24   $0.22 

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Executive Summary

 

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is intended to provide the readers of our financial statements with a narrative discussion about our business. The MD&A is provided as a supplement to and should be read in conjunction with our financial statements and the accompanying notes.

 

We are reporting net sales of $638,318 for the year ended June 30, 2017, which represents a 14.3% increase from the $558,524 reported in the comparable prior year. Gross profit for the year ended June 30, 2017 was $140,792 and our gross margin was 22.1% as compared to gross profit of $142,785 and gross margin of 25.6% in the comparable prior year. Our selling, general and administrative costs (“SG&A”) for the year ended June 30, 2017 increased to $102,340 from $76,820 which we reported in the prior year. Our net income decreased to $11,376, or $0.35 per diluted share, compared to net income of $34,766, or $1.18 per diluted share for the prior year.

 

Our financial position as of June 30, 2017, remains strong, as we had cash, cash equivalents and short-term investments of $57,726, working capital of $251,355 and shareholders’ equity of $407,672. Shareholders’ equity at June 30, 2017 represents a $103,230 increase over our shareholders’ equity at June 30, 2016, principally reflecting net assets acquired in our product purchase agreement with Lucid and Citron and our profitability during the most recently completed fiscal year.

 

Our business is separated into three principal segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals.

 

Products that fall within the Human Health segment include finished dosage form generic drugs and nutraceutical products. Aceto sells generic prescription products and over-the-counter pharmaceutical products to leading wholesalers, chain drug stores, distributors and mass merchandisers. On December 21, 2016, Rising completed the acquisition of certain generic products and related assets of entities formerly known as Citron Pharma LLC (“Citron”), and its affiliate Lucid Pharma LLC (“Lucid”). Rising formed two subsidiaries to consummate the product acquisition – Rising Health, LLC (which acquired certain products and related assets of Citron) and Acetris Health, LLC (which acquired certain products and related assets of Lucid). Citron is a privately-held New Jersey-based pharmaceutical company focused on developing and marketing generic pharmaceutical products in partnership with leading generic pharmaceutical manufacturers based in India and the U.S. Lucid is a privately-held New Jersey-based generic pharmaceutical distributor specializing in providing cost-effective products to various agencies of the U.S. Federal Government including the Veterans Administration and the Defense Logistics Agency. Lucid services 18 national contracts with the Federal Government, nearly all of which have 5-year terms.

 

 27 

 

 

Aceto and Rising Health possess complementary asset-light business models, drug development and manufacturing partnerships and product portfolios. We believe that, consistent with our strategy of expanding our portfolio of finished dosage form generic products through product development partnerships and acquisitions of late stage assets, abbreviated new drug applications (“ANDAs”) and complementary generic drug businesses, this product acquisition significantly expanded our roster of commercialized products and pipeline of products under development. In addition, we believe that this transaction greatly enhanced our size and stature within the generic pharmaceutical industry, expanded our partnership network and offers us opportunities to realize meaningful cost and tax efficiencies, as well as representing an integral component of Aceto's continued strategy to become a Human Health oriented company.

 

Aceto supplies the raw materials used in the production of nutritional and packaged dietary supplements, including vitamins, amino acids, iron compounds and biochemicals used in pharmaceutical and nutritional preparations.

 

The Pharmaceutical Ingredients segment has two product groups: Active Pharmaceutical Ingredients (APIs) and Pharmaceutical Intermediates.

 

We supply APIs to many of the major generic drug companies, who we believe view Aceto as a valued partner in their effort to develop and market generic drugs. The process of introducing a new API from pipeline to market spans a number of years and begins with Aceto partnering with a generic pharmaceutical manufacturer and jointly selecting an API, several years before the expiration of a composition of matter patent, for future genericizing. We then identify the appropriate supplier, and concurrently utilizing our global technical network, work to ensure they meet standards of quality to comply with regulations. Our client, the generic pharmaceutical company, will submit the ANDA for U.S. Food and Drug Administration (“FDA”) approval or European-equivalent approval. The introduction of the API to market occurs after all the development testing has been completed and the ANDA or European-equivalent is approved and the patent expires or is deemed invalid. Aceto, at all times, has a pipeline of APIs at various stages of development both in the United States and Europe. Additionally, as the pressure to lower the overall cost of healthcare increases, Aceto has focused on, and works very closely with our customers to develop new API opportunities to provide alternative, more economical, second-source options for existing generic drugs. By leveraging our worldwide sourcing, regulatory and quality assurance capabilities, we provide to generic drug manufacturers an alternative, economical source for existing API products.

 

Aceto has long been a supplier of pharmaceutical intermediates, the complex chemical compounds that are the building blocks used in producing APIs. These are the critical components of all drugs, whether they are already on the market or currently undergoing clinical trials. Faced with significant economic pressures as well as ever-increasing regulatory barriers, the innovative drug companies look to Aceto as a source for high quality intermediates.

 

Aceto employs, on occasion, the same second source strategy for our pharmaceutical intermediates business that we use in our API business. Historically, pharmaceutical manufacturers have had one source for the intermediates needed to produce their products. Utilizing our global sourcing, regulatory support and quality assurance network, Aceto works with the large, global pharmaceutical companies, sourcing lower cost, quality pharmaceutical intermediates that will meet the same high level standards that their current commercial products adhere to.

 

The Performance Chemicals segment includes specialty chemicals and agricultural protection products.

 

Aceto is a major supplier to many different industrial segments providing chemicals used in the manufacture of plastics, surface coatings, cosmetics and personal care, textiles, fuels and lubricants. The paint and coatings industry produces products that bring color, texture, and protection to houses, furniture, packaging, paper, and durable goods. Many of today's coatings are eco-friendly, by allowing inks and coatings to be cured by ultraviolet light instead of solvents, or allowing power coatings to be cured without solvents. These growing technologies are critical in protecting and enhancing the world's ecology and Aceto is focused on supplying the specialty additives that make modern coating techniques possible.

 

The chemistry that makes much of the modern world possible is often done by building up simple molecules to sophisticated compounds in step-by-step chemical processes. The products that are incorporated in each step are known as intermediates and they can be as varied as the end uses they serve, such as crop protection products, dyes and pigments, textiles, fuel additives, electronics - essentially all things chemical.

 

 28 

 

 

Aceto provides various specialty chemicals for the food, flavor, fragrance, paper and film industries. Aceto’s raw materials are also used in sophisticated technology products, such as high-end electronic parts used for photo tooling, circuit boards, production of computer chips, and in the production of many of today's modern gadgets.

 

Aceto’s agricultural protection products include herbicides, fungicides and insecticides, which control weed growth as well as the spread of insects and microorganisms that can severely damage plant growth. One of Aceto's most widely used agricultural protection products is a sprout inhibitor that extends the storage life of potatoes. Utilizing our global sourcing and regulatory capabilities, we identify and qualify manufacturers either producing the product or with knowledge of the chemistry necessary to produce the product, and then file an application with the U.S. EPA for a product registration. Aceto has an ongoing working relationship with manufacturers in China and India to determine which of the non-patented or generic, agricultural protection products they produce can be effectively marketed in the Western world. We have successfully brought numerous products to market. We have a strong pipeline, which includes future additions to our product portfolio. The combination of our global sourcing and regulatory capabilities makes the generic agricultural market a niche for us and we will continue to offer new product additions in this market.

 

We believe our main business strengths are sourcing, regulatory support, quality assurance and marketing and distribution. We distribute more than 1,100 chemical compounds used principally as finished products or raw materials in the pharmaceutical, nutraceutical, agricultural, coatings and industrial chemical industries. With business operations in ten countries, we believe that our global reach is distinctive in the industry, enabling us to source and supply quality products on a worldwide basis. Leveraging local professionals, we source more than two-thirds of our products from Asia, buying from approximately 500 companies in China and 200 in India.

 

In this MD&A, we explain our general financial condition and results of operations, including, among other things, the following:

 

·factors that affect our business
·our earnings and costs in the periods presented
·changes in earnings and costs between periods
·sources of earnings
·the impact of these factors on our overall financial condition

 

As you read this MD&A, refer to the accompanying consolidated statements of income, which present the results of our operations for the three years ended June 30, 2017. We analyze and explain the differences between periods in the specific line items of the consolidated statements of income.

 

Critical Accounting Estimates and Policies

 

This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. In preparing these financial statements, we were required to make estimates and assumptions that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We regularly evaluate our estimates including those related to allowances for bad debts, partnered products, inventories, goodwill and indefinite-life intangible assets, long-lived assets, environmental and other contingencies, income taxes, stock-based compensation and purchase price allocation. We base our estimates on various factors, including historical experience, advice from outside subject-matter experts, and various assumptions that we believe to be reasonable under the circumstances, which together form the basis for our making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Since June 30, 2017, there have been no significant changes to the assumptions and estimates related to those critical accounting estimates and policies.

 

We believe the following critical accounting policies affected our more significant judgments and estimates used in preparing these consolidated financial statements.

 

Revenue Recognition

 

We recognize revenue from sales of any product when it is shipped and title and risk of loss pass to the customer. We have no acceptance or other post-shipment obligations and we do not offer product warranties or services to our customers.

 

Sales are recorded net of estimated returns of damaged goods from customers, which historically have been immaterial, and sales incentives offered to customers. Sales incentives include volume incentive rebates. We record volume incentive rebates based on the underlying revenue transactions that result in progress by the customer in earning the rebate.

 

 29 

 

 

The Company has arrangements with various third parties, such as drug store chains and managed care organizations, establishing prices for its finished dosage form generics. While these arrangements are made between Aceto and its customers, the customers independently select a wholesaler from which they purchase the products. Alternatively, certain wholesalers may enter into agreements with the customers, with the Company’s concurrence, which establishes the pricing for certain products which the wholesalers provide. Upon each sale of finished dosage form generics, estimates of chargebacks, rebates, returns, government reimbursed rebates, sales discounts and other adjustments are made. These estimates are based on historical experience, future expectations, contractual arrangements with wholesalers and indirect customers, and other factors known to management at the time of accrual. These estimates are recorded as reductions to gross revenues, with corresponding adjustments either as a reduction of accounts receivable or as a liability for price concessions.

 

Under certain arrangements, Aceto will issue a credit (referred to as a “chargeback”) to the wholesaler for the difference between the invoice price to the wholesaler and the customer’s contract price. As sales to the large wholesale customers increase or decrease, the reserve for chargebacks will also generally increase or decrease. The provision for chargebacks varies in relation to changes in sales volume, product mix, pricing and the level of inventory at the wholesalers. The Company continually monitors the reserve for chargebacks and makes adjustments when management believes that expected chargebacks may differ from the actual chargeback reserve.

 

The Company estimates its provision for returns of finished dosage generics based on historical experience, product expiration dates, changes to business practices, credit terms and any extenuating circumstances known to management. While historical experience has allowed for reasonable estimations in the past, future returns may or may not follow historical trends. The Company continually monitors the reserve for returns and makes adjustments when management believes that actual product returns may differ from the established reserve. Generally, the reserve for returns increases as net sales increase.

 

Government rebate accruals are based on estimated payments due to governmental agencies for purchases made by third parties under various governmental programs. Other rebates are offered to the Company’s key chain drug store, distributor and wholesaler customers to promote customer loyalty and increase product sales. These rebate programs provide customers with credits upon attainment of pre-established volumes or attainment of net sales milestones for a specified period. Other promotional programs are incentive programs offered to the customers. The Company provides a provision for government reimbursed rebates and other rebates at the time of sale based on contracted rates and historical redemption rates. Assumptions used to establish the provision include level of customer inventories, contract sales mix and average contract pricing. Aceto regularly reviews the information related to these estimates and adjusts the provision accordingly.

 

Sales discount accruals are based on payment terms extended to customers.

 

Credits issued during a given period represent cash payments or credit memos issued to the Company’s customers as settlement for the related reserve. Management has the experience and access to relevant information that it believes is necessary to reasonably estimate the amounts of such deductions from gross revenues. The Company regularly reviews the information related to these estimates and adjusts its reserves accordingly, if and when actual experience differs from previous estimates.

 

Allowance for Doubtful Accounts

 

We maintain allowances for doubtful accounts relating to estimated losses resulting from customers being unable to make required payments. Allowances for doubtful accounts are based on historical experience and known factors regarding specific customers and the industries in which those customers operate. If the financial condition of our customers were to deteriorate, resulting in their ability to make payments being impaired, additional allowances would be required.

 

Royalty Income

 

We have royalty agreements on certain products where third party pharmaceutical and agricultural protection companies market such products. We earn and collect royalty income based on percentages of net profits as defined in those agreements. Royalty income is included in net sales in our Consolidated Statements of Income.

 

 30 

 

 

Partnered Products

 

The Company has various products that are subject to one of two types of collaborative arrangements with certain pharmaceutical companies. One type of arrangement relates to the Company’s finished dosage form generics business acting strictly as a distributor and purchasing products at arm’s length; in that type of arrangement, there is no profit sharing element. The second type of collaborative arrangement results in a profit sharing agreement between the Company and a developer and/or manufacturer of a finished dosage form generic drug. Both types of collaborative arrangements are conducted in the ordinary course of business. The nature and purpose of both of these arrangements is for the Company to act as a distributor of finished dose products to its customers.  Under these arrangements, the Company maintains distribution rights with respect to specific drugs within the U.S. marketplace.  Generally, the distribution rights are exclusive rights in the territory.  In certain arrangements, the Company is required to maintain service level minimums including, but not limited to, market share and purchase levels, in order to preserve the exclusive rights.  The Company’s accounting policy with respect to these collaborative arrangements calls for the Company to present the sales and associated costs on a gross basis, with the amounts of the shared profits earned by the partners on sales of these products, if applicable, included in cost of sales in the consolidated statements of income. The shared profits are settled on a quarterly basis. For each of the fiscal years 2017, 2016 and 2015, there was approximately $54,454, $41,036 and $51,352 respectively, of shared profits included in cost of sales, related to these types of collaborative arrangements. In the case of a collaborative arrangement where the Company solely acts as a distributor and purchases product at arm’s length, the costs of those purchases are included as a cost of sales similar to any other purchase arrangement.

 

Inventories

 

Inventories, which consist principally of finished goods, are stated at the lower of cost (first-in first-out method) and net realizable value. We write down our inventories for estimated excess and obsolete goods by an amount equal to the difference between the carrying cost of the inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. A significant sudden increase in demand for our products could result in a short-term increase in the cost of inventory purchases, while a significant decrease in demand could result in an increase in the excess inventory quantities on-hand. Additionally, we may overestimate or underestimate the demand for our products which would result in our understating or overstating, respectively, the write-down required for excess and obsolete inventory. Although we make every effort to ensure the accuracy of our forecasts of future product demand, any significant unanticipated changes in demand could have a significant impact on the value of our inventory and reported operating results.

 

Goodwill and Other Indefinite-Lived Intangible Assets

 

Goodwill is calculated as the excess of the cost of purchased businesses over the value of their underlying net assets. Other indefinite-lived intangible assets principally consist of trademarks. Goodwill and other indefinite-lived intangible assets are not amortized.

 

In accordance with GAAP, we test goodwill and other indefinite-lived intangible assets for impairment on at least an annual basis. To determine the fair value of these intangible assets, we use many assumptions and estimates that directly impact the results of the testing. In making these assumptions and estimates, we use industry-accepted valuation models and appropriate market participant assumptions that are reviewed and approved by various levels of management. If our estimates or our related assumptions change in the future, we may be required to record impairment charges for these assets.

 

Long-Lived Assets

 

In accordance with GAAP, long-lived assets and certain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Identifiable intangible assets principally consist of customer relationships, product rights and related intangibles, EPA registrations and related data, patent license, and technology-based intangibles. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability of assets held for sale is measured by comparing the carrying amount of the assets to their estimated fair value. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceed the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.

 

Environmental and Other Contingencies

 

We establish accrued liabilities for environmental matters and other contingencies when it is probable that a liability has been incurred and the amount of the liability can reasonably be estimated. If the contingency is resolved for an amount greater or less than the accrual, or our share of the contingency increases or decreases, or other assumptions relevant to the development of the estimate were to change, we would recognize an additional expense or benefit in income in the period that the determination was made.

 

 31 

 

 

Taxes

 

We account for income taxes in accordance with GAAP. GAAP establishes financial accounting and reporting standards for the effects of income taxes that result from an enterprise’s activities during the current and preceding years. It requires an asset-and-liability approach to financial accounting and reporting of income taxes.

 

As of June 30, 2017, we had current net deferred tax assets of $546 and non-current net deferred tax assets of $12,128. These net deferred tax assets have been recorded based on our projecting that we will have sufficient future earnings to realize these assets, and the net deferred tax assets have been provided for at currently enacted income tax rates. If we determine that we will not be able to realize a deferred tax asset, an adjustment to the deferred tax asset could result in a reduction of net income at that time.

 

Deferred taxes have not been provided for on the majority of undistributed earnings of foreign subsidiaries since substantially all of these earnings are expected to be indefinitely reinvested in our foreign operations. A deferred tax liability is recognized when we expect that we will recover those undistributed earnings in a taxable manner, such as through receipt of dividends or sale of the investments. The Company intends to indefinitely reinvest any undistributed earnings and has no plan for further repatriation. Determination of the amount of the unrecognized U.S. income tax liability on undistributed earnings is not practical because of the complexities of the hypothetical calculation. In addition, we believe unrecognized foreign tax credit carryforwards would be available to reduce a portion of such U.S. tax liability.

 

Stock-based Compensation

 

In accordance with GAAP, we are required to record the fair value of stock-based compensation awards as an expense.  All restricted stock grants include a service requirement for vesting. We have also granted restricted stock units that include either a performance or market condition. The fair value of restricted stock unit with either solely a service requirement or with the combination of service and performance requirements is based on the closing fair market value of our common stock on the date of grant. The fair value of market condition-based awards is estimated at the date of grant using a binomial lattice model or Monte Carlo Simulation. All models incorporate various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the awards. Share-based compensation expense is recognized on a straight-line basis over the service period or over our best estimate of the period over which the performance condition will be met, as applicable.

 

 32 

 

 

Results of Operations

 

Fiscal Year Ended June 30, 2017 Compared to Fiscal Year Ended June 30, 2016

 

  

Net Sales by Segment

Year ended June 30,

 
                   Comparison 2017 
   2017   2016   Over/(Under) 2016 
       % of       % of   $   % 
Segment  Net sales   Total   Net sales   Total   Change   Change 
                         
Human Health  $315,395    49.4%  $228,035    40.8%  $87,360    38.3%
Pharmaceutical Ingredients   157,445    24.7    161,011    28.8    (3,566)   (2.2)
Performance Chemicals   165,478    25.9    169,478    30.4    (4,000)   (2.4)
                               
Net sales  $638,318    100.0%  $558,524    100.0%  $79,794    14.3%

 

  

Gross Profit by Segment

Year ended June 30,

 
                   Comparison 2017 
   2017   2016   Over/(Under) 2016 
   Gross   % of   Gross   % of   $   % 
Segment  Profit   Sales   Profit   Sales   Change   Change 
                         
Human Health  $78,109    24.8%  $77,880    34.2%  $229    0.3%
Pharmaceutical Ingredients   25,474    16.2    28,752    17.9    (3,278)   (11.4)
Performance Chemicals   37,209    22.5    36,153    21.3    1,056    2.9 
                               
Gross profit  $140,792    22.1%  $142,785    25.6%  $(1,993)   (1.4)%

 

 33 

 

 

Net Sales

 

Net sales increased $79,794 or 14.3%, to $638,318 for the year ended June 30, 2017, compared with $558,524 for the prior year. We reported sales increases in our Human Health segment and decreases in our Pharmaceutical Ingredients and Performance Chemicals segment.

 

Human Health

 

Products that fall within the Human Health segment include finished dosage form generic drugs and nutraceutical products. Net sales for the Human Health segment increased by $87,360 for the year ended June 30, 2017, to $315,395, which represents a 38.3% increase over net sales of $228,035 for the prior year. The primary reason for the increase is due to the acquisition of certain products and related assets of Citron and Lucid. Sales from the product acquisition of $122,118 are included in the year ended June 30, 2017. This increase was offset by a decline in sales of Rising products of $30,585 and a decline of $4,173 in sales of nutritional products. The decrease in Rising sales was primarily driven by increased competition, price erosion on certain products in our generic drugs portfolio and delays in contribution from new product launches. We believe this industry wide pricing pressure on the generic business will continue in the near term. However, we have approximately 15 - 20 FDA approved products that we are preparing to launch in the near future, which we believe should mitigate this pricing pressure. The drop in nutraceutical sales primarily occurred abroad, specifically at our German subsidiary.

 

Pharmaceutical Ingredients

 

Net sales for the Pharmaceutical Ingredients segment decreased by $3,566 for the year ended June 30, 2017, to $157,445, which represents a 2.2% decrease from net sales of $161,011 for the prior year. The decrease in sales for this segment was due primarily to a decline in sales of domestic APIs of $2,750, mainly due to reduced orders of a customer-launched API.

 

Performance Chemicals

 

Net sales for the Performance Chemicals segment decreased to $165,478 for the year ended June 30, 2017, representing a decrease of $4,000 or 2.4%, from net sales of $169,478 for the prior year. Performance Chemicals sales were impacted by a $4,696 drop in sales of our agricultural protection products, predominantly from a decline in sales of a wide-range insecticide used on various crops including cereals, citrus, cotton, grapes, ornamental grasses and vegetables.

 

Gross Profit

 

Gross profit decreased $1,993 or 1.4% to $140,792 (22.1% of net sales) for the year ended June 30, 2017, as compared to $142,785 (25.6% of net sales) for the prior year.

 

Human Health

 

Human Health segment’s gross profit of $78,109 for the year ended June 30, 2017 increased $229, or .3%, over the prior year. The gross margin of 24.8% was lower than the prior year’s gross margin of 34.2%. The increase in Human Health’s gross profit was partially related to gross profit of $26,373 on sales from the product acquisition, which is included in the twelve months ended June 30, 2017. This increase was offset by the decline of gross profit and gross margin on Rising sales, primarily driven by increased competition on certain products. In addition, gross profit and gross margin on Rising sales have experienced an unfavorable product mix due to price erosion on certain products, as well as an unfavorable product mix and back orders on certain other products. In addition, $4,502 of step-up in the fair value of the acquired inventory related to the product acquisition was amortized in fiscal 2017.

 

Pharmaceutical Ingredients

 

Gross profit for the year ended June 30, 2017 for the Pharmaceutical Ingredients business decreased by $3,278 or 11.4% over the prior year. The gross margin of 16.2% for the year ended June 30, 2017 was also lower than the prior year’s gross margin of 17.9%. The decrease in gross profit and gross margin was predominantly the result of the decrease in the sales volume of APIs sold both domestically and abroad, as well as a drop in reorders of a certain API which typically yields a significantly higher gross margin

 

 34 

 

 

Performance Chemicals

 

Gross profit for the Performance Chemicals segment increased to $37,209 for the year ended June 30, 2017, versus $36,153 for the prior year, an increase of $1,056, or 2.9%. The gross margin at 22.5% for the year ended June 30, 2017 was also higher than the prior year’s gross margin of 21.3%. The increase in gross profit and gross margin was due to a $370 rise in gross profit for the Agricultural Protection Products business, as well as an increase of $686 of gross profit on sales of specialty chemicals. In addition, both gross profit and gross margin of the Specialty Chemicals business were favorably impacted by the overall decline in costs of products sourced from China, due to the devaluation of the Chinese Renminbi.

 

Selling, General and Administrative Expenses

 

SG&A increased $25,520, or 33.2%, to $102,340 for the year ended June 30, 2017 compared to $76,820 for the prior year. As a percentage of sales, SG&A increased from 13.8% to 16.0% for the year ended June 30, 2017 versus the prior year. SG&A for the current year included $8,818 of transaction costs related to the product purchase agreement associated with Citron and Lucid, as discussed in Note 3 of the consolidated financial statements, as well as $11,517 of amortization expense associated with the purchased intangible assets and $2,030 of consulting services provided by former Citron and Lucid employees in connection with the Transition Services Agreement entered into in connection with the product purchase agreement. The increase in SG&A is also due in part to a $1,528 rise in payroll, fringe benefits, and stock-based compensation expense, reflecting the hiring of certain key management personnel as well as annual merit increases. SG&A also increased due to $552 of separation costs related to the integration of the product acquisition and a $903 environmental remediation charge related to Arsynco. SG&A for the prior year included $1,313 environmental remediation charge related to Arsynco and $1,074 reversal of contingent consideration.

 

Research and Development Expenses

 

Research and development expenses (“R&D”) decreased $39 or 0.5% to $7,898 for the year ended June 30, 2017 compared to $7,937 for the prior year. R&D expenses represent investment in our generic finished dosage form product pipeline. The majority of the R&D expenses are milestone based, which will likely cause fluctuation from quarter to quarter.

 

Operating Income

 

Fiscal 2017 operating income was $30,554 compared to $58,028 in the prior year, a decrease of $27,474 or 47.3%.

 

Interest Expense

 

Interest expense was $15,770 for the year ended June 30, 2017, an increase of $8,773 from the prior year. The increase was primarily due to interest expense associated with the Second Amended and Restated Credit Agreement, which was entered into on December 21, 2016 to help fund our product acquisition, as well as amortization of the debt discount and amortization of debt issuance costs associated with the offering of Convertible Senior Notes during fiscal 2016.

 

Provision for Income Taxes

 

The effective tax rate for the year ended June 30, 2017 decreased to 34.5% compared to 35.4% for the prior year. The decrease in the effective tax rate was due to the mix of profits from the lower tax rate jurisdictions of Europe and Asia compared to the Federal tax rate in the United States.

 

 35 

 

 

Results of Operations

 

Fiscal Year Ended June 30, 2016 Compared to Fiscal Year Ended June 30, 2015

 

  

Net Sales by Segment

Year ended June 30,

 
                     
                   Comparison 2016 
   2016   2015   Over/(Under) 2015 
       % of       % of   $   % 
Segment  Net sales   Total   Net sales   Total   Change   Change 
                               
Human Health  $228,035    40.8%  $225,263    41.2%  $2,772    1.2%
Pharmaceutical Ingredients   161,011    28.8    149,296    27.3    11,715    7.8 
Performance Chemicals   169,478    30.4    172,392    31.5    (2,914)   (1.7)
                               
Net sales  $558,524    100.0%  $546,951    100.0%  $11,573    2.1%

 

  

Gross Profit by Segment

Year ended June 30,

 
                         
                   Comparison 2016 
   2016   2015   Over/(Under) 2015 
   Gross   % of   Gross   % of   $   % 
Segment  Profit   Sales   Profit   Sales   Change   Change 
                               
Human Health  $77,880    34.2%  $75,749    33.6%  $2,131    2.8%
Pharmaceutical Ingredients   28,752    17.9    26,683    17.9    2,069    7.8 
Performance Chemicals   36,153    21.3    33,002    19.1    3,151    9.5 
                               
Gross profit  $142,785    25.6%  $135,434    24.8%  $7,351    5.4%

 

 36 

 

 

Net Sales

 

Net sales increased $11,573 or 2.1%, to $558,524 for the year ended June 30, 2016, compared with $546,951 for the prior year. We reported sales increases in our Human Health and Pharmaceutical Ingredients segments and a decrease in the Performance Chemicals segment.

 

Human Health

 

Products that fall within the Human Health segment include finished dosage form generic drugs and nutraceutical products. Net sales for the Human Health segment increased by $2,772 for the year ended June 30, 2016, to $228,035, which represents a 1.2% increase over net sales of $225,263 for the prior year, largely due to an increase in sales of Rising products of $2,951. The increase in Rising sales was primarily driven by price increases experienced in the prior year on certain products, partially offset by increased competition on certain products in our generic drugs portfolio.

 

Pharmaceutical Ingredients

 

Net sales for the Pharmaceutical Ingredients segment increased by $11,715 for the year ended June 30, 2016, to $161,011, which represents a 7.8% increase from net sales of $149,296 for the prior year. The increase in sales for this segment was due in part to a $14,479 rise in sales volume of APIs sold abroad, specifically by our Singapore and German operations. This increase was partially offset by a decline of $3,560 in sales of intermediates, which represent key components used in the manufacture of certain drug products. The primary reasons for the decline in intermediates was a reduction of demand and a delay in timing of orders for several products that are sold domestically.

 

Performance Chemicals

 

Net sales for the Performance Chemicals segment decreased to $169,478 for the year ended June 30, 2016, representing a decrease of $2,914 or 1.7%, from net sales of $172,392 for the prior year. The primary reason for the decrease in net sales for Performance Chemicals was a decline of $13,775 in domestic sales of products sold by our Specialty Chemicals business. This decrease in domestic specialty chemicals sales included an $8,833 drop in sales of agricultural, dye, pigment and miscellaneous intermediates, as well as a $1,553 decline in sales of polymer additives and a $1,915 decrease in products sold to the food, beverage and cosmetic industries. In addition, overall sales of Specialty Chemicals were down due to the government devaluation of the Chinese Renminbi, as well as the severe drop in oil prices, resulting in reduced customer pricing. The decreases in the Specialty Chemicals business were partially offset by an increase of $8,941 in sales of our agricultural protection products, predominantly from an increase in sales of a wide-range insecticide that is used on various crops including cereals, citrus, cotton, grapes, ornamental grasses and vegetables, as well as an increase in sales volume of our sprout inhibitor products, which extends the storage life of potatoes and an herbicide used to control sedge on rice.

 

Gross Profit

 

Gross profit increased $7,351 or 5.4% to $142,785 (25.6% of net sales) for the year ended June 30, 2016, as compared to $135,434 (24.8% of net sales) for the prior year.

 

Human Health

 

Human Health segment’s gross profit of $77,880 for the year ended June 30, 2016 increased $2,131, or 2.8%, over the prior year. The gross margin of 34.2% was higher than the prior year’s gross margin of 33.6%. The increase in gross profit and gross margin in the Human Health segment predominantly relates to price increases experienced in the prior year on certain Rising products. Overall, our Human Health segment experienced gross profit pressure, including increased chargebacks, from the consolidation of wholesalers with retail drug chains.

 

Pharmaceutical Ingredients

 

Gross profit for the year ended June 30, 2016 for the Pharmaceutical Ingredients business increased by $2,069 or 7.8% over the prior year. The gross margin of 17.9% was unchanged from the prior year. The increase in gross profit was predominantly the result of the increase in the sales volume of APIs sold abroad, specifically by our Singapore and German operations, as well as favorable product mix on sales of domestic APIs.

 

 37 

 

 

Performance Chemicals

 

Gross profit for the Performance Chemicals segment increased to $36,153 for the year ended June 30, 2016, versus $33,002 for the prior year, an increase of $3,151, or 9.5%. The gross margin at 21.3% for the year ended June 30, 2016 was also higher than the prior year’s gross margin of 19.1%. The increase in gross profit was due to $2,292 rise in gross profit for the Agricultural Protection Products business, primarily due to increased sales volume of a wide-range insecticide that is used on various crops, a sprout inhibitor that extends the storage life of potatoes, as well as an herbicide used to control sedge on rice. The Performance Chemicals segment also experienced favorable gross margin impact in the Specialty Chemicals business resulting in overall increased gross profit of $859, due to a decline in sales of lower margin products, as well as $376 of duty refunds related to the Generalized System of Preferences, a tariff system which expired in July 2013 and was not renewed until July 2015. In addition, both gross profit and gross margin of the Specialty Chemicals business were favorably impacted by the overall decline in costs of products sourced from China, due to the devaluation of the Chinese Renminbi.

 

Selling, General and Administrative Expenses

 

SG&A increased $3,661, or 5.0%, to $76,820 for the year ended June 30, 2016 compared to $73,159 for the prior year. As a percentage of sales, SG&A increased from 13.4% to 13.8% for the year ended June 30, 2016 versus the prior year. The increase in SG&A is primarily due to increased stock-based compensation expense of $2,182. SG&A for the year ended June 30, 2016 also included $1,213 of transaction costs related to a potential acquisition of a target company that we evaluated during the year but ultimately determined not to pursue, as well as a $1,313 environmental remediation charge related to Arsynco. These increases in SG&A were offset in part by an $833 reversal of contingent consideration related to the PACK acquisition and a $241 reversal of contingent consideration related to the acquisition of a company in France, due to management’s evaluation and assessment of the potential earnout amounts defined in the purchase agreements. SG&A for the prior year included a $1,618 environmental remediation charge related to Arsynco and $3,468 reversal of contingent consideration related to the PACK acquisition.

 

Research and Development Expenses

 

Research and development expenses (“R&D”) increased $1,995 or 33.6% to $7,937 for the year ended June 30, 2016 compared to $5,942 for the prior year. R&D expenses represent investment in our generic finished dosage form product pipeline. The majority of the R&D expenses are milestone based, which will likely cause fluctuation from quarter to quarter.

 

Operating Income

 

Fiscal 2016 operating income was $58,028 compared to $56,333 in the prior year, an increase of $1,695 or 3.0%.

 

Interest Expense

 

Interest expense was $6,997 for the year ended June 30, 2016, an increase of $3,043 from the prior year. The increase is primarily due to a $420 payment associated with the termination of an interest rate swap, as well as $2,974 amortization of the debt discount associated with the offering of Convertible Senior Notes.

 

Interest and Other Income, Net

 

Interest and other income, net was $2,823 for the year ended June 30, 2016, an increase of $1,337 from the prior year, primarily due to decreases in unrealized foreign exchange losses as well as an increase in income related to a joint venture for one of our agricultural protection products. For the year ended June 30, 2015, we experienced unrealized foreign exchange losses resulting from mark-to-market valuation of foreign currency futures contracts and the strong U.S. dollar compared to the Euro.

 

Provision for Income Taxes

 

The effective tax rate for the year ended June 30, 2016 decreased to 35.4% compared to 37.8% for the prior year.  The decrease in the effective tax rate was due to the mix of profits from the lower tax rate jurisdictions of Europe and Asia compared to the Federal tax rate in the United States as well as a change in the business allocation percentages in certain states in the U.S.

 

 38 

 

 

Liquidity and Capital Resources

 

Cash Flows

 

At June 30, 2017, we had $55,680 in cash, of which $36,865 was outside the United States, $2,046 in short-term investments, all of which is held outside the United States and $353,666 in long-term debt (including the current portion), all of which is an obligation in the United States. Working capital was $251,355 at June 30, 2017 compared to $253,755 at June 30, 2016. The $36,865 of cash held outside of the United States is fully accessible to meet any liquidity needs of the countries in which we operate. The cash located outside of the United States can be transferred into the United States. Although these amounts are fully accessible, transferring these amounts into the United States or any other countries could have certain tax consequences. A deferred tax liability will be recognized when we expect that we will recover undistributed earnings of our foreign subsidiaries in a taxable manner, such as through receipt of dividends or sale of the investments. We intend to indefinitely reinvest these undistributed earnings and have no plan for further repatriation. A portion of our cash is held in operating accounts that are with third party financial institutions. While we monitor daily the cash balances in our operating accounts and adjust the cash balances as appropriate, these cash balances could be impacted if the underlying financial institutions fail or are subject to other adverse conditions in the financial markets. To date, we have experienced no loss or lack of access to cash in our operating accounts.

 

Our cash position at June 30, 2017 decreased $11,148 from the amount at June 30, 2016. Operating activities for the year ended June 30, 2017 provided cash of $44,567 for this period, as compared to cash provided of $31,831 for the prior year. The $44,567 resulted from $11,376 in net income and $39,689 derived from adjustments for non-cash items less a net $6,498 decrease from changes in operating assets and liabilities. The non-cash items included $23,754 in depreciation and amortization expense, $2,336 of earnings on an equity investment in a joint venture, $504 for deferred income taxes, $5,847 for amortization of debt issuance costs and debt discount, $903 for an environmental remediation charge related to Arsynco, $6,956 in non-cash stock compensation expense and $4,502 in amortization of inventory step-up. Trade accounts receivable increased $17,598 during the year ended June 30, 2017, due predominantly to an increase in days sales outstanding, particularly at our Rising subsidiary, whose customers typically yield a longer payment term due to industry standards and recent consolidation of wholesalers and retail drug chains. In addition, trade accounts receivable increased due to an increase in sales from the fourth quarter of 2016. Inventories increased by $2,958 and accounts payable decreased by $3,097 due primarily to increased inventories held in stock in Europe to support the nutritional and intermediates business. Accrued expenses and other liabilities increased $14,010 due primarily to a rise in price concessions and partnered product liabilities for our Rising business.

 

Our cash position at June 30, 2016 increased $32,808 from the amount at June 30, 2015. Operating activities for the year ended June 30, 2016 provided cash of $31,831 for this period, as compared to cash provided of $8,343 for the prior year. The $31,831 resulted from $34,766 in net income and $21,150 derived from adjustments for non-cash items less a net $24,085 decrease from changes in operating assets and liabilities. The non-cash items included $12,698 in depreciation and amortization expense, $2,060 of earnings on an equity investment in a joint venture, $18 for deferred income taxes, $3,496 for amortization of debt issuance costs and debt discount, $1,074 reversal of contingent consideration, $1,313 environmental remediation charge related to Arsynco and $6,719 in non-cash stock compensation expense. Trade accounts receivable increased $6,149 during the year ended June 30, 2016, due predominantly to an increase in days sales outstanding, particularly at our Rising subsidiary, whose customers typically yield a longer payment term due to industry standards and recent consolidation of wholesalers and retail drug chains. Inventories increased by $2,489 and accounts payable decreased by $8,937 due primarily to increased inventories held in stock by our Agricultural Protection Products subsidiary as a result of a delay in sales of a fungicide used to prevent disease on pecan crops, which was shipped in the first quarter of fiscal 2017 and a build-up of inventory at our Rising subsidiary for both new and existing products. Accrued expenses and other liabilities decreased $7,689 due primarily to a decline in price concessions for our Rising subsidiary and timing of income tax payments for international tax jurisdictions. Our cash position at June 30, 2015 decreased $8,877 from the amount at June 30, 2014. Operating activities for the year ended June 30, 2015 provided cash of $8,343 for this period, as compared to cash provided of $25,056 for the comparable period. The $8,343 was comprised of $33,483 in net income and $11,385 derived from adjustments for non-cash items less a net $36,525 decrease from changes in operating assets and liabilities.

 

Investing activities for the year ended June 30, 2017 used cash of $276,378. This use of cash reflects payment for net assets acquired of $270,000 and purchases of investments, intangible assets and property and equipment of $7,287, partially offset by sales of investments in time deposits of $909. Investing activities for the year ended June 30, 2016 used cash of $9,894. This use of cash reflects purchases of intangible assets and property and equipment of $12,377, partially offset by sales of investments in time deposits of $2,517. In September 2015, we purchased three ANDAs for the products Ciprofloxacin Ophthalmic Solution 3%, Levofloxacin Ophthalmic Solution 0.5%, and Diclofenac Sodium Ophthalmic Solution 0.1% from Nexus Pharmaceuticals. Also in September 2015, we purchased three ANDAs from a subsidiary of Endo International plc for the products Methimazole Tablets, Glycopyrrolate Tablets and Meclizine Tablets. In addition, in September 2014, we purchased three ANDAs from Par Pharmaceuticals, from which Dutasteride Softgel Capsules 0.5mg was launched in November 2015. Investing activities for the year ended June 30, 2015 used cash of $4,901 for purchases of property and equipment, intangible assets and investments.

 

 39 

 

 

Financing activities for the year ended June 30, 2017 provided cash of $220,162, primarily from borrowings from banks of $275,000 partially offset by repayment of bank loans of $42,697. Financing activities also included payment of cash dividends of $7,831 and payment of deferred financing costs of $5,407. Financing activities for the year ended June 30, 2016 provided cash of $10,855. In November 2015, we offered $143,750 of 2% convertible senior notes due 2020 in a private offering. In conjunction with the issuing of the notes, we paid $5,153 for debt issuance costs, purchased a hedge for $27,174 and received $13,685 in proceeds from the sale of warrants. In addition, as a direct result of the convertible debt offering, we repaid $122,697 of bank borrowings. Financing activities also included $1,500 payment of contingent consideration to the former owners of Rising, bank borrowings of $15,500, $420 payment for terminating an interest rate swap, $7,084 payment of cash dividends and $1,219 of excess income tax benefits on stock option exercises and restricted stock. Financing activities for the year ended June 30, 2015 used cash of $8,245 primarily from $14,344 of repayment of bank borrowings, $6,964 payment of cash dividends, $4,500 payment of contingent consideration to the former owners of Rising, as well as $3,500 deferred consideration paid to these former owners. This use of cash was offset by bank borrowings of $19,000, proceeds of $1,273 received from the exercise of stock options and $790 of excess income tax benefit on stock option exercises and restricted stock.

 

Credit Facilities

 

We have available credit facilities with certain foreign financial institutions. At June 30, 2017, the Company had available lines of credit with foreign financial institutions totaling $7,351, all of which is available for borrowing by the respective foreign territories. We are not subject to any financial covenants under these arrangements.

 

On December 21, 2016 the Company entered into a Second Amended and Restated Credit Agreement (the “A&R Credit Agreement”), with eleven banks, which amended and restated in its entirety the Amended and Restated Credit Agreement, dated as of October 28, 2015, as amended by Amendment No. 1 to Amended and Restated Credit Agreement, dated as of November 10, 2015, and Amendment No. 2 to Amended and Restated Credit Agreement, dated as of August 26, 2016 (collectively, the “First Amended Credit Agreement”). The A&R Credit Agreement increases the aggregate available revolving commitment under the First Amended Credit Agreement from $150,000 to an initial aggregate available revolving commitment of $225,000 (the “Initial Revolving Commitment”). Under the A&R Credit Agreement, the Company may borrow, repay and reborrow from and as of December 21, 2016, to but excluding December 21, 2021 (the “Maturity Date”) provided, that if any of the Notes remain outstanding on the date that is 91 days prior to the maturity date of the Notes (the “2015 Convertible Maturity Date”), then the Maturity Date shall mean the date that is 91 days prior to the 2015 Convertible Maturity Date. The A&R Credit Agreement provides for (i) Eurodollar Loans (as such terms are defined in the A&R Credit Agreement), (ii) ABR Loans (as such terms are defined in the A&R Credit Agreement) or (iii) a combination thereof. As of June 30, 2017, the Company borrowed Revolving Loans aggregating $90,000 which loans are Eurodollar Loans at interest rates ranging from 3.21% to 3.45 % at June 30, 2017. The applicable interest rate margin percentage is subject to adjustment quarterly based upon the Company’s senior secured net leverage ratio.

 

Under the A&R Credit Agreement, the Company also borrowed $150,000 in term loans (the “Initial Term Loan). Subject to certain conditions, including obtaining commitments from existing or prospective lenders, the Company will have the right to increase the amount of the Initial Revolving Commitment (each, a “Revolving Facility Increase” and, together with the Initial Revolving Commitment, the “Revolving Commitment”) and/or the Initial Term Loan in an aggregate amount not to exceed $100,000 pursuant to an incremental loan feature in the A&R Credit Agreement. As of June 30, 2017, the remaining amount outstanding under the Initial Term Loan is $142,500 and is payable as a Eurodollar Loan at an interest rate of 3.30%. The proceeds of the Initial Revolving Commitment and Initial Term Loan have been used to partially finance the acquisition of generic products and related assets of Citron and its affiliate Lucid, and pay fees and expenses related thereto. The applicable interest rate margin percentage is subject to adjustment quarterly based upon the Company’s senior secured net leverage ratio.

 

The A&R Credit Agreement, similar to Aceto’s First Amended Credit Agreement, provides that commercial letters of credit shall be issued to provide the primary payment mechanism in connection with the purchase of any materials, goods or services in the ordinary course of business. The Company had no open letters of credit at June 30, 2017 and June 30, 2016.

 

The A&R Credit Agreement, like the First Amended Credit Agreement, provides for a security interest in substantially all of the personal property of the Company and certain of its subsidiaries. The A&R Credit Agreement contains several financial covenants including, among other things, maintaining a minimum level of debt service and certain leverage ratios. Under the A&R Credit Agreement, the Company and its subsidiaries are also subject to certain restrictive covenants, including, among other things, covenants governing liens, limitations on indebtedness, limitations on guarantees, limitations on sales of assets and sales of receivables, and limitations on loans and investments. The Company was in compliance with all covenants at June 30, 2017.

 

In conjunction with the Credit Agreement, the Company entered into an interest rate swap on March 21, 2017 for an additional interest cost of 2.005% on a notional amount of $100,000, which has been designated as a cash flow hedge. The expiration date of this interest rate swap is December 21, 2021. The remaining balance of this derivative as of June 30, 2017 is $95,000.

 

 40 

 

 

Working Capital Outlook

 

Working capital was $251,355 at June 30, 2017, compared to $253,755 at June 30, 2016. We continually evaluate possible acquisitions of or investments in businesses that are complementary to our own and such transactions may require the use of cash, as was the case with our December 2016 product acquisition.

 

In connection with the acquisition of certain products and related assets from Citron and Lucid, Aceto committed to make a $50,000 unsecured deferred payment that will bear interest at a rate of 5% per annum to the sellers on December 21, 2021 and to issue 5,122 shares of Aceto common stock beginning on December 21, 2019. The product purchase agreement also provides for a 5-year potential earn-out of up to an additional $50,000 in cash, based on the financial performance of four pre-specified pipeline products that are currently in development. As of June 30, 2017, the Company accrued $2,807 related to this contingent consideration.

 

In October 2015, we filed a universal shelf registration statement with the SEC to allow us to potentially offer an indeterminate principal amount and number of securities in the future with a proposed maximum aggregate offering price of up to $200,000. Under the shelf registration statement, we have the flexibility to publicly offer and sell from time to time common stock, debt securities, preferred stock, warrants and units or any combination of such securities.

 

In November 2015, we offered $125,000 aggregate principal amount of 2% Convertible Senior Notes due 2020 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In addition, we granted the initial purchasers for the offering an option to purchase up to an additional $18,750 aggregate principal amount pursuant to the initial purchasers’ option to purchase additional notes, which was exercised in November 2015. Therefore the total offering was $143,750 aggregate principal amount. The remaining net proceeds received from the offering, after paying down our credit facilities and costs associated with the offering and a related hedge transaction, have been or will be used for general corporate purposes, which may include funding research, development and product manufacturing, acquisitions or investments in businesses, products or technologies that are complementary to Aceto’s own, increasing working capital and funding capital expenditures.

 

We currently expect to spend approximately $6,100 for capital expenditures during fiscal 2018. In connection with our agricultural protection business, we plan to continue to acquire product registrations and related data filed with the United States Environmental Protection Agency as well as payments to various task force groups, which could approximate $2,357 over the next twelve months.

 

In connection with our environmental remediation obligation for Arsynco, we anticipate paying $6,112 towards remediation of the property in the next twelve months, which is included in accrued expenses in our Consolidated Balance Sheet as of June 30, 2017.

 

We believe that our cash, other liquid assets, operating cash flows, borrowing capacity and access to the equity capital markets, taken together, provide adequate resources to fund ongoing operating expenditures, the repayment of our bank loans and the anticipated continuation of cash dividends for the next twelve months.

 

 41 

 

 

Off-Balance Sheet Arrangements and Commitments and Contingencies

 

We have no material financial commitments other than those under bank borrowings, convertible debt, operating lease agreements, letters of credit and unconditional purchase obligations. We have certain contractual cash obligations and other commercial commitments that will affect our short and long-term liquidity. At June 30, 2017, we had no significant obligations for capital expenditures.

 

At June 30, 2017, contractual cash obligations and other commercial commitments were as follows:

 

Contractual Obligations 

Payments Due and/or

Amount of Commitment

(Expiration per Period)

 
                     
  

 

Total

  

Less than

1 year

  

1-3

Years

  

3-5

Years

  

After

5 years

 
                     
Long-term debt obligations (a)  $353,666   $14,466   $28,932   $310,268   $- 
                          
Interest on long term debt obligations (b)   9,583    2,875    5,750    958    - 
                          
Operating leases   14,868    1,673    4,094    2,357    6,744 
                          
Standby letters of credit   1,737    1,737    -    -    - 
                          
Unconditional purchase obligations   61,381    61,381    -    -    - 
                          
Total  $441,235   $82,132   $38,776   $313,583   $6,744 

 

(a) Long-term debt obligations include Convertible Senior Notes due November 2020 and assumes that no notes are converted prior to the November 1, 2020 maturity date. (See Note 9, Debt, in the Notes to the Consolidated Financial Statements in Part II, Item 8 of this Annual Report on Form 10-K.). Long-term debt obligations also include various loans. Interest on the loans are not included in the above table as the majority of the debt is variable in nature. As of June 30, 2017, interest on these variable loans ranged from 3.21% to 3.45%.

 

(b) Represents 2% interest due semi-annually on our Convertible Senior Notes due November 2020 and assumes all interest is paid and the notes are not converted prior to the November 1, 2020 due date. This amount could change if any noteholders convert their notes prior to the due date.

 

Other significant commitments and contingencies include the following:

 

1.A subsidiary of ours markets certain agricultural protection products which are subject to the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA). FIFRA requires that test data be provided to the EPA to register, obtain and maintain approved labels for pesticide products. The EPA requires that follow-on registrants of these products compensate the initial registrant for the cost of producing the necessary test data on a basis prescribed in the FIFRA regulations. Follow-on registrants do not themselves generate or contract for the data. However, when FIFRA requirements mandate that new test data be generated to enable all registrants to continue marketing a pesticide product, often both the initial and follow-on registrants establish a task force to jointly undertake the testing effort. We are presently a member of several such task force groups, which requires payments for such memberships. In addition, in connection with our agricultural protection business, we plan to acquire product registrations and related data filed with the United States Environmental Protection Agency to support such registrations and other supporting data for several products. The acquisition cost of these product registrations and related data filed with the United States Environmental Protection Agency as well as payments to various task force groups could approximate $2,357 through fiscal 2017, of which $0 has been accrued as of June 30, 2017 and June 30, 2016.

 

 42 

 

 

2.We, together with our subsidiaries, are subject to various claims which have arisen in the normal course of business. We provide for costs related to contingencies when a loss from such claims is probable and the amount is reasonably determinable. In determining whether it is possible to provide an estimate of loss, or range of possible loss, we review and evaluate our litigation and regulatory matters on a quarterly basis in light of potentially relevant factual and legal developments. If we determine an unfavorable outcome is not probable or reasonably estimable, we do not accrue for a potential litigation loss. While we have determined that there is a reasonable possibility that a loss has been incurred, no amounts have been recognized in the financial statements, other than what has been discussed below, because the amount of the liability cannot be reasonably estimated at this time.

 

3.The Company has environmental remediation obligations in connection with Arsynco, Inc. (“Arsynco”), a subsidiary formerly involved in manufacturing chemicals located in Carlstadt, New Jersey, which was closed in 1993 and is currently held for sale. Based on continued monitoring of the contamination at the site and the approved plan of remediation, Arsynco received an estimate from an environmental consultant stating that the costs of remediation could be between $21,500 and $23,300. Remediation commenced in fiscal 2010, and as of June 30, 2017 and June 30, 2016, a liability of $8,451 and $12,532, respectively, is included in the accompanying consolidated balance sheets for this matter. For the year ended June 30, 2017, the Company recorded environmental remediation charges of $903, which is included in selling, general and administrative expenses in the accompanying consolidated statements of income for the year ended June 30. In accordance with GAAP, management believes that the majority of costs incurred to remediate the site will be capitalized in preparing the property which is currently classified as held for sale. An appraisal of the fair value of the property by a third-party appraiser supports the assumption that the expected fair value after the remediation is in excess of the amount required to be capitalized. However, these matters, if resolved in a manner different from those assumed in current estimates, could have a material adverse effect on the Company’s financial condition, operating results and cash flows when resolved in a future reporting period.

 

In connection with the environmental remediation obligation for Arsynco, in July 2009, Arsynco entered into a settlement agreement with BASF Corporation (“BASF”), the former owners of the Arsynco property. In accordance with the settlement agreement, BASF paid for a portion of the prior remediation costs and going forward, will co-remediate the property with the Company. The contract requires that BASF pay $550 related to past response costs and pay a proportionate share of the future remediation costs. Accordingly, the Company had recorded a gain of $550 in fiscal 2009. This $550 gain relates to the partial reimbursement of costs of approximately $1,200 that the Company had previously expensed. The Company also recorded an additional receivable from BASF, with an offset against property held for sale, representing its estimated portion of the future remediation costs. The balance of this receivable for future remediation costs as of June 30, 2017 and 2016 is $3,803 and $5,639, respectively, which is included in the accompanying consolidated balance sheets.

 

4.In March 2006, Arsynco received notice from the EPA of its status as a PRP under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) for a site described as the Berry’s Creek Study Area (“BCSA”). Arsynco is one of over 150 PRPs which have potential liability for the required investigation and remediation of the site. The estimate of the potential liability is not quantifiable for a number of reasons, including the difficulty in determining the extent of contamination and the length of time remediation may require. In addition, any estimate of liability must also consider the number of other PRPs and their financial strength. In July 2014, Arsynco received notice from the U.S. Department of Interior (“USDOI”) regarding the USDOI’s intent to perform a Natural Resource Damage (NRD) Assessment at the BCSA. Arsynco has to date declined to participate in the development and performance of the NRD assessment process. Based on prior practice in similar situations, it is possible that the State may assert a claim for natural resource damages with respect to the Arsynco site itself, and either the federal government or the State (or both) may assert claims against Arsynco for natural resource damages in connection with Berry's Creek; any such claim with respect to Berry's Creek could also be asserted against the approximately 150 PRPs which the EPA has identified in connection with that site. Any claim for natural resource damages with respect to the Arsynco site itself may also be asserted against BASF, the former owners of the Arsynco property. In September 2012, Arsynco entered into an agreement with three of the other PRPs that had previously been impleaded into New Jersey Department of Environmental Protection, et al. v. Occidental Chemical Corporation, et al., Docket No. ESX-L-9868-05 (the "NJDEP Litigation") and were considering impleading Arsynco into the same proceeding. Arsynco entered into an agreement to avoid impleader. Pursuant to the agreement, Arsynco agreed to (1) a tolling period that would not be included when computing the running of any statute of limitations that might provide a defense to the NJDEP Litigation; (2) the waiver of certain issue preclusion defenses in the NJDEP Litigation; and (3) arbitration of certain potential future liability allocation claims if the other parties to the agreement are barred by a court of competent jurisdiction from proceeding against Arsynco. In July 2015, Arsynco was contacted by an allocation consultant retained by a group of the named PRPs, inviting Arsynco to participate in the allocation among the PRPs’ investigation and remediation costs relating to the BCSA. Arsynco declined that invitation. Since an amount of the liability cannot be reasonably estimated at this time, no accrual is recorded for these potential future costs. The impact of the resolution of this matter on the Company’s results of operations in a particular reporting period is not currently known.

 

 43 

 

 

In fiscal years 2011, 2009, 2008 and 2007, the Company received letters from the Pulvair Site Group, a group of potentially responsible parties (PRP Group) who are working with the State of Tennessee (the State) to remediate a contaminated property in Tennessee called the Pulvair site. The PRP Group has alleged that Aceto shipped hazardous substances to the site which were released into the environment. The State had begun administrative proceedings against the members of the PRP Group and Aceto with respect to the cleanup of the Pulvair site and the PRP Group has begun to undertake cleanup. The PRP Group is seeking a settlement of approximately $1,700 from the Company for its share to remediate the site contamination. Although the Company acknowledges that it shipped materials to the site for formulation over twenty years ago, the Company believes that the evidence does not show that the hazardous materials sent by Aceto to the site have significantly contributed to the contamination of the environment and thus believes that, at most, it is a de minimis contributor to the site contamination. Accordingly, the Company believes that the settlement offer is unreasonable. Management believes that the ultimate outcome of this matter will not have a material adverse effect on the Company's financial condition or liquidity.

 

Impact of New Accounting Pronouncements

 

In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting, which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-09 is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. The Company does not believe this new accounting standard update will have a material impact on its consolidated financial statements.

 

In January 2017, the FASB issued ASU 2017-04 Intangibles - Goodwill and Other (Topic 350) which would eliminate the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Instead, the amount of an impairment charge would be recognized if the carrying amount of a reporting unit is greater than its fair value. ASU 2017-04 is effective for public companies for fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company does not believe this new accounting pronouncement will have a material impact on its consolidated financial statements.

 

In January 2017, the FASB issued ASU 2017-01 Business Combinations (Topic 805): Clarifying the Definition of a Business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. ASU 2017-01 is effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company does not believe this new accounting pronouncement will have a material impact on its consolidated financial statements.

 

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which addresses eight specific cash flow issues with the objective of reducing diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact of the provisions of ASU 2016-15.

 

In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which will change certain aspects of accounting for share-based payments to employees. ASU 2016-09 is effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2016. ASU 2019-09 requires that all tax benefits and deficiencies related to share-based payments be recognized and recorded through the statement of income for all awards settled or expiring after the adoption of ASU 2016-09. Under prior guidance, tax benefits in excess of compensation costs ("windfalls") were recorded in equity, and any tax deficiencies ("shortfalls") were recorded in equity to the extent of previous windfalls and then to the statement of income. ASU 2016-09 also requires, either prospectively or retrospectively, that all tax-related cash flows resulting from share-based payments be reported as operating activities on the statement of cash flows, a change from prior guidance that required windfall tax benefits to be presented as an inflow from financing activities and an outflow from operating activities on the statement of cash flows. Additionally, ASU 2016-09 allows entities to make an accounting policy election for the impact of most types of forfeitures on the recognition of expense for share-based payment awards by allowing the forfeitures to be either estimated, as was required under prior guidance, or recognized when they actually occur. Under ASU 2016-09, it is possible for equity awards to have a more dilutive effect on earnings per share (EPS). Under prior guidance, anticipated income tax windfalls and shortfalls were included in the calculation of assumed proceeds when applying the treasury stock method for computing the dilutive effect of share-based awards in the calculation of diluted EPS. Because there is no longer any excess tax benefits recognized in additional paid capital under ASU 2016-09, when applying the treasury stock method for computing diluted EPS, the assumed proceeds do not include any windfall tax benefits. As a result, fewer hypothetical shares can be repurchased under the treasury stock method, resulting in an assumption of more incremental shares being issued upon the exercise of shared-based awards. Therefore, equity awards have a more dilutive effect on EPS for any period where the average market price of an entity's underlying stock exceeds the average fair value of outstanding dilutive equity awards for the period.  The provisions of ASU 2016-09 are effective for the Company at the beginning of fiscal 2018. The impact of ASU 2016-09 on the Company's income tax expense or benefit and related cash flows during and after the period of adoption are dependent in part upon future grants and vesting of stock-based compensation awards and other factors that are not fully controllable or predicable by the Company such as the future market price of the Company's common stock, the timing of employee exercises of vested stock options, and the future achievement of performance criteria that affect performance-based awards. Under ASU 2016-09, the Company will recognize forfeitures when they actually occur.

 

 44 

 

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) that replaces existing lease guidance. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. The new guidance will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of income. ASU 2016-02 is effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2018. The Company is currently evaluating the impact of the provisions of ASU 2016-02.

 

In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740) Balance Sheet Classification of Deferred Assets. This ASU is intended to simplify the presentation of deferred taxes on the balance sheet and will require an entity to present all deferred tax assets and deferred tax liabilities as non-current on the balance sheet. Under the current guidance, entities are required to separately present deferred taxes as current or non-current. Netting deferred tax assets and deferred tax liabilities by tax jurisdiction will still be required under the new guidance. This guidance will be effective for Aceto beginning in the first quarter of fiscal 2018. The Company does not believe this new accounting standard update will have a material impact on its consolidated financial statements.

 

In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330) – Simplifying the Measurement of Inventory. This ASU requires that an entity measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The adoption of this standard will not have any impact on the consolidated financial statements of the Company.

 

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which is the new comprehensive revenue recognition standard that will supersede all existing revenue recognition guidance under U.S. GAAP. The standard's core principle is that a company will recognize revenue when it transfers promised goods or services to a customer in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB subsequently issued ASU 2015-14, Revenue from Contracts with Customers - Deferral of the Effective Date, which approved a one year deferral of ASU 2014-09 for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. In March 2016 and April 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers - Principal versus Agent Considerations (Reporting Revenue Gross versus Net), and ASU 2016-10, Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing, respectively, which further clarify the guidance related to those specific topics within ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients, to reduce the risk of diversity in practice for certain aspects in ASU 2014-09, including collectibility, noncash consideration, presentation of sales tax and transition. Additionally, in December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers. ASU 2016-20 makes minor corrections or minor improvements to the standard that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. The Company has made progress in its evaluation of the amended guidance, including identification of revenue streams. The Company recognizes revenue from product sales at the time of shipment and passage of title and risk of loss and control of the goods is transferred to the customer. The Company has no acceptance or other post-shipment obligations and does not offer product warranties or services to its customers. Although the Company is continuing to assess the impact of the amended guidance, Aceto generally anticipates that the timing of recognition of revenue will be substantially unchanged under the amended guidance. The Company is continuing to evaluate the impact on certain other transactions including third-party collaborations and other arrangements. The amended guidance will be effective for Aceto in the first quarter of fiscal 2019 and permits adoption under either the full retrospective approach (recognize effects of the amended guidance in each prior reporting period presented) or the modified retrospective approach (recognize the cumulative effect of adoption as an adjustment to retained earnings at the date of initial application). The Company anticipates adopting this amended standard on a modified retrospective basis.

 

Item 7A. Quantitative and Qualitative Disclosures about Market Risk

 

Market Risk Sensitive Instruments

 

The market risk inherent in our market-risk-sensitive instruments and positions is the potential loss arising from adverse changes in investment market prices, foreign currency exchange-rates and interest rates.

 

 45 

 

 

Investment Market Price Risk

 

We had short-term investments of $2,046 at June 30, 2017 and $881 at June 30, 2016. Those short-term investments consisted of time deposits. Time deposits are short-term in nature and are accordingly valued at cost plus accrued interest, which approximates fair value.

 

Foreign Currency Exchange Risk

 

In order to reduce the risk of foreign currency exchange rate fluctuations, we hedge some of our transactions denominated in a currency other than the functional currencies applicable to each of our various entities. The instruments used for hedging are short-term foreign currency contracts (futures). The changes in market value of such contracts have a high correlation to price changes in the currency of the related hedged transactions. At June 30, 2017, we had foreign currency contracts outstanding that had a notional amount of $62,187. At June 30, 2016, our outstanding foreign currency contracts had a notional amount of $58,087. The difference between the fair market value of the foreign currency contracts and the related commitments at inception and the fair market value of the contracts and the related commitments at June 30, 2017, was not material.

 

We are subject to risk from changes in foreign exchange rates for our subsidiaries that use a foreign currency as their functional currency and are translated into U.S. dollars. These changes result in cumulative translation adjustments, which are included in accumulated other comprehensive income (loss). On June 30, 2017, we had translation exposure to various foreign currencies, with the most significant being the Euro. The potential loss as of June 30, 2017, resulting from a hypothetical 10% adverse change in quoted foreign currency exchange rates amounted to $8,869. On June 30, 2016, such potential loss amounted to $8,143. Actual results may differ.

 

Interest Rate Risk

 

Due to our financing, investing and cash-management activities, we are subject to market risk from exposure to changes in interest rates. We utilize a balanced mix of debt maturities along with both fixed-rate and variable-rate debt to manage our exposure to changes in interest rates. Our financial instrument holdings at year-end were analyzed to determine their sensitivity to interest rate changes. In this sensitivity analysis, we used the same change in interest rate for all maturities. All other factors were held constant. If there were an adverse change in interest rates of 10%, the expected effect on net income related to our financial instruments would be immaterial. However, there can be no assurances that interest rates will not significantly affect our results of operations.

 

In conjunction with the Credit Agreement, the Company entered into an interest rate swap on March 21, 2017 for an additional interest cost of 2.005% on a notional amount of $100,000, which has been designated as a cash flow hedge. The expiration date of this interest rate swap is December 21, 2021. The remaining balance of this derivative as of June 30, 2017 is $95,000. Aceto’s interest rate swaps are classified within Level 2 as the fair value of this hedge was primarily based on observable interest rates.

 

Item 8. Financial Statements and Supplementary Data

 

The financial statements and supplementary data required by this Item 8 are set forth later in this report.

 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

Not applicable.

 

Item 9A. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) are designed to provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. Our disclosure controls and procedures are also designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officer, to allow timely decisions regarding required disclosure. Our chief executive officer and chief financial officer, with assistance from other members of our management, have reviewed the effectiveness of our disclosure controls and procedures as of June 30, 2017 and, based on their evaluation, have concluded that the disclosure controls and procedures were effective as of such date.

 

 46 

 

 

Changes in Internal Control over Financial Reporting

 

There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the three months ended June 30, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

Management’s Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as that term is defined in Rule 13a-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our principal executive and principal financial officers, we assessed, as of June 30, 2017, the effectiveness of our internal control over financial reporting. This assessment was based on criteria established in the framework in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our assessment using those criteria, management concluded that our internal control over financial reporting as of June 30, 2017, was effective.

 

As discussed in Note 3 — Business Combinations, to our Consolidated Financial Statements, on December 21, 2016, wholly owned subsidiaries of Rising Pharmaceuticals, Inc. (“Rising”), a wholly owned subsidiary of Aceto, completed the acquisition of certain generic products and related assets of entities formerly known as Citron Pharma LLC and its affiliate Lucid Pharma LLC. Rising formed two subsidiaries to consummate the product acquisition – Rising Health, LLC (which acquired certain products and related assets of Citron) and Acetris Health, LLC (which acquired certain products and related assets of Lucid). The scope of our evaluation did not include specific processes or transactions unique to Rising Health and Acetris Health since Rising Health and Acetris Health have not been integrated into our internal control systems as of June 30, 2017. We are continuing the integration of Rising Health and Acetris Health into our internal control systems and will include their specific processes and transactions in our fiscal year 2018 evaluation of the effectiveness of internal control over financial reporting. Rising Health and Acetris Health’s assets, which were excluded from our internal control evaluation, accounted for 14% of our total assets at June 30, 2017. Rising Health and Acetris Health accounted for 19% of our total net sales for the year ended June 30, 2017.

 

Our internal control over financial reporting as of June 30, 2017, has been audited by BDO USA, LLP, an independent registered public accounting firm, as stated in its report, which is included herein.

Internal control over financial reporting is defined as a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:

 

·pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;

 

·provide reasonable assurance that transactions are recorded as necessary to permit the preparation of financial statements in accordance with U.S. generally accepted accounting principles and that our receipts and expenditures are being made only in accordance with authorization of our management and directors; and

 

·provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

 

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the internal control system are met. Because of the inherent limitations of any internal control system, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected.

 

 47 

 

 

Report of Independent Registered Public Accounting Firm

 

The Board of Directors and Shareholders

Aceto Corporation

Port Washington, NY

 

We have audited Aceto Corporation and subsidiaries’ internal control over financial reporting as of June 30, 2017, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO criteria). Aceto Corporation's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit.

 

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

 

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

As indicated in the accompanying Management’s Report on Internal Control over Financial Reporting, management’s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of Rising Health and Acetris Health, which acquired certain generic products and related assets of entities formerly known as Citron Pharma LLC and Lucid Pharma LLC on December 21, 2016, and which are included in the consolidated balance sheet of Aceto Corporation as of June 30, 2017, and the related consolidated statements of income, comprehensive income, stockholders’ equity, and cash flows for the year then ended. Rising Health and Acetris Health constituted 14% of assets and 19% of net sales, as of and for the year ended June 30, 2017. Management did not assess the effectiveness of internal control over financial reporting of Rising Health and Acetris Health because of the timing of the acquisition which was completed on December 21, 2016. Our audit of internal control over financial reporting of Aceto Corporation also did not include an evaluation of the internal control over financial reporting of Rising Health and Acetris Health.

 

In our opinion, Aceto Corporation and subsidiaries maintained, in all material respects, effective internal control over financial reporting as of June 30, 2017, based on the COSO criteria.

 

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Aceto Corporation and subsidiaries as of June 30, 2017 and 2016, and the related consolidated statements of income, comprehensive income, stockholders' equity, and cash flows for each of the three years in the period ended June 30, 2017 and our report dated August 25, 2017, expressed an unqualified opinion thereon.

 

/s/ BDO USA, LLP

 

Melville, New York
August 25, 2017

 

 48 

 

 

Item 9B. Other Information

 

None.

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance

 

Incorporated herein by reference to our definitive proxy statement to be filed with the Securities and Exchange Commission with respect to our annual meeting of shareholders.

 

Item 11. Executive Compensation

 

Incorporated herein by reference to our definitive proxy statement to be filed with the Securities and Exchange Commission with respect to our annual meeting of shareholders.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

The information required by this Item, not already provided under the table presented below, is incorporated herein by reference to our definitive proxy statement to be filed with the Securities and Exchange Commission with respect to our annual meeting of shareholders.

 

The following table states certain information with respect to our equity compensation plans at June 30, 2017:

 

Plan category  Number of securities to
be issued upon exercise
of outstanding options		   Weighted-average
exercise price of
outstanding options		   Number of securities
remaining available for
future issuance under
equity compensation plans		 
             
Equity compensation plans approved by security holders   260   $8.36    3,399 
Equity compensation plans not approved by security holders   -    -    - 
Total   260   $8.36    3,399 

 

Item 13. Certain Relationships and Related Transactions and Director Independence

 

Incorporated herein by reference to our definitive proxy statement to be filed with the Securities and Exchange Commission with respect to our annual meeting of shareholders.

 

Item 14. Principal Accounting Fees and Services

 

Incorporated herein by reference to our definitive proxy statement to be filed with the Securities and Exchange Commission with respect to our annual meeting of shareholders.

 

PART IV

 

Item 15. Exhibits and Financial Statement Schedules

 

The following documents are filed as part of this Report:

 

(a) The financial statements listed in the Index to Consolidated Financial Statements are filed as part of this Annual Report on Form 10-K. All financial statement schedules have been included in the Consolidated Financial Statements or Notes thereto.

 

 49 

 

 

(b) Exhibits

 

Exhibit Number  

Description

     
2.1   Asset Purchase Agreement by and among Aceto Corporation, Sun Acquisition Corp., Rising Pharmaceuticals, Inc., Ronald Gold, and David B. Rosen, dated as of December 15, 2010 (incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K dated December 20, 2010).
     
2.2   First Amendment to Asset Purchase Agreement, dated as of December 31, 2010, by and among Aceto Corporation, Sun Acquisition Corp., Rising Pharmaceuticals, Inc., Ronald Gold and David B. Rosen (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K dated January 5, 2011).
     
2.3   Second Amendment, dated as of December 21, 2012, to Asset Purchase Agreement, dated as of December 15, 2010, by and among Aceto Corporation, Rising Pharmaceuticals, Inc., Pearl Ventures Inc., Ronald Gold and David B. Rosen (incorporated by reference to Exhibit 10.3 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2012).
     
2.4   Membership Interest Purchase Agreement, dated March 26, 2014, by and among PACK Pharmaceuticals, LLC, the Aschenbrand and O’Brien Family Trust, dated March 2001, Bryan Aschenbrand – Trustee, Dushyant Chipalkattty, Chris Dungan, Aceto Corporation, Rising Pharmaceuticals, Inc. and Chris Dungan, solely in his capacity as the representative of the Sellers (incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K dated March 28, 2014).
     
2.5   Form of Lock-up Agreement (incorporated by reference to Exhibit 2.2 to our Current Report on Form 8-K dated March 28, 2014).
     
2.6   Product Purchase Agreement, by and among Aceto Corporation, Cedar Pharma LLC (f/k/a Citron Pharma LLC and referred to herein as “Citron”), Aster Pharma LLC (f/k/a Lucid Pharma LLC and together with Citron, the “Sellers”), the direct and indirect equity owners of the Sellers (the Members), Rising Health, LLC (“Purchaser I”), Acetris Health, LLC (together with Purchaser I, the “Purchasers”) and an agent for the Sellers and the Members (the “Agent”), dated as of November 2, 2016 (incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K dated November 2, 2016).
     
2.7   Amendment No. 1 to the Product Purchase Agreement, by and among the Purchasers and the Agent, dated as of December 2, 2016 (incorporated by reference to Exhibit 2.2 to our Current Report on Form 8-K dated December 21, 2016).
     
2.8   Transaction Agreement Amendment and Waiver, dated as of December 21, 2016, by and among the Purchasers, the Agent, Rising Pharmaceuticals, Inc. and Vimal Kavuru (incorporated by reference to Exhibit 2.3 to our Current Report on Form 8-K dated December 21, 2016).
     
3.1    Amended and Restated Certificate of Incorporation filed with the Department of State of the State of New York on November 9, 2015 (incorporated by reference to Exhibit 3.1 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2016).
     
3.2    Amendment to the Amended and Restated Certificate of Incorporation filed with the Department of State of the State of New York on December 15, 2015 (incorporated by reference to Exhibit 3.2 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2016).
     
3.3    Amendment to the Amended and Restated Certificate of Incorporation filed with the Department of State of the State of New York on December 9, 2016 (incorporated by reference to Exhibit 3.3 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2016).
     
3.4   Aceto Corporation By-Laws, amended July 28, 2014 (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K dated July 31, 2014).

 

 50 

 

 

4.1   Indenture, dated November 16, 2015 between Aceto Corporation and Citibank, N.A. (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K dated November 16, 2015).
     
4.2   Form of Global 2.00% Convertible Senior Note due 2020 (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K dated November 16, 2015).
     
10.1   Aceto Corporation 401(k) Retirement Plan, as amended and restated as of July 1, 2002 (incorporated by reference to Exhibit 10.1 to the Company’s annual report on Form 10-K for the fiscal year ended June 30, 2004 (File Number: 000-04217, Film Number: 041025874)).
     
10.2   Supplemental Executive Retirement Plan, as amended and restated effective June 30, 2004 and frozen as of December 31, 2004 (incorporated by reference to Exhibit 10.2 to the Company’s annual report on Form 10-K for the fiscal year ended June 30, 2004 (File Number: 000-04217, Film Number: 041025874)).
     
10.3   1998 Omnibus Equity Award Plan (incorporated by reference to Exhibit 10(v) (c) to the Company’s annual report on Form 10-K for the fiscal year ended June 30, 1999 (File Number: 000-04217, Film Number: 99718824)).
     
10.4   Supplemental Executive Deferred Compensation Plan, effective March 14, 2005 (incorporated by reference to Exhibit 10.1 to the Company’s current report on Form 8-K filed with the Securities and Exchange Commission on March 17, 2005 (File Number: 000-04217, Film Number: 05688328)).
     
10.5   2007 Long-Term Performance Incentive Plan (incorporated by reference to Exhibit 4.1 to Registration Statement No. 333-149586 on Form S-8).
     
10.6   Supplemental Executive Deferred Compensation Plan, amended and restated effective December 8, 2008 (incorporated by reference to Exhibit 10.22 to the Company’s annual report on Form 10-K for the year ended June 30, 2009).
     
10.7   Purchase and Sale Agreement among Schweizerhall Holding AG, Chemische Fabrik Schweizerhall, Schweizerhall, Inc., Aceto Corporation and Aceto Holding B.V., I.O., dated as of January 28, 2001 (incorporated by reference to Exhibit 2.1 to the Company’s current report on Form 8-K filed with the Securities and Exchange Commission on April 4, 2001 (File Number: 000-04217, Film Number: 1595350)).
     
10.8   Form of purchase agreement between Shanghai Zhongjin Real Estate Development Company Limited and Aceto (Hong Kong) Limited, dated November 10, 2004 (incorporated by reference to Exhibit 10.1 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2004 (File Number: 000-04217, Film Number: 05588472)).
     
10.9   Guarantee by Aceto Corporation and subsidiaries in favor of Deutsche Bank, AG, dated March 22, 2001 (incorporated by reference to Exhibit 10.13 to the Company’s annual report on Form 10-K for the year ended June 30, 2001 (File Number: 000-04217, Film Number: 1748270)).
     
10.10   Reaffirmation Agreement by Aceto Corporation, Aceto Agricultural Chemicals Corporation, CDC Products Corporation, Aceto Pharma Corp., Aceto Realty LLC, Acci Realty Corp. and Arsynco Inc., dated as of April 23, 2010 (incorporated by reference to Exhibit 10.3 to the Company’s current report on Form 8-K filed with the Securities and Exchange Commission on April 28, 2010).
     
10.11   Aceto Corporation 2010 Equity Participation Plan (incorporated by reference to Appendix A to our Definitive Proxy Statement on Schedule 14A filed on October 13, 2010).
     
10.12   Aceto Corporation Severance Policy (incorporated by reference to Exhibit 10.4 to our Current Report on Form 8-K dated January 17, 2012).
     
10.13   Aceto Corporation Executive Performance Award Plan (incorporated by reference to Appendix A to our Definitive Proxy Statement on Schedule 14A filed on October 18, 2012).

 

 51 

 

 

10.14   Amended and Restated Aceto Corporation 2010 Equity Participation Plan (incorporated by reference to Appendix B to our Definitive Proxy Statement on Schedule 14A filed on October 18, 2012).
     
10.15   Enhanced Severance Protection Letter Agreement, dated April 3, 2013 between Aceto Corporation and Douglas Roth (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated April 5, 2013).
     
10.16   Aceto Corporation 2013 Senior Executive Retirement Plan (incorporated by reference to Exhibit 10.1 to the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2013).
     
10.17   Note Modification Agreement, dated October 21, 2013, between Aceto Realty LLC and JPMorgan Chase Bank, N.A. (incorporated by reference to Exhibit 10.1 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2013).
     
10.18   Amendment No. 1, dated as of December 26, 2013 to the Change in Control Agreement, dated as of July 2, 2012, by and between the Company and Salvatore J. Guccione (incorporated by reference to Exhibit 10.2 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2013).
     
10.19   Commitment Letter dated March 26, 2014, by and among, Aceto Corporation and the Lead Arrangers and Commitment Lenders (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated March 28, 2014).
     
10.20   Credit Agreement, dated as of April 30, 2014, by and among Aceto Corporation, JPMorgan Chase Bank, N.A. as Administrative Agent, Wells Fargo, as Syndication Agent, and the Lenders (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated May 2, 2014).
     
10.21  

Employment Agreement, effective as of January 1, 2015, between Aceto Corporation and Salvatore Guccione (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated December 18, 2014).

 

10.22   Change in Control Agreement by and between Aceto Corporation and Terry Kippley, dated as of November 5, 2014 (incorporated by reference to Exhibit 10.2 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2014).
     
10.23   Change in Control Agreement by and between Aceto Corporation and Salvatore Guccione (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated February 18, 2015).
     
10.24   Change in Control Agreement by and between Aceto Corporation and Albert L. Eilender (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K dated February 18, 2015).
     
10.25   Change in Control Agreement by and between Aceto Corporation and Douglas Roth (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K dated February 18, 2015).
     
10.26   Change in Control Agreement by and between Aceto Corporation and Frank DeBenedittis (incorporated by reference to Exhibit 10.4 to our Current Report on Form 8-K dated February 18, 2015).
     
10.27   Change in Control Agreement by and between Aceto Corporation and Satish Srinivasan (incorporated by reference to Exhibit 10.5 to our Current Report on Form 8-K dated February 18, 2015).
     
10.28   Change in Control Agreement by and between Aceto Corporation and Charles J. Alaimo, dated as of February 13, 2015 (incorporated by reference to Exhibit 10.6 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2015).
     
10.29   Change in Control Agreement by and between Aceto Corporation and Raymond B. Bartone, dated as of February 13, 2015 (incorporated by reference to Exhibit 10.7 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2015).
     
10.30   Change in Control Agreement by and between Aceto Corporation and Terry Kippley, dated as of February 13, 2015 (incorporated by reference to Exhibit 10.8 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2015).

 

 52 

 

 

10.31   Change in Control Agreement by and between Aceto Corporation and Steven S. Rogers, dated as of February 13, 2015 (incorporated by reference to Exhibit 10.10 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2015).
     
10.32   Change in Control Agreement by and between Aceto Corporation and Nicholas I. Shackley, dated as of February 13, 2015 (incorporated by reference to Exhibit 10.11 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2015).
     
10.33   Amendment No. 1, dated as of June 25, 2015, to the Credit Agreement, dated as of April 30, 2014, by and among Aceto Corporation, JPMorgan Chase Bank, N.A. as Administrative Agent and the Lenders (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated June 25, 2015).
     
10.34   Aceto Corporation 2015 Equity Participation Plan (incorporated by reference to Appendix B to our Definitive Proxy Statement on Schedule 14A filed on October 26, 2015).
     
10.35   Amended and Restated Credit Agreement, dated as of October 28, 2015, by and among Aceto Corporation, the other loan parties thereto, JPMorgan Chase Bank N.A., as administrative agent, Wells Fargo Bank, National Association, as syndication agent, and the lenders party thereto (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated October 28, 2015).
     
10.36   Purchase Agreement, dated November 10, 2015, by and among Aceto Corporation and Wells Fargo Securities, LLC and J.P. Morgan Securities LLC, as representatives of the initial purchasers named therein (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated November 12, 2015).
     
10.37   Convertible Note Hedge Confirmation, dated November 10, 2015, between Aceto Corporation and Wells Fargo Bank, National Association (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K dated November 12, 2015).
     
10.38   Convertible Note Hedge Confirmation, dated November 10, 2015, between Aceto Corporation and JPMorgan Chase Bank, National Association (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K dated November 12, 2015).
     
10.39   Warrant Confirmation, dated November 10, 2015, between ACETO Corporation and Wells Fargo Bank, National Association (incorporated by reference to Exhibit 10.4 to our Current Report on Form 8-K dated November 12, 2015).
     
10.40   Warrant Confirmation, dated November 10, 2015, between ACETO Corporation and JPMorgan Chase Bank, National Association (incorporated by reference to Exhibit 10.5 to our Current Report on Form 8-K dated November 12, 2015).
     
10.41   Amendment No. 1 to the Amended and Restated Credit Agreement, dated as of October 28, 2015, by and among Aceto Corporation, the other loan parties thereto, JPMorgan Chase Bank, N.A., as administrative agent, Wells Fargo Bank, National Association, as syndication agent, and the lenders party thereto (incorporated by reference to Exhibit 10.6 to our Current Report on Form 8-K dated November 12, 2015).
     
10.42   Additional Convertible Note Hedge Confirmation, dated November 18, 2015, between Aceto Corporation and Wells Fargo Bank, National Association (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated November 23, 2015).
     
10.43   Additional Convertible Note Hedge Confirmation, dated November 18, 2015, between Aceto Corporation and JPMorgan Chase Bank, National Association (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K dated November 23, 2015).
     
10.44   Additional Warrant Confirmation, dated November 18, 2015, between Aceto Corporation and Wells Fargo Bank, National Association (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K dated November 23, 2015).

 

 53 

 

 

10.45   Additional Warrant Confirmation, dated November 18, 2015, between Aceto Corporation and JPMorgan Chase Bank, National Association (incorporated by reference to Exhibit 10.4 to our Current Report on Form 8-K dated November 23, 2015).
     
10.46   Letter Agreement between Aceto Corporation and Walter J. Kaczmarek III (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated July 18, 2016).
     
10.47   Change in Control Agreement by and between Aceto Corporation and Walter J. Kaczmarek III (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K dated July 18, 2016).
     
10.48   Amendment No. 2 to the Amended and Restated Credit Agreement, dated as of October 28, 2015, by and among Aceto Corporation, the other loan parties thereto, JPMorgan Chase Bank, N.A., as administrative agent, Wells Fargo Bank, National Association, as syndication agent, and the lenders party thereto (incorporated by reference to Exhibit 10.1 to the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2016).
     
10.49   Form of Restricted Stock Award Agreement (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated July 28, 2016).
     
10.50   Form of Restricted Stock Unit Award Agreement (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K dated July 28, 2016).
     
10.51   Second Amended and Restated Credit Agreement, dated as of December 21, 2016, by and among the Company, the other loan parties thereto, JPMorgan Chase Bank, N.A., as administrative agent, Wells Fargo Bank, National Association, as syndication agent, and the lenders party thereto (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated December 21, 2016).
     
10.52   Stockholders’ Rights Agreement, by and among the Company and the Sellers, dated as of November 2, 2016 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated November 2, 2016).
     
10.53   Voting Agreement, by and among the Company, the Sellers and the Members, dated as of November 2, 2016 (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K dated November 2, 2016).
     
10.54   Employment Agreement, by and between Rising and Vimal Kavuru, dated as of November 2, 2016 (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K dated November 2, 2016).
     
21*   Subsidiaries of the Company.
     
23*   Consent of BDO USA, LLP.
     
31.1*   Certifications of Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
31.2*   Certifications of Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
32.1**   Certifications of Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
32.2**   Certifications of Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS   XBRL Instance Document
     
101.SCH   XBRL Taxonomy Extension Schema Document
     
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document

 

 54 

 

 

101.DEF   XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB   XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document

 

* Filed herewith

 

** Furnished herewith

 

Item 16. Form 10-K Summary

 

None

 

 55 

 

 

ACETO CORPORATION AND SUBSIDIARIES

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

Report of Independent Registered Public Accounting Firm    
     
Consolidated financial statements:    
     
Consolidated balance sheets as of June 30, 2017 and 2016    
     
Consolidated statements of income for the years ended June 30, 2017, 2016 and 2015    
     
Consolidated statements of comprehensive income for the years ended June 30, 2017, 2016 and 2015    
     
Consolidated statements of cash flows for the years ended June 30, 2017, 2016 and 2015    
     
Consolidated statements of shareholders’ equity for the years ended June 30, 2017, 2016 and 2015    
     
Notes to consolidated financial statements    
     
Schedules:    
     
II - Valuation and qualifying accounts    
     
All other schedules are omitted because they are not required or the information required is given in the consolidated financial statements or notes thereto.    

 

 56 

 

 

Report of Independent Registered Public Accounting Firm

 

Board of Directors and Shareholders

Aceto Corporation

Port Washington, NY

 

We have audited the accompanying consolidated balance sheets of Aceto Corporation and subsidiaries as of June 30, 2017 and 2016 and the related consolidated statements of income, comprehensive income, shareholders' equity, and cash flows for each of the three years in the period ended June 30, 2017. In connection with our audits of the consolidated financial statements, we have also audited the financial statement schedule listed in the accompanying index. These consolidated financial statements and schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements and schedule based on our audits.

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements and schedule. We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Aceto Corporation and subsidiaries at June 30, 2017 and 2016, and the results of their operations and their cash flows for each of the three years in the period ended June 30, 2017, in conformity with accounting principles generally accepted in the United States of America.

 

Also, in our opinion, the financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, present fairly, in all material respects, the information set forth therein.

 

We also have audited, in accordance with standards of the Public Company Accounting Oversight Board (United States), Aceto Corporation and subsidiaries’ internal control over financial reporting as of June 30, 2017, based on criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) and our report dated August 25, 2017 expressed an unqualified opinion thereon.

 

/s/ BDO USA, LLP

 

Melville, New York

August 25, 2017

 

 57 

 

 

ACETO CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

AS OF JUNE 30, 2017 AND 2016

(in thousands, except per-share amounts)

 

   2017   2016 
ASSETS          
Current assets:          
Cash and cash equivalents  $55,680   $66,828 
Investments   2,046    881 
Trade receivables: less allowance for doubtful accounts (2017, $485; 2016, $513)   264,896    167,612 
Other receivables   10,664    12,650 
Inventory   136,387    98,107 
Prepaid expenses and other current assets   3,941    3,339 
Deferred income tax asset, net   546    3,244 
Total current assets   474,160    352,661 
           
Property and equipment, net   10,428    10,044 
Property held for sale   7,152    6,868 
Goodwill   236,970    67,871 
Intangible assets, net   285,081    79,071 
Deferred income tax asset, net   19,453    18,053 
Other assets   7,546    6,210 
           
TOTAL ASSETS  $1,040,790   $540,778 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Current liabilities:          
Current portion of long-term debt  $14,466   $197 
Accounts payable   90,011    46,034 
Accrued expenses   118,328    52,675 
Total current liabilities   222,805    98,906 
           
Long-term debt   339,200    118,592 
Long-term liabilities   61,449    6,344 
Environmental remediation liability   2,339    3,352 
Deferred income tax liability   7,325    9,142 
Total liabilities   633,118    236,336 
           
Commitments and contingencies (Note 16)          
           
Shareholders’ equity:          
Preferred stock, 2,000 shares authorized; no shares issued and outstanding   -    - 
Common stock, $.01 par value, 75,000 shares authorized at June 30, 2017 and June 30, 2016; 30,094 and 29,595 shares issued and outstanding at June 30, 2017 and 2016, respectively   301    296 
Capital in excess of par value   214,198    115,667 
Retained earnings   198,285    194,804 
Accumulated other comprehensive loss   (5,112)   (6,325)
Total shareholders’ equity   407,672    304,442 
           
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY  $1,040,790   $540,778 

 

See accompanying notes to consolidated financial statements.

 

 58 

 

 

ACETO CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

FOR THE YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

   2017   2016   2015 
             
Net sales  $638,318   $558,524   $546,951 
Cost of sales   497,526    415,739    411,517 
Gross profit   140,792    142,785    135,434 
                
Selling, general and administrative expenses   102,340    76,820    73,159 
Research and development expenses   7,898    7,937    5,942 
Operating income   30,554    58,028    56,333 
                
Other (expense) income:               
Interest expense   (15,770)   (6,997)   (3,954)
Interest and other income, net   2,577    2,823    1,486 
    (13,193)   (4,174)   (2,468)
                
Income before income taxes   17,361    53,854    53,865 
Provision for income taxes   5,985    19,088    20,382 
Net income  $11,376   $34,766   $33,483 
                
Basic income per common share  $0.35   $1.19   $1.17 
                
Diluted income per common share  $0.35   $1.18   $1.14 
                
Weighted average shares outstanding:               
Basic   32,283    29,110    28,731 
Diluted   32,632    29,581    29,247 

 

See accompanying notes to consolidated financial statements.

 

 59 

 

 

ACETO CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

FOR THE YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands)

 

   2017   2016   2015 
             
Net income  $11,376   $34,766   $33,483 
                
Other comprehensive income (loss):               
Foreign currency translation adjustments   1,780    368    (12,354)
                
Change in fair value of interest rate swaps   (581)   (149)   99 
                
Reclassification for realized loss on interest rate swap included in interest expense   -    487    - 
                
Defined benefit plans, net of tax of $7, $31 and $100 respectively   14    65    (213)
                
Total other comprehensive income (loss)   1,213    771    (12,468)
                
Comprehensive income  $12,589   $35,537   $21,015 

 

See accompanying notes to consolidated financial statements.

 

 60 

 

 

ACETO CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands)

 

   2017   2016   2015 
             
Operating activities:               
Net income  $11,376   $34,766   $33,483 
Adjustments to reconcile net income to net cash provided by operating activities:              
Depreciation and amortization   23,754    12,698    11,849 
Amortization of debt issuance costs and debt discount   5,847    3,496    - 
Amortization of deferred financing costs   570    -    - 
Provision for doubtful accounts   (3)   76    484 
Non-cash stock compensation   6,956    6,719    4,537 
Deferred income taxes   (504)   (18)   (1,874)
Earnings on equity investment in joint venture   (2,336)   (2,060)   (1,761)
Contingent consideration   -    (1,074)   (3,468)
Amortization of inventory step-up   4,502    -    - 
Environmental remediation charge   903    1,313    1,618 
Changes in assets and liabilities:               
Trade accounts receivable   (17,598)   (6,149)   (44,181)
Other receivables   185    136    (5,644)
Inventory   (2,958)   (2,489)   (229)
Prepaid expenses and other current assets   1,209    (243)   304 
Other assets   (157)   (557)   1,254 
Accounts payable   (3,097)   (8,937)   8,133 
Accrued expenses and other liabilities   14,010    (7,689)   1,816 
Distributions from joint venture   1,908    1,843    2,022 
Net cash provided by operating activities   44,567    31,831    8,343 
                
Investing activities:               
Payment for net assets acquired   (270,000)   -    - 
Purchases of investments   (2,035)   (34)   (2,720)
Sales of investments   909    2,517    - 
Payments for intangible assets   (3,359)   (11,249)   (1,564)
Purchases of property and equipment, net   (1,893)   (1,128)   (617)
Net cash used in investing activities   (276,378)   (9,894)   (4,901)
                
Financing activities:               
Proceeds from exercise of stock options   551    729    1,273 
Excess income tax benefit on stock option exercises and restricted stock   546    1,219    790 
Payment of cash dividends   (7,831)   (7,084)   (6,964)
Payment of deferred consideration   -    -    (3,500)
Payment of contingent consideration   -    (1,500)   (4,500)
Proceeds from convertible senior notes   -    143,750    - 
Payment for debt issuance costs   -    (5,153)   - 
Proceeds from sold warrants   -    13,685    - 
Purchase of call option (hedge)   -    (27,174)   - 
Termination payment for interest rate swap   -    (420)   - 
Borrowings of bank loans   275,000    15,500    19,000 
Payment for deferred financing costs   (5,407)   -    - 
Repayment of bank loans   (42,697)   (122,697)   (14,344)
Net cash provided by (used in) financing activities   220,162    10,855    (8,245)
                
Effect of foreign exchange rate changes on cash   501    16    (4,074)
                
Net (decrease) increase in cash and cash equivalents   (11,148)   32,808    (8,877)
Cash and cash equivalents at beginning of period   66,828    34,020    42,897 
Cash and cash equivalents at end of period  $55,680   $66,828   $34,020 

 

See accompanying notes to consolidated financial statements

 

 61 

 

 

ACETO CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

FOR THE YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

   Common Stock   Capital in
Excess of		   Retained   Accumulated
Other
Comprehensive		     
   Shares   Amount   Par Value   Earnings   Income (Loss)   Total 
Balance at June 30, 2014   28,772   $288   $87,156   $140,768   $5,372   $233,584 
Net income   -    -    -    33,483    -    33,483 
Other comprehensive income   -    -    -    -    (12,468)   (12,468)
Stock issued pursuant to employee stock incentive plans   5    -    77    -    -    77 
Issuance of restricted stock, including dividends and net of forfeitures   224    2    (2)   -    -    - 
Dividends declared ($0.24 per share)   -    -    -    (7,043)   -    (7,043)
Share-based compensation   -    -    4,515    -    -    4,515 
Exercise of stock options   146    2    1,271    -    -    1,273 
Tax benefit from employee stock incentive plans   -    -    790    -    -    790 
Balance at June 30, 2015   29,147   $292   $93,807   $167,208   $(7,096)  $254,211 
                               
Net income   -    -    -    34,766    -    34,766 
Other comprehensive loss   -    -    -    -    771    771 
Stock issued pursuant to employee stock incentive plans   7    -    113    -    -    113 
Issuance of restricted stock, net of forfeitures   346    3    (3)   -    -    - 
Sale of warrants   -    -    13,685    -    -    13,685 
Purchase of call option (hedge)   -    -    (27,174)   -    -    (27,174)
Allocation of proceeds from convertible senior notes   -    -    27,241    -    -    27,241 
Equity component of debt issuance costs   -    -    (976)   -    -    (976)
Deferred taxes related to convertible senior notes   -    -    330    -    -    330 
Dividends declared ($0.24 per share)   -    -    -    (7,170)   -    (7,170)
Share-based compensation   -    -    6,697    -    -    6,697 
Exercise of stock options   95    1    728    -    -    729 
Tax benefit from employee stock incentive plans   -    -    1,219    -    -    1,219 
Balance at June 30, 2016   29,595   $296   $115,667   $194,804   $(6,325)  $304,442 
                               
Net income   -    -    -    11,376    -    11,376 
Other comprehensive income   -    -    -    -    1,213    1,213 
Stock issued pursuant to employee stock incentive plans   5    -    109    -    -    109 
Issuance of restricted stock, net of forfeitures   424    4    (4)   -    -    - 
Stock to be issued in connection with acquisition of assets of Citron and Lucid   -    -    90,400    -    -    90,400 
Dividends declared ($0.26 per share)   -    -    -    (7,895)   -    (7,895)
Share-based compensation   -    -    6,930    -    -    6,930 
Exercise of stock options   70    1    550    -    -    551 
Tax benefit from employee stock incentive plans   -    -    546    -    -    546 
Balance at June 30, 2017   30,094   $301   $214,198   $198,285   $(5,112)  $407,672 

 

See accompanying notes to consolidated financial statements.

 

 62 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

(1) Description of Business

 

Aceto Corporation and subsidiaries (“Aceto” or the “Company”) is primarily engaged in the sourcing, regulatory support, quality assurance, development, marketing, sales and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical intermediates and active ingredients, agricultural protection products and specialty chemicals used principally as finished products or raw materials in the pharmaceutical, nutraceutical, agricultural, coatings and industrial chemical consuming industries.

 

(2) Summary of Significant Accounting Policies

 

Principles of Consolidation

 

The consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries. All significant inter-company balances and transactions are eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses reported in those financial statements and the disclosure of contingent assets and liabilities at the date of the financial statements. These judgments can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company’s most critical accounting policies relate to revenue recognition; allowance for doubtful accounts; inventory; goodwill and other indefinite-life intangible assets; long-lived assets; environmental matters and other contingencies; income taxes; stock-based compensation; and purchase price allocation.

 

Cash Equivalents

 

The Company considers all highly liquid debt instruments with original maturities at the time of purchase of three months or less to be cash equivalents. Included in cash equivalents as of June 30, 2017 and June 30, 2016 is $220 and $104, respectively, of restricted cash.

 

Investments

 

The Company classifies investments in marketable securities as trading, available-for-sale or held-to-maturity at the time of purchase and periodically re-evaluates such classifications. Trading securities are carried at fair value, with unrealized holding gains and losses included in earnings. Held-to-maturity securities are recorded at cost and are adjusted for the amortization or accretion of premiums or discounts over the life of the related security. Unrealized holding gains and losses on available-for-sale securities are excluded from earnings and are reported as a separate component of accumulated other comprehensive income (loss) until realized. In determining realized gains and losses, the cost of securities sold is based on the specific identification method. Interest and dividends on the investments are accrued at the balance sheet date.

 

Inventory

 

Inventory, which consists principally of finished goods, are stated at the lower of cost (first-in first-out method) and net realizable value. The Company writes down its inventory for estimated excess and obsolete goods by an amount equal to the difference between the carrying cost of the inventory and net realizable value based upon assumptions about future demand and market conditions.

 

Environmental and Other Contingencies

 

The Company establishes accrued liabilities for environmental matters and other contingencies when it is probable that a liability has been incurred and the amount of the liability is reasonably estimable. If the contingency is resolved for an amount greater or less than the accrual, or the Company’s share of the contingency increases or decreases, or other assumptions relevant to the development of the estimate were to change, the Company would recognize an additional expense or benefit in the consolidated statements of income in the period such determination was made.

 

 63 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

Pension Benefits

 

In connection with certain historical acquisitions in Germany, the Company assumed defined benefit pension plans covering certain employees who meet certain eligibility requirements. The net pension benefit obligations recorded and the related periodic costs are based on, among other things, assumptions of the discount rate, estimated return on plan assets, salary increases and the mortality of participants. The obligation for these claims and the related periodic costs are measured using actuarial techniques and assumptions. Actuarial gains and losses are deferred and amortized over future periods. The Company’s plans are funded in conformity with the funding requirements of applicable government regulations.

 

Accumulated Other Comprehensive Loss

 

The components of accumulated other comprehensive loss as of June 30, 2017 and 2016 are as follows:

 

   2017   2016 
Cumulative foreign currency translation adjustments  $(4,340)  $(6,120)
Fair value of interest rate swaps   (581)   - 
Defined benefit plans, net of tax   (191)   (205)
Total  $(5,112)  $(6,325)

 

The foreign currency translation adjustments for the years ended June 30, 2017 and 2016 primarily relate to the fluctuation of the conversion rate of the Euro. The currency translation adjustments are not adjusted for income taxes as they relate to indefinite investments in non-US subsidiaries.

 

Common Stock

 

At the annual meeting of shareholders of the Company, held on December 15, 2015, the Company’s shareholders approved the proposal to amend Aceto’s Certificate of Incorporation to increase the total number of authorized shares of common stock from 40,000 shares to 75,000 shares.

 

Cash dividends of $0.065 per common share were paid in September, December, March and June of fiscal year 2017. Cash dividends of $0.06 per common share were paid in September, December, March and June of fiscal years 2016 and 2015. On August 24, 2017, the Company's board of directors declared a regular quarterly dividend of $0.065 per share to be distributed on September 21, 2017 to shareholders of record as of September 8, 2017.

 

On May 4, 2017, the Board of Directors of the Company authorized the continuation of the Company’s stock repurchase program, expiring in May 2020. Under the stock repurchase program, the Company is authorized to purchase up to 5,000 shares of common stock in open market or private transactions, at prices not to exceed the market value of the common stock at the time of such purchase. The Company did not repurchase shares in fiscal 2017 or fiscal 2016.

 

The Board of Directors has authority under the Company’s Restated Certificate of Incorporation to issue shares of preferred stock with voting and other relative rights to be determined by the Board of Directors.

 

 64 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

Stock-based Compensation

 

GAAP requires that all stock-based compensation be recognized as an expense in the financial statements and that such costs be measured at the fair value of the award. GAAP also requires that excess tax benefits related to stock option exercises be reflected as financing cash inflows.

 

All restricted stock grants include a service requirement for vesting. The Company has also granted restricted stock units that include either a performance or market condition. The fair value of restricted stock unit with either solely a service requirement or with the combination of service and performance requirements is based on the closing fair market value of Aceto’s common stock on the date of grant. The fair value of market condition-based awards is estimated at the date of grant using a binomial lattice model or Monte Carlo Simulation. All models incorporate various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the awards. Stock-based compensation expense is recognized on a straight-line basis over the service period or over our best estimate of the period over which the performance condition will be met, as applicable.

 

Revenue Recognition

 

The Company recognizes revenue from product sales at the time of shipment and passage of title and risk of loss to the customer. The Company has no acceptance or other post-shipment obligations and does not offer product warranties or services to its customers.

 

Sales are recorded net of estimated returns of damaged goods from customers, which historically have been immaterial, and sales incentives offered to customers. Sales incentives include volume incentive rebates. The Company records volume incentive rebates based on the underlying revenue transactions that result in progress by the customer in earning the rebate.

 

The Company has arrangements with various third parties, such as drug store chains and managed care organizations, establishing prices for its finished dosage form generics. While these arrangements are made between Aceto and its customers, the customers independently select a wholesaler from which they purchase the products. Alternatively, certain wholesalers may enter into agreements with the customers, with the Company’s concurrence, which establishes the pricing for certain products which the wholesalers provide. Upon each sale of finished dosage form generics, estimates of chargebacks, rebates, returns, government reimbursed rebates, sales discounts and other adjustments are made. These estimates are based on historical experience, future expectations, contractual arrangements with wholesalers and indirect customers, and other factors known to management at the time of accrual. These estimates are recorded as reductions to gross revenues, with corresponding adjustments either as a reduction of accounts receivable or as a liability for price concessions.

 

Under certain arrangements, Rising will issue a credit (referred to as a “chargeback”) to the wholesaler for the difference between the invoice price to the wholesaler and the customer’s contract price. As sales to the large wholesale customers increase or decrease, the reserve for chargebacks will also generally increase or decrease. The provision for chargebacks varies in relation to changes in sales volume, product mix, pricing and the level of inventory at the wholesalers. The Company continually monitors the reserve for chargebacks and makes adjustments when management believes that expected chargebacks may differ from the actual chargeback reserve.

 

The Company estimates its provision for returns of finished dosage generics based on historical experience, product expiration dates, changes to business practices, credit terms and any extenuating circumstances known to management. While historical experience has allowed for reasonable estimations in the past, future returns may or may not follow historical trends. The Company continually monitors the reserve for returns and makes adjustments when management believes that actual product returns may differ from the established reserve. Generally, the reserve for returns increases as net sales increase.

 

Government rebate accruals are based on estimated payments due to governmental agencies for purchases made by third parties under various governmental programs. Other rebates are offered to the Company’s key chain drug store, distributor and wholesaler customers to promote customer loyalty and increase product sales. These rebate programs provide customers with credits upon attainment of pre-established volumes or attainment of net sales milestones for a specified period. Other promotional programs are incentive programs offered to the customers. The Company provides a provision for government reimbursed rebates and other rebates at the time of sale based on contracted rates and historical redemption rates. Assumptions used to establish the provision include level of customer inventories, contract sales mix and average contract pricing. Aceto regularly reviews the information related to these estimates and adjusts the provision accordingly.

 

 65 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

Sales discount accruals are based on payment terms extended to customers.

 

The following table summarizes activity in the consolidated balance sheet for contra assets and liability for price concessions for the years ended June 30, 2017, 2016 and 2015:

 

   Accruals for Chargebacks, Rebates, Returns and Other Allowances     
         Government   Other   Sales 
   Chargebacks   Returns   Reimbursed Rebates   Rebates   Discounts 
Balance at June 30, 2014  $10,986   $20,249   $1,005   $3,630   $690 
Current year provision   208,965    21,403    4,259    36,923    9,381 
Credits issued during the year   (187,784)   (10,960)   (4,326)   (36,218)   (7,389)
Balance at June 30, 2015  $32,167   $30,692   $938   $4,335   $2,682 
Current year provision   247,186    7,618    5,124    90,915    10,267 
Credits issued during the year   (256,638)   (15,482)   (4,750)   (88,048)   (10,526)
Balance at June 30, 2016  $22,715   $22,828   $1,312   $7,202   $2,423 
 Acquisitions   23,526    1,496    4,500    28,944    2,360 
Current year provision   431,606    19,666    7,694    162,023    20,129 
Credits issued during the year   (417,928)   (11,631)   (4,642)   (158,836)   (18,875)
Balance at June 30, 2017  $59,919   $32,359   $8,864   $39,333   $6,037 

 

Credits issued during a given period represent cash payments or credit memos issued to the Company’s customers as settlement for the related reserve. Management has the experience and access to relevant information that it believes is necessary to reasonably estimate the amounts of such deductions from gross revenues. The Company regularly reviews the information related to these estimates and adjusts its reserves accordingly, if and when actual experience differs from previous estimates. The Company has not experienced any significant changes in its estimates as it relates to its chargebacks, rebates or sales discounts in each of the years in the three year period ended June 30, 2017. During the year ended June 30, 2015, the Company recorded $3,497 in additional gross profit related to a change in estimate for product returns due to the most recent returns experience. The Company had not experienced any significant changes in its estimates as it relates to its product returns during the years ended June 30, 2017 and June 30, 2016.

 

Partnered Products

 

The Company has various products that are subject to one of two types of collaborative arrangements with certain pharmaceutical companies. One type of arrangement relates to the Company’s finished dosage form generics business acting strictly as a distributor and purchasing products at arm’s length; in that type of arrangement, there is no profit sharing element. The second type of collaborative arrangement results in a profit sharing agreement between the Company and a developer and/or manufacturer of a finished dosage form generic drug. Both types of collaborative arrangements are conducted in the ordinary course of Rising’s business. The nature and purpose of both of these arrangements is for the Company to act as a distributor of finished dose products to its customers.  Under these arrangements, the Company maintains distribution rights with respect to specific drugs within the U.S. marketplace.  Generally, the distribution rights are exclusive rights in the territory.  In certain arrangements, the Company is required to maintain service level minimums including, but not limited to, market share and purchase levels, in order to preserve the exclusive rights.  The Company’s accounting policy with respect to these collaborative arrangements calls for the Company to present the sales and associated costs on a gross basis, with the amounts of the shared profits earned by the pharmaceutical companies on sales of these products, if applicable, included in cost of sales in the consolidated statements of income. The shared profits are settled on a quarterly basis. For each of the fiscal years 2017, 2016 and 2015, there was approximately $54,454, $41,036 and $51,352 respectively, of shared profits included in cost of sales, related to these types of collaborative arrangements. In the case of a collaborative arrangement where the Company solely acts as a distributor and purchases product at arm’s length, the costs of those purchases are included as a cost of sales similar to any other purchase arrangement.

 

 66 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

Shipping and Handling Fees and Costs

 

All amounts billed to a customer in a sales transaction related to shipping and handling represent revenues earned and are included in net sales. The costs incurred by the Company for shipping and handling are reported as a component of cost of sales. Cost of sales also includes inbound freight, receiving, inspection, warehousing, distribution network, and customs and duty costs.

 

Net Income Per Common Share

 

Basic income per common share is based on the weighted average number of common shares outstanding during the period. Diluted income per common share includes the dilutive effect of potential common shares outstanding. The following table sets forth the reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding for the fiscal years ended June 30, 2017, 2016 and 2015:

 

   2017   2016   2015 
             
Weighted average shares outstanding   32,283    29,110    28,731 
                
Dilutive effect of stock options and restricted stock awards and units   349    471    516 
                
Diluted weighted average shares outstanding   32,632    29,581    29,247 

 

The Convertible Senior Notes (see Note 9) will only be included in the dilutive net income per share calculations using the treasury stock method during periods in which the average market price of Aceto’s common stock is above the applicable conversion price of the Convertible Senior Notes, or $33.215 per share, and the impact would not be anti-dilutive.

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

 

Property and Equipment

 

Property and equipment are stated at cost and are depreciated using the straight line method over the estimated useful lives of the related asset. The Company allocates depreciation and amortization to cost of sales. Expenditures for improvements that extend the useful life of an asset are capitalized. Ordinary repairs and maintenance are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any related gains or losses are included in income.

 

 67 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

The components of property and equipment were as follows:

 

   June 30, 2017   June 30, 2016   Estimated useful
life (years)
Machinery and equipment  $398   $405   3-7
Leasehold improvements   979    1,056   Shorter of asset life or lease term
Computer equipment and software   7,255    6,048   3-5
Furniture and fixtures   2,094    2,365   5-10
Automobiles   184    184   3
Building   8,678    8,690   20
Land   1,967    1,960   -
    21,555    20,708    
Accumulated depreciation and amortization   11,127    10,664    
   $10,428   $10,044    

 

Property held for sale represents land and land improvements of $7,152 and $6,868 at June 30, 2017 and 2016, respectively. See Note 8, “Environmental Remediation” for further discussion on property held for sale.

 

Depreciation and amortization of property and equipment amounted to $1,520, $1,522 and $1,571 for the years ended June 30, 2017, 2016, and 2015 respectively.

 

Goodwill and Other Intangibles

 

Goodwill is calculated as the excess of the cost of purchased businesses over the fair value of their underlying net assets. Other intangible assets principally consist of customer relationships, license agreements, technology-based intangibles, EPA registrations and related data, trademarks and product rights and related intangibles. Goodwill and other intangible assets that have an indefinite life are not amortized.

 

In accordance with GAAP, the Company tests goodwill and other indefinite life intangible assets for impairment on at least an annual basis. Goodwill impairment exists if the net book value of a reporting unit exceeds its estimated fair value. Initially, an assessment of qualitative factors is conducted in order to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company determines that it is more likely than not that its carrying amount is greater than its fair value for a reporting unit, then it proceeds with the subsequent two-step process: (i) the Company determines impairment by comparing the fair value of a reporting unit with its carrying value, and (ii) if there is an impairment, the Company measures the amount of impairment loss by comparing the implied fair value of goodwill with the carrying amount of that goodwill. To determine the fair value of these intangible assets, the Company uses many assumptions and estimates using a market participant approach that directly impact the results of the testing. In making these assumptions and estimates, the Company uses industry accepted valuation models and set criteria that are reviewed and approved by various levels of management. The Company has the option to bypass the initial qualitative assessment stage and proceed directly to perform step one of the two-step process. In fiscal 2017, the Company performed step one of the two-step process and in fiscal 2016 the Company performed a qualitative assessment. There was no impairment of goodwill and other intangible assets in fiscal 2017 and fiscal 2016.

 

 68 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

Impairment of Long-Lived Assets and Long-Lived Assets to be Disposed of

 

Long-lived assets and certain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability of assets held for sale is measured by comparing the carrying amount of the assets to their estimated fair value. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceed the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.

 

Accounting for Derivatives and Hedging Activities

 

The Company accounts for derivatives and hedging activities under the provisions of GAAP which establishes accounting and reporting guidelines for derivative instruments and hedging activities. GAAP requires the recognition of all derivative financial instruments as either assets or liabilities in the statement of financial condition and measurement of those instruments at fair value. Changes in the fair values of those derivatives are reported in earnings or other comprehensive income depending on the designation of the derivative and whether it qualifies for hedge accounting. The accounting for gains and losses associated with changes in the fair value of a derivative and the effect on the consolidated financial statements depends on its hedge designation and whether the hedge is highly effective in achieving offsetting changes in the fair value or cash flows of the asset or liability hedged. The method that is used for assessing the effectiveness of a hedging derivative, as well as the measurement approach for determining the ineffective aspects of the hedge, is established at the inception of the hedged instrument.

 

The Company operates internationally, therefore its earnings, cash flows and financial positions are exposed to foreign currency risk from foreign-currency-denominated receivables and payables, which, in the U.S., have been denominated in various foreign currencies, including, among others, Euros, British Pounds, Japanese Yen, Singapore Dollars and Chinese Renminbi and at certain foreign subsidiaries in U.S. dollars and other non-local currencies.

 

Management believes it is prudent to minimize the risk caused by foreign currency fluctuation. Management minimizes the currency risk on its foreign currency receivables and payables by purchasing foreign currency contracts (futures) with one of its financial institutions. Futures are traded on regulated U.S. and international exchanges and represent commitments to purchase or sell a particular foreign currency at a future date and at a specific price. Since futures are purchased for the amount of the foreign currency receivable or for the amount of foreign currency needed to pay for specific purchase orders, and the futures mature on the due date of the related foreign currency vendor invoices or customer receivables, the Company believes that it eliminates risks relating to foreign currency fluctuation. The Company takes delivery of all futures to pay suppliers in the appropriate currency. The gains or losses for the changes in the fair value of the foreign currency contracts are recorded in cost of sales (sales) and offset the gains or losses associated with the impact of changes in foreign exchange rates on trade payables (receivables) denominated in foreign currencies. Senior management and members of the financial department continually monitor foreign currency risks and the use of this derivative instrument.

 

In conjunction with its existing credit agreement (see Note 9), the Company entered into an interest rate swap on March 21, 2017 for an additional interest cost of 2.005% on a notional amount of $100,000, which has been designated as a cash flow hedge. The expiration date of this interest rate swap is December 21, 2021.

 

 69 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

Foreign Currency

 

The financial statements of the Company’s foreign subsidiaries are translated into U.S. dollars in accordance with GAAP. Where the functional currency of a foreign subsidiary is its local currency, balance sheet accounts are translated at the current exchange rate and income statement items are translated at the average exchange rate for the period. Exchange gains or losses resulting from the translation of financial statements of foreign operations are accumulated in other comprehensive income. Where the local currency of a foreign subsidiary is not its functional currency, financial statements are translated at either current or historical exchange rates, as appropriate.

 

(3) Business Combinations

 

On December 21, 2016, wholly owned subsidiaries of Rising Pharmaceuticals, Inc. (“Rising”), a wholly owned subsidiary of Aceto, completed the acquisition of certain generic products and related assets of entities formerly known as Citron Pharma LLC (“Citron”) and its affiliate Lucid Pharma LLC (“Lucid”). Rising formed two subsidiaries to consummate the product acquisition – Rising Health, LLC (“Rising Health”) (which acquired certain products and related assets of Citron) and Acetris Health, LLC (“Acetris Health”) (which acquired certain products and related assets of Lucid). Citron is a privately-held New Jersey-based pharmaceutical company focused on developing and marketing generic pharmaceutical products in partnership with leading generic pharmaceutical manufacturers based in India and the United States. Lucid is a privately-held New Jersey-based generic pharmaceutical distributor specializing in providing cost-effective products to various agencies of the U.S. Federal Government including the Veterans Administration and the Defense Logistics Agency. Lucid services 18 national contracts with the Federal Government, nearly all of which have 5-year terms.

 

Aceto and Rising Health possess complementary asset-light business models, drug development and manufacturing partnerships and product portfolios. The Company believes, consistent with its strategy of expanding Rising’s portfolio of finished dosage form generic products through product development partnerships and acquisitions of late stage assets, abbreviated new drug applications (“ANDAs”) and complementary generic drug businesses, this transaction significantly expanded its roster of commercialized products and pipeline of products under development. The Company believes the acquired assets meet the definition of a business. In addition, the Company believes that this product acquisition greatly enhances its size and stature within the generic pharmaceutical industry, expands its partnership network and offers the Company opportunities to realize meaningful cost and tax efficiencies.

 

At closing, Aceto paid the sellers $270,000 in cash, committed to make a $50,000 unsecured deferred payment that will bear interest at a rate of 5% per annum to the sellers on December 21, 2021 and agreed to issue 5,122 shares of Aceto common stock beginning on December 21, 2019. The product purchase agreement also provides the sellers with a 5-year potential earn-out of up to an additional $50,000 in cash, based on the financial performance of four pre-specified pipeline products that are currently in development. As of June 30, 2017, the Company accrued $2,807 related to this contingent consideration.

 

The product acquisition was accounted for using the purchase method of accounting. The following table summarizes the allocation of the preliminary purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of December 21, 2016:

 

Trade receivables  $78,937 
Inventory   38,995 
Prepaid expenses and other current assets   1,425 
Goodwill   169,071 
Intangible assets   224,850 
Total assets acquired   513,278 
      
Accounts payable   46,840 
Accrued expenses   53,458 
Deferred payment   50,000 
Contingent consideration   2,580 
      
Net assets acquired  $360,400 

 

 70 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

The fair values of the net assets acquired were determined using discounted cash flow analyses and estimates made by management. The preliminary purchase price was allocated to intangible assets as follows: approximately $169,071 to goodwill, which is nonamortizable under generally accepted accounting principles and is deductible for income tax purposes; approximately $135,700 of product rights, amortizable over a period of approximately ten years; approximately $88,800 of customer relationships, amortizable over approximately eleven years; and approximately $350 of trademarks, amortizable over a period of approximately six months. Amortization of the acquired intangible assets is deductible for income tax purposes. Goodwill represents the excess of the preliminary purchase price paid over the fair value of the underlying net assets acquired and was allocated to the Human Health Segment.

 

As part of the product acquisition, the Company entered into an Administrative Services Agreement with the sellers in which excess cash payments may be made by either of the parties in connection with certain liabilities assumed upon the closing of the transaction related to rebates, chargebacks, commercial rebates and Medicaid and other government rebates. As of the closing date, the Company is responsible for the processing and administration of these related adjustments to sales completed prior to the closing date. In general, (i) if the amounts reserved for these liabilities underestimate the amounts that the Company is required to pay with respect to these items, the sellers will be required to reimburse the Company for the difference and (ii) if the amounts reserved for these liabilities overestimate the amounts that the Company is required to pay, the Company will be required to reimburse the sellers for the difference. Settlement is to be made two years after the closing date of December 21, 2016.

 

For the period from December 22, 2016 to June 30, 2017, net sales and income before income taxes from the product acquisition was approximately $122,118 and $7,437, respectively, which have been included in the Consolidated Statement of Income for the year ended June 30, 2017. The following represents unaudited pro forma operating results as if the operations of Rising Health and Acetris Health had been included in the Company’s consolidated statements of operations as of July 1, 2015.

 

   Year ended 
   June 30, 
   2017   2016 
         
Net sales  $739,318   $731,100 
Net income   24,166    30,469 
Net income per common share  $0.70   $0.89 
Diluted net income per common share  $0.69   $0.88 

 

The pro forma financial information includes business combination accounting effects from the product acquisition including amortization charges from acquired intangible assets of approximately $21,000 for both periods presented, increase in interest expense of approximately $13,200 for both periods presented associated with bank borrowings to fund the product acquisition and interest expense associated with the deferred payment to the sellers, $4,502 step-up in the fair value of the acquired inventory in the year ended June 30, 2016, reversal of acquisition related transaction costs of $8,818 and tax related effects in both periods. The unaudited pro forma information as presented above is for informational purposes only and is not indicative of the results of operations that would have been achieved if the product acquisition had taken place at the beginning of fiscal 2016.

 

 71 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

(4) Investments

 

A summary of short-term investments was as follows:

 

   June 30, 2017   June 30, 2016 
Held to Maturity Investments        
Time deposits  $2,046   $881 

 

Short-term investments consist of time deposits that the Company classifies as held-to- maturity and are recorded at cost plus accumulated interest. The Company has classified all investments with maturity dates of greater than three months as current since it has the ability to redeem them within the year and amounts are available for current operations.

 

(5) Fair Value Measurements

 

GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly fashion between market participants at the measurement date. GAAP establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s assumptions (unobservable inputs). The hierarchy consists of three levels:

 

Level 1 – Quoted market prices in active markets for identical assets or liabilities;

 

Level 2 – Inputs other than Level 1 inputs that are either directly or indirectly observable; and

 

Level 3 – Unobservable inputs that are not corroborated by market data.

 

On a recurring basis, Aceto measures at fair value certain financial assets and liabilities, which consist of cash equivalents, investments and foreign currency contracts. The Company classifies cash equivalents and investments within Level 1 if quoted prices are available in active markets. Level 1 assets include instruments valued based on quoted market prices in active markets which generally include corporate equity securities publicly traded on major exchanges. Time deposits are very short-term in nature and are accordingly valued at cost plus accrued interest, which approximates fair value, and are classified within Level 2 of the valuation hierarchy. The Company uses foreign currency futures contracts to minimize the risk caused by foreign currency fluctuation on its foreign currency receivables and payables by purchasing futures with one of its financial institutions. Futures are traded on regulated U.S. and international exchanges and represent commitments to purchase or sell a particular foreign currency at a future date and at a specific price. Aceto’s foreign currency derivative contracts are classified within Level 2 as the fair value of these hedges is primarily based on observable futures foreign exchange rates. At June 30, 2017, the Company had foreign currency contracts outstanding that had a notional amount of $62,187. Unrealized losses on hedging activities for the years ended June 30, 2017, 2016, and 2015, amounted to $515, $10 and $703, respectively, and are included in interest and other income, net, in the consolidated statements of income. The contracts have varying maturities of less than one year.

 

In conjunction with its existing credit agreement (see Note 9), the Company entered into an interest rate swap on March 21, 2017 for an additional interest cost of 2.005% on a notional amount of $100,000, which has been designated as a cash flow hedge. The expiration date of this interest rate swap is December 21, 2021. The remaining balance of this derivative as of June 30, 2017 is $95,000. The unrealized loss to date associated with this derivative, which is recorded in accumulated other comprehensive loss in the consolidated balance sheet at June 30, 2017, is $581. Aceto’s interest rate swaps are classified within Level 2 as the fair value of this hedge is primarily based on observable interest rates.

 

 72 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

At June 30, 2017, the Company had $2,952 of contingent consideration, $2,807 of which related to the acquisition of certain products and related assets of Citron and Lucid, which was completed in December 2016 (see Note 3) and $145 of contingent consideration related to a previously acquired company in France. At June 30, 2016, the Company had $132 of contingent consideration related to a previously acquired company in France. The contingent consideration was calculated using the present value of a probability weighted income approach.

 

During the fourth quarter of each year, the Company evaluates goodwill for impairment at the reporting unit level using a market participant approach using Level 3 inputs. Additionally, on a nonrecurring basis, the Company uses fair value measures when analyzing asset impairment.

 

Changes in contingent consideration during 2017 and 2016 are as follows:

 

Balance as of June 30, 2015  $2,622 
Reversal of fair value of liability-PACK   (833)
Reversal of fair value of liability-France   (241)
Payments   (1,500)
Accrued interest expense   85 
Change in foreign currency exchange rate   (1)
Balance as of June 30, 2016  $132 
Acquisitions   2,580 
Accrued interest expense   237 
Change in foreign currency exchange rate   3 
Balance as of June 30, 2017  $2,952 

 

Long-lived assets and certain identifiable intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  If it is determined such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization periods, their carrying values are reduced to estimated fair value.  Measurements based on undiscounted cash flows are considered to be Level 3 inputs.

 

In November 2015, the Company issued $143,750 aggregate principal amount of Notes (see Note 9). Since Aceto has the option to settle the potential conversion of the Notes in cash, the Company separated the embedded conversion option feature from the debt feature and accounts for each component separately, based on the fair value of the debt component assuming no conversion option. The calculation of the fair value of the debt component required the use of Level 3 inputs, and was determined by calculating the fair value of similar non-convertible debt, using a theoretical borrowing rate of 6.5%. The value of the embedded conversion option was determined using an expected present value technique (income approach) to estimate the fair value of similar non-convertible debt and included utilization of convertible investors’ credit assumptions and high yield bond indices. The carrying amount of the Notes approximate a fair value of $133,000 at June 30, 2017 and $134,400 at June 30, 2016 giving effect for certain factors, including the term of the Notes, current stock price of Aceto stock and effective interest rate. A portion of the offering proceeds was used to simultaneously enter into privately negotiated convertible note hedge transactions with option counterparties, which are affiliates of certain of the initial purchasers in the offering of the Notes and privately negotiated warrant transactions with the option counterparties (see Note 9). The Company calculated the fair value of the bond hedge based on the price that was paid to purchase the call. The Company also calculated the fair value of the warrant based on the price at which the affiliate purchased the warrants from the Company. Since the convertible note hedge and warrant are both indexed to the Company’s common stock and otherwise would be classified as equity, Aceto recorded both elements as equity, resulting in a net reduction to capital in excess of par value of $13,489.

 

 73 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

The carrying values of all financial instruments classified as a current asset or current liability are deemed to approximate fair value because of the short maturity of these instruments. The fair values of the Company’s notes receivable and short-term and long-term bank loans were based upon current rates offered for similar financial instruments to the Company.

 

The following tables summarize the valuation of the Company’s financial assets and liabilities which were determined by using the following inputs at June 30, 2017 and 2016:

 

   Fair Value Measurements at June 30, 2017 Using 
   Quoted Prices
in Active
Markets
(Level 1)		   Significant
Other
Observable
Inputs
(Level 2)		   Significant
Unobservable
Inputs
(Level 3)		   Total 
Cash equivalents:                    
Time deposits   -   $5,781    -   $5,781 
Investments:                    
Time deposits   -    2,046    -    2,046 
                     
Foreign currency contracts-assets (1)   -    486    -    486 
Foreign currency contracts-liabilities (2)   -    137    -    137 
Derivative liability for interest rate swap(3)        581         581 
Contingent consideration (4)   -    -   $2,952    2,952 

 

(1)Included in “Other receivables” in the accompanying Consolidated Balance Sheet as of June 30, 2017.
(2)Included in “Accrued expenses” in the accompanying Consolidated Balance Sheet as of June 30, 2017.
(3)Included in “Long-term liabilities” in the accompanying Consolidated Balance Sheet as of June 30, 2017.
(4)$145 included in “Accrued expenses” and $2,807 included in “Long-term liabilities” in the accompanying Consolidated Balance Sheet as of June 30, 2017.

 

   Fair Value Measurements at June 30, 2016 Using 
   Quoted Prices
in Active
Markets
(Level 1)		   Significant
Other
Observable
Inputs
(Level 2)		   Significant
Unobservable
Inputs
(Level 3)		   Total 
Cash equivalents:                    
Time deposits   -   $6,249    -   $6,249 
Investments:                    
Time deposits   -    881    -    881 
                     
Foreign currency contracts-assets (5)   -    160    -    160 
Foreign currency contracts-liabilities (6)   -    169    -    169 
Contingent consideration (7)   -    -   $132    132 

 

(5)Included in “Other receivables” in the accompanying Consolidated Balance Sheet as of June 30, 2016.
(6)Included in “Accrued expenses” in the accompanying Consolidated Balance Sheet as of June 30, 2016.
(7)Included in “Long-term liabilities” in the accompanying Consolidated Balance Sheet as of June 30, 2016.

 

 74 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

(6) Goodwill and Other Intangible Assets

 

As of June 30, 2017 and June 30, 2016, there was goodwill of $236,970 and $67,871, respectively.

 

Changes in the Company's goodwill during 2017 and 2016 are as follows:

 

   Human
Health
Segment		   Pharmaceutical
Ingredients
Segment		   Performance
Chemicals
Segment		   Total
Goodwill		 
Balance as of June 30, 2015  $66,039   $1,650   $181   $67,870 
Changes in foreign currency exchange rates   -    1    -    1 
Balance as of June 30, 2016   66,039    1,651    181    67,871 
Acquisitions   169,071    -    -    169,071 
Changes in foreign currency exchange rates   -    23    5    28 
Balance as of June 30, 2017  $235,110   $1,674   $186   $236,970 

 

Intangible assets subject to amortization as of June 30, 2017 and 2016 were as follows:

 

   Gross
Carrying
Value		   Accumulated
Amortization		   Net Book
Value		 
June 30, 2017               
Customer relationships  $110,787   $13,968   $96,819 
Trademarks   2,218    2,195    23 
Product rights and related intangibles   221,335    37,677    183,658 
License agreements   6,537    6,035    502 
EPA registrations and related data   14,307    11,011    3,296 
   $355,184   $70,886   $284,298 

 

   Gross
Carrying
Value		   Accumulated
Amortization		   Net Book
Value		 
June 30, 2016               
Customer relationships  $21,761   $7,815   $13,946 
Trademarks   1,868    1,800    68 
Product rights and related intangibles   83,048    23,511    59,537 
License agreements   6,611    5,531    1,080 
EPA registrations and related data   13,591    9,927    3,664 
Technology-based intangibles   155    140    15 
   $127,034   $48,724   $78,310 

 

Intangible assets with definitive useful lives are amortized using the straight-line method over their estimated useful lives. The straight-line method is utilized as it best reflects the use of the asset. The estimated useful lives of customer relationships, trademarks, product rights and related intangibles, license agreements and EPA registrations are 7-11 years, 3-4 years, 3-14 years, 6-11 years and 10 years respectively.

 

As of June 30, 2017 and June 30, 2016, the Company also had $783 and $761, respectively, of intangible assets pertaining to trademarks which have indefinite lives and are not subject to amortization. The change in trademarks with indefinite lives is attributable to foreign currency exchange rates used to translate the financial statements of foreign subsidiaries.

 

 75 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

Amortization expense for intangible assets subject to amortization amounted to $22,234, $11,176 and $10,278 for the years ended June 30, 2017, 2016 and 2015, respectively. The estimated aggregate amortization expense for intangible assets subject to amortization for each of the succeeding years ending June 30, 2018 through June 30, 2023 are as follows: 2018: $16,747; 2019: $32,431; 2020: $31,880; 2021: $31,819; 2022: $31,782 and 2023 and thereafter: $139,639.

 

(7) Accrued Expenses

 

The components of accrued expenses as of June 30, 2017 and 2016 were as follows:

 

   2017   2016 
Accrued compensation  $5,793   $6,880 
Accrued environmental remediation costs-current portion   6,112    9,180 
Reserve for price concessions   80,556    31,342 
Partnered product liabilities   16,068    - 
Other accrued expenses   9,799    5,273 
   $118,328   $52,675 

 

(8) Environmental Remediation

 

In fiscal years 2011, 2009, 2008 and 2007, the Company received letters from the Pulvair Site Group, a group of potentially responsible parties (PRP Group) who are working with the State of Tennessee (the State) to remediate a contaminated property in Tennessee called the Pulvair site. The PRP Group has alleged that Aceto shipped hazardous substances to the site which were released into the environment. The State had begun administrative proceedings against the members of the PRP Group and Aceto with respect to the cleanup of the Pulvair site and the PRP Group has begun to undertake cleanup. The PRP Group is seeking a settlement of approximately $1,700 from the Company for its share to remediate the site contamination. Although the Company acknowledges that it shipped materials to the site for formulation over twenty years ago, the Company believes that the evidence does not show that the hazardous materials sent by Aceto to the site have significantly contributed to the contamination of the environment and thus believes that, at most, it is a de minimis contributor to the site contamination. Accordingly, the Company believes that the settlement offer is unreasonable. Management believes that the ultimate outcome of this matter will not have a material adverse effect on the Company's financial condition or liquidity.

 

The Company has environmental remediation obligations in connection with Arsynco, Inc. (“Arsynco”), a subsidiary formerly involved in manufacturing chemicals located in Carlstadt, New Jersey, which was closed in 1993 and is currently held for sale. Based on continued monitoring of the contamination at the site and the approved plan of remediation, Arsynco received an estimate from an environmental consultant stating that the costs of remediation could be between $21,500 and $23,300. Remediation commenced in fiscal 2010, and as of June 30, 2017 and June 30, 2016, a liability of $8,451 and $12,532, respectively, is included in the accompanying consolidated balance sheets for this matter. For the year ended June 30, 2017, the Company recorded environmental remediation charges of $903, which is included in selling, general and administrative expenses in the accompanying consolidated statements of income for the year ended June 30, 2017. In accordance with GAAP, management believes that the majority of costs incurred to remediate the site will be capitalized in preparing the property which is currently classified as held for sale. An appraisal of the fair value of the property by a third-party appraiser supports the assumption that the expected fair value after the remediation is in excess of the amount required to be capitalized. However, these matters, if resolved in a manner different from those assumed in current estimates, could have a material adverse effect on the Company’s financial condition, operating results and cash flows when resolved in a future reporting period.

 

In connection with the environmental remediation obligation for Arsynco, in July 2009, Arsynco entered into a settlement agreement with BASF Corporation (“BASF”), the former owners of the Arsynco property. In accordance with the settlement agreement, BASF paid for a portion of the prior remediation costs and going forward, will co-remediate the property with the Company. The contract requires that BASF pay $550 related to past response costs and pay a proportionate share of the future remediation costs. Accordingly, the Company had recorded a gain of $550 in fiscal 2009. This $550 gain relates to the partial reimbursement of costs of approximately $1,200 that the Company had previously expensed. The Company also recorded an additional receivable from BASF, with an offset against property held for sale, representing its estimated portion of the future remediation costs. The balance of this receivable for future remediation costs as of June 30, 2017 and June 30, 2016 is $3,803 and $5,639, respectively, which is included in the accompanying consolidated balance sheets.

 

 76 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

In March 2006, Arsynco received notice from the EPA of its status as a PRP under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) for a site described as the Berry’s Creek Study Area (“BCSA”). Arsynco is one of over 150 PRPs which have potential liability for the required investigation and remediation of the site. The estimate of the potential liability is not quantifiable for a number of reasons, including the difficulty in determining the extent of contamination and the length of time remediation may require. In addition, any estimate of liability must also consider the number of other PRPs and their financial strength. In July 2014, Arsynco received notice from the U.S. Department of Interior (“USDOI”) regarding the USDOI’s intent to perform a Natural Resource Damage (NRD) Assessment at the BCSA. Arsynco has to date declined to participate in the development and performance of the NRD assessment process. Based on prior practice in similar situations, it is possible that the State may assert a claim for natural resource damages with respect to the Arsynco site itself, and either the federal government or the State (or both) may assert claims against Arsynco for natural resource damages in connection with Berry's Creek; any such claim with respect to Berry's Creek could also be asserted against the approximately 150 PRPs which the EPA has identified in connection with that site. Any claim for natural resource damages with respect to the Arsynco site itself may also be asserted against BASF, the former owners of the Arsynco property. In September 2012, Arsynco entered into an agreement with three of the other PRPs that had previously been impleaded into New Jersey Department of Environmental Protection, et al. v. Occidental Chemical Corporation, et al., Docket No. ESX-L-9868-05 (the "NJDEP Litigation") and were considering impleading Arsynco into the same proceeding. Arsynco entered into an agreement to avoid impleader. Pursuant to the agreement, Arsynco agreed to (1) a tolling period that would not be included when computing the running of any statute of limitations that might provide a defense to the NJDEP Litigation; (2) the waiver of certain issue preclusion defenses in the NJDEP Litigation; and (3) arbitration of certain potential future liability allocation claims if the other parties to the agreement are barred by a court of competent jurisdiction from proceeding against Arsynco. In July 2015, Arsynco was contacted by an allocation consultant retained by a group of the named PRPs, inviting Arsynco to participate in the allocation among the PRPs’ investigation and remediation costs relating to the BCSA. Arsynco declined that invitation. Since an amount of the liability cannot be reasonably estimated at this time, no accrual is recorded for these potential future costs. The impact of the resolution of this matter on the Company’s results of operations in a particular reporting period is not currently known.

 

(9) Debt

 

Long-term debt

 

   June 30, 
   2017   2016 
         
Convertible Senior Notes, net  $121,676   $115,829 
Revolving bank loans   90,000    - 
Term bank loans   139,227    - 
Mortgage   2,763    2,960 
    353,666    118,789 
Less current portion   14,466    197 
   $339,200   $118,592 

 

Convertible Senior Notes

 

In November 2015, Aceto offered $125,000 aggregate principal amount of Convertible Senior Notes due 2020 (the "Notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In addition, Aceto granted the initial purchasers for the offering an option to purchase up to an additional $18,750 aggregate principal amount pursuant to the initial purchasers’ option to purchase additional Notes, which was exercised in November 2015. Therefore the total offering was $143,750 aggregate principal amount. The Notes are unsecured obligations of Aceto and rank senior in right of payment to any of Aceto’s subordinated indebtedness, equal in right of payment to all of Aceto’s unsecured indebtedness that is not subordinated, effectively junior in right of payment to any of Aceto’s secured indebtedness to the extent of the value of the assets securing such indebtedness and structurally junior in right of payment to all indebtedness and other liabilities (including trade payables) of Aceto’s subsidiaries. The Notes will be convertible into cash, shares of Aceto common stock or a combination thereof, at Aceto’s election, upon the satisfaction of specified conditions and during certain periods. The Notes will mature in November 2020. The Notes pay 2.0% interest semi-annually in arrears on May 1 and November 1 of each year, which commenced on May 1, 2016. The Notes are convertible into 4,328 shares of common stock, based on an initial conversion price of $33.215 per share.

 

 77 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

Holders may convert all or any portion of their notes, in multiples of one thousand dollar principal amount, at their option at any time prior to the close of business on the business day immediately preceding May 1, 2020 only under the following circumstances: (i) during any calendar quarter (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, (ii) during the five consecutive business day period after any five consecutive trading day period (which is referred to as the “measurement period”) in which the trading price per one thousand dollar principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of Aceto’s common stock and the conversion rate on each such trading day; or (iii) upon the occurrence of specified corporate events.

 

Upon conversion by the holders, the Company may elect to settle such conversion in shares of its common stock, cash, or a combination thereof. As a result of its cash conversion option, the Company separately accounted for the value of the embedded conversion option as a debt discount (with an offset to capital in excess of par value). The debt discount is being amortized as additional non-cash interest expense using the effective interest method over the term of the Notes. Debt issuance costs are being amortized as additional non-cash interest expense. The Company presents debt issuance costs as a direct deduction from the carrying value of the debt liability rather than showing the debt issuance costs as a deferred charge on the balance sheet.

 

In connection with the offering of the Notes, Aceto entered into privately negotiated convertible note hedge transactions with option counterparties, which are affiliates of certain of the initial purchasers. The convertible note hedge transactions are expected generally to reduce the potential dilution to Aceto’s common stock and/or offset any cash payments Aceto is required to make in excess of the principal amount of converted Notes upon any conversion of Notes. Aceto also entered into privately negotiated warrant transactions with the option counterparties. The warrant transactions could separately have a dilutive effect to the extent that the market price per share of Aceto’s common stock as measured over the applicable valuation period at the maturity of the warrants exceeds the applicable strike price of the warrants. By entering into these transactions with the option counterparties, the Company issued convertible debt and a freestanding “call-spread.”

 

The carrying value of the Notes is as follows:

 

   June 30,
2017		   June 30,
2016		 
         
Principal amount  $143,750   $143,750 
Unamortized debt discount   (19,255)   (24,267)
Unamortized debt issuance costs   (2,819)   (3,654)
Net carrying value  $121,676   $115,829 

 

 78 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

The following table sets forth the components of total “interest expense” related to the Notes recognized in the accompanying consolidated statements of income for the year ended June 30:

 

   2017   2016 
         
Contractual coupon  $2,867   $1,788 
Amortization of debt discount   5,012    2,974 
Amortization of debt issuance costs   835    522 
   $8,714   $5,284 

 

Credit Facilities

 

On December 21, 2016 the Company entered into a Second Amended and Restated Credit Agreement (the “A&R Credit Agreement”), with eleven banks, which amended and restated in its entirety the Amended and Restated Credit Agreement, dated as of October 28, 2015, as amended by Amendment No. 1 to Amended and Restated Credit Agreement, dated as of November 10, 2015, and Amendment No. 2 to Amended and Restated Credit Agreement, dated as of August 26, 2016 (collectively, the “First Amended Credit Agreement”). The A&R Credit Agreement increases the aggregate available revolving commitment under the First Amended Credit Agreement from $150,000 to an initial aggregate available revolving commitment of $225,000 (the “Initial Revolving Commitment”). Under the A&R Credit Agreement, the Company may borrow, repay and reborrow from and as of December 21, 2016, to but excluding December 21, 2021 (the “Maturity Date”) provided, that if any of the Notes remain outstanding on the date that is 91 days prior to the maturity date of the Notes (the “2015 Convertible Maturity Date”), then the Maturity Date shall mean the date that is 91 days prior to the 2015 Convertible Maturity Date. The A&R Credit Agreement provides for (i) Eurodollar Loans (as such terms are defined in the A&R Credit Agreement), (ii) ABR Loans (as such terms are defined in the A&R Credit Agreement) or (iii) a combination thereof. As of June 30, 2017, the Company borrowed Revolving Loans aggregating $90,000 which loans are Eurodollar Loans at interest rates ranging from 3.21% to 3.45 % at June 30, 2017. The applicable interest rate margin percentage is subject to adjustment quarterly based upon the Company’s senior secured net leverage ratio.

 

Under the A&R Credit Agreement, the Company also borrowed $150,000 in term loans (the “Initial Term Loan). Subject to certain conditions, including obtaining commitments from existing or prospective lenders, the Company will have the right to increase the amount of the Initial Revolving Commitment (each, a “Revolving Facility Increase” and, together with the Initial Revolving Commitment, the “Revolving Commitment”) and/or the Initial Term Loan in an aggregate amount not to exceed $100,000 pursuant to an incremental loan feature in the A&R Credit Agreement. As of June 30, 2017, the remaining amount outstanding under the Initial Term Loan is $142,500 and is payable as a Eurodollar Loan at an interest rate of 3.30%. The proceeds of the Initial Revolving Commitment and Initial Term Loan have been used to partially finance the acquisition of generic products and related assets of Citron and its affiliate Lucid, and pay fees and expenses related thereto. The applicable interest rate margin percentage is subject to adjustment quarterly based upon the Company’s senior secured net leverage ratio.

 

The Initial Term Loan is payable as to principal in nineteen consecutive, equal quarterly installments of $3,750, which commenced on March 31, 2017 and will continue on each March 31, June 30, September 30 and December 31 thereafter. To the extent not previously paid, the final payment on the Term Loan Maturity Date (as defined in the A&R Credit Agreement) shall be in an amount equal to the then outstanding unpaid principal amount of the Initial Term Loan.

 

As such, the Company has classified $15,000 of the Initial Term Loan as short-term in the consolidated balance sheet at June 30, 2017. The A&R Credit Agreement, similar to the First Amended Credit Agreement, provides that commercial letters of credit shall be issued to provide the primary payment mechanism in connection with the purchase of any materials, goods or services in the ordinary course of business. The Company had no open letters of credit at June 30, 2017 and June 30, 2016.

 

In accordance with generally accepted accounting principles, $3,659 of deferred financing costs associated with the Initial Term Loan are presented as a direct deduction from the carrying value of the debt liability rather than showing the deferred financing costs as a deferred charge on the balance sheet. In addition, deferred financing costs of $1,748 associated with the Revolving Commitment have been recorded as a deferred charge on the balance sheet.

 

 79 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

The A&R Credit Agreement, like the First Amended Credit Agreement, provides for a security interest in substantially all of the personal property of the Company and certain of its subsidiaries. The A&R Credit Agreement contains several financial covenants including, among other things, maintaining a minimum level of debt service and certain leverage ratios. Under the A&R Credit Agreement, the Company and its subsidiaries are also subject to certain restrictive covenants, including, among other things, covenants governing liens, limitations on indebtedness, limitations on guarantees, limitations on sales of assets and sales of receivables, and limitations on loans and investments. The Company was in compliance with all covenants at June 30, 2017.

 

The Company has available lines of credit with foreign financial institutions. At June 30, 2017, the Company had available lines of credit with foreign financial institutions totaling $7,351. At June 30, 2016, the Company had available lines of credit with foreign financial institutions totaling $7,397. The Company has issued a cross corporate guarantee to the foreign banks. Short term loans under these agreements bear interest at a fixed rate of 4.5% at June 30, 2017 and June 30, 2016 and 5.0% at June 30, 2015. The Company is not subject to any financial covenants under these arrangements.

 

Under the above financing arrangements, the Company had $232,500 in bank loans and $1,737 in standby letters of credit, leaving an unused facility of $140,613 at June 30, 2017. At June 30, 2016 the Company had $0 in bank loans and $1,758 in standby letters of credit leaving an unused facility of $155,639.

 

Mortgage

 

On June 30, 2011, the Company entered into a mortgage payable for $3,947 on its new corporate headquarters, in Port Washington, New York. This mortgage payable is secured by the land and building and is being amortized over a period of 20 years. The mortgage payable, which was modified in October 2013, bears interest at 4.92% as of June 30, 2017 and matures on June 30, 2021.

 

Maturity of Long-term Debt

 

Long-term debt matures by fiscal year as follows:

 

2018  $14,466 
2019   14,466 
2020   14,466 
2021   138,115 
2022   172,153 
Thereafter   - 
   $353,666 

 

(10) Stock Based Compensation Plans

 

At the annual meeting of shareholders of the Company, held on December 15, 2015, the Company’s shareholders approved the Aceto Corporation 2015 Equity Participation Plan (the “2015 Plan”). Under the 2015 Plan, grants of stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards (“Stock Awards”) may be offered to employees, non-employee directors, consultants and advisors of the Company, including the chief executive officer, chief financial officer and other named executive officers. The maximum number of shares of common stock of the Company that may be issued pursuant to Stock Awards granted under the 2015 Plan will not exceed, in the aggregate, 4,250 shares. Stock Awards that are intended to qualify as “performance-based compensation” for purposes of Section 162(m) of the Internal Revenue Code of 1986, as amended, may be granted.  Performance-based awards may be granted, vested and paid based on the attainment of specified performance goals.

 

 80 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

At the annual meeting of shareholders of the Company, held on December 6, 2012, the Company’s shareholders approved the amended and restated Aceto Corporation 2010 Equity Participation Plan (the “2010 Plan”). Under the 2010 Plan, grants of stock options, restricted stock, restricted stock units, stock appreciation rights, and stock bonuses may be made to employees, non-employee directors and consultants of the Company. The maximum number of shares of common stock of the Company that may be issued pursuant to awards granted under the 2010 Plan will not exceed, in the aggregate, 5,250 shares. In addition, restricted stock may be granted to an eligible participant in lieu of a portion of any annual cash bonus earned by such participant. Such award may include additional shares of restricted stock (premium shares) greater than the portion of bonus paid in restricted stock. The restricted stock award is vested at issuance and the restrictions lapse ratably over a period of years as determined by the Board of Directors, generally three years. The premium shares vest when all the restrictions lapse, provided that the participant remains employed by the Company at that time.

 

At the annual meeting of shareholders of the Company held December 6, 2007, the shareholders approved the Aceto Corporation 2007 Long-Term Performance Incentive Plan (the “2007 Plan”). The Company has reserved 700 shares of common stock for issuance under the 2007 Plan to the Company’s employees and non-employee directors. There are five types of awards that may be granted under the 2007 Plan-options to purchase common stock, stock appreciation rights, restricted stock, restricted stock units and performance incentive units.

 

In September 2016, the Company granted 28 performance stock options to an executive officer at an exercise price of $20.03 per share. The performance options vest if the closing stock price meets or exceeds the target price of $40 for 20 consecutive trading days prior to June 30, 2021 and the explicit service period of 1 year has been met. The options will expire June 30, 2021, if the stock price target is not achieved. If it is achieved, the options will expire ten years from the date of grant. There were no stock options granted in fiscal years 2016 or 2015.

 

As of June 30, 2017, there were 3,144, 255 and 0 shares of common stock available for grant under the 2015, 2010 and 2007 Plans, respectively.

 

In December 1998, the Company adopted the Aceto Corporation 1998 Omnibus Equity Award Plan (1998 Plan). The 1998 Plan expired in December 2008. Outstanding options survive the expiration of the 1998 Plan.

 

The following summarizes the shares of common stock under options for all plans at June 30, 2017, 2016 and 2015, and the activity with respect to options for the respective years then ended:

 

   Shares subject to
option		   Weighted average
exercise price per
share		   Aggregate
Intrinsic
Value		 
Balance at June 30, 2014   551   $7.72      
Granted   -    -      
Exercised   (146)   8.74      
Forfeited (including cancelled options)   (8)   10.94      
Balance at June 30, 2015   397   $7.28      
Granted   -    -      
Exercised   (95)   7.56      
Forfeited (including cancelled options)   -    -      
Balance at June 30, 2016   302   $7.19      
Granted   28    20.03      
Exercised   (70)   7.90      
Forfeited (including cancelled options)   -    -      
Balance at June 30, 2017   260   $8.36   $1,968 
Options exercisable at June 30, 2017   232   $6.98   $1,968 

 

The total intrinsic value of stock options exercised during the years ended June 30, 2017, 2016 and 2015 was approximately $865, $1,700 and $1,713, respectively. The weighted average remaining contractual life of options outstanding at June 30, 2017 was approximately 4 years. At June 30, 2017, outstanding options had expiration dates ranging from December 2017 to June 2021.

 

 81 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

Under the 2015 Plan, 2010 Plan, 2002 Plan and the 1998 Plan, compensation expense is recorded for the fair value of the restricted stock awards in the year the related bonus is earned and over the vesting period for the market value at the date of grant of the premium shares granted. In fiscal 2017, 2016 and 2015, restricted stock awarded and premium shares vested of 5, 7 and 5 common shares, respectively, were issued under employee incentive plans, which increased stockholders’ equity by $109, $113 and $77, respectively. The related non-cash compensation expense related to the vesting of premium shares during the year was $26, $22 and $22 in fiscal 2017, 2016 and 2015, respectively. Additionally, non-cash compensation expense of $55, $0 and $21 was recorded in fiscal 2017, 2016 and 2015, respectively, relating to stock option grants, which is included in selling, general and administrative expenses. As of June 30, 2017, the total unrecognized compensation cost related to option awards is $95.

 

The following summarizes the non-vested stock options at June 30, 2017 and the activity with respect to non-vested options for the year ended June 30, 2017:

 

   Shares
subject to
option		   Weighted
average grant
date fair value		 
Non-vested at June 30, 2016   -    - 
Granted   28   $5.44 
Vested   -    - 
Forfeited   -    - 
Non-vested at June 30, 2017   28   $5.44 

 

The per-share fair value of stock options granted during 2017 was $5.44 on the date of the grant using a Monte Carlo simulation option-pricing model with the following assumptions:

 

   2017 
     
Expected life   4.9 years 
Expected volatility   39.4%
Risk-free interest rate   1.26%
Dividend yield   1.30%

 

During the year ended June 30, 2017, the Company granted 277 shares of restricted common stock to its employees that vest over three years and 22 shares of restricted common stock to its non-employee directors, which vest over approximately one year as well as 42 restricted stock units that have varying vest dates through July 2017. In addition, the Company also issued a target grant of 160 performance-vested restricted stock units, which grant could be as much as 280 restricted stock units if certain performance criteria and market conditions are met. Performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant.

 

During the year ended June 30, 2016, the Company granted 221 shares of restricted common stock to its employees that vest over three years and 14 shares of restricted common stock to its non-employee directors, which vest over approximately one year as well as 46 restricted stock units that have varying vest dates through July 2017. In addition, the Company also issued a target grant of 142 performance-vested restricted stock units, which grant could be as much as 248 if certain performance criteria and market conditions are met. Performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant.

 

During the year ended June 30, 2015, the Company granted 165 shares of restricted common stock to its employees that vest over three years and 12 shares of restricted common stock to its non-employee directors, which vest over approximately one year as well as 67 restricted stock units that have varying vest dates through August 2016. In addition, the Company also issued a target grant of 116 performance-vested restricted stock units, which grant could be as much as 203 if certain performance criteria and market conditions are met. Performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant.

 

 82 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

For the years ended June 30, 2017, 2016 and 2015, the Company recorded stock-based compensation expense of approximately $6,875, $6,697, and $4,494, respectively, which is included in selling, general and administrative expenses, for shares of restricted common stock and restricted stock units.

 

The remaining stock-based compensation expense for restricted stock awards and units is approximately $8,382 at June 30, 2017 and the related weighted average period over which it is expected that such unrecognized compensation cost will be recognized is approximately 1.8 years.

 

A summary of restricted stock awards including restricted stock units as of June 30, 2017, is presented below:

 

   Shares   Weighted
average grant
date fair value		 
Non-vested at beginning of year   795   $20.73 
Granted   501    18.92 
Vested   (396)   17.26 
Forfeited   (103)   21.33 
Non-vested at June 30, 2017   797   $21.24 

 

(11) Interest and Other Income

 

Interest and other income during fiscal 2017, 2016 and 2015 was comprised of the following:

 

   2017   2016   2015 
Dividends  $277   $222   $233 
Interest   264    313    282 
Foreign government subsidies received   64    25    22 
Joint venture equity earnings   2,336    2,060    1,761 
Foreign currency (losses) gains    (298)   56    (1,065)
Deferred compensation plan losses   (257)   (35)   (96)
Rental income   158    154    151 
Miscellaneous income   33    28    198 
   $2,577   $2,823   $1,486 

 

The Company’s joint venture earnings represent the Company’s investment in a corporate joint venture established for the purpose of selling a particular agricultural protection product. The Company’s initial investment was $6 in fiscal 2009, representing a 30% ownership and the Company accounts for this joint venture using the equity method of accounting.

 

(12) Income Taxes

 

The components of income before the provision for income taxes are as follows:

 

   2017   2016   2015 
Domestic operations  $9,555   $43,906   $48,276 
Foreign operations   7,806    9,948    5,589 
   $17,361   $53,854   $53,865 

 

 83 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

The components of the provision for income taxes are as follows:

 

   2017   2016   2015 
Federal:               
Current  $3,713   $15,129   $18,393 
Deferred   (585)   (204)   (1,357)
State and local:               
Current   555    755    1,526 
Deferred   (110)   173    189 
Foreign:               
Current   2,221    3,222    2,337 
Deferred   191    13    (706)
   $5,985   $19,088   $20,382 

 

Income taxes payable, which is included in accrued expenses, was $64 and $2,119 at June 30, 2017 and 2016, respectively.

 

The tax effects of temporary differences that give rise to the deferred tax assets and liabilities at June 30, 2017 and 2016 are presented below:

 

   2017   2016 
Deferred tax assets:          
Accrued deferred compensation  $4,229   $4,122 
Accrual for sales deductions not currently deductible   5,796    5,925 
Additional inventoried costs for tax purposes   697    389 
Allowance for doubtful accounts receivable   106    106 
Depreciation and amortization   11,957    7,784 
Debt issuance costs   7,611    9,462 
Foreign deferred tax assets   983    1,121 
Domestic net operating loss carryforwards   81    109 
Foreign net operating loss carryforwards   692    685 
Total gross deferred tax assets   32,152    29,703 
Valuation allowances   (773)   (794)
    31,379    28,909 
           
Deferred tax liabilities:          
Foreign deferred tax liabilities   (65)   (27)
Goodwill   (10,244)   (7,586)
Original issue discount – convertible senior notes   (7,260)   (9,115)
Other   (1,136)   (26)
Total gross deferred tax liabilities   (18,705)   (16,754)
           
Net deferred tax assets  $12,674   $12,155 

 

The following table shows the current and non-current deferred tax assets (liabilities) at June 30, 2017 and 2016:

 

   2017   2016 
Current deferred tax assets, net  $546   $3,244 
Non-current deferred tax assets, net   19,453    18,053 
Non-current deferred tax liabilities   (7,325)   (9,142)
Net deferred tax assets  $12,674   $12,155 

 

 84 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

The net change in the total valuation allowance for the years ended June 30, 2017 and June 30, 2016 was a decrease of $21 and $16, respectively. A valuation allowance is provided when it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The Company has established valuation allowances primarily for net operating loss carryforwards in certain foreign countries. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets are not expected to be realized. The assessment of the amount of value assigned to the Company’s deferred tax assets under the applicable accounting rules is judgmental. Management is required to consider all available positive and negative evidence in evaluating the likelihood that the Company will be able to realize the benefit of its deferred tax assets in the future. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which net operating loss carryforwards are utilizable and temporary differences become deductible. The Company has federal and state net operating loss carryforwards of $0 and $81, respectively, which will expire in fiscal year 2018. The Company has foreign net operating loss carryforwards of $692 which do not have any expiry dates. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, taxable income in carryback years if carryback is permitted and tax planning strategies in making this assessment. In order to fully realize the net deferred tax assets recognized at June 30, 2017, the Company will need to generate future taxable income of approximately $34,638.

 

Based upon the level of historical taxable income and projections for taxable income over the periods which the deferred tax assets are deductible, management believes it is more likely than not the Company will realize the benefits of these deductible differences. There can be no assurance, however, that the Company will generate any earnings or any specific level of continuing earnings in the future. The amount of the deferred tax asset considered realizable, however, could be reduced in the near term if estimates of future taxable income during the carryforward period are reduced.

 

Deferred taxes have not been provided for undistributed earnings of foreign subsidiaries amounting to approximately $111,569 at June 30, 2017 since substantially all of these earnings are expected to be indefinitely reinvested in foreign operations. A deferred tax liability will be recognized when the Company expects that it will recover these undistributed earnings in a taxable manner, such as through the receipt of dividends or sale of the investments. The Company intends to indefinitely reinvest the remaining undistributed earnings and has no plan for further repatriation. Determination of the amount of unrecognized deferred U.S. income tax liabilities, net of unrecognized foreign tax credits, is not practical to calculate because of the complexity of this hypothetical calculation resulting in various methods available, each with different U.S. tax consequences.

 

A reconciliation of the statutory federal income tax rate and the effective tax rate for continuing operations for the fiscal years ended June 30, 2017, 2016 and 2015 follows:

 

   2017   2016   2015 
Federal statutory tax rate   35.0%   35.0%   35.0%
State and local taxes, net of federal income tax benefit   1.2    1.7    2.4 
Decrease (increase) in valuation allowance   0.1    -    0.4 
Foreign tax rate differential   (1.8)   (0.4)   (0.9)
Other   -    (0.9)   0.9 
Effective tax rate   34.5%   35.4%   37.8%

 

The Company operates in various tax jurisdictions, and although it believes that it has provided for income and other taxes in accordance with the relevant regulations, if the applicable regulations were ultimately interpreted differently by a taxing authority, the Company may be exposed to additional tax liabilities.

 

There are no material unrecognized tax benefits included in the consolidated balance sheet that would, if recognized, have a material effect on the Company’s effective tax rate. The Company is continuing its practice of recognizing interest and penalties related to income tax matters in income tax expense. The Company did not recognize interest and penalties during the years ended June 30, 2017 and June 30, 2016. The Company files U.S. federal, U.S. state, and foreign tax returns, and is generally no longer subject to tax examinations for fiscal years prior to 2013 (in the case of certain foreign tax returns, fiscal year 2012).

 

 85 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

(13) Supplemental Cash Flow Information

 

Cash paid for interest and income taxes during fiscal 2017, 2016 and 2015 was as follows:

 

   2017   2016   2015 
Interest  $7,794   $2,970   $3,954 
Income taxes, net of refunds  $7,912   $16,076   $25,459 

 

In connection with the acquisition of certain products and related assets of Citron and Lucid, approximately 5,122 shares of Aceto common stock with a fair value of $90,400, to be issued beginning on December 21, 2019, a $50,000 unsecured deferred payment payable on December 21, 2021 and a contingent earn out liability of $2,580 are non-cash items and are excluded from the Consolidated Statement of Cash Flows during the year ended June 30, 2017. In addition, the Company had non-cash items excluded from the Consolidated Statements of Cash Flows during the years ended June 30, 2017, 2016 and 2015 of $284, $294 and $726, respectively related to capitalized environmental remediation costs and property held for sale and $1,578 measurement period adjustments to goodwill during the year ended June 30, 2015.

 

(14) Retirement Plans

 

Defined Contribution Plans

 

The Company has defined contribution retirement plans in which certain employees are eligible to participate, including deferred compensation plans (see below). The Company's annual contribution per employee, which is at management's discretion, is based on a percentage of the employee’s compensation. The Company's provision for these defined contribution plans amounted to $1,794, $1,957 and $1,849 in fiscal 2017, 2016 and 2015, respectively.

 

Defined Benefit Plans

 

The Company sponsors certain defined benefit pension plans covering certain employees of its German subsidiaries who meet the plan’s eligibility requirements. The accrued pension liability as of June 30, 2017 was $883. The accrued pension liability as of June 30, 2016 was $853. Net periodic pension costs, which consists principally of interest cost and service cost was $30 in fiscal 2017, $28 in fiscal 2016 and $53 in fiscal 2015. The Company’s plans are funded in conformity with the funding requirements of the applicable government regulations. An assumed weighted average discount rate of 2.0%, 1.9% and 1.6% and a compensation increase rate of 0.0% were used in determining the actuarial present value of benefit obligations as of June 30, 2017, 2016 and 2015, respectively.

 

Deferred Compensation Plans

 

To comply with the requirements of the American Jobs Creation Act of 2004, as of December 2004, the Company froze its non-qualified Supplemental Executive Retirement Plan (the Frozen Plan) and has not allowed any further deferrals or contributions to the Frozen Plan after December 31, 2004. All of the earned benefits of the participants in the Frozen Plan as of December 31, 2004, will be preserved under the existing plan provisions.

 

On March 14, 2005, the Company’s Board of Directors adopted the Aceto Corporation Supplemental Executive Deferred Compensation Plan (the Plan). The Plan is a non-qualified deferred compensation plan intended to provide certain qualified executives with supplemental benefits beyond the Company’s 401(k) plan, as well as to permit additional deferrals of a portion of their compensation. The Plan is intended to comply with the provisions of section 409A of the Internal Revenue Code of 1986, as amended, and is designed to provide comparable benefits to those under the Frozen Plan. Substantially all compensation deferred under the Plan, as well as Company contributions, is held by the Company in a grantor trust, which is considered an asset of the Company. The assets held by the grantor trust are in life insurance policies. Effective July 1, 2013, the Plan was frozen and a new plan, entitled “Aceto Corporation 2013 Senior Executive Retirement Plan” was adopted by the Company’s Board of Directors.

 

 86 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

As of June 30, 2017, the Company recorded a liability under the Plans of $3,551 (of which $3,337 is included in long-term liabilities and $214 is included in accrued expenses) and an asset (included in other assets) of $3,087, primarily representing mutual fund investments owned by the Company. As of June 30, 2016, the Company recorded a liability under the Plans of $3,046 (of which $3,028 is included in long-term liabilities and $18 is included in accrued expenses) and an asset (included in other assets) of $2,693, primarily representing the cash surrender value of policies owned by the Company.

 

(15) Financial Instruments

 

Derivative Financial Instruments

 

The Company is exposed to credit losses in the event of non-performance by the financial institutions, who are the counterparties, on its future foreign currency contracts. The Company anticipates, however, that the financial institutions will be able to fully satisfy their obligations under the contracts. The Company does not obtain collateral to support financial instruments, but monitors the credit standing of the financial institutions.

 

Fair Value of Financial Instruments

 

The carrying values of all financial instruments classified as a current asset or current liability are deemed to approximate fair value because of the short maturity of these instruments. The fair value of the Company’s notes receivable and accrued expenses was based upon current rates offered for similar financial instruments to the Company. The Company believes that borrowings outstanding under its long-term bank loans and mortgage approximate fair value because such borrowings bear interest at current variable market rates.

 

Business and Credit Concentration

 

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of trade receivables. The Company’s customers are dispersed across many industries and are located throughout the United States as well as in Canada, France, Germany, Malaysia, The Netherlands, Switzerland, the United Kingdom, and other countries. The Company estimates an allowance for doubtful accounts based upon the creditworthiness of its customers as well as general economic conditions. Consequently, an adverse change in those factors could affect the Company’s estimate of this allowance. At June 30, 2017, three customers approximated 31%, 21% and 15%, respectively, of net trade accounts receivable. At June 30, 2016, three customers approximated 34%, 20% and 11%, respectively, of net trade accounts receivable.

 

One customer accounted for 12% of net sales in fiscal 2017, 14% of net sales in fiscal 2016 and 13% of net sales in fiscal 2015. Another customer accounted for 11% of net sales in fiscal 2017, 7% of net sales in 2016 and 6% of net sales in 2015. No single product accounted for as much as 10% of net sales in fiscal 2017, 2016 or 2015.

 

During the fiscal years ended June 30, 2017, 2016 and 2015, approximately 62%, 56% and 65%, respectively, of the Company’s purchases came from Asia and approximately 17%, 22% and 12%, respectively, came from Europe.

 

The Company maintains operations located outside of the United States. Net assets located in Europe and Asia approximated $68,235 and $50,641, respectively at June 30, 2017. Net assets located in Europe and Asia approximated $62,399 and $48,846, respectively at June 30, 2016.

 

(16) Commitments, Contingencies and Other Matters

 

As of June 30, 2017, the Company has outstanding purchase obligations totaling $61,381 with suppliers to the Company’s domestic and foreign operations to acquire certain products for resale to third party customers.

 

 87 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

The Company and its subsidiaries are subject to various claims which have arisen in the normal course of business. The Company provides for costs related to contingencies when a loss from such claims is probable and the amount is reasonably determinable. In determining whether it is possible to provide an estimate of loss, or range of possible loss, the Company reviews and evaluates its litigation and regulatory matters on a quarterly basis in light of potentially relevant factual and legal developments. If the Company determines an unfavorable outcome is not probable or reasonably estimable, the Company does not accrue for a potential litigation loss. While the Company has determined that there is a reasonable possibility that a loss has been incurred, no amounts have been recognized in the financial statements, other than what has been discussed below, because the amount of the liability cannot be reasonably estimated at this time.

 

In fiscal years 2011, 2009, 2008 and 2007, the Company received letters from the Pulvair Site Group, a group of potentially responsible parties (PRP Group) who are working with the State of Tennessee (the State) to remediate a contaminated property in Tennessee called the Pulvair site. The PRP Group has alleged that Aceto shipped hazardous substances to the site which were released into the environment. The State had begun administrative proceedings against the members of the PRP Group and Aceto with respect to the cleanup of the Pulvair site and the PRP Group has begun to undertake cleanup. The PRP Group is seeking a settlement of approximately $1,700 from the Company for its share to remediate the site contamination. Although the Company acknowledges that it shipped materials to the site for formulation over twenty years ago, the Company believes that the evidence does not show that the hazardous materials sent by Aceto to the site have significantly contributed to the contamination of the environment and thus believes that, at most, it is a de minimis contributor to the site contamination. Accordingly, the Company believes that the settlement offer is unreasonable. Management believes that the ultimate outcome of this matter will not have a material adverse effect on the Company's financial condition or liquidity.

 

The Company has environmental remediation obligations in connection with Arsynco, Inc. (“Arsynco”), a subsidiary formerly involved in manufacturing chemicals located in Carlstadt, New Jersey, which was closed in 1993 and is currently held for sale. Based on continued monitoring of the contamination at the site and the approved plan of remediation, Arsynco received an estimate from an environmental consultant stating that the costs of remediation could be between $21,500 and $23,300. Remediation commenced in fiscal 2010, and as of June 30, 2017 and June 30, 2016, a liability of $8,451 and $12,532, respectively, is included in the accompanying consolidated balance sheets for this matter. For the year ended June 30, 2017, the Company recorded environmental remediation charges of $903 which is included in selling, general and administrative expenses in the accompanying consolidated statements of income for the year ended June 30, 2017. In accordance with GAAP, management believes that the majority of costs incurred to remediate the site will be capitalized in preparing the property which is currently classified as held for sale. An appraisal of the fair value of the property by a third-party appraiser supports the assumption that the expected fair value after the remediation is in excess of the amount required to be capitalized. However, these matters, if resolved in a manner different from those assumed in current estimates, could have a material adverse effect on the Company’s financial condition, operating results and cash flows when resolved in a future reporting period.

 

In connection with the environmental remediation obligation for Arsynco, in July 2009, Arsynco entered into a settlement agreement with BASF Corporation (“BASF”), the former owners of the Arsynco property. In accordance with the settlement agreement, BASF paid for a portion of the prior remediation costs and going forward, will co-remediate the property with the Company. The contract requires that BASF pay $550 related to past response costs and pay a proportionate share of the future remediation costs. Accordingly, the Company had recorded a gain of $550 in fiscal 2009. This $550 gain relates to the partial reimbursement of costs of approximately $1,200 that the Company had previously expensed. The Company also recorded an additional receivable from BASF, with an offset against property held for sale, representing its estimated portion of the future remediation costs. The balance of this receivable for future remediation costs as of June 30, 2017 and June 30, 2016 is $3,803 and $5,639, respectively, which is included in the accompanying consolidated balance sheets.

 

 88 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

In March 2006, Arsynco received notice from the EPA of its status as a PRP under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) for a site described as the Berry’s Creek Study Area (“BCSA”). Arsynco is one of over 150 PRPs which have potential liability for the required investigation and remediation of the site. The estimate of the potential liability is not quantifiable for a number of reasons, including the difficulty in determining the extent of contamination and the length of time remediation may require. In addition, any estimate of liability must also consider the number of other PRPs and their financial strength. In July 2014, Arsynco received notice from the U.S. Department of Interior (“USDOI”) regarding the USDOI’s intent to perform a Natural Resource Damage (NRD) Assessment at the BCSA. Arsynco has to date declined to participate in the development and performance of the NRD assessment process. Based on prior practice in similar situations, it is possible that the State may assert a claim for natural resource damages with respect to the Arsynco site itself, and either the federal government or the State (or both) may assert claims against Arsynco for natural resource damages in connection with Berry's Creek; any such claim with respect to Berry's Creek could also be asserted against the approximately 150 PRPs which the EPA has identified in connection with that site. Any claim for natural resource damages with respect to the Arsynco site itself may also be asserted against BASF, the former owners of the Arsynco property. In September 2012, Arsynco entered into an agreement with three of the other PRPs that had previously been impleaded into New Jersey Department of Environmental Protection, et al. v. Occidental Chemical Corporation, et al., Docket No. ESX-L-9868-05 (the "NJDEP Litigation") and were considering impleading Arsynco into the same proceeding. Arsynco entered into an agreement to avoid impleader. Pursuant to the agreement, Arsynco agreed to (1) a tolling period that would not be included when computing the running of any statute of limitations that might provide a defense to the NJDEP Litigation; (2) the waiver of certain issue preclusion defenses in the NJDEP Litigation; and (3) arbitration of certain potential future liability allocation claims if the other parties to the agreement are barred by a court of competent jurisdiction from proceeding against Arsynco. In July 2015, Arsynco was contacted by an allocation consultant retained by a group of the named PRPs, inviting Arsynco to participate in the allocation among the PRPs’ investigation and remediation costs relating to the BCSA. Arsynco declined that invitation. Since an amount of the liability cannot be reasonably estimated at this time, no accrual is recorded for these potential future costs. The impact of the resolution of this matter on the Company’s results of operations in a particular reporting period is not currently known.

 

A subsidiary of the Company markets certain agricultural protection products which are subject to the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA). FIFRA requires that test data be provided to the EPA to register, obtain and maintain approved labels for pesticide products. The EPA requires that follow-on registrants of these products compensate the initial registrant for the cost of producing the necessary test data on a basis prescribed in the FIFRA regulations. Follow-on registrants do not themselves generate or contract for the data. However, when FIFRA requirements mandate that new test data be generated to enable all registrants to continue marketing a pesticide product, often both the initial and follow-on registrants establish a task force to jointly undertake the testing effort. The Company is presently a member of several such task force groups, which requires payments for such memberships. In addition, in connection with our agricultural protection business, the Company plans to acquire product registrations and related data filed with the United States Environmental Protection Agency to support such registrations and other supporting data for several products. The acquisition of these product registrations and related data filed with the United States Environmental Protection Agency as well as payments to various task force groups could approximate $2,357 through fiscal 2018, of which $0 has been accrued as of June 30, 2017 and June 30, 2016.

 

The Company leases office facilities in the United States, The Netherlands, Germany, France, Singapore and the Philippines expiring at various dates between October 2017 and June 2021.

 

At June 30, 2017, the future minimum lease payments for office facilities and equipment for each of the five succeeding years and in the aggregate are as follows:

 

Fiscal year  Amount 
2018  $1,673 
2019   2,327 
2020   1,766 
2021   1,327 
2022   1,031 
Thereafter   6,744 
   $14,868 

 

Total rental expense amounted to $1,301, $1,265 and $1,567 for fiscal 2017, 2016 and 2015, respectively.

 

(17) Related Party Transactions

 

During fiscal 2017, 2016 and 2015, the Company purchased inventory from its corporate joint venture in the amount of $3,236, $2,831 and $3,204, respectively.

 

 89 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

During fiscal 2017, Rising Health and Acetris Health incurred costs of $1,865 and $165, respectively, related to consulting services provided by former Citron and Lucid employees, in connection with a transition services agreement entered into at the time of the Company’s 2016 product purchase agreement. Citron and Lucid are affiliates of Vimal Kavuru, a member of the Company’s Board of Directors.

 

In October 2017, Rising will commence leasing approximately 125,000 gross square feet of warehouse space in Somerset, New Jersey. This building is owned by an affiliate of Mr. Kavuru.

 

On November 2, 2016, the Company, Citron and Cronus Research Labs Private Limited, a research and development company headquartered in India that is affiliated with Vimal Kavuru (“Cronus”), entered into two amended and restated joint development agreements pursuant to which Cronus has been engaged to develop a portfolio of nine pipeline products (“Development Agreement I”) and certain other products (“Development Agreement II” and together with Development Agreement I, the “Development Agreements”) on behalf of Citron. Under the terms of Development Agreement I, Cronus has agreed to pay the first $3,500 of the development costs incurred after December 21, 2016, and 50% of any development costs incurred above that threshold in exchange for obtaining reimbursement for its costs funded out of the profits earned, if any, from the pipeline products that are commercially launched, and a specified portion of the profits from those products thereafter. Under the terms of Development Agreement II, Cronus has agreed to pay the development costs for the products covered thereby in exchange for obtaining reimbursement for its costs funded out of the profits earned, if any, from such products that are commercially launched (subject to a $1,445 maximum), and a specified portion of the profits from those products thereafter.

 

Mr. Kavuru was not a member of the Company’s Board at the time that the above-mentioned transition services agreement, lease or Development Agreements were executed.

 

(18) Recent Accounting Pronouncements

 

In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting, which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-09 is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. The Company does not believe this new accounting standard update will have a material impact on its consolidated financial statements.

 

In January 2017, the FASB issued ASU 2017-04 Intangibles - Goodwill and Other (Topic 350) which would eliminate the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Instead, the amount of an impairment charge would be recognized if the carrying amount of a reporting unit is greater than its fair value. ASU 2017-04 is effective for public companies for fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company does not believe this new accounting pronouncement will have a material impact on its consolidated financial statements.

 

In January 2017, the FASB issued ASU 2017-01 Business Combinations (Topic 805): Clarifying the Definition of a Business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. ASU 2017-01 is effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company does not believe this new accounting pronouncement will have a material impact on its consolidated financial statements.

 

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which addresses eight specific cash flow issues with the objective of reducing diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact of the provisions of ASU 2016-15.

 

 90 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which will change certain aspects of accounting for share-based payments to employees. ASU 2016-09 is effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2016. ASU 2019-09 requires that all tax benefits and deficiencies related to share-based payments be recognized and recorded through the statement of income for all awards settled or expiring after the adoption of ASU 2016-09. Under prior guidance, tax benefits in excess of compensation costs ("windfalls") were recorded in equity, and any tax deficiencies ("shortfalls") were recorded in equity to the extent of previous windfalls and then to the statement of income. ASU 2016-09 also requires, either prospectively or retrospectively, that all tax-related cash flows resulting from share-based payments be reported as operating activities on the statement of cash flows, a change from prior guidance that required windfall tax benefits to be presented as an inflow from financing activities and an outflow from operating activities on the statement of cash flows. Additionally, ASU 2016-09 allows entities to make an accounting policy election for the impact of most types of forfeitures on the recognition of expense for share-based payment awards by allowing the forfeitures to be either estimated, as was required under prior guidance, or recognized when they actually occur. Under ASU 2016-09, it is possible for equity awards to have a more dilutive effect on earnings per share (EPS). Under prior guidance, anticipated income tax windfalls and shortfalls were included in the calculation of assumed proceeds when applying the treasury stock method for computing the dilutive effect of share-based awards in the calculation of diluted EPS. Because there is no longer any excess tax benefits recognized in additional paid capital under ASU 2016-09, when applying the treasury stock method for computing diluted EPS, the assumed proceeds do not include any windfall tax benefits. As a result, fewer hypothetical shares can be repurchased under the treasury stock method, resulting in an assumption of more incremental shares being issued upon the exercise of shared-based awards. Therefore, equity awards have a more dilutive effect on EPS for any period where the average market price of an entity's underlying stock exceeds the average fair value of outstanding dilutive equity awards for the period.  The provisions of ASU 2016-09 are effective for the Company at the beginning of fiscal 2018. The impact of ASU 2016-09 on the Company's income tax expense or benefit and related cash flows during and after the period of adoption are dependent in part upon future grants and vesting of stock-based compensation awards and other factors that are not fully controllable or predicable by the Company such as the future market price of the Company's common stock, the timing of employee exercises of vested stock options, and the future achievement of performance criteria that affect performance-based awards. Under ASU 2016-09, the Company will recognize forfeitures when they actually occur.

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) that replaces existing lease guidance. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. The new guidance will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of income. ASU 2016-02 is effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2018. The Company is currently evaluating the impact of the provisions of ASU 2016-02.

 

In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740) Balance Sheet Classification of Deferred Assets. This ASU is intended to simplify the presentation of deferred taxes on the balance sheet and will require an entity to present all deferred tax assets and deferred tax liabilities as non-current on the balance sheet. Under the current guidance, entities are required to separately present deferred taxes as current or non-current. Netting deferred tax assets and deferred tax liabilities by tax jurisdiction will still be required under the new guidance. This guidance will be effective for Aceto beginning in the first quarter of fiscal 2018. The Company does not believe this new accounting standard update will have a material impact on its consolidated financial statements.

 

In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330) – Simplifying the Measurement of Inventory. This ASU requires that an entity measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The adoption of this standard will not have any impact on the consolidated financial statements of the Company.

 

 91 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which is the new comprehensive revenue recognition standard that will supersede all existing revenue recognition guidance under U.S. GAAP. The standard's core principle is that a company will recognize revenue when it transfers promised goods or services to a customer in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB subsequently issued ASU 2015-14, Revenue from Contracts with Customers - Deferral of the Effective Date, which approved a one year deferral of ASU 2014-09 for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. In March 2016 and April 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers - Principal versus Agent Considerations (Reporting Revenue Gross versus Net), and ASU 2016-10, Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing, respectively, which further clarify the guidance related to those specific topics within ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients, to reduce the risk of diversity in practice for certain aspects in ASU 2014-09, including collectibility, noncash consideration, presentation of sales tax and transition. Additionally, in December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers. ASU 2016-20 makes minor corrections or minor improvements to the standard that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. The Company has made progress in its evaluation of the amended guidance, including identification of revenue streams. The Company recognizes revenue from product sales at the time of shipment and passage of title and risk of loss and control of the goods is transferred to the customer. The Company has no acceptance or other post-shipment obligations and does not offer product warranties or services to its customers. Although the Company is continuing to assess the impact of the amended guidance, Aceto generally anticipates that the timing of recognition of revenue will be substantially unchanged under the amended guidance. The Company is continuing to evaluate the impact on certain other transactions including third-party collaborations and other arrangements. The amended guidance will be effective for Aceto in the first quarter of fiscal 2019 and permits adoption under either the full retrospective approach (recognize effects of the amended guidance in each prior reporting period presented) or the modified retrospective approach (recognize the cumulative effect of adoption as an adjustment to retained earnings at the date of initial application). The Company anticipates adopting this amended standard on a modified retrospective basis.

 

(19) Segment Information

 

The Company's business is organized along product lines into three principal segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals.

 

Human Health - includes finished dosage form generic drugs and nutraceutical products.

 

Pharmaceutical Ingredients – includes pharmaceutical intermediates and active pharmaceutical ingredients (“APIs”).

 

Performance Chemicals - The Performance Chemicals segment is made up of two product groups: Specialty Chemicals and Agricultural Protection Products. Specialty Chemicals include a variety of chemicals used in the manufacture of plastics, surface coatings, cosmetics and personal care, textiles, fuels and lubricants, perform to their designed capabilities. Dye and pigment intermediates are used in the color-producing industries such as textiles, inks, paper, and coatings. Organic intermediates are used in the production of agrochemicals.

 

Agricultural Protection Products include herbicides, fungicides and insecticides that control weed growth as well as control the spread of insects and other microorganisms that can severely damage plant growth.

 

The Company's chief operating decision maker evaluates performance of the segments based on net sales, gross profit and income before income taxes. Unallocated corporate amounts are deemed by the Company as administrative, oversight costs, not managed by the segment managers. The Company does not allocate assets by segment because the chief operating decision maker does not review the assets by segment to assess the segments' performance, as the assets are managed on an entity-wide basis. During all periods presented, our chief operating decision maker has been the Chief Executive Officer of the Company. In accordance with GAAP, the Company has aggregated certain operating segments into reportable segments because they have similar economic characteristics, and the operating segments are similar in all of the following areas: (a) the nature of the products and services; (b) the nature of the production processes; (c) the type or class of customer for their products and services; (d) the methods used to distribute their products or provide their services; and (e) the nature of the regulatory environment.

 

 92 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

   Human
Health		   Pharmaceutical
Ingredients		   Performance
Chemicals		   Unallocated
Corporate		   Consolidated
Totals		 
2017                         
Net sales  $315,395   $157,445   $165,478   $-   $638,318 
Gross profit   78,109    25,474    37,209    -    140,792 
Income before income taxes   15,434    9,322    18,829    (26,224)   17,361 
                          
2016                         
Net sales  $228,035   $161,011   $169,478   $-   $558,524 
Gross profit   77,880    28,752    36,153    -    142,785 
Income before income taxes   36,362    11,856    17,799    (12,163)   53,854 
                          
2015                         
Net sales  $225,263   $149,296   $172,392   $-   $546,951 
Gross profit   75,749    26,683    33,002    -    135,434 
Income before income taxes   35,152    8,697    14,289    (4,273)   53,865 

 

Net sales and gross profit by source country for the years ended June 30, 2017, 2016 and 2015 were as follows:

 

   Net Sales   Gross Profit 
   2017   2016   2015   2017   2016   2015 
United States  $483,678   $400,883   $407,101   $116,792   $117,180   $111,734 
Germany   79,105    76,666    69,889    13,609    15,154    14,660 
Netherlands   9,949    16,217    14,656    1,231    1,598    1,325 
France   35,796    30,177    27,976    4,651    4,043    3,634 
Asia-Pacific   29,790    34,581    27,329    4,509    4,810    4,081 
Total  $638,318   $558,524   $546,951   $140,792   $142,785   $135,434 

 

Sales generated from the United States to foreign countries amounted to $21,750, $23,810 and $38,295 for the fiscal years ended June 30, 2017, 2016 and 2015, respectively.

 

Long-lived assets by geographic region as of June 30, 2017 and June 30, 2016 were as follows:

 

   Long-lived assets 
   2017   2016 
United States  $528,359   $152,701 
Europe   2,538    2,504 
Asia-Pacific   1,582    1,781 
Total  $532,479   $156,986 

 

 93 

 

 

ACETO CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2017, 2016 AND 2015

(in thousands, except per-share amounts)

 

(20) Unaudited Quarterly Financial Data

 

The following is a summary of the unaudited quarterly results of operations for the years ended June 30, 2017 and 2016.

 

   For the quarter ended 
Fiscal year ended June 30, 2017  September 30,
2016 (1)		   December 31,
2016(2)		   March 31,
2017(2)(3)		   June 30,
2017 (2)(4)		 
Net sales  $128,018   $125,552   $190,128   $194,620 
Gross profit   30,839    30,805    42,319    36,829 
Net income (loss)   4,385    (564)   5,588    1,967 
                     
Net income (loss) per diluted share  $0.15   $(0.02)  $0.16   $0.06 

 

   For the quarter ended 
Fiscal year ended June 30, 2016  September 30,
2015		   December 31,
2015		   March 31,
2016(5)		   June 30,
2016(6)		 
Net sales  $133,500   $131,674   $157,926   $135,424 
Gross profit   34,581    35,868    38,289    34,047 
Net income   9,298    8,270    10,424    6,774 
                     
Net income per diluted share  $0.32   $0.28   $0.35   $0.23 

 

The net income per common share calculation for each of the quarters is based on the weighted average number of shares outstanding in each period. Therefore, the sum of the quarters in a year does not necessarily equal the year’s net income per common share.

 

(1) Includes pretax item of $170 environmental remediation charge in connection with Arsynco.

(2) Results for the last nine days of the quarter ended December 31, 2016 and for the subsequent two quarters reflect the acquisition of certain generic products and related assets from Citron and Lucid on December 21, 2016.

(3) Includes pretax item of $733 environmental remediation charge in connection with Arsynco.

(4) Includes pretax item of $3,139 representing immaterial correction of an error associated with certain accrued expenses.

(5) Includes pretax items consisting of $833 reversal of contingent consideration related to the PACK acquisition and $241 reversal of contingent consideration related to the acquisition of a company in France.

(6) Includes pretax item of $1,313 environmental remediation charge in connection with Arsynco.

 

 94 

 

 

Schedule II

 

ACETO CORPORATION AND SUBSIDIARIES

 

Valuation and Qualifying Accounts

 

For the years ended June 30, 2017, 2016 and 2015

(dollars in thousands)

 

Description  Balance at
beginning of
year		   Charged to
costs and
expenses		   Charged to
other
accounts		   Deductions   Balance at
end of year		 
Year ended June 30, 2017                         
Allowance for doubtful accounts  $513   $(3)   -   $25(a)  $485 
Year ended June 30, 2016                         
Allowance for doubtful accounts  $691   $76    -   $254(a)  $513 
Year ended June 30, 2015                         
Allowance for doubtful accounts  $517   $484    -   $310(a)  $691 

 

(a) Specific accounts written off as uncollectible.

 

 95 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  ACETO CORPORATION
     
  By /s/ Salvatore Guccione
  Salvatore Guccione, President and Chief Executive Officer
  (Principal Executive Officer)
   
  Date: August 25, 2017

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the dates indicated.

 

Signatures   Title   Date
         
/s/Salvatore Guccione   President and Chief Executive Officer   08-25-17
Salvatore Guccione   (Principal Executive Officer)    
         
/s/Douglas Roth   Assistant Secretary/Treasurer and   08-25-17
Douglas Roth   Chief Financial Officer    
   

(Principal Financial and Accounting Officer)

    
         
/s/ Albert L. Eilender   Chairman   08-25-17
Albert L. Eilender        
         
/s/ Vimal Kavuru   Director   08-25-17
Vimal Kavuru        
         
/s/Hans C. Noetzli   Director   08-25-17

Hans C. Noetzli

        
         
/s/William N. Britton   Director   08-25-17
William Britton        
         
/s/ Natasha Giordano   Director   08-25-17
Natasha Giordano        
         
/s/Alan G. Levin   Director   08-25-17
Alan G. Levin        
         
/s/ Daniel Yarosh   Director   08-25-17
Daniel Yarosh  

 

    
         
/s/ William C. Kennally III   Director   08-25-17
William C. Kennally III        

 

 96 

 

 

EXHIBIT INDEX

 

Exhibit Number   Description
     
2.1   Asset Purchase Agreement by and among Aceto Corporation, Sun Acquisition Corp., Rising Pharmaceuticals, Inc., Ronald Gold, and David B. Rosen, dated as of December 15, 2010 (incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K dated December 20, 2010).
     
2.2   First Amendment to Asset Purchase Agreement, dated as of December 31, 2010, by and among Aceto Corporation, Sun Acquisition Corp., Rising Pharmaceuticals, Inc., Ronald Gold and David B. Rosen (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K dated January 5, 2011).
     
2.3   Second Amendment, dated as of December 21, 2012, to Asset Purchase Agreement, dated as of December 15, 2010, by and among Aceto Corporation, Rising Pharmaceuticals, Inc., Pearl Ventures Inc., Ronald Gold and David B. Rosen (incorporated by reference to Exhibit 10.3 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2012).
     
2.4   Membership Interest Purchase Agreement, dated March 26, 2014, by and among PACK Pharmaceuticals, LLC, the Aschenbrand and O’Brien Family Trust, dated March 2001, Bryan Aschenbrand – Trustee, Dushyant Chipalkattty, Chris Dungan, Aceto Corporation, Rising Pharmaceuticals, Inc. and Chris Dungan, solely in his capacity as the representative of the Sellers (incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K dated March 28, 2014).
     
2.5   Form of Lock-up Agreement (incorporated by reference to Exhibit 2.2 to our Current Report on Form 8-K dated March 28, 2014).
     
2.6   Product Purchase Agreement, by and among Aceto Corporation, Cedar Pharma LLC (f/k/a Citron Pharma LLC and referred to herein as “Citron”), Aster Pharma LLC (f/k/a Lucid Pharma LLC and together with Citron, the “Sellers”), the direct and indirect equity owners of the Sellers (the Members), Rising Health, LLC (“Purchaser I”), Acetris Health, LLC (together with Purchaser I, the “Purchasers”) and an agent for the Sellers and the Members (the “Agent”), dated as of November 2, 2016 (incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K dated November 2, 2016).
     
2.7   Amendment No. 1 to the Product Purchase Agreement, by and among the Purchasers and the Agent, dated as of December 2, 2016 (incorporated by reference to Exhibit 2.2 to our Current Report on Form 8-K dated December 21, 2016).
     
2.8   Transaction Agreement Amendment and Waiver, dated as of December 21, 2016, by and among the Purchasers, the Agent, Rising Pharmaceuticals, Inc. and Vimal Kavuru (incorporated by reference to Exhibit 2.3 to our Current Report on Form 8-K dated December 21, 2016).
     
3.1   Amended and Restated Certificate of Incorporation filed with the Department of State of the State of New York on November 9, 2015 (incorporated by reference to Exhibit 3.1 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2016).
     
3.2   Amendment to the Amended and Restated Certificate of Incorporation filed with the Department of State of the State of New York on December 15, 2015 (incorporated by reference to Exhibit 3.2 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2016).
     

3.3

 

 

   Amendment to the Amended and Restated Certificate of Incorporation filed with the Department of State of the State of New York on December 9, 2016 (incorporated by reference to Exhibit 3.3 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2016).
     
3.4   Aceto Corporation By-Laws, amended July 28, 2014 (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K dated July 31, 2014).

 

 97 

 

 

4.1   Indenture, dated November 16, 2015 between Aceto Corporation and Citibank, N.A. (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K dated November 16, 2015).
     
4.2   Form of Global 2.00% Convertible Senior Note due 2020 (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K dated November 16, 2015).
     
10.1   Aceto Corporation 401(k) Retirement Plan, as amended and restated as of July 1, 2002 (incorporated by reference to Exhibit 10.1 to the Company’s annual report on Form 10-K for the fiscal year ended June 30, 2004 (File Number: 000-04217, Film Number: 041025874)).
     
10.2   Supplemental Executive Retirement Plan, as amended and restated effective June 30, 2004 and frozen as of December 31, 2004 (incorporated by reference to Exhibit 10.2 to the Company’s annual report on Form 10-K for the fiscal year ended June 30, 2004 (File Number: 000-04217, Film Number: 041025874)).
     
10.3   1998 Omnibus Equity Award Plan (incorporated by reference to Exhibit 10(v) (c) to the Company’s annual report on Form 10-K for the fiscal year ended June 30, 1999 (File Number: 000-04217, Film Number: 99718824)).
     
10.4   Supplemental Executive Deferred Compensation Plan, effective March 14, 2005 (incorporated by reference to Exhibit 10.1 to the Company’s current report on Form 8-K filed with the Securities and Exchange Commission on March 17, 2005 (File Number: 000-04217, Film Number: 05688328)).
     
10.5   2007 Long-Term Performance Incentive Plan (incorporated by reference to Exhibit 4.1 to Registration Statement No. 333-149586 on Form S-8).
     
10.6   Supplemental Executive Deferred Compensation Plan, amended and restated effective December 8, 2008 (incorporated by reference to Exhibit 10.22 to the Company’s annual report on Form 10-K for the year ended June 30, 2009).
     
10.7   Purchase and Sale Agreement among Schweizerhall Holding AG, Chemische Fabrik Schweizerhall, Schweizerhall, Inc., Aceto Corporation and Aceto Holding B.V., I.O., dated as of January 28, 2001 (incorporated by reference to Exhibit 2.1 to the Company’s current report on Form 8-K filed with the Securities and Exchange Commission on April 4, 2001 (File Number: 000-04217, Film Number: 1595350)).
     
10.8   Form of purchase agreement between Shanghai Zhongjin Real Estate Development Company Limited and Aceto (Hong Kong) Limited, dated November 10, 2004 (incorporated by reference to Exhibit 10.1 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2004 (File Number: 000-04217, Film Number: 05588472)).
     
10.9   Guarantee by Aceto Corporation and subsidiaries in favor of Deutsche Bank, AG, dated March 22, 2001 (incorporated by reference to Exhibit 10.13 to the Company’s annual report on Form 10-K for the year ended June 30, 2001 (File Number: 000-04217, Film Number: 1748270)).
     
10.10   Reaffirmation Agreement by Aceto Corporation, Aceto Agricultural Chemicals Corporation, CDC Products Corporation, Aceto Pharma Corp., Aceto Realty LLC, Acci Realty Corp. and Arsynco Inc., dated as of April 23, 2010 (incorporated by reference to Exhibit 10.3 to the Company’s current report on Form 8-K filed with the Securities and Exchange Commission on April 28, 2010).
     

10.11

 

   Aceto Corporation 2010 Equity Participation Plan (incorporated by reference to Appendix A to our Definitive Proxy Statement on Schedule 14A filed on October 13, 2010).
     
10.12   Aceto Corporation Severance Policy (incorporated by reference to Exhibit 10.4 to our Current Report on Form 8-K dated January 17, 2012).
     
10.13   Aceto Corporation Executive Performance Award Plan (incorporated by reference to Appendix A to our Definitive Proxy Statement on Schedule 14A filed on October 18, 2012).

 

 98 

 

 

10.14   Amended and Restated Aceto Corporation 2010 Equity Participation Plan (incorporated by reference to Appendix B to our Definitive Proxy Statement on Schedule 14A filed on October 18, 2012).
     

10.15

 

   Enhanced Severance Protection Letter Agreement, dated April 3, 2013 between Aceto Corporation and Douglas Roth (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated April 5, 2013).
     
10.16   Aceto Corporation 2013 Senior Executive Retirement Plan (incorporated by reference to Exhibit 10.1 to the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2013).
     

10.17

 

   Note Modification Agreement, dated October 21, 2013, between Aceto Realty LLC and JPMorgan Chase Bank, N.A. (incorporated by reference to Exhibit 10.1 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2013).
     

10.18

 

   Amendment No. 1, dated as of December 26, 2013 to the Change in Control Agreement, dated as of July 2, 2012, by and between the Company and Salvatore J. Guccione (incorporated by reference to Exhibit 10.2 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2013).
     
10.19   Commitment Letter dated March 26, 2014, by and among, Aceto Corporation and the Lead Arrangers and Commitment Lenders (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated March 28, 2014).
     
10.20   Credit Agreement, dated as of April 30, 2014, by and among Aceto Corporation, JPMorgan Chase Bank, N.A. as Administrative Agent, Wells Fargo, as Syndication Agent, and the Lenders (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated May 2, 2014).
     
10.21   Employment Agreement, effective as of January 1, 2015, between Aceto Corporation and Salvatore Guccione (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated December 18, 2014).
     
10.22   Change in Control Agreement by and between Aceto Corporation and Terry Kippley, dated as of November 5, 2014 (incorporated by reference to Exhibit 10.2 to the Company’s quarterly report on Form 10-Q for the quarter ended December 31, 2014).
     
10.23   Change in Control Agreement by and between Aceto Corporation and Salvatore Guccione (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated February 18, 2015).
     
10.24   Change in Control Agreement by and between Aceto Corporation and Albert L. Eilender (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K dated February 18, 2015).
     
10.25   Change in Control Agreement by and between Aceto Corporation and Douglas Roth (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K dated February 18, 2015).
     
10.26   Change in Control Agreement by and between Aceto Corporation and Frank DeBenedittis (incorporated by reference to Exhibit 10.4 to our Current Report on Form 8-K dated February 18, 2015).
     
10.27   Change in Control Agreement by and between Aceto Corporation and Satish Srinivasan (incorporated by reference to Exhibit 10.5 to our Current Report on Form 8-K dated February 18, 2015).
     
10.28   Change in Control Agreement by and between Aceto Corporation and Charles J. Alaimo, dated as of February 13, 2015 (incorporated by reference to Exhibit 10.6 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2015).
     
10.29   Change in Control Agreement by and between Aceto Corporation and Raymond B. Bartone, dated as of February 13, 2015 (incorporated by reference to Exhibit 10.7 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2015).

 

 99 

 

 

10.30   Change in Control Agreement by and between Aceto Corporation and Terry Kippley, dated as of February 13, 2015 (incorporated by reference to Exhibit 10.8 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2015).
     
10.31   Change in Control Agreement by and between Aceto Corporation and Steven S. Rogers, dated as of February 13, 2015 (incorporated by reference to Exhibit 10.10 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2015).
     
10.32   Change in Control Agreement by and between Aceto Corporation and Nicholas I. Shackley, dated as of February 13, 2015 (incorporated by reference to Exhibit 10.11 to the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2015).
     
10.33   Amendment No. 1, dated as of June 25, 2015, to the Credit Agreement, dated as of April 30, 2014, by and among Aceto Corporation, JPMorgan Chase Bank, N.A. as Administrative Agent and the Lenders (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated June 25, 2015).
     
10.34   Aceto Corporation 2015 Equity Participation Plan (incorporated by reference to Appendix B to our Definitive Proxy Statement on Schedule 14A filed on October 26, 2015).
     
10.35   Amended and Restated Credit Agreement, dated as of October 28, 2015, by and among Aceto Corporation, the other loan parties thereto, JPMorgan Chase Bank N.A., as administrative agent, Wells Fargo Bank, National Association, as syndication agent, and the lenders party thereto (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated October 28, 2015).
     
10.36   Purchase Agreement, dated November 10, 2015, by and among Aceto Corporation and Wells Fargo Securities, LLC and J.P. Morgan Securities LLC, as representatives of the initial purchasers named therein (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated November 12, 2015).
     
10.37   Convertible Note Hedge Confirmation, dated November 10, 2015, between Aceto Corporation and Wells Fargo Bank, National Association (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K dated November 12, 2015).
     
10.38   Convertible Note Hedge Confirmation, dated November 10, 2015, between Aceto Corporation and JPMorgan Chase Bank, National Association (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K dated November 12, 2015).
     
10.39   Warrant Confirmation, dated November 10, 2015, between ACETO Corporation and Wells Fargo Bank, National Association (incorporated by reference to Exhibit 10.4 to our Current Report on Form 8-K dated November 12, 2015).
     
10.40   Warrant Confirmation, dated November 10, 2015, between ACETO Corporation and JPMorgan Chase Bank, National Association (incorporated by reference to Exhibit 10.5 to our Current Report on Form 8-K dated November 12, 2015).
     
10.41   Amendment No. 1 to the Amended and Restated Credit Agreement, dated as of October 28, 2015, by and among Aceto Corporation, the other loan parties thereto, JPMorgan Chase Bank, N.A., as administrative agent, Wells Fargo Bank, National Association, as syndication agent, and the lenders party thereto (incorporated by reference to Exhibit 10.6 to our Current Report on Form 8-K dated November 12, 2015).
     
10.42   Additional Convertible Note Hedge Confirmation, dated November 18, 2015, between Aceto Corporation and Wells Fargo Bank, National Association (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated November 23, 2015).
     
10.43   Additional Convertible Note Hedge Confirmation, dated November 18, 2015, between Aceto Corporation and JPMorgan Chase Bank, National Association (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K dated November 23, 2015).

 

 100 

 

 

10.44   Additional Warrant Confirmation, dated November 18, 2015, between Aceto Corporation and Wells Fargo Bank, National Association (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K dated November 23, 2015).
     
10.45   Additional Warrant Confirmation, dated November 18, 2015, between Aceto Corporation and JPMorgan Chase Bank, National Association (incorporated by reference to Exhibit 10.4 to our Current Report on Form 8-K dated November 23, 2015).
     
10.46   Letter Agreement between Aceto Corporation and Walter J. Kaczmarek III (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated July 18, 2016).
     
10.47   Change in Control Agreement by and between Aceto Corporation and Walter J. Kaczmarek III (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K dated July 18, 2016).
     
10.48   Amendment No. 2 to the Amended and Restated Credit Agreement, dated as of October 28, 2015, by and among Aceto Corporation, the other loan parties thereto, JPMorgan Chase Bank, N.A., as administrative agent, Wells Fargo Bank, National Association, as syndication agent, and the lenders party thereto (incorporated by reference to Exhibit 10.1 to the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2016).
     
10.49   Form of Restricted Stock Award Agreement (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated July 28, 2016).
     
10.50   Form of Restricted Stock Unit Award Agreement (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K dated July 28, 2016).
     
10.51   Second Amended and Restated Credit Agreement, dated as of December 21, 2016, by and among the Company, the other loan parties thereto, JPMorgan Chase Bank, N.A., as administrative agent, Wells Fargo Bank, National Association, as syndication agent, and the lenders party thereto (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated December 21, 2016).
     
10.52   Stockholders’ Rights Agreement, by and among the Company and the Sellers, dated as of November 2, 2016 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K dated November 2, 2016).
     
10.53   Voting Agreement, by and among the Company, the Sellers and the Members, dated as of November 2, 2016 (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K dated November 2, 2016).
     
10.54   Employment Agreement, by and between Rising and Vimal Kavuru, dated as of November 2, 2016 (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K dated November 2, 2016).
     
21*   Subsidiaries of the Company.
     
23*   Consent of BDO USA, LLP.
     
31.1*   Certifications of Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
31.2*   Certifications of Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     

32.1**

 

   Certifications of Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
   

32.2**

 

   Certifications of Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS   XBRL Instance Document

 

 101 

 

 

101.SCH   XBRL Taxonomy Extension Schema Document
     
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB   XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document

 

* Filed herewith

 

** Furnished herewith

 

 102 

 

 

 EX-21 2 v472462_ex21.htm EXHIBIT 21

 

 

Exhibit 21

 

SUBSIDIARIES OF ACETO CORPORATION

 

 

Subsidiary

   State or other jurisdiction of
corporation or organization
     
Acci Realty Corp.   New York
Aceto (Holding) B.V.   The Netherlands
Aceto (Hong Kong) Ltd.   Hong Kong
Aceto Agricultural Chemical Corporation Limited   United Kingdom
Aceto Agricultural Chemicals Corp.   New York
Aceto B.V.   The Netherlands
Aceto FineChem GmbH   Germany
Aceto France S.A.S.   France
Aceto Health Ingredients GmbH   Germany
Aceto Holding GmbH   Germany
Aceto Ltd.   Bermuda
Aceto Luxembourg S.a.r.L.   Luxembourg
Aceto Holding Luxembourg S.a.r.L.   Luxembourg
Aceto Agricultural Chemicals Corp. Mx, S De R. L. DE C.V   Mexico
Aceto Pharma Corp.   Delaware
Aceto Pharma India Pvt. Ltd.   India
Aceto (Shanghai) Ltd.   China
Aceto Pharma GmbH   Germany
Acetopharma Philippines, Inc.   Philippines
Aceto Pte Ltd.   Singapore
Aceto Realty LLC   New York
Acetris Health, LLC   Delaware
Arsynco, Inc.   New Jersey
Canegrass, LLC   Delaware
PACK Pharmaceuticals,  LLC   Arizona
Pharma Waldhof GmbH   Germany
Rising Health, LLC   Delaware
Rising Pharmaceuticals, Inc.   Delaware

  

 

 EX-23 3 v472462_ex23.htm EXHIBIT 23

 

 

Exhibit 23

 

Consent of Independent Registered Public Accounting Firm

 

Aceto Corporation

Port Washington, NY

 

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-207394) and Form S-8 (No. 333-209693, No. 333-187353, No. 333-174834, No. 333-149586, No. 333-90929, and No. 333-110653) of Aceto Corporation and subsidiaries of our reports dated August 25, 2017, relating to the consolidated financial statements and financial statement schedule, and the effectiveness of Aceto Corporation and subsidiaries’ internal control over financial reporting, which appear in this Form 10-K.

 

Melville, New York

August 25, 2017 

 

 

 EX-31.1 4 v472462_ex31-1.htm EXHIBIT 31.1

 

 

Exhibit 31.1

 

CERTIFICATION

 

I, Salvatore Guccione, certify that:

 

1.I have reviewed this annual report on Form 10-K of Aceto Corporation (the “Registrant”);

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

 

4.The Registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

 

a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

 

5.The Registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

 

a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

 

b)any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

 

Dated: August 25, 2017  
   
/s/ Salvatore Guccione  
President and Chief Executive Officer  
(Principal Executive Officer)  

 

 

 EX-31.2 5 v472462_ex31-2.htm EXHIBIT 31.2

 

 

Exhibit 31.2

 

CERTIFICATION

 

I, Douglas Roth, certify that:

 

1.I have reviewed this annual report on Form 10-K of Aceto Corporation (the “Registrant”);

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

 

4.The Registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

 

a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

 

5.The Registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

 

a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

 

b)any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

 

Dated: August 25, 2017  
   
/s/ Douglas Roth  
Chief Financial Officer  
(Principal Financial and Accounting Officer)  

 

 

 EX-32.1 6 v472462_ex32-1.htm EXHIBIT 32.1

 

 

Exhibit 32.1

 

CERTIFICATION

 

In connection with the Annual Report of Aceto Corporation, a New York corporation (the “Company”), on Form 10-K for the period ended June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Salvatore Guccione, President and Chief Executive Officer of the Company, certify, pursuant to Section 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Salvatore Guccione  
President and Chief Executive Officer  
(Principal Executive Officer)  
August 25, 2017  

 

 

 EX-32.2 7 v472462_ex32-2.htm EXHIBIT 32.2

 

 

Exhibit 32.2

 

CERTIFICATION

 

In connection with the Annual Report of Aceto Corporation, a New York corporation (the “Company”), on Form 10-K for the period ended June 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Douglas Roth, Chief Financial Officer of the Company, certify, pursuant to Section 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Douglas Roth  
Chief Financial Officer  
(Principal Financial and Accounting Officer)  
August 25, 2017  

 

 

 EX-101.INS 8 acet-20170630.xml XBRL INSTANCE DOCUMENT 0000002034 acet:Plan2007Member 2007-12-06 0000002034 acet:BASFCorporationMember 2008-07-01 2009-06-30 0000002034 2009-06-30 0000002034 us-gaap:MortgagesMember 2011-06-30 0000002034 us-gaap:MortgagesMember 2011-06-01 2011-06-30 0000002034 acet:Plan2010Member 2012-12-06 0000002034 2014-06-30 0000002034 us-gaap:EmployeeStockOptionMember 2014-06-30 0000002034 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-06-30 0000002034 us-gaap:RetainedEarningsMember 2014-06-30 0000002034 us-gaap:CommonStockMember 2014-06-30 0000002034 us-gaap:AdditionalPaidInCapitalMember 2014-06-30 0000002034 acet:ChargebacksMember 2014-06-30 0000002034 us-gaap:AllowanceForSalesReturnsMember 2014-06-30 0000002034 acet:GovernmentReimbursedRebatesMember 2014-06-30 0000002034 acet:OtherRebatesMember 2014-06-30 0000002034 acet:SalesDiscountsMember 2014-06-30 0000002034 us-gaap:AllowanceForDoubtfulAccountsMember 2014-06-30 0000002034 2014-07-01 2014-09-30 0000002034 2014-10-01 2014-12-31 0000002034 2015-01-01 2015-03-31 0000002034 2015-04-01 2015-06-30 0000002034 2014-07-01 2015-06-30 0000002034 us-gaap:EmployeeStockOptionMember 2014-07-01 2015-06-30 0000002034 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2014-07-01 2015-06-30 0000002034 us-gaap:RetainedEarningsMember 2014-07-01 2015-06-30 0000002034 us-gaap:CommonStockMember 2014-07-01 2015-06-30 0000002034 us-gaap:AdditionalPaidInCapitalMember 2014-07-01 2015-06-30 0000002034 us-gaap:CorporateNonSegmentMember 2014-07-01 2015-06-30 0000002034 acet:RestrictedStockAndRestrictedStockUnitsMember 2014-07-01 2015-06-30 0000002034 us-gaap:OperatingSegmentsMember acet:HumanHealthMember 2014-07-01 2015-06-30 0000002034 us-gaap:OperatingSegmentsMember acet:PharmaceuticalIngredientsMember 2014-07-01 2015-06-30 0000002034 us-gaap:OperatingSegmentsMember acet:PerformanceChemicalsMember 2014-07-01 2015-06-30 0000002034 us-gaap:PerformanceSharesMember 2014-07-01 2015-06-30 0000002034 us-gaap:RestrictedStockMember acet:NonEmployeeDirectorMember 2014-07-01 2015-06-30 0000002034 us-gaap:RestrictedStockMember acet:EmployeeMember 2014-07-01 2015-06-30 0000002034 us-gaap:ForeignExchangeContractMember 2014-07-01 2015-06-30 0000002034 us-gaap:ReportableGeographicalComponentsMember country:FR 2014-07-01 2015-06-30 0000002034 us-gaap:ReportableGeographicalComponentsMember country:NL 2014-07-01 2015-06-30 0000002034 us-gaap:ReportableGeographicalComponentsMember country:DE 2014-07-01 2015-06-30 0000002034 us-gaap:ReportableGeographicalComponentsMember country:US 2014-07-01 2015-06-30 0000002034 us-gaap:ReportableGeographicalComponentsMember us-gaap:AsiaPacificMember 2014-07-01 2015-06-30 0000002034 us-gaap:GeographicConcentrationRiskMember us-gaap:CostOfGoodsTotalMember us-gaap:AsiaMember 2014-07-01 2015-06-30 0000002034 us-gaap:GeographicConcentrationRiskMember us-gaap:CostOfGoodsTotalMember us-gaap:EuropeMember 2014-07-01 2015-06-30 0000002034 us-gaap:CorporateJointVentureMember 2014-07-01 2015-06-30 0000002034 acet:ForeignSegmentMember country:US 2014-07-01 2015-06-30 0000002034 acet:EmployeeMember us-gaap:RestrictedStockUnitsRSUMember 2014-07-01 2015-06-30 0000002034 acet:ChargebacksMember 2014-07-01 2015-06-30 0000002034 us-gaap:AllowanceForSalesReturnsMember 2014-07-01 2015-06-30 0000002034 acet:GovernmentReimbursedRebatesMember 2014-07-01 2015-06-30 0000002034 acet:OtherRebatesMember 2014-07-01 2015-06-30 0000002034 acet:SalesDiscountsMember 2014-07-01 2015-06-30 0000002034 acet:CustomerOneMember us-gaap:SalesRevenueNetMember 2014-07-01 2015-06-30 0000002034 us-gaap:AllowanceForDoubtfulAccountsMember 2014-07-01 2015-06-30 0000002034 2015-06-30 0000002034 us-gaap:EmployeeStockOptionMember 2015-06-30 0000002034 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-06-30 0000002034 us-gaap:RetainedEarningsMember 2015-06-30 0000002034 us-gaap:CommonStockMember 2015-06-30 0000002034 us-gaap:AdditionalPaidInCapitalMember 2015-06-30 0000002034 acet:ChargebacksMember 2015-06-30 0000002034 us-gaap:AllowanceForSalesReturnsMember 2015-06-30 0000002034 acet:GovernmentReimbursedRebatesMember 2015-06-30 0000002034 acet:OtherRebatesMember 2015-06-30 0000002034 acet:SalesDiscountsMember 2015-06-30 0000002034 acet:CustomerOneMember us-gaap:SalesRevenueNetMember 2015-06-30 0000002034 us-gaap:AllowanceForDoubtfulAccountsMember 2015-06-30 0000002034 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember 2015-06-30 0000002034 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2015-06-30 0000002034 acet:PharmaceuticalIngredientsSegmentMember 2015-06-30 0000002034 acet:HumanHealthSegmentMember 2015-06-30 0000002034 acet:PerformanceChemicalsSegmentMember 2015-06-30 0000002034 2015-07-01 2015-09-30 0000002034 2015-11-30 0000002034 us-gaap:SeniorNotesMember 2015-11-30 0000002034 2015-11-01 2015-11-30 0000002034 us-gaap:SeniorNotesMember 2015-11-01 2015-11-30 0000002034 2015-12-14 0000002034 acet:Plan2015Member 2015-12-15 0000002034 2015-10-01 2015-12-31 0000002034 2016-01-01 2016-03-31 0000002034 acet:PackPharmaceuticalsLlcMember 2016-01-01 2016-03-31 0000002034 2016-04-01 2016-06-30 0000002034 acet:ArsyncoIncMember 2016-04-01 2016-06-30 0000002034 2015-07-01 2016-06-30 0000002034 us-gaap:EmployeeStockOptionMember 2015-07-01 2016-06-30 0000002034 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-07-01 2016-06-30 0000002034 us-gaap:RetainedEarningsMember 2015-07-01 2016-06-30 0000002034 us-gaap:CommonStockMember 2015-07-01 2016-06-30 0000002034 us-gaap:AdditionalPaidInCapitalMember 2015-07-01 2016-06-30 0000002034 us-gaap:CorporateNonSegmentMember 2015-07-01 2016-06-30 0000002034 acet:RestrictedStockAndRestrictedStockUnitsMember 2015-07-01 2016-06-30 0000002034 us-gaap:OperatingSegmentsMember acet:HumanHealthMember 2015-07-01 2016-06-30 0000002034 us-gaap:OperatingSegmentsMember acet:PharmaceuticalIngredientsMember 2015-07-01 2016-06-30 0000002034 us-gaap:OperatingSegmentsMember acet:PerformanceChemicalsMember 2015-07-01 2016-06-30 0000002034 us-gaap:PerformanceSharesMember 2015-07-01 2016-06-30 0000002034 us-gaap:RestrictedStockMember acet:NonEmployeeDirectorMember 2015-07-01 2016-06-30 0000002034 us-gaap:RestrictedStockMember acet:EmployeeMember 2015-07-01 2016-06-30 0000002034 us-gaap:ForeignExchangeContractMember 2015-07-01 2016-06-30 0000002034 us-gaap:ReportableGeographicalComponentsMember country:FR 2015-07-01 2016-06-30 0000002034 us-gaap:ReportableGeographicalComponentsMember country:NL 2015-07-01 2016-06-30 0000002034 us-gaap:ReportableGeographicalComponentsMember country:DE 2015-07-01 2016-06-30 0000002034 us-gaap:ReportableGeographicalComponentsMember country:US 2015-07-01 2016-06-30 0000002034 us-gaap:ReportableGeographicalComponentsMember us-gaap:AsiaPacificMember 2015-07-01 2016-06-30 0000002034 us-gaap:GeographicConcentrationRiskMember us-gaap:CostOfGoodsTotalMember us-gaap:AsiaMember 2015-07-01 2016-06-30 0000002034 us-gaap:GeographicConcentrationRiskMember us-gaap:CostOfGoodsTotalMember us-gaap:EuropeMember 2015-07-01 2016-06-30 0000002034 us-gaap:CorporateJointVentureMember 2015-07-01 2016-06-30 0000002034 acet:ForeignSegmentMember country:US 2015-07-01 2016-06-30 0000002034 acet:EmployeeMember us-gaap:RestrictedStockUnitsRSUMember 2015-07-01 2016-06-30 0000002034 acet:ChargebacksMember 2015-07-01 2016-06-30 0000002034 us-gaap:AllowanceForSalesReturnsMember 2015-07-01 2016-06-30 0000002034 acet:GovernmentReimbursedRebatesMember 2015-07-01 2016-06-30 0000002034 acet:OtherRebatesMember 2015-07-01 2016-06-30 0000002034 acet:SalesDiscountsMember 2015-07-01 2016-06-30 0000002034 acet:CustomerOneMember us-gaap:SalesRevenueNetMember 2015-07-01 2016-06-30 0000002034 us-gaap:AllowanceForDoubtfulAccountsMember 2015-07-01 2016-06-30 0000002034 acet:PackPharmaceuticalsLlcMember 2015-07-01 2016-06-30 0000002034 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2015-07-01 2016-06-30 0000002034 acet:PharmaceuticalIngredientsSegmentMember 2015-07-01 2016-06-30 0000002034 us-gaap:InterestExpenseMember 2015-07-01 2016-06-30 0000002034 acet:CompanyInFranceMember 2015-07-01 2016-06-30 0000002034 acet:BusinessCombinationProFormaOperatingResultsAsOf1July2015Member acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember 2015-07-01 2016-06-30 0000002034 acet:AcquisitionIntangibleAssetsMember acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember 2015-07-01 2016-06-30 0000002034 acet:AcquisitionRelatedInterestExpenseMember acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember 2015-07-01 2016-06-30 0000002034 us-gaap:FairValueAdjustmentToInventoryMember acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember 2015-07-01 2016-06-30 0000002034 2016-06-30 0000002034 acet:BASFCorporationMember 2016-06-30 0000002034 us-gaap:EmployeeStockOptionMember 2016-06-30 0000002034 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-06-30 0000002034 us-gaap:RetainedEarningsMember 2016-06-30 0000002034 us-gaap:CommonStockMember 2016-06-30 0000002034 us-gaap:AdditionalPaidInCapitalMember 2016-06-30 0000002034 acet:RestrictedStockAndRestrictedStockUnitsMember 2016-06-30 0000002034 us-gaap:ReportableGeographicalComponentsMember country:US 2016-06-30 0000002034 us-gaap:ReportableGeographicalComponentsMember us-gaap:AsiaPacificMember 2016-06-30 0000002034 us-gaap:GeographicConcentrationRiskMember us-gaap:CostOfGoodsTotalMember us-gaap:AsiaMember 2016-06-30 0000002034 us-gaap:GeographicConcentrationRiskMember us-gaap:CostOfGoodsTotalMember us-gaap:EuropeMember 2016-06-30 0000002034 acet:ChargebacksMember 2016-06-30 0000002034 us-gaap:AllowanceForSalesReturnsMember 2016-06-30 0000002034 acet:GovernmentReimbursedRebatesMember 2016-06-30 0000002034 acet:OtherRebatesMember 2016-06-30 0000002034 acet:SalesDiscountsMember 2016-06-30 0000002034 acet:CustomerOneMember us-gaap:SalesRevenueNetMember 2016-06-30 0000002034 us-gaap:AllowanceForDoubtfulAccountsMember 2016-06-30 0000002034 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember 2016-06-30 0000002034 us-gaap:RevolvingCreditFacilityMember 2016-06-30 0000002034 us-gaap:SeniorNotesMember 2016-06-30 0000002034 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2016-06-30 0000002034 acet:PharmaceuticalIngredientsSegmentMember 2016-06-30 0000002034 us-gaap:MediumTermNotesMember 2016-06-30 0000002034 acet:ArsyncoIncMember 2016-06-30 0000002034 acet:EPARegistrationsAndRelatedDataMember 2016-06-30 0000002034 us-gaap:TrademarksMember 2016-06-30 0000002034 us-gaap:TechnologyBasedIntangibleAssetsMember 2016-06-30 0000002034 us-gaap:ReportableGeographicalComponentsMember us-gaap:EuropeMember 2016-06-30 0000002034 acet:ProductRightsAndRelatedIntangiblesMember 2016-06-30 0000002034 us-gaap:CustomerRelationshipsMember 2016-06-30 0000002034 us-gaap:LicensingAgreementsMember 2016-06-30 0000002034 us-gaap:AccountsReceivableMember 2016-06-30 0000002034 us-gaap:BankTimeDepositsMember 2016-06-30 0000002034 us-gaap:AccountsReceivableMember acet:CustomerOneMember 2016-06-30 0000002034 us-gaap:LeaseholdImprovementsMember 2016-06-30 0000002034 us-gaap:BuildingMember 2016-06-30 0000002034 us-gaap:AutomobilesMember 2016-06-30 0000002034 us-gaap:AccountsReceivableMember acet:CustomerTwoMember 2016-06-30 0000002034 us-gaap:MachineryAndEquipmentMember 2016-06-30 0000002034 acet:ComputerEquipmentAndCapitalizedSoftwareMember 2016-06-30 0000002034 us-gaap:FurnitureAndFixturesMember 2016-06-30 0000002034 us-gaap:LandMember 2016-06-30 0000002034 acet:StandbyLetterOfCreditMember 2016-06-30 0000002034 us-gaap:FairValueInputsLevel3Member 2016-06-30 0000002034 us-gaap:FairValueInputsLevel2Member 2016-06-30 0000002034 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member 2016-06-30 0000002034 us-gaap:BankTimeDepositsMember 2016-06-30 0000002034 us-gaap:FairValueInputsLevel1Member 2016-06-30 0000002034 us-gaap:FairValueInputsLevel1Member us-gaap:BankTimeDepositsMember 2016-06-30 0000002034 us-gaap:FairValueInputsLevel3Member us-gaap:BankTimeDepositsMember 2016-06-30 0000002034 acet:CustomerThreeMember us-gaap:AccountsReceivableMember 2016-06-30 0000002034 us-gaap:AcquisitionRelatedCostsMember acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember 2016-06-30 0000002034 acet:FranceCompanyMember 2016-06-30 0000002034 acet:HumanHealthSegmentMember 2016-06-30 0000002034 acet:PerformanceChemicalsSegmentMember 2016-06-30 0000002034 us-gaap:SubsidiariesMember 2016-06-30 0000002034 us-gaap:RevolvingCreditFacilityMember acet:AmendedCreditAgreementMember 2016-08-26 0000002034 2016-07-01 2016-09-30 0000002034 acet:ArsyncoIncMember 2016-07-01 2016-09-30 0000002034 acet:PerformanceStockOptionsMember us-gaap:ExecutiveOfficerMember 2016-09-30 0000002034 acet:PerformanceStockOptionsMember us-gaap:ExecutiveOfficerMember 2016-09-01 2016-09-30 0000002034 us-gaap:RevolvingCreditFacilityMember acet:AmendedCreditAgreementMember 2016-12-21 0000002034 acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember 2016-12-21 0000002034 acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember acet:ProductRightsMember 2016-12-21 0000002034 acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember us-gaap:CustomerRelationshipsMember 2016-12-21 0000002034 acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember us-gaap:TrademarksMember 2016-12-21 0000002034 us-gaap:MediumTermNotesMember acet:AmendedCreditAgreementMember 2016-12-21 0000002034 2016-12-02 2016-12-21 0000002034 us-gaap:MediumTermNotesMember 2016-12-02 2016-12-21 0000002034 us-gaap:RevolvingCreditFacilityMember acet:AmendedCreditAgreementMember 2016-12-02 2016-12-21 0000002034 acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember 2016-12-02 2016-12-21 0000002034 acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember acet:ProductRightsMember 2016-12-02 2016-12-21 0000002034 acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember us-gaap:CustomerRelationshipsMember 2016-12-02 2016-12-21 0000002034 acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember us-gaap:TrademarksMember 2016-12-02 2016-12-21 0000002034 acet:RisingPharmaceuticalsIncMember 2016-12-02 2016-12-21 0000002034 2016-10-01 2016-12-31 0000002034 2016-12-31 0000002034 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember acet:ExpirationDateDecember212021Member 2017-03-21 0000002034 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember acet:ExpirationDateDecember212021Member 2017-03-01 2017-03-21 0000002034 2017-01-01 2017-03-31 0000002034 acet:ArsyncoIncMember 2017-01-01 2017-03-31 0000002034 2017-05-04 0000002034 2017-05-01 2017-05-04 0000002034 2017-04-01 2017-06-30 0000002034 2016-07-01 2017-06-30 0000002034 us-gaap:EmployeeStockOptionMember 2016-07-01 2017-06-30 0000002034 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-07-01 2017-06-30 0000002034 us-gaap:RetainedEarningsMember 2016-07-01 2017-06-30 0000002034 us-gaap:CommonStockMember 2016-07-01 2017-06-30 0000002034 us-gaap:AdditionalPaidInCapitalMember 2016-07-01 2017-06-30 0000002034 us-gaap:CorporateNonSegmentMember 2016-07-01 2017-06-30 0000002034 acet:RestrictedStockAndRestrictedStockUnitsMember 2016-07-01 2017-06-30 0000002034 us-gaap:OperatingSegmentsMember acet:HumanHealthMember 2016-07-01 2017-06-30 0000002034 us-gaap:OperatingSegmentsMember acet:PharmaceuticalIngredientsMember 2016-07-01 2017-06-30 0000002034 us-gaap:OperatingSegmentsMember acet:PerformanceChemicalsMember 2016-07-01 2017-06-30 0000002034 us-gaap:PerformanceSharesMember 2016-07-01 2017-06-30 0000002034 us-gaap:RestrictedStockMember acet:NonEmployeeDirectorMember 2016-07-01 2017-06-30 0000002034 us-gaap:RestrictedStockMember acet:EmployeeMember 2016-07-01 2017-06-30 0000002034 us-gaap:ForeignExchangeContractMember 2016-07-01 2017-06-30 0000002034 us-gaap:ReportableGeographicalComponentsMember country:FR 2016-07-01 2017-06-30 0000002034 us-gaap:ReportableGeographicalComponentsMember country:NL 2016-07-01 2017-06-30 0000002034 us-gaap:ReportableGeographicalComponentsMember country:DE 2016-07-01 2017-06-30 0000002034 us-gaap:ReportableGeographicalComponentsMember country:US 2016-07-01 2017-06-30 0000002034 us-gaap:ReportableGeographicalComponentsMember us-gaap:AsiaPacificMember 2016-07-01 2017-06-30 0000002034 us-gaap:GeographicConcentrationRiskMember us-gaap:CostOfGoodsTotalMember us-gaap:AsiaMember 2016-07-01 2017-06-30 0000002034 us-gaap:GeographicConcentrationRiskMember us-gaap:CostOfGoodsTotalMember us-gaap:EuropeMember 2016-07-01 2017-06-30 0000002034 us-gaap:CorporateJointVentureMember 2016-07-01 2017-06-30 0000002034 acet:ForeignSegmentMember country:US 2016-07-01 2017-06-30 0000002034 acet:EmployeeMember us-gaap:RestrictedStockUnitsRSUMember 2016-07-01 2017-06-30 0000002034 acet:ChargebacksMember 2016-07-01 2017-06-30 0000002034 us-gaap:AllowanceForSalesReturnsMember 2016-07-01 2017-06-30 0000002034 acet:GovernmentReimbursedRebatesMember 2016-07-01 2017-06-30 0000002034 acet:OtherRebatesMember 2016-07-01 2017-06-30 0000002034 acet:SalesDiscountsMember 2016-07-01 2017-06-30 0000002034 acet:CustomerOneMember us-gaap:SalesRevenueNetMember 2016-07-01 2017-06-30 0000002034 us-gaap:AllowanceForDoubtfulAccountsMember 2016-07-01 2017-06-30 0000002034 us-gaap:SeniorNotesMember 2016-07-01 2017-06-30 0000002034 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2016-07-01 2017-06-30 0000002034 acet:PharmaceuticalIngredientsSegmentMember 2016-07-01 2017-06-30 0000002034 us-gaap:InterestExpenseMember 2016-07-01 2017-06-30 0000002034 acet:BusinessCombinationProFormaOperatingResultsAsOf1July2015Member acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember 2016-07-01 2017-06-30 0000002034 acet:AcquisitionIntangibleAssetsMember acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember 2016-07-01 2017-06-30 0000002034 acet:AcquisitionRelatedInterestExpenseMember acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember 2016-07-01 2017-06-30 0000002034 acet:ArsyncoIncMember 2016-07-01 2017-06-30 0000002034 acet:EPARegistrationsAndRelatedDataMember 2016-07-01 2017-06-30 0000002034 us-gaap:LeaseholdImprovementsMember 2016-07-01 2017-06-30 0000002034 us-gaap:BuildingMember 2016-07-01 2017-06-30 0000002034 us-gaap:AutomobilesMember 2016-07-01 2017-06-30 0000002034 acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember 2016-07-01 2017-06-30 0000002034 acet:HumanHealthSegmentMember 2016-07-01 2017-06-30 0000002034 acet:PerformanceChemicalsSegmentMember 2016-07-01 2017-06-30 0000002034 acet:PulvairSiteGroupMember 2016-07-01 2017-06-30 0000002034 us-gaap:MaximumMember acet:ProductRightsAndRelatedIntangiblesMember 2016-07-01 2017-06-30 0000002034 us-gaap:MinimumMember acet:ProductRightsAndRelatedIntangiblesMember 2016-07-01 2017-06-30 0000002034 us-gaap:MaximumMember us-gaap:CustomerRelationshipsMember 2016-07-01 2017-06-30 0000002034 us-gaap:MinimumMember us-gaap:CustomerRelationshipsMember 2016-07-01 2017-06-30 0000002034 us-gaap:MaximumMember us-gaap:LicensingAgreementsMember 2016-07-01 2017-06-30 0000002034 us-gaap:MinimumMember us-gaap:LicensingAgreementsMember 2016-07-01 2017-06-30 0000002034 acet:ComputerEquipmentAndCapitalizedSoftwareMember us-gaap:MaximumMember 2016-07-01 2017-06-30 0000002034 us-gaap:FurnitureAndFixturesMember us-gaap:MaximumMember 2016-07-01 2017-06-30 0000002034 acet:ComputerEquipmentAndCapitalizedSoftwareMember us-gaap:MinimumMember 2016-07-01 2017-06-30 0000002034 us-gaap:FurnitureAndFixturesMember us-gaap:MinimumMember 2016-07-01 2017-06-30 0000002034 us-gaap:TrademarksMember us-gaap:MinimumMember 2016-07-01 2017-06-30 0000002034 acet:ArsyncoIncMember us-gaap:MinimumMember 2016-07-01 2017-06-30 0000002034 acet:ArsyncoIncMember us-gaap:MaximumMember 2016-07-01 2017-06-30 0000002034 acet:AcetrisHealthMember 2016-07-01 2017-06-30 0000002034 acet:RisingHealthMember 2016-07-01 2017-06-30 0000002034 acet:CitronAndLucidMember acet:ExpirationDateDecember212019Member 2016-07-01 2017-06-30 0000002034 us-gaap:MachineryAndEquipmentMember us-gaap:MinimumMember 2016-07-01 2017-06-30 0000002034 us-gaap:MachineryAndEquipmentMember us-gaap:MaximumMember 2016-07-01 2017-06-30 0000002034 us-gaap:TrademarksMember us-gaap:MaximumMember 2016-07-01 2017-06-30 0000002034 2017-06-30 0000002034 acet:Plan2007Member 2017-06-30 0000002034 acet:BASFCorporationMember 2017-06-30 0000002034 us-gaap:MortgagesMember 2017-06-30 0000002034 acet:Plan2010Member 2017-06-30 0000002034 us-gaap:EmployeeStockOptionMember 2017-06-30 0000002034 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-06-30 0000002034 us-gaap:RetainedEarningsMember 2017-06-30 0000002034 us-gaap:CommonStockMember 2017-06-30 0000002034 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0000002034 acet:RestrictedStockAndRestrictedStockUnitsMember 2017-06-30 0000002034 us-gaap:ForeignExchangeContractMember 2017-06-30 0000002034 us-gaap:ReportableGeographicalComponentsMember country:US 2017-06-30 0000002034 us-gaap:ReportableGeographicalComponentsMember us-gaap:AsiaPacificMember 2017-06-30 0000002034 us-gaap:GeographicConcentrationRiskMember us-gaap:CostOfGoodsTotalMember us-gaap:AsiaMember 2017-06-30 0000002034 us-gaap:GeographicConcentrationRiskMember us-gaap:CostOfGoodsTotalMember us-gaap:EuropeMember 2017-06-30 0000002034 acet:ChargebacksMember 2017-06-30 0000002034 us-gaap:AllowanceForSalesReturnsMember 2017-06-30 0000002034 acet:GovernmentReimbursedRebatesMember 2017-06-30 0000002034 acet:OtherRebatesMember 2017-06-30 0000002034 acet:SalesDiscountsMember 2017-06-30 0000002034 acet:CustomerOneMember us-gaap:SalesRevenueNetMember 2017-06-30 0000002034 us-gaap:AllowanceForDoubtfulAccountsMember 2017-06-30 0000002034 us-gaap:ProductConcentrationRiskMember us-gaap:SalesRevenueNetMember 2017-06-30 0000002034 us-gaap:RevolvingCreditFacilityMember 2017-06-30 0000002034 us-gaap:SeniorNotesMember 2017-06-30 0000002034 acet:Plan2015Member 2017-06-30 0000002034 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2017-06-30 0000002034 acet:PharmaceuticalIngredientsSegmentMember 2017-06-30 0000002034 us-gaap:MediumTermNotesMember 2017-06-30 0000002034 acet:ArsyncoIncMember 2017-06-30 0000002034 acet:EPARegistrationsAndRelatedDataMember 2017-06-30 0000002034 us-gaap:TrademarksMember 2017-06-30 0000002034 us-gaap:ReportableGeographicalComponentsMember us-gaap:EuropeMember 2017-06-30 0000002034 acet:ProductRightsAndRelatedIntangiblesMember 2017-06-30 0000002034 us-gaap:CustomerRelationshipsMember 2017-06-30 0000002034 us-gaap:LicensingAgreementsMember 2017-06-30 0000002034 us-gaap:AccountsReceivableMember 2017-06-30 0000002034 us-gaap:BankTimeDepositsMember 2017-06-30 0000002034 us-gaap:AccountsReceivableMember acet:CustomerOneMember 2017-06-30 0000002034 us-gaap:LeaseholdImprovementsMember 2017-06-30 0000002034 us-gaap:BuildingMember 2017-06-30 0000002034 us-gaap:AutomobilesMember 2017-06-30 0000002034 us-gaap:AccountsReceivableMember acet:CustomerTwoMember 2017-06-30 0000002034 us-gaap:MachineryAndEquipmentMember 2017-06-30 0000002034 acet:ComputerEquipmentAndCapitalizedSoftwareMember 2017-06-30 0000002034 us-gaap:FurnitureAndFixturesMember 2017-06-30 0000002034 us-gaap:LandMember 2017-06-30 0000002034 acet:StandbyLetterOfCreditMember 2017-06-30 0000002034 us-gaap:FairValueInputsLevel3Member 2017-06-30 0000002034 us-gaap:FairValueInputsLevel2Member 2017-06-30 0000002034 us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member 2017-06-30 0000002034 us-gaap:BankTimeDepositsMember 2017-06-30 0000002034 us-gaap:FairValueInputsLevel1Member 2017-06-30 0000002034 us-gaap:FairValueInputsLevel1Member us-gaap:BankTimeDepositsMember 2017-06-30 0000002034 us-gaap:FairValueInputsLevel3Member us-gaap:BankTimeDepositsMember 2017-06-30 0000002034 acet:CustomerThreeMember us-gaap:AccountsReceivableMember 2017-06-30 0000002034 us-gaap:RevolvingCreditFacilityMember acet:AmendedCreditAgreementMember 2017-06-30 0000002034 acet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember 2017-06-30 0000002034 acet:FranceCompanyMember 2017-06-30 0000002034 acet:HumanHealthSegmentMember 2017-06-30 0000002034 acet:PerformanceChemicalsSegmentMember 2017-06-30 0000002034 us-gaap:LongTermDebtMember 2017-06-30 0000002034 us-gaap:AccruedLiabilitiesMember 2017-06-30 0000002034 us-gaap:SeniorNotesMember 2017-06-30 0000002034 acet:ArsyncoIncMember acet:BerrysCreekStudyAreaMember 2017-06-30 0000002034 us-gaap:MediumTermNotesMember acet:AmendedCreditAgreementMember 2017-06-30 0000002034 us-gaap:MediumTermNotesMember acet:AmendedCreditAgreementMember us-gaap:EurodollarMember 2017-06-30 0000002034 acet:CitronAndLucidMember acet:ExpirationDateDecember212021Member 2017-06-30 0000002034 us-gaap:EurodollarMember us-gaap:RevolvingCreditFacilityMember acet:AmendedCreditAgreementMember us-gaap:MaximumMember 2017-06-30 0000002034 us-gaap:EurodollarMember us-gaap:RevolvingCreditFacilityMember acet:AmendedCreditAgreementMember us-gaap:MinimumMember 2017-06-30 0000002034 us-gaap:SubsidiariesMember 2017-06-30 0000002034 2017-08-21 0000002034 us-gaap:SubsequentEventMember 2017-08-01 2017-08-24 0000002034 acet:RisingHealthMember us-gaap:SubsequentEventMember 2017-10-31 xbrli:shares iso4217:USD iso4217:USDxbrli:shares acet:Contract xbrli:pure acet:Subsidiary acet:Entity acet:Share acet:Day acet:Bank acet:Installment acet:Customer acet:Product utr:sqft ACETO CORP 0000002034 acet Yes No --06-30 Large Accelerated Filer No 30109417 564677707 10-K 2017-06-30 false 2017 FY 42897000 34020000 66828000 55680000 881000 2046000 167612000 264896000 12650000 10664000 98107000 136387000 3339000 3941000 3244000 546000 352661000 474160000 10044000 10428000 6868000 7152000 67870000 1650000 66039000 181000 67871000 1651000 66039000 181000 169071000 236970000 1674000 235110000 186000 79071000 285081000 18053000 19453000 6210000 7546000 540778000 1040790000 197000 14466000 46034000 90011000 52675000 118328000 98906000 222805000 118592000 339200000 6344000 61449000 3352000 2339000 9142000 7325000 236336000 633118000 296000 301000 115667000 214198000 194804000 198285000 -6325000 -5112000 233584000 5372000 140768000 288000 87156000 254211000 -7096000 167208000 292000 93807000 304442000 -6325000 194804000 296000 115667000 407672000 -5112000 198285000 301000 214198000 540778000 1040790000 513000 485000 2000000 2000000 0 0 0 0 0.01 0.01 40000000 75000000 75000000 29595000 30094000 29595000 30094000 546951000 225263000 149296000 172392000 27976000 14656000 69889000 407101000 27329000 133500000 131674000 157926000 135424000 558524000 228035000 161011000 169478000 30177000 16217000 76666000 400883000 34581000 128018000 125552000 190128000 194620000 638318000 315395000 157445000 165478000 35796000 9949000 79105000 483678000 29790000 411517000 415739000 497526000 135434000 75749000 26683000 33002000 3634000 1325000 14660000 111734000 4081000 34581000 35868000 38289000 34047000 142785000 77880000 28752000 36153000 4043000 1598000 15154000 117180000 4810000 30839000 30805000 42319000 36829000 140792000 78109000 25474000 37209000 4651000 1231000 13609000 116792000 4509000 73159000 76820000 102340000 5942000 7937000 7898000 56333000 58028000 30554000 3954000 6997000 15770000 1486000 2823000 2577000 -2468000 -4174000 -13193000 53865000 -4273000 35152000 8697000 14289000 53854000 -12163000 36362000 11856000 17799000 17361000 -26224000 15434000 9322000 18829000 20382000 19088000 5985000 33483000 33483000 9298000 8270000 10424000 6774000 34766000 34766000 4385000 -564000 5588000 1967000 11376000 11376000 1.17 1.19 0.35 1.14 0.32 0.28 0.35 0.23 1.18 0.15 -0.02 0.16 0.06 0.35 28731000 29110000 32283000 29247000 29581000 32632000 -12354000 368000 1780000 99000 -149000 -581000 -487000 -213000 65000 14000 -12468000 -12468000 771000 771000 1213000 1213000 21015000 35537000 12589000 100000 31000 7000 11849000 12698000 23754000 3496000 5847000 570000 484000 76000 -3000 4537000 6719000 6956000 -1874000 -18000 -504000 1761000 2060000 2336000 -3468000 -833000 -1074000 -833000 -241000 4502000 1618000 1313000 1313000 170000 733000 903000 903000 44181000 6149000 17598000 5644000 -136000 -185000 229000 2489000 2958000 -304000 243000 -1209000 -1254000 557000 157000 8133000 -8937000 -3097000 1816000 -7689000 14010000 2022000 1843000 1908000 8343000 31831000 44567000 270000000 270000000 2720000 34000 2035000 2517000 909000 1564000 11249000 3359000 617000 1128000 1893000 -4901000 -9894000 -276378000 1273000 729000 551000 790000 1219000 546000 6964000 7084000 7831000 3500000 4500000 1500000 143750000 143750000 5153000 13685000 27174000 420000 19000000 15500000 275000000 5407000 14344000 122697000 42697000 -8245000 10855000 220162000 -4074000 16000 501000 -8877000 32808000 -11148000 28772000 29147000 29595000 30094000 77000 77000 113000 113000 109000 109000 5000 7000 5000 2000 -2000 3000 -3000 4000 -4000 224000 346000 424000 13685000 13685000 90400000 90400000 7043000 7043000 7170000 7170000 7895000 7895000 4515000 4515000 6697000 6697000 6930000 6930000 1273000 2000 1271000 729000 1000 728000 551000 1000 550000 146000 146000 95000 95000 70000 70000 790000 790000 1219000 1219000 546000 546000 27174000 27174000 27241000 27241000 976000 976000 330000 330000 0.24 0.24 0.26 0.065 <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>(1) Description of Business</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Aceto Corporation and subsidiaries (&#8220;Aceto&#8221; or the &#8220;Company&#8221;) is primarily engaged in the sourcing, regulatory support, quality assurance, development, marketing, sales and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical intermediates and active ingredients, agricultural protection products and specialty chemicals used principally as finished products or raw materials in the pharmaceutical, nutraceutical, agricultural, coatings and industrial chemical consuming industries.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>(2) Summary of Significant Accounting Policies</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Principles of Consolidation</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries. All significant inter-company balances and transactions are eliminated in consolidation.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Use of Estimates</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses reported in those financial statements and the disclosure of contingent assets and liabilities at the date of the financial statements. These judgments can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company&#8217;s most critical accounting policies relate to revenue recognition; allowance for doubtful accounts; inventory; goodwill and other indefinite-life intangible assets; long-lived assets; environmental matters and other contingencies; income taxes; stock-based compensation; and purchase price allocation.</font></p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Cash Equivalents</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The Company considers all highly liquid debt instruments with original maturities at the time of purchase of three months or less to be cash equivalents. Included in cash equivalents as of June 30, 2017 and June 30, 2016 is $220 and $104, respectively, of restricted cash.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Investments</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The Company classifies investments in marketable securities as trading, available-for-sale or held-to-maturity at the time of purchase and periodically re-evaluates such classifications. Trading securities are carried at fair value, with unrealized holding gains and losses included in earnings. Held-to-maturity securities are recorded at cost and are adjusted for the amortization or accretion of premiums or discounts over the life of the related security. Unrealized holding gains and losses on available-for-sale securities are excluded from earnings and are reported as a separate component of accumulated other comprehensive income (loss) until realized. In determining realized gains and losses, the cost of securities sold is based on the specific identification method. Interest and dividends on the investments are accrued at the balance sheet date.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Inventory</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Inventory, which consists principally of finished goods, are stated at the lower of cost (first-in first-out method) and net realizable value. The Company writes down its inventory for estimated excess and obsolete goods by an amount equal to the difference between the carrying cost of the inventory and net realizable value based upon assumptions about future demand and market conditions.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Environmental and Other Contingencies</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The Company establishes accrued liabilities for environmental matters and other contingencies when it is probable that a liability has been incurred and the amount of the liability is reasonably estimable. If the contingency is resolved for an amount greater or less than the accrual, or the Company&#8217;s share of the contingency increases or decreases, or other assumptions relevant to the development of the estimate were to change, the Company would recognize an additional expense or benefit in the consolidated statements of income in the period such determination was made.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>&#160;</b></font><font style="font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Pension Benefits</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">In connection with certain historical acquisitions in Germany, the Company assumed defined benefit pension plans covering certain employees who meet certain eligibility requirements. The net pension benefit obligations recorded and the related periodic costs are based on, among other things, assumptions of the discount rate, estimated return on plan assets, salary increases and the mortality of participants. The obligation for these claims and the related periodic costs are measured using actuarial techniques and assumptions. Actuarial gains and losses are deferred and amortized over future periods. The Company&#8217;s plans are funded in conformity with the funding requirements of applicable government regulations.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Accumulated Other Comprehensive Loss</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The components of accumulated other comprehensive loss as of June 30, 2017 and 2016 are as follows:</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; width: 630px;">Cumulative foreign currency translation adjustments</td> <td style="width: 9px;">&#160;</td> <td style="text-align: left; width: 9px;">$</td> <td style="text-align: right; width: 134px;">(4,340</td> <td style="text-align: left; width: 9px;">)</td> <td style="width: 9px;">&#160;</td> <td style="text-align: left; width: 8px;">$</td> <td style="text-align: right; width: 133px;">(6,120</td> <td style="text-align: left; width: 8px;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Fair value of interest rate swaps</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(581</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2px;">Defined benefit plans, net of tax</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(191</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(205</td> <td style="text-align: left; padding-bottom: 2px;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 4px;">Total</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">(5,112</td> <td style="text-align: left; padding-bottom: 4px;">)</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">(6,325</td> <td style="text-align: left; padding-bottom: 4px;">)</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The foreign currency translation adjustments for the years ended June 30, 2017 and 2016 primarily relate to the fluctuation of the conversion rate of the Euro. The currency translation adjustments are not adjusted for income taxes as they relate to indefinite investments in non-US subsidiaries.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt courier; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Common Stock</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt courier; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">At the annual meeting of shareholders of the Company, held on December 15, 2015, the Company&#8217;s shareholders approved the proposal to amend Aceto&#8217;s Certificate of Incorporation to increase the total number of authorized shares of common stock from 40,000 shares to 75,000 shares.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Cash dividends of $0.065 per common share were paid in September, December, March and June of fiscal year 2017. Cash dividends of $0.06 per common share were paid in September, December, March and June of fiscal years 2016 and 2015. On August 24, 2017, the Company's board of directors declared a regular quarterly dividend of $0.065 per share to be distributed on September 21, 2017 to shareholders of record as of September 8, 2017.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">On May 4, 2017, the Board of Directors of the Company authorized the continuation of the Company&#8217;s stock repurchase program, expiring in May 2020. Under the stock repurchase program, the Company is authorized to purchase up to 5,000 shares of common stock in open market or private transactions, at prices not to exceed the market value of the common stock at the time of such purchase. The Company did not repurchase shares in fiscal 2017 or fiscal 2016.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The Board of Directors has authority under the Company&#8217;s Restated Certificate of Incorporation to issue shares of preferred stock with voting and other relative rights to be determined by the Board of Directors.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: bold 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Stock-based Compensation</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">GAAP requires that all stock-based compensation be recognized as an expense in the financial statements and that such costs be measured at the fair value of the award. GAAP also requires that excess tax benefits related to stock option exercises be reflected as financing cash inflows.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt courier; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">All restricted stock grants include a service requirement for vesting. The Company has also granted restricted stock units that include either a performance or market condition. The fair value of restricted stock unit with either solely a service requirement or with the combination of service and performance requirements is based on the closing fair market value of Aceto&#8217;s common stock on the date of grant. The fair value of market condition-based awards is estimated at the date of grant using a binomial lattice model or Monte Carlo Simulation. All models incorporate various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the awards. Stock-based compensation expense is recognized on a straight-line basis over the service period or over our best estimate of the period over which the performance condition will be met, as applicable.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Revenue Recognition</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The Company recognizes revenue from product sales at the time of shipment and passage of title and risk of loss to the customer. The Company has no acceptance or other post-shipment obligations and does not offer product warranties or services to its customers.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Sales are recorded net of estimated returns of damaged goods from customers, which historically have been immaterial, and sales incentives offered to customers. Sales incentives include volume incentive rebates. The Company records volume incentive rebates based on the underlying revenue transactions that result in progress by the customer in earning the rebate.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The Company has arrangements with various third parties, such as drug store chains and managed care organizations, establishing prices for its finished dosage form generics. While these arrangements are made between Aceto and its customers, the customers independently select a wholesaler from which they purchase the products. Alternatively, certain wholesalers may enter into agreements with the customers, with the Company&#8217;s concurrence, which establishes the pricing for certain products which the wholesalers provide. Upon each sale of finished dosage form generics, estimates of chargebacks, rebates, returns, government reimbursed rebates, sales discounts and other adjustments are made. These estimates are based on historical experience, future expectations, contractual arrangements with wholesalers and indirect customers, and other factors known to management at the time of accrual. These estimates are recorded as reductions to gross revenues, with corresponding adjustments either as a reduction of accounts receivable or as a liability for price concessions.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Under certain arrangements, Rising will issue a credit (referred to as a &#8220;chargeback&#8221;) to the wholesaler for the difference between the invoice price to the wholesaler and the customer&#8217;s contract price. As sales to the large wholesale customers increase or decrease, the reserve for chargebacks will also generally increase or decrease. The provision for chargebacks varies in relation to changes in sales volume, product mix, pricing and the level of inventory at the wholesalers. The Company continually monitors the reserve for chargebacks and makes adjustments when management believes that expected chargebacks may differ from the actual chargeback reserve.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The Company estimates its provision for returns of finished dosage generics based on historical experience, product expiration dates, changes to business practices, credit terms and any extenuating circumstances known to management. While historical experience has allowed for reasonable estimations in the past, future returns may or may not follow historical trends. The Company continually monitors the reserve for returns and makes adjustments when management believes that actual product returns may differ from the established reserve. Generally, the reserve for returns increases as net sales increase.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Government rebate accruals are based on estimated payments due to governmental agencies for purchases made by third parties under various governmental programs. Other rebates are offered to the Company&#8217;s key chain drug store, distributor and wholesaler customers to promote customer loyalty and increase product sales. These rebate programs provide customers with credits upon attainment of pre-established volumes or attainment of net sales milestones for a specified period. Other promotional programs are incentive programs offered to the customers. The Company provides a provision for government reimbursed rebates and other rebates at the time of sale based on contracted rates and historical redemption rates. Assumptions used to establish the provision include level of customer inventories, contract sales mix and average contract pricing. Aceto regularly reviews the information related to these estimates and adjusts the provision accordingly.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 0.2in; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Sales discount accruals are based on payment terms extended to customers.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The following table summarizes activity in the consolidated balance sheet for contra assets and liability for price concessions for the years ended June 30, 2017, 2016 and 2015:</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"></p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: left;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="14" nowrap="nowrap">Accruals for Chargebacks, Rebates, Returns and Other Allowances</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap"></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap"></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap">Government</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap">Other</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap">Sales</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Chargebacks</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Returns</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Reimbursed&#160;Rebates</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Rebates</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Discounts</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 478px;">Balance at June 30, 2014</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 137px;">10,986</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 137px;">20,249</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 136px;">1,005</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 136px;">3,630</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 136px;">690</td> <td style="text-align: left; width: 13px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Current year provision</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">208,965</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">21,403</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">4,259</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">36,923</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">9,381</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2px; padding-left: 9pt;">Credits issued during the year</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(187,784</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(10,960</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(4,326</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(36,218</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(7,389</td> <td style="text-align: left; padding-bottom: 2px;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 4px;">Balance at June 30, 2015</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">32,167</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">30,692</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">938</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">4,335</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">2,682</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Current year provision</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">247,186</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">7,618</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5,124</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">90,915</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">10,267</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2px; padding-left: 9pt;">Credits issued during the year</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(256,638</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(15,482</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(4,750</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(88,048</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(10,526</td> <td style="text-align: left; padding-bottom: 2px;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 4px;">Balance at June 30, 2016</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">22,715</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">22,828</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">1,312</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">7,202</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">2,423</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">&#160;Acquisitions</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">23,526</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,496</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">4,500</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">28,944</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,360</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Current year provision</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">431,606</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">19,666</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">7,694</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">162,023</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">20,129</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2px; padding-left: 9pt;">Credits issued during the year</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(417,928</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(11,631</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(4,642</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(158,836</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(18,875</td> <td style="text-align: left; padding-bottom: 2px;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 4px;">Balance at June 30, 2017</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">59,919</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">32,359</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">8,864</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">39,333</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">6,037</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Credits issued during a given period represent cash payments or credit memos issued to the Company&#8217;s customers as settlement for the related reserve. Management has the experience and access to relevant information that it believes is necessary to reasonably estimate the amounts of such deductions from gross revenues. The Company regularly reviews the information related to these estimates and adjusts its reserves accordingly, if and when actual experience differs from previous estimates. The Company has not experienced any significant changes in its estimates as it relates to its chargebacks, rebates or sales discounts in each of the years in the three year period ended June 30, 2017. During the year ended June 30, 2015, the Company recorded $3,497 in additional gross profit related to a change in estimate for product returns due to the most recent returns experience. The Company had not experienced any significant changes in its estimates as it relates to its product returns during the years ended June 30, 2017 and June 30, 2016.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Partnered Products</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><i>&#160;</i></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The Company has various products that are subject to one of two types of collaborative arrangements with certain pharmaceutical companies. One type of arrangement relates to the Company&#8217;s finished dosage form generics business acting strictly as a distributor and purchasing products at arm&#8217;s length; in that type of arrangement, there is no profit sharing element. The second type of collaborative arrangement results in a profit sharing agreement between the Company and a developer and/or manufacturer of a finished dosage form generic drug. Both types of collaborative arrangements are conducted in the ordinary course of Rising&#8217;s business. The nature and purpose of both of these arrangements is for the Company to act as a distributor of finished dose products to its customers.&#160; Under these arrangements, the Company maintains distribution rights with respect to specific drugs within the U.S. marketplace.&#160; Generally, the distribution rights are exclusive rights in the territory.&#160; In certain arrangements, the Company is required to maintain service level minimums including, but not limited to, market share and purchase levels, in order to preserve the exclusive rights.&#160; The Company&#8217;s accounting policy with respect to these collaborative arrangements calls for the Company to present the sales and associated costs on a gross basis, with the amounts of the shared profits earned by the pharmaceutical companies on sales of these products, if applicable, included in cost of sales in the consolidated statements of income. The shared profits are settled on a quarterly basis. For each of the fiscal years 2017, 2016 and 2015, there was approximately $54,454, $41,036 and $51,352 respectively, of shared profits included in cost of sales, related to these types of collaborative arrangements. In the case of a collaborative arrangement where the Company solely acts as a distributor and purchases product at arm&#8217;s length, the costs of those purchases are included as a cost of sales similar to any other purchase arrangement.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: bold 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Shipping and Handling Fees and Costs</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">All amounts billed to a customer in a sales transaction related to shipping and handling represent revenues earned and are included in net sales. The costs incurred by the Company for shipping and handling are reported as a component of cost of sales. Cost of sales also includes inbound freight, receiving, inspection, warehousing, distribution network, and customs and duty costs.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Net Income Per Common Share</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Basic income per common share is based on the weighted average number of common shares outstanding during the period. Diluted income per common share includes the dilutive effect of potential common shares outstanding. The following table sets forth the reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding for the fiscal years ended June 30, 2017, 2016 and 2015:</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt; width: 652px;">Weighted average shares outstanding</td> <td style="width: 11px;">&#160;</td> <td style="text-align: left; width: 11px;">&#160;</td> <td style="text-align: right; width: 109px;">32,283</td> <td style="text-align: left; width: 11px;">&#160;</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">&#160;</td> <td style="text-align: right; width: 109px;">29,110</td> <td style="text-align: left; width: 10px;">&#160;</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">&#160;</td> <td style="text-align: right; width: 109px;">28,731</td> <td style="text-align: left; width: 10px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2px; text-indent: -10pt; padding-left: 10pt;">Dilutive effect of stock options and restricted stock awards and units</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">349</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">471</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">516</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; text-indent: -10pt; padding-left: 10pt;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 4px;">Diluted weighted average shares outstanding</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">&#160;</td> <td style="border-bottom: black 4px double; text-align: right;">32,632</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">&#160;</td> <td style="border-bottom: black 4px double; text-align: right;">29,581</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">&#160;</td> <td style="border-bottom: black 4px double; text-align: right;">29,247</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The Convertible Senior Notes (see Note 9) will only be included in the dilutive net income per share calculations using the treasury stock method during periods in which the average market price of Aceto&#8217;s common stock is above the applicable conversion price of the Convertible Senior Notes, or $33.215 per share, and the impact would not be anti-dilutive.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Income Taxes</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Property and Equipment</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Property and equipment are stated at cost and are depreciated using the straight line method over the estimated useful lives of the related asset. The Company allocates depreciation and amortization to cost of sales. Expenditures for improvements that extend the useful life of an asset are capitalized. Ordinary repairs and maintenance are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any related gains or losses are included in income.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The components of property and equipment were as follows:</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">June&#160;30,&#160;2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">June&#160;30,&#160;2016</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" nowrap="nowrap">Estimated&#160;useful<br />life&#160;(years)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; width: 749px;">Machinery and equipment</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 122px;">398</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">405</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: center; width: 146px;">3-7</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in;">Leasehold improvements</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">979</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,056</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: center;">Shorter of asset life or lease term</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Computer equipment and software</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">7,255</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">6,048</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: center;">3-5</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Furniture and fixtures</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,094</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,365</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: center;">5-10</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Automobiles</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">184</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">184</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: center;">3</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Building</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">8,678</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">8,690</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: center;">20</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2px;">Land</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">1,967</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">1,960</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: center; padding-bottom: 2px;">-</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">21,555</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">20,708</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: center;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2px;">Accumulated depreciation and amortization</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">11,127</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">10,664</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: center; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">10,428</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">10,044</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px; text-decoration: underline;">&#160;</td> <td style="text-align: center; padding-bottom: 4px; text-decoration: underline;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Property held for sale represents land and land improvements of $7,152 and $6,868 at June 30, 2017 and 2016, respectively. See Note 8, &#8220;Environmental Remediation&#8221; for further discussion on property held for sale.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Depreciation and amortization of property and equipment amounted to $1,520, $1,522 and $1,571 for the years ended June 30, 2017, 2016, and 2015 respectively.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Goodwill and Other Intangibles</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Goodwill is calculated as the excess of the cost of purchased businesses over the fair value of their underlying net assets. Other intangible assets principally consist of customer relationships, license agreements, technology-based intangibles, EPA registrations and related data, trademarks and product rights and related intangibles. Goodwill and other intangible assets that have an indefinite life are not amortized.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">In accordance with GAAP, the Company tests goodwill and other indefinite life intangible assets for impairment on at least an annual basis. Goodwill impairment exists if the net book value of a reporting unit exceeds its estimated fair value. Initially, an assessment of qualitative factors is conducted in order to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company determines that it is more likely than not that its carrying amount is greater than its fair value for a reporting unit, then it proceeds with the subsequent two-step process: (i) the Company determines impairment by comparing the fair value of a reporting unit with its carrying value, and (ii) if there is an impairment, the Company measures the amount of impairment loss by comparing the implied fair value of goodwill with the carrying amount of that goodwill. To determine the fair value of these intangible assets, the Company uses many assumptions and estimates using a market participant approach that directly impact the results of the testing. In making these assumptions and estimates, the Company uses industry accepted valuation models and set criteria that are reviewed and approved by various levels of management. The Company has the option to bypass the initial qualitative assessment stage and proceed directly to perform step one of the two-step process. In fiscal 2017, the Company performed step one of the two-step process and in fiscal 2016 the Company performed a qualitative assessment. There was no impairment of goodwill and other intangible assets in fiscal 2017 and fiscal 2016.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Impairment of Long-Lived Assets and Long-Lived Assets to be Disposed of</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Long-lived assets and certain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability of assets held for sale is measured by comparing the carrying amount of the assets to their estimated fair value. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceed the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Accounting for Derivatives and Hedging Activities</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The Company accounts for derivatives and hedging activities under the provisions of GAAP which establishes accounting and reporting guidelines for derivative instruments and hedging activities. GAAP requires the recognition of all derivative financial instruments as either assets or liabilities in the statement of financial condition and measurement of those instruments at fair value. Changes in the fair values of those derivatives are reported in earnings or other comprehensive income depending on the designation of the derivative and whether it qualifies for hedge accounting. The accounting for gains and losses associated with changes in the fair value of a derivative and the effect on the consolidated financial statements depends on its hedge designation and whether the hedge is highly effective in achieving offsetting changes in the fair value or cash flows of the asset or liability hedged. The method that is used for assessing the effectiveness of a hedging derivative, as well as the measurement approach for determining the ineffective aspects of the hedge, is established at the inception of the hedged instrument.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: bold 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The Company operates internationally, therefore its earnings, cash flows and financial positions are exposed to foreign currency risk from foreign-currency-denominated receivables and payables, which, in the U.S., have been denominated in various foreign currencies, including, among others, Euros, British Pounds, Japanese Yen, Singapore Dollars and Chinese Renminbi and at certain foreign subsidiaries in U.S. dollars and other non-local currencies.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Management believes it is prudent to minimize the risk caused by foreign currency fluctuation. Management minimizes the currency risk on its foreign currency receivables and payables by purchasing foreign currency contracts (futures) with one of its financial institutions. Futures are traded on regulated U.S. and international exchanges and represent commitments to purchase or sell a particular foreign currency at a future date and at a specific price. Since futures are purchased for the amount of the foreign currency receivable or for the amount of foreign currency needed to pay for specific purchase orders, and the futures mature on the due date of the related foreign currency vendor invoices or customer receivables, the Company believes that it eliminates risks relating to foreign currency fluctuation. The Company takes delivery of all futures to pay suppliers in the appropriate currency. The gains or losses for the changes in the fair value of the foreign currency contracts are recorded in cost of sales (sales) and offset the gains or losses associated with the impact of changes in foreign exchange rates on trade payables (receivables) denominated in foreign currencies. Senior management and members of the financial department continually monitor foreign currency risks and the use of this derivative instrument.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font: 10pt 'times new roman', times, serif; font-stretch: normal;">In conjunction with its existing credit agreement (see Note 9), the Company entered into an interest rate swap on March 21, 2017 for an additional interest cost of 2.005% on a notional amount of $100,000, which has been designated as a cash flow hedge</font><font style="font-family: 'times new roman', times, serif;">. <font style="font-size: 10pt;">The expiration date of this interest rate swap is December 21, 2021.</font></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Foreign Currency</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The financial statements of the Company&#8217;s foreign subsidiaries are translated into U.S. dollars in accordance with GAAP. Where the functional currency of a foreign subsidiary is its local currency, balance sheet accounts are translated at the current exchange rate and income statement items are translated at the average exchange rate for the period. Exchange gains or losses resulting from the translation of financial statements of foreign operations are accumulated in other comprehensive income. Where the local currency of a foreign subsidiary is not its functional currency, financial statements are translated at either current or historical exchange rates, as appropriate.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>(3) Business Combinations</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">On December 21, 2016, wholly owned subsidiaries of Rising Pharmaceuticals, Inc. (&#8220;Rising&#8221;), a wholly owned subsidiary of Aceto, completed the acquisition of certain generic products and related assets of entities formerly known as Citron Pharma LLC (&#8220;Citron&#8221;) and its affiliate Lucid Pharma LLC (&#8220;Lucid&#8221;). Rising formed two subsidiaries to consummate the product acquisition &#8211; Rising Health, LLC (&#8220;Rising Health&#8221;) (which acquired certain products and related assets of Citron) and Acetris Health, LLC (&#8220;Acetris Health&#8221;) (which acquired certain products and related assets of Lucid). Citron is a privately-held New Jersey-based pharmaceutical company focused on developing and marketing generic pharmaceutical products in partnership with leading generic pharmaceutical manufacturers based in India and the United States. Lucid is a privately-held New Jersey-based generic pharmaceutical distributor specializing in providing cost-effective products to various agencies of the U.S. Federal Government including the Veterans Administration and the Defense Logistics Agency. Lucid services 18 national contracts with the Federal Government, nearly all of which have 5-year terms.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Aceto and Rising Health possess complementary asset-light business models, drug development and manufacturing partnerships and product portfolios. The Company believes, consistent with its strategy of expanding Rising&#8217;s portfolio of finished dosage form generic products through product development partnerships and acquisitions of late stage assets, abbreviated new drug applications (&#8220;ANDAs&#8221;) and complementary generic drug businesses, this transaction significantly expanded its roster of commercialized products and pipeline of products under development. The Company believes the acquired assets meet the definition of a business. In addition, the Company believes that this product acquisition greatly enhances its size and stature within the generic pharmaceutical industry, expands its partnership network and offers the Company opportunities to realize meaningful cost and tax efficiencies.</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">At closing, Aceto paid the sellers $270,000 in cash, committed to make a $50,000 unsecured deferred payment that will bear interest at a rate of 5% per annum to the sellers on December 21, 2021 and agreed to issue 5,122 shares of Aceto common stock beginning on December 21, 2019. The product purchase agreement also provides the sellers with a 5-year potential earn-out of up to an additional $50,000 in cash, based on the financial performance of four pre-specified pipeline products that are currently in development. As of June 30, 2017, the Company accrued $2,807 related to this contingent consideration.</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The product acquisition was accounted for using the purchase method of accounting. The following table summarizes the allocation of the preliminary purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of December 21, 2016:</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="width: 60%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; margin-left: 0.5in; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 793px;">Trade receivables</td> <td style="width: 9px;">&#160;</td> <td style="text-align: left; width: 9px;">$</td> <td style="text-align: right; width: 133px;">78,937</td> <td style="text-align: left; width: 8px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Inventory</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">38,995</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Prepaid expenses and other current assets</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,425</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Goodwill</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">169,071</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2px;">Intangible assets</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">224,850</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Total assets acquired</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">513,278</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Accounts payable</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">46,840</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Accrued expenses</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">53,458</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Deferred payment</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">50,000</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2px;">Contingent consideration</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">2,580</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 4px; padding-left: 9pt;">Net assets acquired</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">360,400</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The fair values of the net assets acquired were determined using discounted cash flow analyses and estimates made by management. The preliminary purchase price was allocated to intangible assets as follows: approximately $169,071 to goodwill, which is nonamortizable under generally accepted accounting principles and is deductible for income tax purposes; approximately $135,700 of product rights, amortizable over a period of approximately ten years; approximately $88,800 of customer relationships, amortizable over approximately eleven years; and approximately $350 of trademarks, amortizable over a period of approximately six months. Amortization of the acquired intangible assets is deductible for income tax purposes. Goodwill represents the excess of the preliminary purchase price paid over the fair value of the underlying net assets acquired and was allocated to the Human Health Segment.</font></p> <p style="margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">As part of the product acquisition, the Company entered into an Administrative Services Agreement with the sellers in which excess cash payments may be made by either of the parties in connection with certain liabilities assumed upon the closing of the transaction related to rebates, chargebacks, commercial rebates and Medicaid and other government rebates. As of the closing date, the Company is responsible for the processing and administration of these related adjustments to sales completed prior to the closing date. In general, (i) if the amounts reserved for these liabilities underestimate the amounts that the Company is required to pay with respect to these items, the sellers will be required to reimburse the Company for the difference and (ii) if the amounts reserved for these liabilities overestimate the amounts that the Company is required to pay, the Company will be required to reimburse the sellers for the difference. Settlement is to be made two years after the closing date of December 21, 2016.</font></p> <p style="margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">For the period from December 22, 2016 to June 30, 2017, net sales and income before income taxes from the product acquisition was approximately $122,118 and $7,437, respectively, which have been included in the Consolidated Statement of Income for the year ended June 30, 2017. The following represents unaudited pro forma operating results as if the operations of Rising Health and Acetris Health had been included in the Company&#8217;s consolidated statements of operations as of July 1, 2015.</font></p> <p style="margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="width: 60%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="6" nowrap="nowrap">Year ended</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="6" nowrap="nowrap">June 30,</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 630px;">Net sales</td> <td style="width: 9px;">&#160;</td> <td style="text-align: left; width: 9px;">$</td> <td style="text-align: right; width: 134px;">739,318</td> <td style="text-align: left; width: 9px;">&#160;</td> <td style="width: 9px;">&#160;</td> <td style="text-align: left; width: 8px;">$</td> <td style="text-align: right; width: 133px;">731,100</td> <td style="text-align: left; width: 8px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Net income</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">24,166</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">30,469</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Net income per common share</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.70</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.89</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Diluted net income per common share</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.69</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.88</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The pro forma financial information includes business combination accounting effects from the product acquisition including amortization charges from acquired intangible assets of approximately $21,000 for both periods presented, increase in interest expense of approximately $13,200 for both periods presented associated with bank borrowings to fund the product acquisition and interest expense associated with the deferred payment to the sellers, $4,502 step-up in the fair value of the acquired inventory in the year ended June 30, 2016, reversal of acquisition related transaction costs of $8,818 and tax related effects in both periods. The unaudited pro forma information as presented above is for informational purposes only and is not indicative of the results of operations that would have been achieved if the product acquisition had taken place at the beginning of fiscal 2016.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>(4) Investments</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">A summary of short-term investments was as follows:</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: left;" nowrap="nowrap">&#160;</td> <td style="text-align: left; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;" colspan="2" nowrap="nowrap">June 30, 2017</td> <td style="text-align: left; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td> <td style="text-align: left; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;" colspan="2" nowrap="nowrap">June 30, 2016</td> <td style="text-align: left; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 1pt;" nowrap="nowrap"><u>Held to Maturity Investments</u></td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; width: 606px;">Time deposits</td> <td style="width: 8px;">&#160;</td> <td style="text-align: left; width: 8px;">$</td> <td style="text-align: right; width: 82px;">2,046</td> <td style="text-align: left; width: 7px;">&#160;</td> <td style="width: 7px;">&#160;</td> <td style="text-align: left; width: 7px;">$</td> <td style="text-align: right; width: 81px;">881</td> <td style="text-align: left; width: 7px;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Short-term investments consist of time deposits that the Company classifies as held-to- maturity and are recorded at cost plus accumulated interest. The Company has classified all investments with maturity dates of greater than three months as current since it has the ability to redeem them within the year and amounts are available for current operations.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;"><b>(5) Fair Value Measurements</b></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly fashion between market participants at the measurement date. GAAP establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s assumptions (unobservable inputs). The hierarchy consists of three levels:</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 9pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">Level 1 &#8211; Quoted market prices in active markets for identical assets or liabilities;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 9pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 9pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">Level 2 &#8211; Inputs other than Level 1 inputs that are either directly or indirectly observable; and</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 9pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 9pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">Level 3 &#8211; Unobservable inputs that are not corroborated by market data.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">On a recurring basis, Aceto measures at fair value certain financial assets and liabilities, which consist of cash equivalents, investments and foreign currency contracts. The Company classifies cash equivalents and investments within Level 1 if quoted prices are available in active markets. Level 1 assets include instruments valued based on quoted market prices in active markets which generally include corporate equity securities publicly traded on major exchanges. Time deposits are very short-term in nature and are accordingly valued at cost plus accrued interest, which approximates fair value, and are classified within Level 2 of the valuation hierarchy. The Company uses foreign currency futures contracts to minimize the risk caused by foreign currency fluctuation on its foreign currency receivables and payables by purchasing futures with one of its financial institutions. Futures are traded on regulated U.S. and international exchanges and represent commitments to purchase or sell a particular foreign currency at a future date and at a specific price. Aceto&#8217;s foreign currency derivative contracts are classified within Level 2 as the fair value of these hedges is primarily based on observable futures foreign exchange rates. At June 30, 2017, the Company had foreign currency contracts outstanding that had a notional amount of $62,187. Unrealized losses on hedging activities for the years ended June 30, 2017, 2016, and 2015, amounted to $515, $10 and $703, respectively, and are included in interest and other income, net, in the consolidated statements of income. The contracts have varying maturities of less than one year.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In conjunction with its existing credit agreement (see Note 9), the Company entered into an interest rate swap on March 21, 2017 for an additional interest cost of 2.005% on a notional amount of $100,000, which has been designated as a cash flow hedge</font><font style="font-family: 'times new roman', times, serif;">.&#160;<font style="font-size: 10pt;">The expiration date of this interest rate swap is December 21, 2021. The remaining balance of this derivative as of June 30, 2017 is $95,000.</font>&#160;<font style="font-size: 10pt;">The unrealized loss to date associated with this derivative, which is recorded in accumulated other comprehensive loss in the consolidated balance sheet at June 30, 2017, is $581. Aceto&#8217;s interest rate swaps are classified within Level 2 as the fair value of this hedge is primarily based on observable interest rates.</font></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;"></font>&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">At June 30, 2017, the Company had $2,952 of contingent consideration, $2,807 of which related to the acquisition of certain products and related assets of Citron and Lucid, which was completed in December 2016 (see Note 3) and $145 of contingent consideration related to a previously acquired company in France. At June 30, 2016, the Company had $132 of contingent consideration related to a previously acquired company in France. The contingent consideration was calculated using the present value of a probability weighted income approach.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">During the fourth quarter of each year, the Company evaluates goodwill for impairment at the reporting unit level using a market participant approach using Level 3 inputs.</font><font style="font-family: 'times new roman', times, serif;">&#160;<font style="font-size: 10pt;">Additionally, on a nonrecurring basis, the Company uses fair value measures when analyzing asset impairment.</font></font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">Changes in contingent consideration during 2017 and 2016 are as follows:</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 80%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 910px; text-align: justify;">Balance as of June 30, 2015</td> <td style="width: 11px;">&#160;</td> <td style="width: 11px; text-align: left;">$</td> <td style="width: 154px; text-align: right;">2,622</td> <td style="width: 10px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Reversal of fair value of liability-PACK</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(833</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Reversal of fair value of liability-France</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(241</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Payments</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(1,500</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Accrued interest expense</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">85</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify; padding-bottom: 2px;">Change in foreign currency exchange rate</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">(1</td> <td style="text-align: left; padding-bottom: 2px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify; padding-bottom: 4px;">Balance as of June 30, 2016</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">132</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Acquisitions</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,580</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Accrued interest expense</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">237</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify; padding-bottom: 2px;">Change in foreign currency exchange rate</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">3</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify; padding-bottom: 4px;">Balance as of June 30, 2017</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">2,952</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">Long-lived assets and certain identifiable intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&#160;&#160;If it is determined such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization periods, their carrying values are reduced to estimated fair value.&#160;&#160;Measurements based on undiscounted cash flows are considered to be Level 3 inputs.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">In November 2015, the Company issued $143,750 aggregate principal amount of Notes (see Note 9). Since Aceto has the option to settle the potential conversion of the Notes in cash, the Company separated the embedded conversion option feature from the debt feature and accounts for each component separately, based on the fair value of the debt component assuming no conversion option. The calculation of the fair value of the debt component required the use of Level 3 inputs, and was determined by calculating the fair value of similar non-convertible debt, using a theoretical borrowing rate of 6.5%. The value of the embedded conversion option was determined using an expected present value technique (income approach) to estimate the fair value of similar non-convertible debt and included utilization of convertible investors&#8217; credit assumptions and high yield bond indices. The carrying amount of the Notes approximate a fair value of $133,000 at June 30, 2017 and $134,400 at June 30, 2016 giving effect for certain factors, including the term of the Notes, current stock price of Aceto stock and effective interest rate. A portion of the offering proceeds was used to simultaneously enter into privately negotiated convertible note hedge transactions with option counterparties, which are affiliates of certain of the initial purchasers in the offering of the Notes and privately negotiated warrant transactions with the option counterparties (see Note 9). The Company calculated the fair value of the bond hedge based on the price that was paid to purchase the call. The Company also calculated the fair value of the warrant based on the price at which the affiliate purchased the warrants from the Company. Since the convertible note hedge and warrant are both indexed to the Company&#8217;s common stock and otherwise would be classified as equity, Aceto recorded both elements as equity, resulting in a net reduction to capital in excess of par value of $13,489.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">The carrying values of all financial instruments classified as a current asset or current liability are deemed to approximate fair value because of the short maturity of these instruments. The fair values of the Company&#8217;s notes receivable and short-term and long-term bank loans were based upon current rates offered for similar financial instruments to the Company.</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">The following tables summarize the valuation of the Company&#8217;s financial assets and liabilities which were determined by using the following inputs at June 30, 2017 and 2016:</font></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 90%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="14" nowrap="nowrap">Fair&#160;Value&#160;Measurements&#160;at&#160;June&#160;30,&#160;2017&#160;Using</td> <td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Quoted&#160;Prices<br />in&#160;Active<br />Markets<br />(Level&#160;1)</td> <td style="padding-bottom: 1pt; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" nowrap="nowrap">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Significant<br />Other<br />Observable<br />Inputs<br />(Level&#160;2)</td> <td style="padding-bottom: 1pt; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" nowrap="nowrap">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Significant<br />Unobservable<br />Inputs<br />(Level&#160;3)</td> <td style="padding-bottom: 1pt; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" nowrap="nowrap">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Total</td> <td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Cash equivalents:</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 665px; text-align: left; padding-left: 9pt;">Time deposits</td> <td style="width: 15px;">&#160;</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 141px; text-align: right;">-</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">5,781</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 141px; text-align: right;">-</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">5,781</td> <td style="width: 14px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Investments:</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-left: 9pt;">Time deposits</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,046</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,046</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Foreign currency contracts-assets (1)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">486</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">486</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Foreign currency contracts-liabilities (2)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">137</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">137</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Derivative liability for interest rate swap(3)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">581</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">581</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Contingent consideration (4)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">2,952</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,952</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0pt; margin-bottom: 0pt; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0px;"></td> <td style="width: 0.5in;"><font style="font-family: 'times new roman', times, serif;">(1)</font></td> <td style="text-align: justify;"><font style="font-family: 'times new roman', times, serif;">Included in &#8220;Other receivables&#8221; in the accompanying Consolidated Balance Sheet as of June 30, 2017.</font></td> </tr> </table> <table style="font: 10pt/normal 'times new roman', times, serif; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0in;"></td> <td style="width: 0.5in; text-align: left;"><font style="font-family: 'times new roman', times, serif;">(2)</font></td> <td><font style="font-family: 'times new roman', times, serif;">Included in &#8220;Accrued expenses&#8221; in the accompanying Consolidated Balance Sheet as of June 30, 2017.</font></td> </tr> </table> <table style="font: 10pt/normal 'times new roman', times, serif; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0in;"></td> <td style="width: 0.5in; text-align: left;"><font style="font-family: 'times new roman', times, serif;">(3)</font></td> <td><font style="font-family: 'times new roman', times, serif;">Included in &#8220;Long-term liabilities&#8221; in the accompanying Consolidated Balance Sheet as of June 30, 2017.</font></td> </tr> </table> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0pt; margin-bottom: 0pt; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0px;"></td> <td style="width: 0.5in;"><font style="font-family: 'times new roman', times, serif;">(4)</font></td> <td style="text-align: justify;"><font style="font-family: 'times new roman', times, serif;">$145 included in &#8220;Accrued expenses&#8221; and $2,807 included in &#8220;Long-term liabilities&#8221; in the accompanying Consolidated Balance Sheet as of June 30, 2017.</font></td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 90%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="14" nowrap="nowrap">Fair&#160;Value&#160;Measurements&#160;at&#160;June&#160;30,&#160;2016&#160;Using</td> <td style="padding-bottom: 1pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Quoted&#160;Prices<br />in&#160;Active<br />Markets<br />(Level&#160;1)</td> <td style="padding-bottom: 1pt; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="padding-bottom: 1pt; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Significant<br />Other<br />Observable<br />Inputs<br />(Level&#160;2)</td> <td style="padding-bottom: 1pt; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="padding-bottom: 1pt; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Significant<br />Unobservable<br />Inputs<br />(Level&#160;3)</td> <td style="padding-bottom: 1pt; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="padding-bottom: 1pt; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Total</td> <td style="padding-bottom: 1pt;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Cash equivalents:</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 665px; text-align: left; padding-left: 9pt;">Time deposits</td> <td style="width: 15px;">&#160;</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 141px; text-align: right;">-</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">6,249</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 141px; text-align: right;">-</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">6,249</td> <td style="width: 14px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Investments:</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-left: 9pt;">Time deposits</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">881</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">881</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Foreign currency contracts-assets (5)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">160</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">160</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Foreign currency contracts-liabilities (6)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">169</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">169</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Contingent consideration (7)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">132</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">132</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: -0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0pt; margin-bottom: 0pt; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0px;"></td> <td style="width: 0.5in;"><font style="font-family: 'times new roman', times, serif;">(5)</font></td> <td style="text-align: justify;"><font style="font-family: 'times new roman', times, serif;">Included in &#8220;Other receivables&#8221; in the accompanying Consolidated Balance Sheet as of June 30, 2016.</font></td> </tr> </table> <table style="font: 10pt/normal 'times new roman', times, serif; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0in;"></td> <td style="width: 0.5in; text-align: left;"><font style="font-family: 'times new roman', times, serif;">(6)</font></td> <td><font style="font-family: 'times new roman', times, serif;">Included in &#8220;Accrued expenses&#8221; in the accompanying Consolidated Balance Sheet as of June 30, 2016.</font></td> </tr> </table> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0pt; margin-bottom: 0pt; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0px;"></td> <td style="width: 0.5in;"><font style="font-family: 'times new roman', times, serif;">(7)</font></td> <td style="text-align: justify;"><font style="font-family: 'times new roman', times, serif;">Included in &#8220;Long-term liabilities&#8221; in the accompanying Consolidated Balance Sheet as of June 30, 2016.</font></td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>(6) Goodwill and Other Intangible Assets</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">As of June 30, 2017 and June 30, 2016, there was goodwill of $236,970 and $67,871, respectively.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Changes in the Company's goodwill during 2017 and 2016 are as follows:</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 90%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Human<br />Health<br />Segment</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Pharmaceutical<br />Ingredients<br />Segment</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Performance<br />Chemicals<br />Segment</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Total<br />Goodwill</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; width: 589px;">Balance as of June 30, 2015</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 123px;">66,039</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">1,650</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">181</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">67,870</td> <td style="text-align: left; width: 12px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2px;">Changes in foreign currency exchange rates</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">1</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">1</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Balance as of June 30, 2016</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">66,039</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,651</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">181</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">67,871</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Acquisitions</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">169,071</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">169,071</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2px;">Changes in foreign currency exchange rates</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left; padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right; padding-bottom: 2px;">23</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left; padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right; padding-bottom: 2px;">5</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left; padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right; padding-bottom: 2px;">28</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 4px;">Balance as of June 30, 2017</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">235,110</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">1,674</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">186</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">236,970</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Intangible assets subject to amortization as of June 30, 2017 and 2016 were as follows:</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 90%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Gross<br />Carrying<br />Value</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Accumulated<br />Amortization</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Net&#160;Book<br />Value</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; text-decoration: underline;">June 30, 2017</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; width: 665px;">Customer relationships</td> <td style="width: 11px;">&#160;</td> <td style="text-align: left; width: 11px;">$</td> <td style="text-align: right; width: 109px;">110,787</td> <td style="text-align: left; width: 11px;">&#160;</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">$</td> <td style="text-align: right; width: 109px;">13,968</td> <td style="text-align: left; width: 10px;">&#160;</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">$</td> <td style="text-align: right; width: 109px;">96,819</td> <td style="text-align: left; width: 10px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Trademarks</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,218</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,195</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">23</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Product rights and related intangibles</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">221,335</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">37,677</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">183,658</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">License agreements</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">6,537</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">6,035</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">502</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2px;">EPA registrations and related data</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">14,307</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">11,011</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">3,296</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">355,184</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">70,886</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">284,298</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 90%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Gross<br />Carrying<br />Value</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Accumulated<br />Amortization</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Net&#160;Book<br />Value</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; text-decoration: underline;">June 30, 2016</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; width: 665px;">Customer relationships</td> <td style="width: 11px;">&#160;</td> <td style="text-align: left; width: 11px;">$</td> <td style="text-align: right; width: 109px;">21,761</td> <td style="text-align: left; width: 11px;">&#160;</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">$</td> <td style="text-align: right; width: 109px;">7,815</td> <td style="text-align: left; width: 10px;">&#160;</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">$</td> <td style="text-align: right; width: 109px;">13,946</td> <td style="text-align: left; width: 10px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Trademarks</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,868</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,800</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">68</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Product rights and related intangibles</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">83,048</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">23,511</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">59,537</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">License agreements</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">6,611</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5,531</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,080</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">EPA registrations and related data</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">13,591</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">9,927</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">3,664</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2px;">Technology-based intangibles</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">155</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">140</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">15</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">127,034</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">48,724</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">78,310</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Intangible assets with definitive useful lives are amortized using the straight-line method over their estimated useful lives. The straight-line method is utilized as it best reflects the use of the asset. The estimated useful lives of customer relationships, trademarks, product rights and related intangibles, license agreements and EPA registrations are 7-11 years, 3-4 years, 3-14 years, 6-11 years and 10 years respectively.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">As of June 30, 2017 and June 30, 2016, the Company also had $783 and $761, respectively, of intangible assets pertaining to trademarks which have indefinite lives and are not subject to amortization. The change in trademarks with indefinite lives is attributable to foreign currency exchange rates used to translate the financial statements of foreign subsidiaries.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Amortization expense for intangible assets subject to amortization amounted to $22,234, $11,176 and $10,278 for the years ended June 30, 2017, 2016 and 2015, respectively. The estimated aggregate amortization expense for intangible assets subject to amortization for each of the succeeding years ending June 30, 2018 through June 30, 2023 are as follows: 2018: $16,747; 2019: $32,431; 2020: $31,880; 2021: $31,819; 2022: $31,782 and 2023 and thereafter: $139,639.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>(7) Accrued Expenses</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The components of accrued expenses as of June 30, 2017 and 2016 were as follows:</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; width: 909px;">Accrued compensation</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">5,793</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">6,880</td> <td style="text-align: left; width: 12px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Accrued environmental remediation costs-current portion</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">6,112</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">9,180</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Reserve for price concessions</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">80,556</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">31,342</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Partnered product liabilities</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">16,068</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2px;">Other accrued expenses</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">9,799</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">5,273</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">118,328</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">52,675</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>(8) Environmental Remediation</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In fiscal years 2011, 2009, 2008 and 2007, the Company received letters from the Pulvair Site Group, a group of potentially responsible parties (PRP Group) who are working with the State of Tennessee (the State) to remediate a contaminated property in Tennessee called the Pulvair site. The PRP Group has alleged that Aceto shipped hazardous substances to the site which were released into the environment. The State had begun administrative proceedings against the members of the PRP Group and Aceto with respect to the cleanup of the Pulvair site and the PRP Group has begun to undertake cleanup. The PRP Group is seeking a settlement of approximately $1,700 from the Company for its share to remediate the site contamination. Although the Company acknowledges that it shipped materials to the site for formulation over twenty years ago, the Company believes that the evidence does not show that the hazardous materials sent by Aceto to the site have significantly contributed to the contamination of the environment and thus believes that, at most, it is a de minimis contributor to the site contamination. Accordingly, the Company believes that the settlement offer is unreasonable. Management believes that the ultimate outcome of this matter will not have a material adverse effect on the Company's financial condition or liquidity.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company has environmental remediation obligations in connection with Arsynco, Inc. (&#8220;Arsynco&#8221;), a subsidiary formerly involved in manufacturing chemicals located in Carlstadt, New Jersey, which was closed in 1993 and is currently held for sale. Based on continued monitoring of the contamination at the site and the approved plan of remediation, Arsynco received an estimate from an environmental consultant stating that the costs of remediation could be between $21,500 and $23,300. Remediation commenced in fiscal 2010, and as of June 30, 2017 and June 30, 2016, a liability of $8,451 and $12,532, respectively, is included in the accompanying consolidated balance sheets for this matter. For the year ended June 30, 2017, the Company recorded environmental remediation charges of $903, which is included in selling, general and administrative expenses in the accompanying consolidated statements of income for the year ended June 30, 2017. In accordance with GAAP, management believes that the majority of costs incurred to remediate the site will be capitalized in preparing the property which is currently classified as held for sale. An appraisal of the fair value of the property by a third-party appraiser supports the assumption that the expected fair value after the remediation is in excess of the amount required to be capitalized. However, these matters, if resolved in a manner different from those assumed in current estimates, could have a material adverse effect on the Company&#8217;s financial condition, operating results and cash flows when resolved in a future reporting period.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In connection with the environmental remediation obligation for Arsynco, in July 2009, Arsynco entered into a settlement agreement with BASF Corporation (&#8220;BASF&#8221;), the former owners of the Arsynco property. In accordance with the settlement agreement, BASF paid for a portion of the prior remediation costs and going forward, will co-remediate the property with the Company. The contract requires that BASF pay $550 related to past response costs and pay a proportionate share of the future remediation costs. Accordingly, the Company had recorded a gain of $550 in fiscal 2009. This $550 gain relates to the partial reimbursement of costs of approximately $1,200 that the Company had previously expensed. The Company also recorded an additional receivable from BASF, with an offset against property held for sale, representing its estimated portion of the future remediation costs. The balance of this receivable for future remediation costs as of June 30, 2017 and June 30, 2016 is $3,803 and $5,639, respectively, which is included in the accompanying consolidated balance sheets.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In March 2006, Arsynco received notice from the EPA of its status as a PRP under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) for a site described as the Berry&#8217;s Creek Study Area (&#8220;BCSA&#8221;). Arsynco is one of over 150 PRPs which have potential liability for the required investigation and remediation of the site. The estimate of the potential liability is not quantifiable for a number of reasons, including the difficulty in determining the extent of contamination and the length of time remediation may require. In addition, any estimate of liability must also consider the number of other PRPs and their financial strength. In July 2014, Arsynco received notice from the U.S. Department of Interior (&#8220;USDOI&#8221;) regarding the USDOI&#8217;s intent to perform a Natural Resource Damage (NRD) Assessment at the BCSA. Arsynco has to date declined to participate in the development and performance of the NRD assessment process. Based on prior practice in similar situations, it is possible that the State may assert a claim for natural resource damages with respect to the Arsynco site itself, and either the federal government or the State (or both) may assert claims against Arsynco for natural resource damages in connection with Berry's Creek; any such claim with respect to Berry's Creek could also be asserted against the approximately 150 PRPs which the EPA has identified in connection with that site. Any claim for natural resource damages with respect to the Arsynco site itself may also be asserted against BASF, the former owners of the Arsynco property. In September 2012, Arsynco entered into an agreement with three of the other PRPs that had previously been impleaded into New Jersey Department of Environmental Protection, et al. v. Occidental Chemical Corporation, et al., Docket No. ESX-L-9868-05 (the "NJDEP Litigation") and were considering impleading Arsynco into the same proceeding. Arsynco entered into an agreement to avoid impleader. Pursuant to the agreement, Arsynco agreed to (1) a tolling period that would not be included when computing the running of any statute of limitations that might provide a defense to the NJDEP Litigation; (2) the waiver of certain issue preclusion defenses in the NJDEP Litigation; and (3) arbitration of certain potential future liability allocation claims if the other parties to the agreement are barred by a court of competent jurisdiction from proceeding against Arsynco. In July 2015, Arsynco was contacted by an allocation consultant retained by a group of the named PRPs, inviting Arsynco to participate in the allocation among the PRPs&#8217; investigation and remediation costs relating to the BCSA. Arsynco declined that invitation. Since an amount of the liability cannot be reasonably estimated at this time, no accrual is recorded for these potential future costs. The impact of the resolution of this matter on the Company&#8217;s results of operations in a particular reporting period is not currently known.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>(9) Debt</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><i>Long-term debt</i></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="6" nowrap="nowrap">June 30,</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 751px;">Convertible Senior Notes, net</td> <td style="width: 11px;">&#160;</td> <td style="text-align: left; width: 11px;">$</td> <td style="text-align: right; width: 130px;">121,676</td> <td style="text-align: left; width: 10px;">&#160;</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">$</td> <td style="text-align: right; width: 130px;">115,829</td> <td style="text-align: left; width: 10px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt;">Revolving bank loans</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">90,000</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt;">Term bank loans</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">139,227</td> <td style="text-align: left;">&#160;</td> <td style="font-weight: bold;">&#160;</td> <td style="text-align: left; font-weight: bold;">&#160;</td> <td style="text-align: right; font-weight: bold;">-</td> <td style="text-align: left; font-weight: bold;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2px; text-indent: -10pt; padding-left: 10pt;">Mortgage</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">2,763</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">2,960</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2px; text-indent: -10pt; padding-left: 10pt;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="text-align: right; padding-bottom: 2px;">353,666</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">118,789</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2px; text-indent: -10pt; padding-left: 10pt;">Less current portion</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">14,466</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">197</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 4px; text-indent: -10pt; padding-left: 10pt;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">339,200</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">118,592</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><i>Convertible Senior Notes</i></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">In November 2015, Aceto offered $125,000 aggregate principal amount of Convertible Senior Notes due 2020 (the "Notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In addition, Aceto granted the initial purchasers for the offering an option to purchase up to an additional $18,750 aggregate principal amount pursuant to the initial purchasers&#8217; option to purchase additional Notes, which was exercised in November 2015. Therefore the total offering was $143,750 aggregate principal amount. The Notes are unsecured obligations of Aceto and rank senior in right of payment to any of Aceto&#8217;s subordinated indebtedness, equal in right of payment to all of Aceto&#8217;s unsecured indebtedness that is not subordinated, effectively junior in right of payment to any of Aceto&#8217;s secured indebtedness to the extent of the value of the assets securing such indebtedness and structurally junior in right of payment to all indebtedness and other liabilities (including trade payables) of Aceto&#8217;s subsidiaries. The Notes will be convertible into cash, shares of Aceto common stock or a combination thereof, at Aceto&#8217;s election, upon the satisfaction of specified conditions and during certain periods. The Notes will mature in November 2020. The Notes pay 2.0% interest semi-annually in arrears on May 1 and November 1 of each year, which commenced on May 1, 2016. The Notes are convertible into 4,328 shares of common stock, based on an initial conversion price of $33.215 per share.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Holders may convert all or any portion of their notes, in multiples of one thousand dollar principal amount, at their option at any time prior to the close of business on the business day immediately preceding May 1, 2020 only under the following circumstances: (i) during any calendar quarter (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, (ii) during the five consecutive business day period after any five consecutive trading day period (which is referred to as the &#8220;measurement period&#8221;) in which the trading price per one thousand dollar principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of Aceto&#8217;s common stock and the conversion rate on each such trading day; or (iii) upon the occurrence of specified corporate events.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Upon conversion by the holders, the Company may elect to settle such conversion in shares of its common stock, cash, or a combination thereof. As a result of its cash conversion option, the Company separately accounted for the value of the embedded conversion option as a debt discount (with an offset to capital in excess of par value). The debt discount is being amortized as additional non-cash interest expense using the effective interest method over the term of the Notes. Debt issuance costs are being amortized as additional non-cash interest expense. The Company presents debt issuance costs as a direct deduction from the carrying value of the debt liability rather than showing the debt issuance costs as a deferred charge on the balance sheet.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">In connection with the offering of the Notes, Aceto entered into privately negotiated convertible note hedge transactions with option counterparties, which are affiliates of certain of the initial purchasers. The convertible note hedge transactions are expected generally to reduce the potential dilution to Aceto&#8217;s common stock and/or offset any cash payments Aceto is required to make in excess of the principal amount of converted Notes upon any conversion of Notes. Aceto also entered into privately negotiated warrant transactions with the option counterparties. The warrant transactions could separately have a dilutive effect to the extent that the market price per share of Aceto&#8217;s common stock as measured over the applicable valuation period at the maturity of the warrants exceeds the applicable strike price of the warrants. By entering into these transactions with the option counterparties, the Company issued convertible debt and a freestanding &#8220;call-spread.&#8221;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The carrying value of the Notes is as follows:</font></p> <p style="text-align: justify; widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">June&#160;30,<br />2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">June&#160;30,<br />2016</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 751px;">Principal amount</td> <td style="width: 11px;">&#160;</td> <td style="text-align: left; width: 11px;">$</td> <td style="text-align: right; width: 130px;">143,750</td> <td style="text-align: left; width: 10px;">&#160;</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">$</td> <td style="text-align: right; width: 130px;">143,750</td> <td style="text-align: left; width: 10px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt;">Unamortized debt discount</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(19,255</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(24,267</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt;">Unamortized debt issuance costs</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(2,819</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(3,654</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 4px; text-indent: -10pt; padding-left: 10pt;">Net carrying value</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">121,676</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">115,829</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font>&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The following table sets forth the components of total &#8220;interest expense&#8221; related to the Notes recognized in the accompanying consolidated statements of income for the year ended June 30:</p> <p style="text-align: justify; widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 751px;">Contractual coupon</td> <td style="width: 11px;">&#160;</td> <td style="text-align: left; width: 11px;">$</td> <td style="text-align: right; width: 130px;">2,867</td> <td style="text-align: left; width: 10px;">&#160;</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">$</td> <td style="text-align: right; width: 130px;">1,788</td> <td style="text-align: left; width: 10px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt;">Amortization of debt discount</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5,012</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,974</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -10pt; padding-left: 10pt;">Amortization of debt issuance costs</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">835</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">522</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 4px; text-indent: -10pt; padding-left: 10pt;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">8,714</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">5,284</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><i>&#160;</i></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><i>Credit Facilities</i></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">On December 21, 2016 the Company entered into a Second Amended and Restated Credit Agreement (the &#8220;A&amp;R Credit Agreement&#8221;), with eleven banks, which amended and restated in its entirety the Amended and Restated Credit Agreement, dated as of October 28, 2015, as amended by Amendment No. 1 to Amended and Restated Credit Agreement, dated as of November 10, 2015, and Amendment No. 2 to Amended and Restated Credit Agreement, dated as of August 26, 2016 (collectively, the &#8220;First Amended Credit Agreement&#8221;). The A&amp;R Credit Agreement increases the aggregate available revolving commitment under the First Amended Credit Agreement from $150,000 to an initial aggregate available revolving commitment of $225,000 (the &#8220;Initial Revolving Commitment&#8221;). Under the A&amp;R Credit Agreement, the Company may borrow, repay and reborrow from and as of December 21, 2016, to but excluding December 21, 2021 (the &#8220;Maturity Date&#8221;) provided, that if any of the Notes remain outstanding on the date that is 91 days prior to the maturity date of the Notes (the &#8220;2015 Convertible Maturity Date&#8221;), then the Maturity Date shall mean the date that is 91 days prior to the 2015 Convertible Maturity Date. The A&amp;R Credit Agreement provides for (i) Eurodollar Loans (as such terms are defined in the A&amp;R Credit Agreement), (ii) ABR Loans (as such terms are defined in the A&amp;R Credit Agreement) or (iii) a combination thereof. As of June 30, 2017, the Company borrowed Revolving Loans aggregating $90,000 which loans are Eurodollar Loans at interest rates ranging from 3.21% to 3.45 % at June 30, 2017. The applicable interest rate margin percentage is subject to adjustment quarterly based upon the Company&#8217;s senior secured net leverage ratio.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Under the A&amp;R Credit Agreement, the Company also borrowed $150,000 in term loans (the &#8220;Initial Term Loan). Subject to certain conditions, including obtaining commitments from existing or prospective lenders, the Company will have the right to increase the amount of the Initial Revolving Commitment (each, a &#8220;Revolving Facility Increase&#8221; and, together with the Initial Revolving Commitment, the &#8220;Revolving Commitment&#8221;) and/or the Initial Term Loan in an aggregate amount not to exceed $100,000 pursuant to an incremental loan feature in the A&amp;R Credit Agreement. As of June 30, 2017, the remaining amount outstanding under the Initial Term Loan is $142,500 and is payable as a Eurodollar Loan at an interest rate of 3.30%. The proceeds of the Initial Revolving Commitment and Initial Term Loan have been used to partially finance the acquisition of generic products and related assets of Citron and its affiliate Lucid, and pay fees and expenses related thereto. The applicable interest rate margin percentage is subject to adjustment quarterly based upon the Company&#8217;s senior secured net leverage ratio.</font></p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The Initial Term Loan is payable as to principal in nineteen consecutive, equal quarterly installments of $3,750, which commenced on March 31, 2017 and will continue on each March 31, June 30, September 30 and December 31 thereafter. To the extent not previously paid, the final payment on the Term Loan Maturity Date (as defined in the A&amp;R Credit Agreement) shall be in an amount equal to the then outstanding unpaid principal amount of the Initial Term Loan.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">As such, the Company has classified $15,000 of the Initial Term Loan as short-term in the consolidated balance sheet at June 30, 2017. The A&amp;R Credit Agreement, similar to the First Amended Credit Agreement, provides that commercial letters of credit shall be issued to provide the primary payment mechanism in connection with the purchase of any materials, goods or services in the ordinary course of business. The Company had no open letters of credit at June 30, 2017 and June 30, 2016.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">In accordance with generally accepted accounting principles, $3,659 of deferred financing costs associated with the Initial Term Loan are presented as a direct deduction from the carrying value of the debt liability rather than showing the deferred financing costs as a deferred charge on the balance sheet. In addition, deferred financing costs of $1,748 associated with the Revolving Commitment have been recorded as a deferred charge on the balance sheet.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font>&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The A&amp;R Credit Agreement, like the First Amended Credit Agreement, provides for a security interest in substantially all of the personal property of the Company and certain of its subsidiaries. The A&amp;R Credit Agreement contains several financial covenants including, among other things, maintaining a minimum level of debt service and certain leverage ratios. Under the A&amp;R Credit Agreement, the Company and its subsidiaries are also subject to certain restrictive covenants, including, among other things, covenants governing liens, limitations on indebtedness, limitations on guarantees, limitations on sales of assets and sales of receivables, and limitations on loans and investments. The Company was in compliance with all covenants at June 30, 2017.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company has available lines of credit with foreign financial institutions. At June 30, 2017, the Company had available lines of credit with foreign financial institutions totaling $7,351. At June 30, 2016, the Company had available lines of credit with foreign financial institutions totaling $7,397. The Company has issued a cross corporate guarantee to the foreign banks. Short term loans under these agreements bear interest at a fixed rate of 4.5% at June 30, 2017 and June 30, 2016 and 5.0% at June 30, 2015. The Company is not subject to any financial covenants under these arrangements.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Under the above financing arrangements, the Company had $232,500 in bank loans and $1,737 in standby letters of credit, leaving an unused facility of $140,613 at June 30, 2017. At June 30, 2016 the Company had $0 in bank loans and $1,758 in standby letters of credit leaving an unused facility of $155,639.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt courier; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><i>Mortgage</i></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><i>&#160;</i></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">On June 30, 2011, the Company entered into a mortgage payable for $3,947 on its new corporate headquarters, in Port Washington, New York. This mortgage payable is secured by the land and building and is being amortized over a period of 20 years. The mortgage payable, which was modified in October 2013, bears interest at 4.92% as of June 30, 2017 and matures on June 30, 2021.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><i>&#160;</i></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><i>Maturity of Long-term Debt</i></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><i>&#160;</i></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Long-term debt matures by fiscal year as follows:</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 60%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; width: 727px;">2018</td> <td style="width: 8px;">&#160;</td> <td style="text-align: left; width: 8px;">$</td> <td style="text-align: right; width: 132px;">14,466</td> <td style="text-align: left; width: 8px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">2019</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">14,466</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">2020</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">14,466</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">2021</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">138,115</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">2022</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">172,153</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2px;">Thereafter</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">353,666</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>(10) Stock Based Compensation Plans</b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">At the annual meeting of shareholders of the Company, held on December 15, 2015, the Company&#8217;s shareholders approved the Aceto Corporation 2015 Equity Participation Plan (the &#8220;2015 Plan&#8221;). Under the 2015 Plan, grants of stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards (&#8220;Stock Awards&#8221;) may be offered to employees, non-employee directors, consultants and advisors of the Company, including the chief executive officer, chief financial officer and other named executive officers. The maximum number of shares of common stock of the Company that may be issued pursuant to Stock Awards granted under the 2015 Plan will not exceed, in the aggregate, 4,250 shares. Stock Awards that are intended to qualify as &#8220;performance-based compensation&#8221; for purposes of Section 162(m) of the Internal Revenue Code of 1986, as amended, may be granted.&#160;&#160;Performance-based awards may be granted, vested and paid based on the attainment of specified performance goals.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">At the annual meeting of shareholders of the Company, held on December 6, 2012, the Company&#8217;s shareholders approved the amended and restated Aceto Corporation 2010 Equity Participation Plan (the &#8220;2010 Plan&#8221;). Under the 2010 Plan, grants of stock options, restricted stock, restricted stock units, stock appreciation rights, and stock bonuses may be made to employees, non-employee directors and consultants of the Company. The maximum number of shares of common stock of the Company that may be issued pursuant to awards granted under the 2010 Plan will not exceed, in the aggregate, 5,250 shares. In addition, restricted stock may be granted to an eligible participant in lieu of a portion of any annual cash bonus earned by such participant. Such award may include additional shares of restricted stock (premium shares) greater than the portion of bonus paid in restricted stock. The restricted stock award is vested at issuance and the restrictions lapse ratably over a period of years as determined by the Board of Directors, generally three years. The premium shares vest when all the restrictions lapse, provided that the participant remains employed by the Company at that time.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">At the annual meeting of shareholders of the Company held December 6, 2007, the shareholders approved the Aceto Corporation 2007 Long-Term Performance Incentive Plan (the &#8220;2007 Plan&#8221;). The Company has reserved 700 shares of common stock for issuance under the 2007 Plan to the Company&#8217;s employees and non-employee directors. There are five types of awards that may be granted under the 2007 Plan-options to purchase common stock, stock appreciation rights, restricted stock, restricted stock units and performance incentive units.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In September 2016, the Company granted 28 performance stock options to an executive officer at an exercise price of $20.03 per share.&#160;<font style="font-family: 'times new roman', times, serif;">The performance options vest if the closing stock price meets or exceeds the target price of $40 for 20 consecutive trading days prior to June 30, 2021 and the explicit service period of 1 year has been met.</font>&#160;The options will expire June 30, 2021, if the stock price target is not achieved. If it is achieved, the options will expire ten years from the date of grant. There were no stock options granted in fiscal years 2016 or 2015.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of June 30, 2017, there were 3,144, 255 and 0 shares of common stock available for grant under the 2015, 2010 and 2007 Plans, respectively.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In December 1998, the Company adopted the Aceto Corporation 1998 Omnibus Equity Award Plan (1998 Plan). The 1998 Plan expired in December 2008. Outstanding options survive the expiration of the 1998 Plan.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following summarizes the shares of common stock under options for all plans at June 30, 2017, 2016 and 2015, and the activity with respect to options for the respective years then ended:</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 85%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Shares&#160;subject&#160;to<br />option</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Weighted&#160;average<br />exercise&#160;price&#160;per<br />share</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Aggregate<br />Intrinsic<br />Value</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 861px;">Balance at June 30, 2014</td> <td style="width: 14px;">&#160;</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 141px; text-align: right;">551</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">7.72</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 141px; text-align: right;">&#160;</td> <td style="width: 14px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Granted</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Exercised</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(146</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">8.74</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">Forfeited (including cancelled options)</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">(8</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">)</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">10.94</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Balance at June 30, 2015</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">397</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">7.28</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Granted</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Exercised</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(95</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">7.56</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">Forfeited (including cancelled options)</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">-</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">-</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Balance at June 30, 2016</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">302</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">7.19</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Granted</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">28</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">20.03</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Exercised</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(70</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">7.90</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">Forfeited (including cancelled options)</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">-</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">-</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">Balance at June 30, 2017</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">260</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">8.36</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">1,968</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Options exercisable at June 30, 2017</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">232</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">6.98</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">1,968</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="color: black;">The total intrinsic value of stock options exercised during the years ended June 30, 2017, 2016 and 2015 was approximately $865, $1,700 and $1,713, respectively.&#160;</font>The weighted average remaining contractual life of options outstanding at June 30, 2017 was approximately 4 years. At June 30, 2017, outstanding options had expiration dates ranging from December 2017 to June 2021.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Under the 2015 Plan, 2010 Plan, 2002 Plan and the 1998 Plan, compensation expense is recorded for the fair value of the restricted stock awards in the year the related bonus is earned and over the vesting period for the market value at the date of grant of the premium shares granted. In fiscal 2017, 2016 and 2015, restricted stock awarded and premium shares vested of 5, 7 and 5 common shares, respectively, were issued under employee incentive plans, which increased stockholders&#8217; equity by $109, $113 and $77, respectively. The related non-cash compensation expense related to the vesting of premium shares during the year was $26, $22 and $22 in fiscal 2017, 2016 and 2015, respectively. Additionally, non-cash compensation expense of $55, $0 and $21 was recorded in fiscal 2017, 2016 and 2015, respectively, relating to stock option grants, which is included in selling, general and administrative expenses. As of June 30, 2017, the total unrecognized compensation cost related to option awards is $95.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following summarizes the non-vested stock options at June 30, 2017 and the activity with respect to non-vested options for the year ended June 30, 2017:</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 80%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Shares<br />subject&#160;to<br />option</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Weighted<br />average&#160;grant<br />date&#160;fair&#160;value</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 724px; text-align: justify;">Non-vested at June 30, 2016</td> <td style="width: 11px;">&#160;</td> <td style="width: 11px; text-align: left;">&#160;</td> <td style="width: 154px; text-align: right;">-</td> <td style="width: 11px; text-align: left;">&#160;</td> <td style="width: 11px;">&#160;</td> <td style="width: 11px; text-align: left;">&#160;</td> <td style="width: 153px; text-align: right;">-</td> <td style="width: 10px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Granted</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">28</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">5.44</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Vested</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Forfeited</td> <td>&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">-</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">-</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Non-vested at June 30, 2017</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">28</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">5.44</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The per-share fair value of stock options granted during 2017 was $5.44 on the date of the grant using a Monte Carlo simulation option-pricing model with the following assumptions:</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 80%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;"><u style="text-decoration: none;">2017</u></font></td> <td style="padding-bottom: 1pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Expected life</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;" nowrap="nowrap">4.9 years</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 885px; text-align: left;">Expected volatility</td> <td style="width: 10px;">&#160;</td> <td style="width: 10px; text-align: left;">&#160;</td> <td style="width: 101px; text-align: right;">39.4</td> <td style="width: 12px; text-align: left;">%</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Risk-free interest rate</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1.26</td> <td style="text-align: left;">%</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Dividend yield</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1.30</td> <td style="text-align: left;">%</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">During the year ended June 30, 2017, the Company granted 277 shares of restricted common stock to its employees that vest over three years and 22 shares of restricted common stock to its non-employee directors, which vest over approximately one year as well as 42 restricted stock units that have varying vest dates through July 2017. In addition, the Company also issued a target grant of 160 performance-vested restricted stock units, which grant could be as much as 280 restricted stock units if certain performance criteria and market conditions are met. Performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">During the year ended June 30, 2016, the Company granted 221 shares of restricted common stock to its employees that vest over three years and 14 shares of restricted common stock to its non-employee directors, which vest over approximately one year as well as 46 restricted stock units that have varying vest dates through July 2017. In addition, the Company also issued a target grant of 142 performance-vested restricted stock units, which grant could be as much as 248 if certain performance criteria and market conditions are met. Performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">During the year ended June 30, 2015, the Company granted 165 shares of restricted common stock to its employees that vest over three years and 12 shares of restricted common stock to its non-employee directors, which vest over approximately one year as well as 67 restricted stock units that have varying vest dates through August 2016. In addition, the Company also issued a target grant of 116 performance-vested restricted stock units, which grant could be as much as 203 if certain performance criteria and market conditions are met. Performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the years ended June 30, 2017, 2016 and 2015, the Company recorded stock-based compensation expense of approximately $6,875, $6,697, and $4,494, respectively, which is included in selling, general and administrative expenses, for shares of restricted common stock and restricted stock units.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The remaining stock-based compensation expense for restricted stock awards and units is approximately $8,382 at June 30, 2017 and the related weighted average period over which it is expected that such unrecognized compensation cost will be recognized is approximately 1.8 years.</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">A summary of restricted stock awards including restricted stock units as of June 30, 2017, is presented below:</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 80%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Shares</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Weighted<br />average&#160;grant<br />date&#160;fair&#160;value</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 724px; text-align: left;">Non-vested at beginning of year</td> <td style="width: 11px;">&#160;</td> <td style="width: 11px; text-align: left;">&#160;</td> <td style="width: 154px; text-align: right;">795</td> <td style="width: 11px; text-align: left;">&#160;</td> <td style="width: 11px;">&#160;</td> <td style="width: 11px; text-align: left;">$</td> <td style="width: 153px; text-align: right;">20.73</td> <td style="width: 10px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Granted</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">501</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">18.92</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Vested</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(396</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">17.26</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Forfeited</td> <td>&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">(103</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">)</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">21.33</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Non-vested at June 30, 2017</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">797</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">21.24</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>(11) Interest and Other Income</b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Interest and other income during fiscal 2017, 2016 and 2015 was comprised of the following:</p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 85%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 614px;">Dividends</td> <td style="width: 13px;">&#160;</td> <td style="width: 13px; text-align: left;">$</td> <td style="width: 176px; text-align: right;">277</td> <td style="width: 13px; text-align: left;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="width: 13px; text-align: left;">$</td> <td style="width: 175px; text-align: right;">222</td> <td style="width: 12px; text-align: left;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="width: 12px; text-align: left;">$</td> <td style="width: 175px; text-align: right;">233</td> <td style="width: 12px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Interest</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">264</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">313</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">282</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Foreign government subsidies received</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">64</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">25</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">22</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Joint venture equity earnings</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,336</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,060</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,761</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Foreign currency (losses) gains</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(298</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">56</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(1,065</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Deferred compensation plan losses</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(257</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(35</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(96</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Rental income</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">158</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">154</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">151</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 2px;">Miscellaneous income</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">33</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">28</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">198</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">2,577</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">2,823</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">1,486</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b>&#160;</b></p> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company&#8217;s joint venture earnings represent the Company&#8217;s investment in a corporate joint venture established for the purpose of selling a particular agricultural protection product. The Company&#8217;s initial investment was $6 in fiscal 2009, representing a 30% ownership and the Company accounts for this joint venture using the equity method of accounting.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>(12) Income Taxes</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>&#160;</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The components of income before the provision for income taxes are as follows:</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 534px;">Domestic operations</td> <td style="width: 11px;">&#160;</td> <td style="text-align: left; width: 11px;">$</td> <td style="text-align: right; width: 153px;">9,555</td> <td style="text-align: left; width: 11px;">&#160;</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">$</td> <td style="text-align: right; width: 152px;">43,906</td> <td style="text-align: left; width: 10px;">&#160;</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">$</td> <td style="text-align: right; width: 152px;">48,276</td> <td style="text-align: left; width: 10px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2px;">Foreign operations</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">7,806</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">9,948</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">5,589</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">17,361</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">53,854</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">53,865</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The components of the provision for income taxes are as follows:</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center; text-decoration: none;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px; text-decoration: none;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; text-decoration: none;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px; text-decoration: none;">&#160;</td> <td style="padding-bottom: 2px; text-decoration: none;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; text-decoration: none;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px; text-decoration: none;">&#160;</td> <td style="padding-bottom: 2px; text-decoration: none;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; text-decoration: none;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 2px; text-decoration: none;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Federal:</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 9pt; width: 522px;">Current</td> <td style="width: 11px;">&#160;</td> <td style="text-align: left; width: 11px;">$</td> <td style="text-align: right; width: 153px;">3,713</td> <td style="text-align: left; width: 11px;">&#160;</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">$</td> <td style="text-align: right; width: 152px;">15,129</td> <td style="text-align: left; width: 10px;">&#160;</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">$</td> <td style="text-align: right; width: 152px;">18,393</td> <td style="text-align: left; width: 10px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 9pt;">Deferred</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(585</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(204</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(1,357</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">State and local:</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 9pt;">Current</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">555</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">755</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,526</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 9pt;">Deferred</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(110</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">173</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">189</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Foreign:</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 9pt;">Current</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,221</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">3,222</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,337</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2px; padding-left: 9pt;">Deferred</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">191</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">13</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(706</td> <td style="text-align: left; padding-bottom: 2px;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">5,985</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">19,088</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">20,382</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Income taxes payable, which is included in accrued expenses, was $64 and $2,119 at June 30, 2017 and 2016, respectively.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The tax effects of temporary differences that give rise to the deferred tax assets and liabilities at June 30, 2017 and 2016 are presented below:</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Deferred tax assets:</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt; width: 796px;">Accrued deferred compensation</td> <td style="width: 11px;">&#160;</td> <td style="text-align: left; width: 11px;">$</td> <td style="text-align: right; width: 109px;">4,229</td> <td style="text-align: left; width: 10px;">&#160;</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">$</td> <td style="text-align: right; width: 109px;">4,122</td> <td style="text-align: left; width: 10px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Accrual for sales deductions not currently deductible</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5,796</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5,925</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Additional inventoried costs for tax purposes</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">697</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">389</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Allowance for doubtful accounts receivable</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">106</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">106</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Depreciation and amortization</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">11,957</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">7,784</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Debt issuance costs</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">7,611</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">9,462</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Foreign deferred tax assets</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">983</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,121</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Domestic net operating loss carryforwards</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">81</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">109</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Foreign net operating loss carryforwards</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">692</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">685</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 0.25in;">Total gross deferred tax assets</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">32,152</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">29,703</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 0.25in;">Valuation allowances</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(773</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(794</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 0.25in;">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">31,379</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">28,909</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Deferred tax liabilities:</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Foreign deferred tax liabilities</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(65</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(27</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 9pt;">Goodwill</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(10,244</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(7,586</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Original issue discount &#8211; convertible senior notes</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(7,260</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(9,115</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2px; padding-left: 9pt;">Other</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(1,136</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(26</td> <td style="text-align: left; padding-bottom: 2px;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2px; padding-left: 0.25in;">Total gross deferred tax liabilities</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(18,705</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(16,754</td> <td style="text-align: left; padding-bottom: 2px;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 0.25in;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 4px;">Net deferred tax assets</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">12,674</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">12,155</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The following table shows the current and non-current deferred tax assets (liabilities) at June 30, 2017 and 2016:</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 70%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td> <td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 668px;">Current deferred tax assets, net</td> <td style="width: 9px;">&#160;</td> <td style="text-align: left; width: 9px;">$</td> <td style="text-align: right; width: 115px;">546</td> <td style="text-align: left; width: 9px;">&#160;</td> <td style="width: 9px;">&#160;</td> <td style="text-align: left; width: 9px;">$</td> <td style="text-align: right; width: 114px;">3,244</td> <td style="text-align: left; width: 8px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Non-current deferred tax assets, net</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">19,453</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">18,053</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Non-current deferred tax liabilities</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(7,325</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(9,142</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 4px; padding-left: 9pt;">Net deferred tax assets</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">12,674</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">12,155</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The net change in the total valuation allowance for the years ended June 30, 2017 and June 30, 2016 was a decrease of $21 and $16, respectively. A valuation allowance is provided when it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The Company has established valuation allowances primarily for net operating loss carryforwards in certain foreign countries. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets are not expected to be realized. The assessment of the amount of value assigned to the Company&#8217;s deferred tax assets under the applicable accounting rules is judgmental. Management is required to consider all available positive and negative evidence in evaluating the likelihood that the Company will be able to realize the benefit of its deferred tax assets in the future. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which net operating loss carryforwards are utilizable and temporary differences become deductible. The Company has federal and state net operating loss carryforwards of $0 and $81, respectively, which will expire in fiscal year 2018. The Company has foreign net operating loss carryforwards of $692 which do not have any expiry dates. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, taxable income in carryback years if carryback is permitted and tax planning strategies in making this assessment. In order to fully realize the net deferred tax assets recognized at June 30, 2017, the Company will need to generate future taxable income of approximately $34,638.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Based upon the level of historical taxable income and projections for taxable income over the periods which the deferred tax assets are deductible, management believes it is more likely than not the Company will realize the benefits of these deductible differences. There can be no assurance, however, that the Company will generate any earnings or any specific level of continuing earnings in the future. The amount of the deferred tax asset considered realizable, however, could be reduced in the near term if estimates of future taxable income during the carryforward period are reduced.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Deferred taxes have not been provided for undistributed earnings of foreign subsidiaries amounting to approximately $111,569 at June 30, 2017 since substantially all of these earnings are expected to be indefinitely reinvested in foreign operations. A deferred tax liability will be recognized when the Company expects that it will recover these undistributed earnings in a taxable manner, such as through the receipt of dividends or sale of the investments. The Company intends to indefinitely reinvest the remaining undistributed earnings and has no plan for further repatriation. Determination of the amount of unrecognized deferred U.S. income tax liabilities, net of unrecognized foreign tax credits, is not practical to calculate because of the complexity of this hypothetical calculation resulting in various methods available, each with different U.S. tax consequences<b>.</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">A reconciliation of the statutory federal income tax rate and the effective tax rate for continuing operations for the fiscal years ended June 30, 2017, 2016 and 2015 follows:</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 665px;">Federal statutory tax rate</td> <td style="width: 11px;">&#160;</td> <td style="text-align: left; width: 10px;">&#160;</td> <td style="text-align: right; width: 109px;">35.0</td> <td style="text-align: left; width: 11px;">%</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">&#160;</td> <td style="text-align: right; width: 109px;">35.0</td> <td style="text-align: left; width: 11px;">%</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">&#160;</td> <td style="text-align: right; width: 109px;">35.0</td> <td style="text-align: left; width: 11px;">%</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;">State and local taxes, net of federal income tax benefit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1.2</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1.7</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2.4</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Decrease (increase) in valuation allowance</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">0.1</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">0.4</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Foreign tax rate differential</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(1.8</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(0.4</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(0.9</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2px;">Other</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(0.9</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">0.9</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 4px;">Effective tax rate</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">&#160;</td> <td style="border-bottom: black 4px double; text-align: right;">34.5</td> <td style="text-align: left; padding-bottom: 4px;">%</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">&#160;</td> <td style="border-bottom: black 4px double; text-align: right;">35.4</td> <td style="text-align: left; padding-bottom: 4px;">%</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">&#160;</td> <td style="border-bottom: black 4px double; text-align: right;">37.8</td> <td style="text-align: left; padding-bottom: 4px;">%</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>&#160;</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company operates in various tax jurisdictions, and although it believes that it has provided for income and other taxes in accordance with the relevant regulations, if the applicable regulations were ultimately interpreted differently by a taxing authority, the Company may be exposed to additional tax liabilities.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">There are no material unrecognized tax benefits included in the consolidated balance sheet that would, if recognized, have a material effect on the Company&#8217;s effective tax rate. The Company is continuing its practice of recognizing interest and penalties related to income tax matters in income tax expense. The Company did not recognize interest and penalties during the years ended June 30, 2017 and June 30, 2016. The Company files U.S. federal, U.S. state, and foreign tax returns, and is generally no longer subject to tax examinations for fiscal years prior to 2013 (in the case of certain foreign tax returns, fiscal year 2012).</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>(13) Supplemental Cash Flow Information</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Cash paid for interest and income taxes during fiscal 2017, 2016 and 2015 was as follows:</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="width: 665px;">Interest</td> <td style="width: 11px;">&#160;</td> <td style="text-align: left; width: 11px;">$</td> <td style="text-align: right; width: 109px;">7,794</td> <td style="text-align: left; width: 11px;">&#160;</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">$</td> <td style="text-align: right; width: 109px;">2,970</td> <td style="text-align: left; width: 10px;">&#160;</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">$</td> <td style="text-align: right; width: 109px;">3,954</td> <td style="text-align: left; width: 10px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Income taxes, net of refunds</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">7,912</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">16,076</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">25,459</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>&#160;</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In connection with the acquisition of certain products and related assets of Citron and Lucid, approximately 5,122 shares of Aceto common stock with a fair value of $90,400, to be issued beginning on December 21, 2019, a $50,000 unsecured deferred payment payable on December 21, 2021 and a contingent earn out liability of $2,580 are non-cash items and are excluded from the Consolidated Statement of Cash Flows during the year ended June 30, 2017. In addition, the Company had non-cash items excluded from the Consolidated Statements of Cash Flows during the years ended June 30, 2017, 2016 and 2015 of $284, $294 and $726, respectively related to capitalized environmental remediation costs and property held for sale and $1,578 measurement period adjustments to goodwill during the year ended June 30, 2015.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>(14) Retirement Plans</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Defined Contribution Plans</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company has defined contribution retirement plans in which certain employees are eligible to participate, including deferred compensation plans (see below). The Company's annual contribution per employee, which is at management's discretion, is based on a percentage of the employee&#8217;s compensation. The Company's provision for these defined contribution plans amounted to $1,794, $1,957 and $1,849 in fiscal 2017, 2016 and 2015, respectively.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>&#160;</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Defined Benefit Plans</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company sponsors certain defined benefit pension plans covering certain employees of its German subsidiaries who meet the plan&#8217;s eligibility requirements. The accrued pension liability as of June 30, 2017 was $883. The accrued pension liability as of June 30, 2016 was $853. Net periodic pension costs, which consists principally of interest cost and service cost was $30 in fiscal 2017, $28 in fiscal 2016 and $53 in fiscal 2015. The Company&#8217;s plans are funded in conformity with the funding requirements of the applicable government regulations. An assumed weighted average discount rate of 2.0%, 1.9% and 1.6% and a compensation increase rate of 0.0% were used in determining the actuarial present value of benefit obligations as of June 30, 2017, 2016 and 2015, respectively.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Deferred Compensation Plans</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-weight: normal;">&#160;</font></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-weight: normal;">To comply with the requirements of the American Jobs Creation Act of 2004, as of December 2004, the Company froze its non-qualified Supplemental Executive Retirement Plan (the Frozen Plan) and has not allowed any further deferrals or contributions to the Frozen Plan after December 31, 2004. All of the earned benefits of the participants in the Frozen Plan as of December 31, 2004, will be preserved under the existing plan provisions.</font></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-weight: normal;">&#160;</font></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-weight: normal;">On March 14, 2005, the Company&#8217;s Board of Directors adopted the Aceto Corporation Supplemental Executive Deferred Compensation Plan (the Plan). The Plan is a non-qualified deferred compensation plan intended to provide certain qualified executives with supplemental benefits beyond the Company&#8217;s 401(k) plan, as well as to permit additional deferrals of a portion of their compensation. The Plan is intended to comply with the provisions of section 409A of the Internal Revenue Code of 1986, as amended, and is designed to provide comparable benefits to those under the Frozen Plan. Substantially all compensation deferred under the Plan, as well as Company contributions, is held by the Company in a grantor trust, which is considered an asset of the Company. The assets held by the grantor trust are in life insurance policies. Effective July 1, 2013, the Plan was frozen and a new plan, entitled &#8220;Aceto Corporation 2013 Senior Executive Retirement Plan&#8221; was adopted by the Company&#8217;s Board of Directors.</font></p><div style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</div><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-weight: normal;">As of June 30, 2017, the Company recorded a liability under the Plans of $3,551 (of which $3,337 is included in long-term liabilities and $214 is included in accrued expenses) and an asset (included in other assets) of $3,087, primarily representing mutual fund investments owned by the Company. As of June 30, 2016, the Company recorded a liability under the Plans of $3,046 (of which $3,028 is included in long-term liabilities and $18 is included in accrued expenses) and an asset (included in other assets) of $2,693, primarily representing the cash surrender value of policies owned by the Company.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>(15) Financial Instruments</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>&#160;</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Derivative Financial Instruments</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company is exposed to credit losses in the event of non-performance by the financial institutions, who are the counterparties, on its future foreign currency contracts. The Company anticipates, however, that the financial institutions will be able to fully satisfy their obligations under the contracts. The Company does not obtain collateral to support financial instruments, but monitors the credit standing of the financial institutions.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Fair Value of Financial Instruments</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The carrying values of all financial instruments classified as a current asset or current liability are deemed to approximate fair value because of the short maturity of these instruments. The fair value of the Company&#8217;s notes receivable and accrued expenses was based upon current rates offered for similar financial instruments to the Company.&#160;<font style="color: black;">The Company believes that borrowings outstanding under its long-term bank loans and mortgage approximate fair value because such borrowings bear interest at current variable market rates.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>&#160;</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Business and Credit Concentration</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of trade receivables. The Company&#8217;s customers are dispersed across many industries and are located throughout the United States as well as in Canada, France, Germany, Malaysia, The Netherlands, Switzerland, the United Kingdom, and other countries. The Company estimates an allowance for doubtful accounts based upon the creditworthiness of its customers as well as general economic conditions. Consequently, an adverse change in those factors could affect the Company&#8217;s estimate of this allowance. At June 30, 2017, three customers approximated 31%, 21% and 15%, respectively, of net trade accounts receivable. At June 30, 2016, three customers approximated 34%, 20% and 11%, respectively, of net trade accounts receivable.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">One customer accounted for 12% of net sales in fiscal 2017, 14% of net sales in fiscal 2016 and 13% of net sales in fiscal 2015. Another customer accounted for 11% of net sales in fiscal 2017, 7% of net sales in 2016 and 6% of net sales in 2015. No single product accounted for as much as 10% of net sales in fiscal 2017, 2016 or 2015.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">During the fiscal years ended June 30, 2017, 2016 and 2015, approximately 62%, 56% and 65%, respectively, of the Company&#8217;s purchases came from Asia and approximately 17%, 22% and 12%, respectively, came from Europe.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company maintains operations located outside of the United States. Net assets located in Europe and Asia approximated $68,235 and $50,641, respectively at June 30, 2017. Net assets located in Europe and Asia approximated $62,399 and $48,846, respectively at June 30, 2016.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>(16) Commitments, Contingencies and Other Matters</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">As of June 30, 2017, the Company has outstanding purchase obligations totaling $61,381 with suppliers to the Company&#8217;s domestic and foreign operations to acquire certain products for resale to third party customers.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company and its subsidiaries are subject to various claims which have arisen in the normal course of business. The Company provides for costs related to contingencies when a loss from such claims is probable and the amount is reasonably determinable. In determining whether it is possible to provide an estimate of loss, or range of possible loss, the Company reviews and evaluates its litigation and regulatory matters on a quarterly basis in light of potentially relevant factual and legal developments. If the Company determines an unfavorable outcome is not probable or reasonably estimable, the Company does not accrue for a potential litigation loss. While the Company has determined that there is a reasonable possibility that a loss has been incurred, no amounts have been recognized in the financial statements, other than what has been discussed below, because the amount of the liability cannot be reasonably estimated at this time.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In fiscal years 2011, 2009, 2008 and 2007, the Company received letters from the Pulvair Site Group, a group of potentially responsible parties (PRP Group) who are working with the State of Tennessee (the State) to remediate a contaminated property in Tennessee called the Pulvair site. The PRP Group has alleged that Aceto shipped hazardous substances to the site which were released into the environment. The State had begun administrative proceedings against the members of the PRP Group and Aceto with respect to the cleanup of the Pulvair site and the PRP Group has begun to undertake cleanup. The PRP Group is seeking a settlement of approximately $1,700 from the Company for its share to remediate the site contamination. Although the Company acknowledges that it shipped materials to the site for formulation over twenty years ago, the Company believes that the evidence does not show that the hazardous materials sent by Aceto to the site have significantly contributed to the contamination of the environment and thus believes that, at most, it is a de minimis contributor to the site contamination. Accordingly, the Company believes that the settlement offer is unreasonable. Management believes that the ultimate outcome of this matter will not have a material adverse effect on the Company's financial condition or liquidity.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company has environmental remediation obligations in connection with Arsynco, Inc. (&#8220;Arsynco&#8221;), a subsidiary formerly involved in manufacturing chemicals located in Carlstadt, New Jersey, which was closed in 1993 and is currently held for sale. Based on continued monitoring of the contamination at the site and the approved plan of remediation, Arsynco received an estimate from an environmental consultant stating that the costs of remediation could be between $21,500 and $23,300. Remediation commenced in fiscal 2010, and as of June 30, 2017 and June 30, 2016, a liability of $8,451 and $12,532, respectively, is included in the accompanying consolidated balance sheets for this matter. For the year ended June 30, 2017, the Company recorded environmental remediation charges of $903 which is included in selling, general and administrative expenses in the accompanying consolidated statements of income for the year ended June 30, 2017. In accordance with GAAP, management believes that the majority of costs incurred to remediate the site will be capitalized in preparing the property which is currently classified as held for sale. An appraisal of the fair value of the property by a third-party appraiser supports the assumption that the expected fair value after the remediation is in excess of the amount required to be capitalized. However, these matters, if resolved in a manner different from those assumed in current estimates, could have a material adverse effect on the Company&#8217;s financial condition, operating results and cash flows when resolved in a future reporting period.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In connection with the environmental remediation obligation for Arsynco, in July 2009, Arsynco entered into a settlement agreement with BASF Corporation (&#8220;BASF&#8221;), the former owners of the Arsynco property. In accordance with the settlement agreement, BASF paid for a portion of the prior remediation costs and going forward, will co-remediate the property with the Company. The contract requires that BASF pay $550 related to past response costs and pay a proportionate share of the future remediation costs. Accordingly, the Company had recorded a gain of $550 in fiscal 2009. This $550 gain relates to the partial reimbursement of costs of approximately $1,200 that the Company had previously expensed. The Company also recorded an additional receivable from BASF, with an offset against property held for sale, representing its estimated portion of the future remediation costs. The balance of this receivable for future remediation costs as of June 30, 2017 and June 30, 2016 is $3,803 and $5,639, respectively, which is included in the accompanying consolidated balance sheets.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In March 2006, Arsynco received notice from the EPA of its status as a PRP under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) for a site described as the Berry&#8217;s Creek Study Area (&#8220;BCSA&#8221;). Arsynco is one of over 150 PRPs which have potential liability for the required investigation and remediation of the site. The estimate of the potential liability is not quantifiable for a number of reasons, including the difficulty in determining the extent of contamination and the length of time remediation may require. In addition, any estimate of liability must also consider the number of other PRPs and their financial strength. In July 2014, Arsynco received notice from the U.S. Department of Interior (&#8220;USDOI&#8221;) regarding the USDOI&#8217;s intent to perform a Natural Resource Damage (NRD) Assessment at the BCSA. Arsynco has to date declined to participate in the development and performance of the NRD assessment process. Based on prior practice in similar situations, it is possible that the State may assert a claim for natural resource damages with respect to the Arsynco site itself, and either the federal government or the State (or both) may assert claims against Arsynco for natural resource damages in connection with Berry's Creek; any such claim with respect to Berry's Creek could also be asserted against the approximately 150 PRPs which the EPA has identified in connection with that site. Any claim for natural resource damages with respect to the Arsynco site itself may also be asserted against BASF, the former owners of the Arsynco property. In September 2012, Arsynco entered into an agreement with three of the other PRPs that had previously been impleaded into New Jersey Department of Environmental Protection, et al. v. Occidental Chemical Corporation, et al., Docket No. ESX-L-9868-05 (the "NJDEP Litigation") and were considering impleading Arsynco into the same proceeding. Arsynco entered into an agreement to avoid impleader. Pursuant to the agreement, Arsynco agreed to (1) a tolling period that would not be included when computing the running of any statute of limitations that might provide a defense to the NJDEP Litigation; (2) the waiver of certain issue preclusion defenses in the NJDEP Litigation; and (3) arbitration of certain potential future liability allocation claims if the other parties to the agreement are barred by a court of competent jurisdiction from proceeding against Arsynco. In July 2015, Arsynco was contacted by an allocation consultant retained by a group of the named PRPs, inviting Arsynco to participate in the allocation among the PRPs&#8217; investigation and remediation costs relating to the BCSA. Arsynco declined that invitation. Since an amount of the liability cannot be reasonably estimated at this time, no accrual is recorded for these potential future costs. The impact of the resolution of this matter on the Company&#8217;s results of operations in a particular reporting period is not currently known.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">A subsidiary of the Company markets certain agricultural protection products which are subject to the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA). FIFRA requires that test data be provided to the EPA to register, obtain and maintain approved labels for pesticide products. The EPA requires that follow-on registrants of these products compensate the initial registrant for the cost of producing the necessary test data on a basis prescribed in the FIFRA regulations. Follow-on registrants do not themselves generate or contract for the data. However, when FIFRA requirements mandate that new test data be generated to enable all registrants to continue marketing a pesticide product, often both the initial and follow-on registrants establish a task force to jointly undertake the testing effort. The Company is presently a member of several such task force groups, which requires payments for such memberships. In addition, in connection with our agricultural protection business, the Company plans to acquire product registrations and related data filed with the United States Environmental Protection Agency to support such registrations and other supporting data for several products. The acquisition of these product registrations and related data filed with the United States Environmental Protection Agency as well as payments to various task force groups could approximate $2,357 through fiscal 2018, of which $0 has been accrued as of June 30, 2017 and June 30, 2016.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company leases office facilities in the United States, The Netherlands, Germany, France, Singapore and the Philippines expiring at various dates between October 2017 and June 2021.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">At June 30, 2017, the future minimum lease payments for office facilities and equipment for each of the five succeeding years and in the aggregate are as follows:</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><table style="widows: 2; text-transform: none; text-indent: 0px; width: 45%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="border-bottom: black 2px solid; text-align: center;" nowrap="nowrap">Fiscal year</td><td style="border-bottom: black 2px solid;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Amount</td><td style="padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; width: 619px;">2018</td><td style="width: 8px;">&#160;</td><td style="text-align: left; width: 8px;">$</td><td style="text-align: right; width: 141px;">1,673</td><td style="text-align: left; width: 7px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">2019</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,327</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">2020</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,766</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">2021</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,327</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">2022</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,031</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2px;">Thereafter</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">6,744</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">14,868</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td></tr></table><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Total rental expense amounted to $1,301, $1,265 and $1,567 for fiscal 2017, 2016 and 2015, respectively.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>(17) Related Party Transactions</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">During fiscal 2017, 2016 and 2015, the Company purchased inventory from its corporate joint venture in the amount of $3,236, $2,831 and $3,204, respectively.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">During fiscal 2017, Rising Health and Acetris Health incurred costs of $1,865 and $165, respectively, related to consulting services provided by former Citron and Lucid employees, in connection with a transition services agreement entered into at the time of the Company&#8217;s 2016 product purchase agreement. Citron and Lucid are affiliates of Vimal Kavuru, a member of the Company&#8217;s Board of Directors.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In October 2017, Rising will commence leasing approximately 125,000 gross square feet of warehouse space in Somerset, New Jersey. This building is owned by an affiliate of Mr. Kavuru.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">On November 2, 2016, the Company, Citron and Cronus Research Labs Private Limited,&#160;<font style="background-color: white;">a research and development company headquartered in India that is</font>&#160;affiliated with Vimal Kavuru (&#8220;Cronus&#8221;), entered into two amended and restated joint development agreements pursuant to which Cronus has been engaged to develop a portfolio of nine pipeline products (&#8220;Development Agreement I&#8221;) and certain other products (&#8220;Development Agreement II&#8221; and together with Development Agreement I, the &#8220;Development Agreements&#8221;) on behalf of Citron. Under the terms of Development Agreement I, Cronus has agreed to pay the first $3,500 of the development costs incurred after December 21, 2016, and 50% of any development costs incurred above that threshold in exchange for obtaining reimbursement for its costs funded out of the profits earned, if any, from the pipeline products that are commercially launched, and a specified portion of the profits from those products thereafter. Under the terms of Development Agreement II, Cronus has agreed to pay the development costs for the products covered thereby in exchange for obtaining reimbursement for its costs funded out of the profits earned, if any, from such products that are commercially launched (subject to a $1,445 maximum), and a specified portion of the profits from those products thereafter.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Mr. Kavuru was not a member of the Company&#8217;s Board at the time that the above-mentioned transition services agreement, lease or Development Agreements were executed.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>(18) Recent Accounting Pronouncements</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-size: 10pt;">In May 2017, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2017-09,&#160;<i>Compensation &#8211; Stock Compensation (Topic 718): Scope of Modification Accounting,</i></font>&#160;<font style="font-size: 10pt;">which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-09 is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. The Company does not believe this new accounting standard update will have a material impact on its consolidated financial statements.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In January 2017, the FASB issued ASU 2017-04&#160;<i>Intangibles - Goodwill and Other (Topic 350)&#160;</i>which would eliminate the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Instead, the amount of an impairment charge would be recognized if the carrying amount of a reporting unit is greater than its fair value. ASU 2017-04 is effective for public companies for fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company does not believe this new accounting pronouncement will have a material impact on its consolidated financial statements.</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In January 2017, the FASB issued ASU 2017-01&#160;<i>Business Combinations (Topic 805): Clarifying the Definition of a Business&#160;</i>with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. ASU 2017-01 is effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company does not believe this new accounting pronouncement will have a material impact on its consolidated financial statements.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In August 2016, the FASB issued ASU 2016-15,&#160;<i>Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,</i>&#160;which addresses eight specific cash flow issues with the objective of reducing diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact of the provisions of ASU 2016-15.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In March 2016, the FASB issued ASU 2016-09,&#160;<i>Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</i>, which will change certain aspects of accounting for share-based payments to employees. ASU 2016-09 is effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2016. ASU 2019-09 requires that all tax benefits and deficiencies related to share-based payments be recognized and recorded through the statement of income for all awards settled or expiring after the adoption of ASU 2016-09. Under prior guidance, tax benefits in excess of compensation costs ("windfalls") were recorded in equity, and any tax deficiencies ("shortfalls") were recorded in equity to the extent of previous windfalls and then to the statement of income. ASU 2016-09 also requires, either prospectively or retrospectively, that all tax-related cash flows resulting from share-based payments be reported as operating activities on the statement of cash flows, a change from prior guidance that required windfall tax benefits to be presented as an inflow from financing activities and an outflow from operating activities on the statement of cash flows. Additionally, ASU 2016-09 allows entities to make an accounting policy election for the impact of most types of forfeitures on the recognition of expense for share-based payment awards by allowing the forfeitures to be either estimated, as was required under prior guidance, or recognized when they actually occur. Under ASU 2016-09, it is possible for equity awards to have a more dilutive effect on earnings per share (EPS). Under prior guidance, anticipated income tax windfalls and shortfalls were included in the calculation of assumed proceeds when applying the treasury stock method for computing the dilutive effect of share-based awards in the calculation of diluted EPS. Because there is no longer any excess tax benefits recognized in additional paid capital under ASU 2016-09, when applying the treasury stock method for computing diluted EPS, the assumed proceeds do not include any windfall tax benefits. As a result, fewer hypothetical shares can be repurchased under the treasury stock method, resulting in an assumption of more incremental shares being issued upon the exercise of shared-based awards. Therefore, equity awards have a more dilutive effect on EPS for any period where the average market price of an entity's underlying stock exceeds the average fair value of outstanding dilutive equity awards for the period. &#160;The provisions of ASU 2016-09 are effective for the Company at the beginning of fiscal 2018. The impact of ASU 2016-09 on the Company's income tax expense or benefit and related cash flows during and after the period of adoption are dependent in part upon future grants and vesting of stock-based compensation awards and other factors that are not fully controllable or predicable by the Company such as the future market price of the Company's common stock, the timing of employee exercises of vested stock options, and the future achievement of performance criteria that affect performance-based awards.&#160;<font style="font-family: 'times new roman', times, serif;">Under ASU 2016-09, the Company will recognize forfeitures when they actually occur.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In February 2016, the FASB issued ASU 2016-02,&#160;<i>Leases (Topic 842)</i>&#160;that replaces existing lease guidance. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. The new guidance will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of income. ASU 2016-02 is effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2018. The Company is currently evaluating the impact of the provisions of ASU 2016-02.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In November 2015, the FASB issued ASU 2015-17,&#160;<i>Income Taxes (Topic 740) Balance Sheet Classification of Deferred Assets.&#160;</i>This ASU is intended to<i>&#160;</i>simplify the presentation of deferred taxes on the balance sheet and will require an entity to present all deferred tax assets and deferred tax liabilities as non-current on the balance sheet. Under the current guidance, entities are required to separately present deferred taxes as current or non-current. Netting deferred tax assets and deferred tax liabilities by tax jurisdiction will still be required under the new guidance. This guidance will be effective for Aceto beginning in the first quarter of fiscal 2018. The Company does not believe this new accounting standard update will have a material impact on its consolidated financial statements.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In July 2015, the FASB issued ASU 2015-11,&#160;<i>Inventory (Topic 330)</i>&#160;&#8211;&#160;<i>Simplifying the Measurement of Inventory.</i>&#160;This ASU requires that an entity measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The adoption of this standard will not have any impact on the consolidated financial statements of the Company.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In May 2014, the FASB issued ASU 2014-09,&#160;<i>Revenue from Contracts with Customers (Topic 606),</i>&#160;which is the new comprehensive revenue recognition standard that will supersede all existing revenue recognition guidance under U.S. GAAP. The standard's core principle is that a company will recognize revenue when it transfers promised goods or services to a customer in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB subsequently issued ASU 2015-14, Revenue from Contracts with Customers - Deferral of the Effective Date, which approved a one year deferral of ASU 2014-09 for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. In March 2016 and April 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers - Principal versus Agent Considerations (Reporting Revenue Gross versus Net), and ASU 2016-10, Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing, respectively, which further clarify the guidance related to those specific topics within ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients, to reduce the risk of diversity in practice for certain aspects in ASU 2014-09, including collectibility, noncash consideration, presentation of sales tax and transition. Additionally, in December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers. ASU 2016-20 makes minor corrections or minor improvements to the standard that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. The Company has made progress in its evaluation of the amended guidance, including identification of revenue streams. The Company recognizes revenue from product sales at the time of shipment and passage of title and risk of loss and control of the goods is transferred to the customer. The Company has no acceptance or other post-shipment obligations and does not offer product warranties or services to its customers. Although the Company is continuing to assess the impact of the amended guidance, Aceto generally anticipates that the timing of recognition of revenue will be substantially unchanged under the amended guidance. The Company is continuing to evaluate the impact on certain other transactions including third-party collaborations and other arrangements. The amended guidance will be effective for Aceto in the first quarter of fiscal 2019 and permits adoption under either the full retrospective approach (recognize effects of the amended guidance in each prior reporting period presented) or the modified retrospective approach (recognize the cumulative effect of adoption as an adjustment to retained earnings at the date of initial application). The Company anticipates adopting this amended standard on a modified retrospective basis.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>(19) Segment Information</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company's business is organized along product lines into three principal segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Human Health</b>&#160;- includes finished dosage form generic drugs and nutraceutical products.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Pharmaceutical Ingredients &#8211;&#160;</b>includes<b>&#160;</b>pharmaceutical intermediates and active pharmaceutical ingredients (&#8220;APIs&#8221;).</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>&#160;</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Performance Chemicals&#160;</b>- The Performance Chemicals segment is made up of two product groups: Specialty Chemicals and Agricultural Protection Products. Specialty Chemicals include a variety of chemicals used in the manufacture of plastics, surface coatings, cosmetics and personal care, textiles, fuels and lubricants, perform to their designed capabilities. Dye and pigment intermediates are used in the color-producing industries such as textiles, inks, paper, and coatings. Organic intermediates are used in the production of agrochemicals.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Agricultural Protection Products include herbicides, fungicides and insecticides that control weed growth as well as control the spread of insects and other microorganisms that can severely damage plant growth.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-size: 10pt;">The Company's chief operating decision maker evaluates performance of the segments based on net sales, gross profit and income before income taxes. Unallocated corporate amounts are deemed by the Company as administrative, oversight costs, not managed by the segment managers. The Company does not allocate assets by segment because the chief operating decision maker does not review the assets by segment to assess the segments' performance, as the assets are managed on an entity-wide basis.</font>&#160;<font style="font-size: 10pt;">During all periods presented, our chief operating decision maker has been the Chief Executive Officer of the Company.</font>&#160;<font style="font-size: 10pt;">In accordance with GAAP, the Company has aggregated certain operating segments into reportable segments because they have similar economic characteristics, and the operating segments are similar in all of the following areas: (a) the nature of the products and services; (b) the nature of the production processes; (c) the type or class of customer for their products and services; (d) the methods used to distribute their products or provide their services; and (e) the nature of the regulatory environment.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom; text-decoration: none;"> <td style="text-align: center; text-decoration: none;" nowrap="nowrap">&#160;</td> <td style="text-decoration: none;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; text-decoration: none;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Human</font><br /><font style="font-size: 10pt;">Health</font></td> <td style="text-decoration: none;">&#160;</td> <td style="text-decoration: none;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; text-decoration: none;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Pharmaceutical</font><br /><font style="font-size: 10pt;">Ingredients</font></td> <td style="text-decoration: none;">&#160;</td> <td style="font-weight: normal; text-decoration: none;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: normal; text-decoration: none;" colspan="2" nowrap="nowrap"><font style="font-family: 'times new roman', times, serif; font-weight: normal;">Performance</font><br /><font style="font-family: 'times new roman', times, serif; font-weight: normal;">Chemicals</font></td> <td style="font-weight: normal; text-decoration: none;">&#160;</td> <td style="text-decoration: none;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; text-decoration: none;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Unallocated</font><br /><font style="font-size: 10pt;">Corporate</font></td> <td style="text-decoration: none;">&#160;</td> <td style="text-decoration: none;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; text-decoration: none;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Consolidated</font><br /><font style="font-size: 10pt;">Totals</font></td> <td style="text-decoration: none;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; text-decoration: underline;">2017</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 478px;">Net sales</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 137px;">315,395</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 137px;">157,445</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 136px;">165,478</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 136px;">-</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 136px;">638,318</td> <td style="text-align: left; width: 13px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Gross profit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">78,109</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">25,474</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">37,209</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">140,792</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Income before income taxes</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">15,434</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">9,322</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">18,829</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(26,224</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">17,361</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-decoration: underline;">2016</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Net sales</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">228,035</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">161,011</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">169,478</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">558,524</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Gross profit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">77,880</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">28,752</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">36,153</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">142,785</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Income before income taxes</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">36,362</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">11,856</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">17,799</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(12,163</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">53,854</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-decoration: underline;">2015</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Net sales</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">225,263</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">149,296</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">172,392</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">546,951</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Gross profit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">75,749</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">26,683</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">33,002</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">135,434</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Income before income taxes</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">35,152</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">8,697</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">14,289</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(4,273</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">53,865</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Net sales and gross profit by source country for the years ended June 30, 2017, 2016 and 2015 were as follows:</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="10" nowrap="nowrap">Net Sales</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="10" nowrap="nowrap">Gross Profit</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 270px;">United States</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 123px;">483,678</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">400,883</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">407,101</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">116,792</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">117,180</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">111,734</td> <td style="text-align: left; width: 12px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Germany</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">79,105</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">76,666</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">69,889</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">13,609</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">15,154</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">14,660</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Netherlands</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">9,949</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">16,217</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">14,656</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,231</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,598</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,325</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>France</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">35,796</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">30,177</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">27,976</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">4,651</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">4,043</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">3,634</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2px;">Asia-Pacific</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">29,790</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">34,581</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">27,329</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">4,509</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">4,810</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">4,081</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 4px;">Total</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">638,318</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">558,524</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">546,951</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">140,792</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">142,785</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">135,434</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>&#160;</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Sales generated from the United States to foreign countries amounted to $21,750, $23,810 and $38,295 for the fiscal years ended June 30, 2017, 2016 and 2015, respectively.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Long-lived assets by geographic region as of June 30, 2017 and June 30, 2016 were as follows:</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>&#160;</b></p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 50%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;" colspan="6" nowrap="nowrap">Long-lived assets</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 477px;">United States</td> <td style="width: 6px;">&#160;</td> <td style="text-align: left; width: 7px;">$</td> <td style="text-align: right; width: 82px;">528,359</td> <td style="text-align: left; width: 6px;">&#160;</td> <td style="width: 6px;">&#160;</td> <td style="text-align: left; width: 6px;">$</td> <td style="text-align: right; width: 81px;">152,701</td> <td style="text-align: left; width: 6px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Europe</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,538</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,504</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2px;">Asia-Pacific</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">1,582</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">1,781</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 4px;">Total</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">532,479</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">156,986</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>(20) Unaudited Quarterly Financial Data</b></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The following is a summary of the unaudited quarterly results of operations for the years ended June 30, 2017 and 2016.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="14" nowrap="nowrap">For&#160;the&#160;quarter&#160;ended</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-weight: bold;" nowrap="nowrap">Fiscal&#160;year&#160;ended&#160;June&#160;30,&#160;2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">September&#160;30,<br />2016&#160;(1)</td> <td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">December&#160;31,<br />2016(2)</td> <td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">March&#160;31,<br />2017(2)(3)</td> <td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">June&#160;30,<br />2017&#160;(2)(4)</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 622px;">Net sales</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 130px;">128,018</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 130px;">125,552</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 130px;">190,128</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 129px;">194,620</td> <td style="text-align: left; width: 12px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Gross profit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">30,839</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">30,805</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">42,319</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">36,829</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Net income (loss)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">4,385</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(564</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5,588</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,967</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Net income (loss) per diluted share</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.15</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(0.02</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.16</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.06</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="14" nowrap="nowrap">For&#160;the&#160;quarter&#160;ended</td> <td style="border-bottom: black 2px solid;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-weight: bold;" nowrap="nowrap">Fiscal&#160;year&#160;ended&#160;June&#160;30,&#160;2016</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">September&#160;30,<br />2015</td> <td style="border-bottom: black 2px solid;">&#160;</td> <td style="border-bottom: black 2px solid;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">December&#160;31,<br />2015</td> <td style="border-bottom: black 2px solid;">&#160;</td> <td style="border-bottom: black 2px solid;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">March&#160;31,<br />2016(5)</td> <td style="border-bottom: black 2px solid;">&#160;</td> <td style="border-bottom: black 2px solid;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">June&#160;30,<br />2016(6)</td> <td style="border-bottom: black 2px solid;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 622px;">Net sales</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 130px;">133,500</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 130px;">131,674</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 130px;">157,926</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 129px;">135,424</td> <td style="text-align: left; width: 12px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Gross profit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">34,581</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">35,868</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">38,289</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">34,047</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Net income</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">9,298</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">8,270</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">10,424</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">6,774</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Net income per diluted share</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.32</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.28</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.35</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.23</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The net income per common share calculation for each of the quarters is based on the weighted average number of shares outstanding in each period. Therefore, the sum of the quarters in a year does not necessarily equal the year&#8217;s net income per common share.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">(1) Includes pretax item of $170 environmental remediation charge in connection with Arsynco.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">(2) Results for the last nine days of the quarter ended December 31, 2016 and for the subsequent two quarters reflect the acquisition of certain generic products and related assets from Citron and Lucid on December 21, 2016.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">(3) Includes pretax item of $733 environmental remediation charge in connection with Arsynco.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">(4) Includes pretax item of $3,139 representing immaterial correction of an error associated with certain accrued expenses.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">(5) Includes pretax items consisting of $833 reversal of contingent consideration related to the PACK acquisition and $241 reversal of contingent consideration related to the acquisition of a company in France.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">(6) Includes pretax item of $1,313 environmental remediation charge in connection with Arsynco.</p> <p style="text-align: center; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Valuation and Qualifying Accounts</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: center; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">For the years ended June 30, 2017, 2016 and 2015</p><p style="text-align: center; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">(dollars in thousands)</p><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="border-bottom: black 2px solid; text-align: justify;" nowrap="nowrap">Description</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid;" colspan="2" nowrap="nowrap">Balance at&#160;<br />beginning of&#160;<br />year</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid;" colspan="2" nowrap="nowrap">Charged to&#160;<br />costs and&#160;<br />expenses</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid;" colspan="2" nowrap="nowrap">Charged to&#160;<br />other&#160;<br />accounts</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid;" colspan="2" nowrap="nowrap">Deductions</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid;" colspan="2" nowrap="nowrap">Balance at&#160;<br />end of year</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;" nowrap="nowrap">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Year ended June 30, 2017</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 4px; width: 549px;">Allowance for doubtful accounts</td><td style="padding-bottom: 4px; width: 16px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left; width: 16px;">$</td><td style="border-bottom: black 4px double; text-align: right; width: 157px;">513</td><td style="text-align: left; padding-bottom: 4px; width: 16px;">&#160;</td><td style="padding-bottom: 4px; width: 16px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left; width: 16px;">$</td><td style="border-bottom: black 4px double; text-align: right; width: 157px;">(3</td><td style="text-align: left; padding-bottom: 4px; width: 16px;">)</td><td style="padding-bottom: 4px; width: 16px;">&#160;</td><td style="text-align: left; padding-bottom: 4px; width: 16px;">&#160;</td><td style="text-align: right; padding-bottom: 4px; width: 157px;">-</td><td style="text-align: left; padding-bottom: 4px; width: 16px;">&#160;</td><td style="padding-bottom: 4px; width: 16px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left; width: 15px;">$</td><td style="border-bottom: black 4px double; text-align: right; width: 156px;">25</td><td style="text-align: left; padding-bottom: 4px; width: 15px;">(a)</td><td style="padding-bottom: 4px; width: 15px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left; width: 15px;">$</td><td style="border-bottom: black 4px double; text-align: right; width: 156px;">485</td><td style="text-align: left; padding-bottom: 4px; width: 15px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Year ended June 30, 2016</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 4px;">Allowance for doubtful accounts</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">691</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">76</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="text-align: right; padding-bottom: 4px;">-</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">254</td><td style="text-align: left; padding-bottom: 4px;">(a)</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">513</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Year ended June 30, 2015</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 4px;">Allowance for doubtful accounts</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">517</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">484</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="text-align: right; padding-bottom: 4px;">-</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">310</td><td style="text-align: left; padding-bottom: 4px;">(a)</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">691</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td></tr></table><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">(a) Specific accounts written off as uncollectible.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Principles of Consolidation</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries. All significant inter-company balances and transactions are eliminated in consolidation.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Use of Estimates</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses reported in those financial statements and the disclosure of contingent assets and liabilities at the date of the financial statements. These judgments can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company&#8217;s most critical accounting policies relate to revenue recognition; allowance for doubtful accounts; inventory; goodwill and other indefinite-life intangible assets; long-lived assets; environmental matters and other contingencies; income taxes; stock-based compensation; and purchase price allocation.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Cash Equivalents</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company considers all highly liquid debt instruments with original maturities at the time of purchase of three months or less to be cash equivalents. Included in cash equivalents as of June 30, 2017 and June 30, 2016 is $220 and $104, respectively, of restricted cash.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Investments</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company classifies investments in marketable securities as trading, available-for-sale or held-to-maturity at the time of purchase and periodically re-evaluates such classifications. Trading securities are carried at fair value, with unrealized holding gains and losses included in earnings. Held-to-maturity securities are recorded at cost and are adjusted for the amortization or accretion of premiums or discounts over the life of the related security. Unrealized holding gains and losses on available-for-sale securities are excluded from earnings and are reported as a separate component of accumulated other comprehensive income (loss) until realized. In determining realized gains and losses, the cost of securities sold is based on the specific identification method. Interest and dividends on the investments are accrued at the balance sheet date.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Inventory</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Inventory, which consists principally of finished goods, are stated at the lower of cost (first-in first-out method) and net realizable value. The Company writes down its inventory for estimated excess and obsolete goods by an amount equal to the difference between the carrying cost of the inventory and net realizable value based upon assumptions about future demand and market conditions.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Environmental and Other Contingencies</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Company establishes accrued liabilities for environmental matters and other contingencies when it is probable that a liability has been incurred and the amount of the liability is reasonably estimable. If the contingency is resolved for an amount greater or less than the accrual, or the Company&#8217;s share of the contingency increases or decreases, or other assumptions relevant to the development of the estimate were to change, the Company would recognize an additional expense or benefit in the consolidated statements of income in the period such determination was made.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Pension Benefits</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In connection with certain historical acquisitions in Germany, the Company assumed defined benefit pension plans covering certain employees who meet certain eligibility requirements. The net pension benefit obligations recorded and the related periodic costs are based on, among other things, assumptions of the discount rate, estimated return on plan assets, salary increases and the mortality of participants. The obligation for these claims and the related periodic costs are measured using actuarial techniques and assumptions. Actuarial gains and losses are deferred and amortized over future periods. The Company&#8217;s plans are funded in conformity with the funding requirements of applicable government regulations.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Accumulated Other Comprehensive Loss</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The components of accumulated other comprehensive loss as of June 30, 2017 and 2016 are as follows:</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 60%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; width: 630px;">Cumulative foreign currency translation adjustments</td> <td style="width: 9px;">&#160;</td> <td style="text-align: left; width: 9px;">$</td> <td style="text-align: right; width: 134px;">(4,340</td> <td style="text-align: left; width: 9px;">)</td> <td style="width: 9px;">&#160;</td> <td style="text-align: left; width: 8px;">$</td> <td style="text-align: right; width: 133px;">(6,120</td> <td style="text-align: left; width: 8px;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Fair value of interest rate swaps</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(581</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2px;">Defined benefit plans, net of tax</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(191</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(205</td> <td style="text-align: left; padding-bottom: 2px;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 4px;">Total</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">(5,112</td> <td style="text-align: left; padding-bottom: 4px;">)</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">(6,325</td> <td style="text-align: left; padding-bottom: 4px;">)</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The foreign currency translation adjustments for the years ended June 30, 2017 and 2016 primarily relate to the fluctuation of the conversion rate of the Euro. The currency translation adjustments are not adjusted for income taxes as they relate to indefinite investments in non-US subsidiaries.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Common Stock</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">At the annual meeting of shareholders of the Company, held on December 15, 2015, the Company&#8217;s shareholders approved the&#160;<font style="color: black;">proposal to amend Aceto&#8217;s Certificate of Incorporation to increase the total number of authorized shares of common stock from 40,000 shares to 75,000 shares.</font></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Cash dividends of $0.065 per common share were paid in September, December, March and June of fiscal year 2017. Cash dividends of $0.06 per common share were paid in September, December, March and June of fiscal years 2016 and 2015. On August 24, 2017, the Company's board of directors declared a regular quarterly dividend of $0.065 per share to be distributed on September 21, 2017 to shareholders of record as of September 8, 2017.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">On May 4, 2017, the Board of Directors of the Company authorized the continuation of the Company&#8217;s stock repurchase program, expiring in May 2020. Under the stock repurchase program, the Company is authorized to purchase up to 5,000 shares of common stock in open market or private transactions, at prices not to exceed the market value of the common stock at the time of such purchase. The Company did not repurchase shares in fiscal 2017 or fiscal 2016.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Board of Directors has authority under the Company&#8217;s Restated Certificate of Incorporation to issue shares of preferred stock with voting and other relative rights to be determined by the Board of Directors.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: bold 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Stock-based Compensation</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">GAAP requires that all stock-based compensation be recognized as an expense in the financial statements and that such costs be measured at the fair value of the award. GAAP also requires that excess tax benefits related to stock option exercises be reflected as financing cash inflows.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">All restricted stock grants include a service requirement for vesting. The Company has also granted restricted stock units that include either a performance or market condition. The fair value of restricted stock unit with either solely a service requirement or with the combination of service and performance requirements is based on the closing fair market value of Aceto&#8217;s common stock on the date of grant. The fair value of market condition-based awards is estimated at the date of grant using a binomial lattice model or Monte Carlo Simulation. All models incorporate various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the awards. Stock-based compensation expense is recognized on a straight-line basis over the service period or over our best estimate of the period over which the performance condition will be met, as applicable.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Revenue Recognition</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The Company recognizes revenue from product sales at the time of shipment and passage of title and risk of loss to the customer. The Company has no acceptance or other post-shipment obligations and does not offer product warranties or services to its customers.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Sales are recorded net of estimated returns of damaged goods from customers, which historically have been immaterial, and sales incentives offered to customers. Sales incentives include volume incentive rebates. The Company records volume incentive rebates based on the underlying revenue transactions that result in progress by the customer in earning the rebate.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The Company has arrangements with various third parties, such as drug store chains and managed care organizations, establishing prices for its finished dosage form generics. While these arrangements are made between Aceto and its customers, the customers independently select a wholesaler from which they purchase the products. Alternatively, certain wholesalers may enter into agreements with the customers, with the Company&#8217;s concurrence, which establishes the pricing for certain products which the wholesalers provide. Upon each sale of finished dosage form generics, estimates of chargebacks, rebates, returns, government reimbursed rebates, sales discounts and other adjustments are made. These estimates are based on historical experience, future expectations, contractual arrangements with wholesalers and indirect customers, and other factors known to management at the time of accrual. These estimates are recorded as reductions to gross revenues, with corresponding adjustments either as a reduction of accounts receivable or as a liability for price concessions.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Under certain arrangements, Rising will issue a credit (referred to as a &#8220;chargeback&#8221;) to the wholesaler for the difference between the invoice price to the wholesaler and the customer&#8217;s contract price. As sales to the large wholesale customers increase or decrease, the reserve for chargebacks will also generally increase or decrease. The provision for chargebacks varies in relation to changes in sales volume, product mix, pricing and the level of inventory at the wholesalers. The Company continually monitors the reserve for chargebacks and makes adjustments when management believes that expected chargebacks may differ from the actual chargeback reserve.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The Company estimates its provision for returns of finished dosage generics based on historical experience, product expiration dates, changes to business practices, credit terms and any extenuating circumstances known to management. While historical experience has allowed for reasonable estimations in the past, future returns may or may not follow historical trends. The Company continually monitors the reserve for returns and makes adjustments when management believes that actual product returns may differ from the established reserve. Generally, the reserve for returns increases as net sales increase.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Government rebate accruals are based on estimated payments due to governmental agencies for purchases made by third parties under various governmental programs. Other rebates are offered to the Company&#8217;s key chain drug store, distributor and wholesaler customers to promote customer loyalty and increase product sales. These rebate programs provide customers with credits upon attainment of pre-established volumes or attainment of net sales milestones for a specified period. Other promotional programs are incentive programs offered to the customers. The Company provides a provision for government reimbursed rebates and other rebates at the time of sale based on contracted rates and historical redemption rates. Assumptions used to establish the provision include level of customer inventories, contract sales mix and average contract pricing. Aceto regularly reviews the information related to these estimates and adjusts the provision accordingly.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 0.2in; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Sales discount accruals are based on payment terms extended to customers.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The following table summarizes activity in the consolidated balance sheet for contra assets and liability for price concessions for the years ended June 30, 2017, 2016 and 2015:</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"></p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: left;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="14" nowrap="nowrap">Accruals for Chargebacks, Rebates, Returns and Other Allowances</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap"></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap"></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap">Government</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap">Other</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap">Sales</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Chargebacks</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Returns</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Reimbursed&#160;Rebates</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Rebates</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Discounts</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 478px;">Balance at June 30, 2014</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 137px;">10,986</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 137px;">20,249</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 136px;">1,005</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 136px;">3,630</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 136px;">690</td> <td style="text-align: left; width: 13px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Current year provision</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">208,965</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">21,403</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">4,259</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">36,923</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">9,381</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2px; padding-left: 9pt;">Credits issued during the year</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(187,784</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(10,960</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(4,326</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(36,218</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(7,389</td> <td style="text-align: left; padding-bottom: 2px;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 4px;">Balance at June 30, 2015</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">32,167</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">30,692</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">938</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">4,335</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">2,682</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Current year provision</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">247,186</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">7,618</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5,124</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">90,915</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">10,267</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2px; padding-left: 9pt;">Credits issued during the year</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(256,638</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(15,482</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(4,750</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(88,048</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(10,526</td> <td style="text-align: left; padding-bottom: 2px;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 4px;">Balance at June 30, 2016</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">22,715</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">22,828</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">1,312</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">7,202</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">2,423</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">&#160;Acquisitions</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">23,526</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,496</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">4,500</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">28,944</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,360</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Current year provision</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">431,606</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">19,666</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">7,694</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">162,023</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">20,129</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2px; padding-left: 9pt;">Credits issued during the year</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(417,928</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(11,631</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(4,642</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(158,836</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(18,875</td> <td style="text-align: left; padding-bottom: 2px;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 4px;">Balance at June 30, 2017</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">59,919</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">32,359</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">8,864</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">39,333</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">6,037</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Credits issued during a given period represent cash payments or credit memos issued to the Company&#8217;s customers as settlement for the related reserve. Management has the experience and access to relevant information that it believes is necessary to reasonably estimate the amounts of such deductions from gross revenues. The Company regularly reviews the information related to these estimates and adjusts its reserves accordingly, if and when actual experience differs from previous estimates. The Company has not experienced any significant changes in its estimates as it relates to its chargebacks, rebates or sales discounts in each of the years in the three year period ended June 30, 2017. During the year ended June 30, 2015, the Company recorded $3,497 in additional gross profit related to a change in estimate for product returns due to the most recent returns experience. The Company had not experienced any significant changes in its estimates as it relates to its product returns during the years ended June 30, 2017 and June 30, 2016.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Partnered Products</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><i>&#160;</i></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The Company has various products that are subject to one of two types of collaborative arrangements with certain pharmaceutical companies. One type of arrangement relates to the Company&#8217;s finished dosage form generics business acting strictly as a distributor and purchasing products at arm&#8217;s length; in that type of arrangement, there is no profit sharing element. The second type of collaborative arrangement results in a profit sharing agreement between the Company and a developer and/or manufacturer of a finished dosage form generic drug. Both types of collaborative arrangements are conducted in the ordinary course of Rising&#8217;s business. The nature and purpose of both of these arrangements is for the Company to act as a distributor of finished dose products to its customers.&#160; Under these arrangements, the Company maintains distribution rights with respect to specific drugs within the U.S. marketplace.&#160; Generally, the distribution rights are exclusive rights in the territory.&#160; In certain arrangements, the Company is required to maintain service level minimums including, but not limited to, market share and purchase levels, in order to preserve the exclusive rights.&#160; The Company&#8217;s accounting policy with respect to these collaborative arrangements calls for the Company to present the sales and associated costs on a gross basis, with the amounts of the shared profits earned by the pharmaceutical companies on sales of these products, if applicable, included in cost of sales in the consolidated statements of income. The shared profits are settled on a quarterly basis. For each of the fiscal years 2017, 2016 and 2015, there was approximately $54,454, $41,036 and $51,352 respectively, of shared profits included in cost of sales, related to these types of collaborative arrangements. In the case of a collaborative arrangement where the Company solely acts as a distributor and purchases product at arm&#8217;s length, the costs of those purchases are included as a cost of sales similar to any other purchase arrangement.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: bold 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Shipping and Handling Fees and Costs</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">All amounts billed to a customer in a sales transaction related to shipping and handling represent revenues earned and are included in net sales. The costs incurred by the Company for shipping and handling are reported as a component of cost of sales. Cost of sales also includes inbound freight, receiving, inspection, warehousing, distribution network, and customs and duty costs.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Net Income Per Common Share</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Basic income per common share is based on the weighted average number of common shares outstanding during the period. Diluted income per common share includes the dilutive effect of potential common shares outstanding. The following table sets forth the reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding for the fiscal years ended June 30, 2017, 2016 and 2015:</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>&#160;</b></p><table style="widows: 2; text-transform: none; text-indent: 0px; width: 70%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;" nowrap="nowrap">&#160;</td><td style="text-align: center; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td><td style="text-align: center; padding-bottom: 2px;">&#160;</td><td style="text-align: center; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td><td style="text-align: center; padding-bottom: 2px;">&#160;</td><td style="text-align: center; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;2015</font></td><td style="text-align: center; padding-bottom: 2px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap">&#160;</td><td>&#160;</td><td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; text-indent: -10pt; padding-left: 10pt; width: 751px;">Weighted average shares outstanding</td><td style="width: 13px;">&#160;</td><td style="text-align: left; width: 13px;">&#160;</td><td style="text-align: right; width: 126px;">32,283</td><td style="text-align: left; width: 13px;">&#160;</td><td style="width: 13px;">&#160;</td><td style="text-align: left; width: 12px;">&#160;</td><td style="text-align: right; width: 125px;">29,110</td><td style="text-align: left; width: 12px;">&#160;</td><td style="width: 12px;">&#160;</td><td style="text-align: left; width: 12px;">&#160;</td><td style="text-align: right; width: 125px;">28,731</td><td style="text-align: left; width: 12px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; text-indent: -10pt; padding-left: 10pt;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2px; text-indent: -10pt; padding-left: 10pt;">Dilutive effect of stock options and restricted stock awards and units</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">349</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">471</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">516</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; text-indent: -10pt; padding-left: 10pt;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 4px; text-indent: -10pt; padding-left: 10pt;">Diluted weighted average shares outstanding</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">&#160;</td><td style="border-bottom: black 4px double; text-align: right;">32,632</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">&#160;</td><td style="border-bottom: black 4px double; text-align: right;">29,581</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">&#160;</td><td style="border-bottom: black 4px double; text-align: right;">29,247</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td></tr></table><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The Convertible Senior Notes (see Note 9) will only be included in the dilutive net income per share calculations using the treasury stock method during periods in which the average market price of Aceto&#8217;s common stock is above the applicable conversion price of the Convertible Senior Notes, or $33.215 per share, and the impact would not be anti-dilutive.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Income Taxes</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Property and Equipment</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Property and equipment are stated at cost and are depreciated using the straight line method over the estimated useful lives of the related asset. The Company allocates depreciation and amortization to cost of sales. Expenditures for improvements that extend the useful life of an asset are capitalized. Ordinary repairs and maintenance are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any related gains or losses are included in income.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The components of property and equipment were as follows:</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><table style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;" colspan="2" nowrap="nowrap"><p style="text-align: right; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;">&#160;</p><p style="text-align: right; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;">June 30, 2017</p></td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;" colspan="2" nowrap="nowrap"><p style="text-align: right; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;">&#160;</p><p style="text-align: right; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;">June 30, 2016</p></td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" nowrap="nowrap">Estimated useful&#160;<br />life (years)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; width: 861px;">Machinery and equipment</td><td style="width: 14px;">&#160;</td><td style="text-align: left; width: 14px;">$</td><td style="text-align: right; width: 141px;">398</td><td style="text-align: left; width: 14px;">&#160;</td><td style="width: 14px;">&#160;</td><td style="text-align: left; width: 14px;">$</td><td style="text-align: right; width: 141px;">405</td><td style="text-align: left; width: 14px;">&#160;</td><td style="width: 14px;">&#160;</td><td style="text-align: center; width: 169px;">3-7</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in;">Leasehold improvements</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">979</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,056</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">Shorter of asset life or lease term</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">Computer equipment and software</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">7,255</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6,048</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">3-5</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">Furniture and fixtures</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,094</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,365</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">5-10</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">Automobiles</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">184</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">184</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">3</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">Building</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">8,678</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">8,690</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">20</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2px;">Land</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">1,967</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">1,960</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="text-align: center; padding-bottom: 2px;">-</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">21,555</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">20,708</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2px;">Accumulated depreciation and amortization</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">11,127</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">10,664</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="text-align: center; padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">10,428</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">10,044</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;"></td><td style="text-align: center; padding-bottom: 4px;">&#160;</td></tr></table><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Property held for sale represents land and land improvements of $7,152 and $6,868 at June 30, 2017 and 2016, respectively. See Note 8, &#8220;Environmental Remediation&#8221; for further discussion on property held for sale.</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Depreciation and amortization of property and equipment amounted to $1,520, $1,522 and $1,571 for the years ended June 30, 2017, 2016, and 2015 respectively.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Goodwill and Other Intangibles</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Goodwill is calculated as the excess of the cost of purchased businesses over the fair value of their underlying net assets. Other intangible assets principally consist of customer relationships, license agreements, technology-based intangibles, EPA registrations and related data, trademarks and product rights and related intangibles. Goodwill and other intangible assets that have an indefinite life are not amortized.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">In accordance with GAAP, the Company tests goodwill and other indefinite life intangible assets for impairment on at least an annual basis. Goodwill impairment exists if the net book value of a reporting unit exceeds its estimated fair value. Initially, an assessment of qualitative factors is conducted in order to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company determines that it is more likely than not that its carrying amount is greater than its fair value for a reporting unit, then it proceeds with the subsequent two-step process: (i) the Company determines impairment by comparing the fair value of a reporting unit with its carrying value, and (ii) if there is an impairment, the Company measures the amount of impairment loss by comparing the implied fair value of goodwill with the carrying amount of that goodwill. To determine the fair value of these intangible assets, the Company uses many assumptions and estimates using a market participant approach that directly impact the results of the testing. In making these assumptions and estimates, the Company uses industry accepted valuation models and set criteria that are reviewed and approved by various levels of management. The Company has the option to bypass the initial qualitative assessment stage and proceed directly to perform step one of the two-step process. In fiscal 2017, the Company performed step one of the two-step process and in fiscal 2016 the Company performed a qualitative assessment. There was no impairment of goodwill and other intangible assets in fiscal 2017 and fiscal 2016.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Impairment of Long-Lived Assets and Long-Lived Assets to be Disposed of</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Long-lived assets and certain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability of assets held for sale is measured by comparing the carrying amount of the assets to their estimated fair value. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceed the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><b>Accounting for Derivatives and Hedging Activities</b></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The Company accounts for derivatives and hedging activities under the provisions of GAAP which establishes accounting and reporting guidelines for derivative instruments and hedging activities. GAAP requires the recognition of all derivative financial instruments as either assets or liabilities in the statement of financial condition and measurement of those instruments at fair value. Changes in the fair values of those derivatives are reported in earnings or other comprehensive income depending on the designation of the derivative and whether it qualifies for hedge accounting. The accounting for gains and losses associated with changes in the fair value of a derivative and the effect on the consolidated financial statements depends on its hedge designation and whether the hedge is highly effective in achieving offsetting changes in the fair value or cash flows of the asset or liability hedged. The method that is used for assessing the effectiveness of a hedging derivative, as well as the measurement approach for determining the ineffective aspects of the hedge, is established at the inception of the hedged instrument.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: bold 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">The Company operates internationally, therefore its earnings, cash flows and financial positions are exposed to foreign currency risk from foreign-currency-denominated receivables and payables, which, in the U.S., have been denominated in various foreign currencies, including, among others, Euros, British Pounds, Japanese Yen, Singapore Dollars and Chinese Renminbi and at certain foreign subsidiaries in U.S. dollars and other non-local currencies.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Management believes it is prudent to minimize the risk caused by foreign currency fluctuation. Management minimizes the currency risk on its foreign currency receivables and payables by purchasing foreign currency contracts (futures) with one of its financial institutions. Futures are traded on regulated U.S. and international exchanges and represent commitments to purchase or sell a particular foreign currency at a future date and at a specific price. Since futures are purchased for the amount of the foreign currency receivable or for the amount of foreign currency needed to pay for specific purchase orders, and the futures mature on the due date of the related foreign currency vendor invoices or customer receivables, the Company believes that it eliminates risks relating to foreign currency fluctuation. The Company takes delivery of all futures to pay suppliers in the appropriate currency. The gains or losses for the changes in the fair value of the foreign currency contracts are recorded in cost of sales (sales) and offset the gains or losses associated with the impact of changes in foreign exchange rates on trade payables (receivables) denominated in foreign currencies. Senior management and members of the financial department continually monitor foreign currency risks and the use of this derivative instrument.</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><font style="font: 10pt 'times new roman', times, serif; font-stretch: normal;">In conjunction with its existing credit agreement (see Note 9), the Company entered into an interest rate swap on March 21, 2017 for an additional interest cost of 2.005% on a notional amount of $100,000, which has been designated as a cash flow hedge</font><font style="font-family: 'times new roman', times, serif;">. <font style="font-size: 10pt;">The expiration date of this interest rate swap is December 21, 2021.</font></font></p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>Foreign Currency</b></p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The financial statements of the Company&#8217;s foreign subsidiaries are translated into U.S. dollars in accordance with GAAP. Where the functional currency of a foreign subsidiary is its local currency, balance sheet accounts are translated at the current exchange rate and income statement items are translated at the average exchange rate for the period. Exchange gains or losses resulting from the translation of financial statements of foreign operations are accumulated in other comprehensive income. Where the local currency of a foreign subsidiary is not its functional currency, financial statements are translated at either current or historical exchange rates, as appropriate.</p> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 70%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td><td style="padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td><td style="padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; width: 724px;">Cumulative foreign currency translation adjustments</td><td style="width: 11px;">&#160;</td><td style="text-align: left; width: 11px;">$</td><td style="text-align: right; width: 154px;">(4,340</td><td style="text-align: left; width: 11px;">)</td><td style="width: 11px;">&#160;</td><td style="text-align: left; width: 11px;">$</td><td style="text-align: right; width: 153px;">(6,120</td><td style="text-align: left; width: 10px;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Fair value of interest rate swaps</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(581</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1pt;">Defined benefit plans, net of tax</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(191</td><td style="text-align: left; padding-bottom: 1pt;">)</td><td style="padding-bottom: 1pt;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: left;">&#160;</td><td style="border-bottom: black 1pt solid; text-align: right;">(205</td><td style="text-align: left; padding-bottom: 1pt;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 4px;">Total</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">(5,112</td><td style="text-align: left; padding-bottom: 4px;">)</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">(6,325</td><td style="text-align: left; padding-bottom: 4px;">)</td></tr></table> <table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-size-adjust: none;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2px;" nowrap="nowrap">&#160;</td> <td style="text-align: justify; padding-bottom: 2px;" nowrap="nowrap">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="14" nowrap="nowrap"><font style="font-size: 10pt;">Accruals for Chargebacks, Rebates, Returns and Other Allowances</font></td> <td style="text-align: justify; padding-bottom: 2px;" nowrap="nowrap">&#160;</td> <td style="text-align: justify; padding-bottom: 2px;" nowrap="nowrap">&#160;</td> <td style="text-align: center; padding-bottom: 2px;" colspan="2" nowrap="nowrap">&#160;</td> <td style="text-align: justify; padding-bottom: 2px;" nowrap="nowrap">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Government</font></td> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Other</font></td> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="text-align: center;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Sales</font></td> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2px;" nowrap="nowrap">&#160;</td> <td style="text-align: justify; padding-bottom: 2px;" nowrap="nowrap">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Chargebacks</font></td> <td style="text-align: justify; padding-bottom: 2px;" nowrap="nowrap">&#160;</td> <td style="text-align: justify; padding-bottom: 2px;" nowrap="nowrap">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Returns</font></td> <td style="text-align: justify; padding-bottom: 2px;" nowrap="nowrap">&#160;</td> <td style="text-align: justify; padding-bottom: 2px;" nowrap="nowrap">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Reimbursed Rebates</font></td> <td style="text-align: justify; padding-bottom: 2px;" nowrap="nowrap">&#160;</td> <td style="text-align: justify; padding-bottom: 2px;" nowrap="nowrap">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Rebates</font></td> <td style="text-align: justify; padding-bottom: 2px;" nowrap="nowrap">&#160;</td> <td style="text-align: justify; padding-bottom: 2px;" nowrap="nowrap">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Discounts</font></td> <td style="text-align: justify; padding-bottom: 2px;" nowrap="nowrap">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 471px; text-align: justify;"><font style="font-size: 10pt;">Balance at June 30, 2014</font></td> <td style="width: 16px; text-align: justify;">&#160;</td> <td style="width: 16px; text-align: justify;"><font style="font-size: 10pt;">$</font></td> <td style="width: 157px; text-align: right;"><font style="font-size: 10pt;">10,986</font></td> <td style="width: 16px; text-align: justify;">&#160;</td> <td style="width: 16px; text-align: justify;">&#160;</td> <td style="width: 16px; text-align: justify;"><font style="font-size: 10pt;">$</font></td> <td style="width: 126px; text-align: right;"><font style="font-size: 10pt;">20,249</font></td> <td style="width: 16px; text-align: justify;">&#160;</td> <td style="width: 16px; text-align: justify;">&#160;</td> <td style="width: 16px; text-align: justify;"><font style="font-size: 10pt;">$</font></td> <td style="width: 267px; text-align: right;"><font style="font-size: 10pt;">1,005</font></td> <td style="width: 15px; text-align: justify;">&#160;</td> <td style="width: 15px; text-align: justify;">&#160;</td> <td style="width: 15px; text-align: justify;"><font style="font-size: 10pt;">$</font></td> <td style="width: 188px; text-align: right;"><font style="font-size: 10pt;">3,630</font></td> <td style="width: 15px; text-align: justify;">&#160;</td> <td style="width: 15px; text-align: justify;">&#160;</td> <td style="width: 15px; text-align: justify;"><font style="font-size: 10pt;">$</font></td> <td style="width: 125px; text-align: right;"><font style="font-size: 10pt;">690</font></td> <td style="width: 15px; text-align: justify;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify; padding-left: 9pt;"><font style="font-size: 10pt;">Current year provision</font></td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">208,965</font></td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">21,403</font></td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">4,259</font></td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">36,923</font></td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">9,381</font></td> <td style="text-align: justify;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2px; padding-left: 9pt;"><font style="font-size: 10pt;">Credits issued during the year</font></td> <td style="text-align: justify; padding-bottom: 2px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-size: 10pt;">(187,784</font></td> <td style="text-align: justify; padding-bottom: 2px;"><font style="font-size: 10pt;">)</font></td> <td style="text-align: justify; padding-bottom: 2px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-size: 10pt;">(10,960</font></td> <td style="text-align: justify; padding-bottom: 2px;"><font style="font-size: 10pt;">)</font></td> <td style="text-align: justify; padding-bottom: 2px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-size: 10pt;">(4,326</font></td> <td style="text-align: justify; padding-bottom: 2px;"><font style="font-size: 10pt;">)</font></td> <td style="text-align: justify; padding-bottom: 2px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-size: 10pt;">(36,218</font></td> <td style="text-align: justify; padding-bottom: 2px;"><font style="font-size: 10pt;">)</font></td> <td style="text-align: justify; padding-bottom: 2px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-size: 10pt;">(7,389</font></td> <td style="text-align: justify; padding-bottom: 2px;"><font style="font-size: 10pt;">)</font></td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 4px;"><font style="font-size: 10pt;">Balance at June 30, 2015</font></td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">$</font></td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">32,167</font></td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">$</font></td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">30,692</font></td> <td style="padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">$</font></td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">938</font></td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">$</font></td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">4,335</font></td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">$</font></td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">2,682</font></td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify; padding-left: 9pt;"><font style="font-size: 10pt;">Current year provision</font></td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">247,186</font></td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">7,618</font></td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">5,124</font></td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">90,915</font></td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">10,267</font></td> <td style="text-align: justify;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2px; padding-left: 9pt;"><font style="font-size: 10pt;">Credits issued during the year</font></td> <td style="text-align: justify; padding-bottom: 2px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-size: 10pt;">(256,638</font></td> <td style="text-align: justify; padding-bottom: 2px;"><font style="font-size: 10pt;">)</font></td> <td style="text-align: justify; padding-bottom: 2px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-size: 10pt;">(15,482</font></td> <td style="text-align: justify; padding-bottom: 2px;"><font style="font-size: 10pt;">)</font></td> <td style="text-align: justify; padding-bottom: 2px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-size: 10pt;">(4,750</font></td> <td style="text-align: justify; padding-bottom: 2px;"><font style="font-size: 10pt;">)</font></td> <td style="text-align: justify; padding-bottom: 2px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-size: 10pt;">(88,048</font></td> <td style="text-align: justify; padding-bottom: 2px;"><font style="font-size: 10pt;">)</font></td> <td style="text-align: justify; padding-bottom: 2px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-size: 10pt;">(10,526</font></td> <td style="text-align: justify; padding-bottom: 2px;"><font style="font-size: 10pt;">)</font></td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 4px;"><font style="font-size: 10pt;">Balance at June 30, 2016</font></td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">$</font></td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">22,715</font></td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">$</font></td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">22,828</font></td> <td style="padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">$</font></td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">1,312</font></td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">$</font></td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">7,202</font></td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">$</font></td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">2,423</font></td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-left: 9pt;"><font style="font-size: 10pt;">Acquisitions</font></td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: center;"><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;23,526</font></td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">1,496</font></td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">4,500</font></td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">28,944</font></td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">2,360</font></td> <td style="text-align: justify;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify; padding-left: 9pt;"><font style="font-size: 10pt;">Current year provision</font></td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">431,606</font></td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">19,666</font></td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">7,694</font></td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">162,023</font></td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: justify;">&#160;</td> <td style="text-align: right;"><font style="font-size: 10pt;">20,129</font></td> <td style="text-align: justify;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2px; padding-left: 9pt;"><font style="font-size: 10pt;">Credits issued during the year</font></td> <td style="text-align: justify; padding-bottom: 2px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-size: 10pt;">(417,928</font></td> <td style="text-align: justify; padding-bottom: 2px;"><font style="font-size: 10pt;">)</font></td> <td style="text-align: justify; padding-bottom: 2px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-size: 10pt;">(11,631</font></td> <td style="text-align: justify; padding-bottom: 2px;"><font style="font-size: 10pt;">)</font></td> <td style="text-align: justify; padding-bottom: 2px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-size: 10pt;">(4,642</font></td> <td style="text-align: justify; padding-bottom: 2px;"><font style="font-size: 10pt;">)</font></td> <td style="text-align: justify; padding-bottom: 2px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-size: 10pt;">(158,836</font></td> <td style="text-align: justify; padding-bottom: 2px;"><font style="font-size: 10pt;">)</font></td> <td style="text-align: justify; padding-bottom: 2px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;"><font style="font-size: 10pt;">(18,875</font></td> <td style="text-align: justify; padding-bottom: 2px;"><font style="font-size: 10pt;">)</font></td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 4px;"><font style="font-size: 10pt;">Balance at June 30, 2017</font></td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">$</font></td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">59,919</font></td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">$</font></td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">32,359</font></td> <td style="padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">$</font></td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">8,864</font></td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">$</font></td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">39,333</font></td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="text-align: justify; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">$</font></td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;"><font style="font-size: 10pt;">6,037</font></td> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> </tr> </table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;" nowrap="nowrap">&#160;</td><td style="text-align: center; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td><td style="text-align: center; padding-bottom: 2px;">&#160;</td><td style="text-align: center; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td><td style="text-align: center; padding-bottom: 2px;">&#160;</td><td style="text-align: center; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;2015</font></td><td style="text-align: center; padding-bottom: 2px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap">&#160;</td><td>&#160;</td><td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; text-indent: -10pt; padding-left: 10pt; width: 751px;">Weighted average shares outstanding</td><td style="width: 13px;">&#160;</td><td style="text-align: left; width: 13px;">&#160;</td><td style="text-align: right; width: 126px;">32,283</td><td style="text-align: left; width: 13px;">&#160;</td><td style="width: 13px;">&#160;</td><td style="text-align: left; width: 12px;">&#160;</td><td style="text-align: right; width: 125px;">29,110</td><td style="text-align: left; width: 12px;">&#160;</td><td style="width: 12px;">&#160;</td><td style="text-align: left; width: 12px;">&#160;</td><td style="text-align: right; width: 125px;">28,731</td><td style="text-align: left; width: 12px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; text-indent: -10pt; padding-left: 10pt;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2px; text-indent: -10pt; padding-left: 10pt;">Dilutive effect of stock options and restricted stock awards and units</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">349</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">471</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">516</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; text-indent: -10pt; padding-left: 10pt;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 4px; text-indent: -10pt; padding-left: 10pt;">Diluted weighted average shares outstanding</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">&#160;</td><td style="border-bottom: black 4px double; text-align: right;">32,632</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">&#160;</td><td style="border-bottom: black 4px double; text-align: right;">29,581</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">&#160;</td><td style="border-bottom: black 4px double; text-align: right;">29,247</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td></tr></table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;" colspan="2" nowrap="nowrap"><p style="text-align: right; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;">&#160;</p><p style="text-align: right; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;">June 30, 2017</p></td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;" colspan="2" nowrap="nowrap"><p style="text-align: right; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;">&#160;</p><p style="text-align: right; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;">June 30, 2016</p></td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" nowrap="nowrap">Estimated useful&#160;<br />life (years)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; width: 861px;">Machinery and equipment</td><td style="width: 14px;">&#160;</td><td style="text-align: left; width: 14px;">$</td><td style="text-align: right; width: 141px;">398</td><td style="text-align: left; width: 14px;">&#160;</td><td style="width: 14px;">&#160;</td><td style="text-align: left; width: 14px;">$</td><td style="text-align: right; width: 141px;">405</td><td style="text-align: left; width: 14px;">&#160;</td><td style="width: 14px;">&#160;</td><td style="text-align: center; width: 169px;">3-7</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in;">Leasehold improvements</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">979</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,056</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">Shorter of asset life or lease term</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">Computer equipment and software</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">7,255</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6,048</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">3-5</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">Furniture and fixtures</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,094</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,365</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">5-10</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">Automobiles</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">184</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">184</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">3</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">Building</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">8,678</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">8,690</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">20</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2px;">Land</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">1,967</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">1,960</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="text-align: center; padding-bottom: 2px;">-</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">21,555</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">20,708</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2px;">Accumulated depreciation and amortization</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">11,127</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">10,664</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="text-align: center; padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">10,428</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">10,044</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;"></td><td style="text-align: center; padding-bottom: 4px;">&#160;</td></tr></table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 60%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; width: 818px;">Trade receivables</td><td style="width: 10px;">&#160;</td><td style="text-align: left; width: 9px;">$</td><td style="text-align: right; width: 94px;">78,937</td><td style="text-align: left; width: 9px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Inventory</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">38,995</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Prepaid expenses and other current assets</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,425</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Goodwill</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">169,071</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px;">Intangible assets</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">224,850</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-left: 9pt;">Total assets acquired</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">513,278</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Accounts payable</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">46,840</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Accrued expenses</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">53,458</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Deferred payment</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">50,000</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px;">Contingent consideration</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">2,580</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 4px; padding-left: 9pt;">Net assets acquired</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">360,400</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td></tr></table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 60%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td style="text-align: center;" colspan="6" nowrap="nowrap">Year ended</td><td nowrap="nowrap">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="6" nowrap="nowrap">June 30,</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="6" nowrap="nowrap">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td><td style="padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td><td style="padding-bottom: 2px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">&#160;</td><td>&#160;</td><td colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; width: 696px;">Net sales</td><td style="width: 10px;">&#160;</td><td style="text-align: left; width: 10px;">$</td><td style="text-align: right; width: 94px;">739,318</td><td style="text-align: left; width: 9px;">&#160;</td><td style="width: 9px;">&#160;</td><td style="text-align: left; width: 9px;">$</td><td style="text-align: right; width: 94px;">731,100</td><td style="text-align: left; width: 9px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Net income</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">24,166</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">30,469</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Net income per common share</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.70</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.89</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Diluted net income per common share</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.69</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.88</td><td style="text-align: left;">&#160;</td></tr></table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 60%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: left;" nowrap="nowrap">&#160;</td> <td style="text-align: left; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;" colspan="2" nowrap="nowrap">June 30, 2017</td> <td style="text-align: left; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td> <td style="text-align: left; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;" colspan="2" nowrap="nowrap">June 30, 2016</td> <td style="text-align: left; padding-bottom: 1pt;" nowrap="nowrap">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 1pt;" nowrap="nowrap"><u>Held to Maturity Investments</u></td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; width: 606px;">Time deposits</td> <td style="width: 8px;">&#160;</td> <td style="text-align: left; width: 8px;">$</td> <td style="text-align: right; width: 82px;">2,046</td> <td style="text-align: left; width: 7px;">&#160;</td> <td style="width: 7px;">&#160;</td> <td style="text-align: left; width: 7px;">$</td> <td style="text-align: right; width: 81px;">881</td> <td style="text-align: left; width: 7px;">&#160;</td> </tr> </table> <table style="font: 10pt/normal 'times new roman', times, serif; width: 80%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 910px; text-align: justify;">Balance as of June 30, 2015</td> <td style="width: 11px;">&#160;</td> <td style="width: 11px; text-align: left;">$</td> <td style="width: 154px; text-align: right;">2,622</td> <td style="width: 10px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Reversal of fair value of liability-PACK</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(833</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Reversal of fair value of liability-France</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(241</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Payments</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(1,500</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Accrued interest expense</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">85</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify; padding-bottom: 2px;">Change in foreign currency exchange rate</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">(1</td> <td style="text-align: left; padding-bottom: 2px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify; padding-bottom: 4px;">Balance as of June 30, 2016</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">132</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Acquisitions</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,580</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Accrued interest expense</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">237</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify; padding-bottom: 2px;">Change in foreign currency exchange rate</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">3</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify; padding-bottom: 4px;">Balance as of June 30, 2017</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">2,952</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="14" nowrap="nowrap">Fair Value Measurements at June 30, 2017 Using</td><td style="padding-bottom: 2px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Quoted Prices&#160;<br />in Active&#160;<br />Markets&#160;<br />(Level 1)</td><td style="border-bottom: black 2px solid;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Significant&#160;<br />Other&#160;<br />Observable&#160;<br />Inputs&#160;<br />(Level 2)</td><td style="border-bottom: black 2px solid;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Significant&#160;<br />Unobservable&#160;<br />Inputs&#160;<br />(Level 3)</td><td style="border-bottom: black 2px solid;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Total</td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Cash equivalents:</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-left: 9pt; width: 665px;">Time deposits</td><td style="width: 15px;">&#160;</td><td style="text-align: left; width: 14px;">&#160;</td><td style="text-align: right; width: 141px;">-</td><td style="text-align: left; width: 14px;">&#160;</td><td style="width: 14px;">&#160;</td><td style="text-align: left; width: 14px;">$</td><td style="text-align: right; width: 141px;">5,781</td><td style="text-align: left; width: 14px;">&#160;</td><td style="width: 14px;">&#160;</td><td style="text-align: left; width: 14px;">&#160;</td><td style="text-align: right; width: 141px;">-</td><td style="text-align: left; width: 14px;">&#160;</td><td style="width: 14px;">&#160;</td><td style="text-align: left; width: 14px;">$</td><td style="text-align: right; width: 141px;">5,781</td><td style="text-align: left; width: 14px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Investments:</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">&#160;&#160;&#160;&#160;Time deposits</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,046</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,046</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Foreign currency contracts-assets (1)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">486</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">486</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Foreign currency contracts-liabilities (2)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">137</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">137</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Derivative liability for interest rate swap(3)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">581</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">581</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Contingent consideration (4)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">2,952</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,952</td><td style="text-align: left;">&#160;</td></tr></table><p style="widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal;">&#160;</p><table style="widows: 2; text-transform: none; margin-top: 0pt; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0px;"></td><td style="width: 0.5in;">(1)</td><td style="text-align: justify;">Included in &#8220;Other receivables&#8221; in the accompanying Consolidated Balance Sheet as of June 30, 2017.</td></tr></table><table style="widows: 2; text-transform: none; margin-top: 0pt; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0px;"></td><td style="text-align: left; width: 0.5in;">(2)</td><td>Included in &#8220;Accrued expenses&#8221; in the accompanying Consolidated Balance Sheet as of June 30, 2017.</td></tr></table><table style="widows: 2; text-transform: none; margin-top: 0pt; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0px;"></td><td style="text-align: left; width: 0.5in;">(3)</td><td>Included in &#8220;Long-term liabilities&#8221; in the accompanying Consolidated Balance Sheet as of June 30, 2017.</td></tr></table><table style="widows: 2; text-transform: none; margin-top: 0pt; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0px;"></td><td style="width: 0.5in;">(4)</td><td style="text-align: justify;">$145 included in &#8220;Accrued expenses&#8221; and $2,807 included in &#8220;Long-term liabilities&#8221; in the accompanying Consolidated Balance Sheet as of June 30, 2017.</td></tr></table><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="14" nowrap="nowrap">Fair Value Measurements at June 30, 2016 Using</td><td style="padding-bottom: 2px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Quoted Prices&#160;<br />in Active&#160;<br />Markets&#160;<br />(Level 1)</td><td style="border-bottom: black 2px solid;">&#160;</td><td style="border-bottom: black 2px solid;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Significant&#160;<br />Other&#160;<br />Observable&#160;<br />Inputs&#160;<br />(Level 2)</td><td style="border-bottom: black 2px solid;">&#160;</td><td style="border-bottom: black 2px solid;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Significant&#160;<br />Unobservable&#160;<br />Inputs&#160;<br />(Level 3)</td><td style="border-bottom: black 2px solid;">&#160;</td><td style="border-bottom: black 2px solid;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Total</td><td style="padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Cash equivalents:</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; width: 677px;">&#160;&#160;&#160;&#160;Time deposits</td><td style="width: 15px;">&#160;</td><td style="text-align: left; width: 14px;">&#160;</td><td style="text-align: right; width: 141px;">-</td><td style="text-align: left; width: 14px;">&#160;</td><td style="width: 14px;">&#160;</td><td style="text-align: left; width: 14px;">$</td><td style="text-align: right; width: 141px;">6,249</td><td style="text-align: left; width: 14px;">&#160;</td><td style="width: 14px;">&#160;</td><td style="text-align: left; width: 14px;">&#160;</td><td style="text-align: right; width: 141px;">-</td><td style="text-align: left; width: 14px;">&#160;</td><td style="width: 14px;">&#160;</td><td style="text-align: left; width: 14px;">$</td><td style="text-align: right; width: 141px;">6,249</td><td style="text-align: left; width: 14px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Investments:</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">&#160;&#160;&#160;&#160;Time deposits</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">881</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">881</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Foreign currency contracts-assets (5)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">160</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">160</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Foreign currency contracts-liabilities (6)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">169</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">169</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Contingent consideration (7)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">132</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">132</td><td style="text-align: left;">&#160;</td></tr></table><p style="widows: 2; text-transform: none; font-style: normal; margin-top: 0px; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0px; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal;">&#160;</p><table style="widows: 2; text-transform: none; margin-top: 0pt; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0px;"></td><td style="width: 0.5in;">(5)</td><td style="text-align: justify;">Included in &#8220;Other receivables&#8221; in the accompanying Consolidated Balance Sheet as of June 30, 2016.</td></tr></table><table style="widows: 2; text-transform: none; margin-top: 0pt; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0px;"></td><td style="text-align: left; width: 0.5in;">(6)</td><td>Included in &#8220;Accrued expenses&#8221; in the accompanying Consolidated Balance Sheet as of June 30, 2016.</td></tr></table><table style="widows: 2; text-transform: none; margin-top: 0pt; text-indent: 0px; width: 100%; font: 10pt 'times new roman', times, serif; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0px;"></td><td style="width: 0.5in;">(7)</td><td style="text-align: justify;">Included in &#8220;Long-term liabilities&#8221; in the accompanying Consolidated Balance Sheet as of June 30, 2016.</td></tr></table> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 90%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Human<br />Health<br />Segment</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Pharmaceutical<br />Ingredients<br />Segment</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Performance<br />Chemicals<br />Segment</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Total<br />Goodwill</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 677px; text-align: justify;">Balance as of June 30, 2015</td> <td style="width: 15px;">&#160;</td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">66,039</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">1,650</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">181</td> <td style="width: 14px; text-align: left;">&#160;</td> <td style="width: 14px;">&#160;</td> <td style="width: 14px; text-align: left;">$</td> <td style="width: 141px; text-align: right;">67,870</td> <td style="width: 14px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify; padding-bottom: 2px;">Changes in foreign currency exchange rates</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">-</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">1</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">-</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">1</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Balance as of June 30, 2016</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">66,039</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,651</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">181</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">67,871</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Acquisitions</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">169,071</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">169,071</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify; padding-bottom: 2px;">Changes in foreign currency exchange rates</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">-</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: left; padding-bottom: 2px; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; padding-bottom: 2px; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">23</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: left; padding-bottom: 2px; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; padding-bottom: 2px; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">5</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: left; padding-bottom: 2px; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; padding-bottom: 2px; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">28</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify; padding-bottom: 4px;">Balance as of June 30, 2017</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">235,110</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">1,674</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">186</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">236,970</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap"><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;">Gross&#160;<br />Carrying</p><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;">Value</p></td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap"><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;">Accumulated<br />Amortization</p></td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap"><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;">Net Book<br />Value</p></td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; text-decoration: underline;">June 30, 2017</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; width: 765px;">Customer relationships</td><td style="width: 13px;">&#160;</td><td style="text-align: left; width: 13px;">$</td><td style="text-align: right; width: 126px;">110,787</td><td style="text-align: left; width: 13px;">&#160;</td><td style="width: 13px;">&#160;</td><td style="text-align: left; width: 12px;">$</td><td style="text-align: right; width: 125px;">13,968</td><td style="text-align: left; width: 12px;">&#160;</td><td style="width: 12px;">&#160;</td><td style="text-align: left; width: 12px;">$</td><td style="text-align: right; width: 125px;">96,819</td><td style="text-align: left; width: 12px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">Trademarks</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,218</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,195</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">23</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">Product rights and related intangibles</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">221,335</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">37,677</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">183,658</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">License agreements</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6,537</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6,035</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">502</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2px;">EPA registrations and related data</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">14,307</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">11,011</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">3,296</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">355,184</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">70,886</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">284,298</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td></tr></table><p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p><table style="widows: 2; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap"><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;">Gross&#160;<br />Carrying<br />Value</p></td><td style="padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap"><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;">Accumulated<br />Amortization</p></td><td style="padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap"><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;">Net Book<br />Value</p></td><td style="padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; text-decoration: underline;">June 30, 2016</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; width: 765px;">Customer relationships</td><td style="width: 13px;">&#160;</td><td style="text-align: left; width: 13px;">$</td><td style="text-align: right; width: 126px;">21,761</td><td style="text-align: left; width: 13px;">&#160;</td><td style="width: 13px;">&#160;</td><td style="text-align: left; width: 12px;">$</td><td style="text-align: right; width: 125px;">7,815</td><td style="text-align: left; width: 12px;">&#160;</td><td style="width: 12px;">&#160;</td><td style="text-align: left; width: 12px;">$</td><td style="text-align: right; width: 125px;">13,946</td><td style="text-align: left; width: 12px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">Trademarks</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,868</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,800</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">68</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">Product rights and related intangibles</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">83,048</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">23,511</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">59,537</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">License agreements</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6,611</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5,531</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,080</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">EPA registrations and related data</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">13,591</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">9,927</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">3,664</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2px;">Technology-based intangibles</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">155</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">140</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">15</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">127,034</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">48,724</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">78,310</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td></tr></table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; width: 909px;">Accrued compensation</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">5,793</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">6,880</td> <td style="text-align: left; width: 12px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Accrued environmental remediation costs-current portion</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">6,112</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">9,180</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Reserve for price concessions</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">80,556</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">31,342</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Partnered product liabilities</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">16,068</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2px;">Other accrued expenses</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">9,799</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">5,273</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">118,328</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">52,675</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 70%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="6" nowrap="nowrap">June 30,</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td><td style="padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td><td style="padding-bottom: 2px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap">&#160;</td><td>&#160;</td><td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 798px;">Convertible Senior Notes, net</td><td style="width: 11px;">&#160;</td><td style="text-align: left; width: 11px;">$</td><td style="text-align: right; width: 110px;">121,676</td><td style="text-align: left; width: 11px;">&#160;</td><td style="width: 11px;">&#160;</td><td style="text-align: left; width: 11px;">$</td><td style="text-align: right; width: 109px;">115,829</td><td style="text-align: left; width: 10px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt;">Revolving bank loans</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">90,000</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt;">Term bank loans</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">139,227</td><td style="text-align: left;">&#160;</td><td style="font-weight: bold;">&#160;</td><td style="text-align: left; font-weight: bold;">&#160;</td><td style="text-align: right; font-weight: bold;">-</td><td style="text-align: left; font-weight: bold;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 2px; text-indent: -10pt; padding-left: 10pt;">Mortgage</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">2,763</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">2,960</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-indent: -10pt; padding-left: 10pt;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">353,666</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">118,789</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px; text-indent: -10pt; padding-left: 10pt;">Less current portion</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">14,466</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">197</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 4px; text-indent: -10pt; padding-left: 10pt;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">339,200</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">118,592</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td></tr></table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 70%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap"><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;">June 30,</p><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;">2017</p></td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap"><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;">June 30,</p><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;">2016</p></td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap">&#160;</td><td>&#160;</td><td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 798px;">Principal amount</td><td style="width: 11px;">&#160;</td><td style="text-align: left; width: 11px;">$</td><td style="text-align: right; width: 110px;">143,750</td><td style="text-align: left; width: 11px;">&#160;</td><td style="width: 11px;">&#160;</td><td style="text-align: left; width: 11px;">$</td><td style="text-align: right; width: 109px;">143,750</td><td style="text-align: left; width: 10px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt;">Unamortized debt discount</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(19,255</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(24,267</td><td style="text-align: left;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px; text-indent: -10pt; padding-left: 10pt;">Unamortized debt issuance costs</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">(2,819</td><td style="text-align: left; padding-bottom: 2px;">)</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">(3,654</td><td style="text-align: left; padding-bottom: 2px;">)</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 4px; text-indent: -10pt; padding-left: 10pt;">Net carrying value</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">121,676</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">115,829</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td></tr></table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 70%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td><td style="padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td><td style="padding-bottom: 2px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap">&#160;</td><td>&#160;</td><td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: justify;" colspan="2" nowrap="nowrap">&#160;</td><td>&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt; width: 798px;">Contractual coupon</td><td style="width: 11px;">&#160;</td><td style="text-align: left; width: 11px;">$</td><td style="text-align: right; width: 110px;">2,867</td><td style="text-align: left; width: 11px;">&#160;</td><td style="width: 11px;">&#160;</td><td style="text-align: left; width: 11px;">$</td><td style="text-align: right; width: 109px;">1,788</td><td style="text-align: left; width: 10px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; text-indent: -10pt; padding-left: 10pt;">Amortization of debt discount</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5,012</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,974</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px; text-indent: -10pt; padding-left: 10pt;">Amortization of debt issuance costs</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">835</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">522</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 4px; text-indent: -10pt; padding-left: 10pt;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">8,714</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">5,284</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td></tr></table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 50%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; width: 682px;">2018</td><td style="width: 8px;">&#160;</td><td style="text-align: left; width: 8px;">$</td><td style="text-align: right; width: 78px;">14,466</td><td style="text-align: left; width: 7px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">2019</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">14,466</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">2020</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">14,466</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">2021</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">138,115</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">2022</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">172,153</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2px;">Thereafter</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">-</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: center; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">353,666</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td></tr></table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Shares subject to&#160;<br />option</td><td style="border-bottom: black 2px solid;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Weighted average&#160;<br />exercise price per&#160;<br />share</td><td style="border-bottom: black 2px solid;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Aggregate&#160;<br />Intrinsic&#160;<br />Value</td><td style="padding-bottom: 2px;" nowrap="nowrap">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="width: 861px;">Balance at June 30, 2014</td><td style="width: 14px;">&#160;</td><td style="text-align: left; width: 14px;">&#160;</td><td style="text-align: right; width: 141px;">551</td><td style="text-align: left; width: 14px;">&#160;</td><td style="width: 14px;">&#160;</td><td style="text-align: left; width: 14px;">$</td><td style="text-align: right; width: 141px;">7.72</td><td style="text-align: left; width: 14px;">&#160;</td><td style="width: 14px;">&#160;</td><td style="text-align: left; width: 14px;">&#160;</td><td style="text-align: right; width: 141px;">&#160;</td><td style="text-align: left; width: 14px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Granted</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Exercised</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(146</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">8.74</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="border-bottom: black 2px solid; text-align: left;">Forfeited (including cancelled options)</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">(8</td><td style="border-bottom: black 2px solid; text-align: left; padding-bottom: 2px;">)</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">10.94</td><td style="border-bottom: black 2px solid; text-align: left; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left; padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Balance at June 30, 2015</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">397</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">7.28</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Granted</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Exercised</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(95</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">7.56</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="border-bottom: black 2px solid; text-align: left; padding-bottom: 2px;">Forfeited (including cancelled options)</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">-</td><td style="border-bottom: black 2px solid; text-align: left; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">-</td><td style="border-bottom: black 2px solid; text-align: left; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left; padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Balance at June 30, 2016</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">302</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">7.19</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Granted</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">28</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">20.03</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Exercised</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(70</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">7.90</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="border-bottom: black 2px solid; text-align: left; padding-bottom: 2px;">Forfeited (including cancelled options)</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">-</td><td style="border-bottom: black 2px solid; text-align: left; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">-</td><td style="border-bottom: black 2px solid; text-align: left; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left; padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="border-bottom: black 2px solid; padding-bottom: 2px;">Balance at June 30, 2017</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">260</td><td style="border-bottom: black 2px solid; text-align: left; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">$</td><td style="border-bottom: black 2px solid; text-align: right;">8.36</td><td style="border-bottom: black 2px solid; text-align: left; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">$</td><td style="border-bottom: black 2px solid; text-align: right;">1,968</td><td style="border-bottom: black 2px solid; text-align: left; padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Options exercisable at June 30, 2017</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">232</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">6.98</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">1,968</td><td style="text-align: left;">&#160;</td></tr></table> <table style="font: 10pt/normal 'times new roman', times, serif; width: 85%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Shares<br />subject&#160;to<br />option</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Weighted<br />average&#160;grant<br />date&#160;fair&#160;value</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 724px; text-align: justify;">Non-vested at June 30, 2016</td> <td style="width: 11px;">&#160;</td> <td style="width: 11px; text-align: left;">&#160;</td> <td style="width: 154px; text-align: right;">-</td> <td style="width: 11px; text-align: left;">&#160;</td> <td style="width: 11px;">&#160;</td> <td style="width: 11px; text-align: left;">&#160;</td> <td style="width: 153px; text-align: right;">-</td> <td style="width: 10px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Granted</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">28</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">5.44</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Vested</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Forfeited</td> <td>&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">-</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">-</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify;">Non-vested at June 30, 2017</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">28</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">5.44</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 90%; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 1pt;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;"><u style="text-decoration: none;">2017</u></font></td> <td style="padding-bottom: 1pt;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2" nowrap="nowrap">&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Expected life</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;" nowrap="nowrap">4.9 years</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 885px; text-align: left;">Expected volatility</td> <td style="width: 10px;">&#160;</td> <td style="width: 10px; text-align: left;">&#160;</td> <td style="width: 101px; text-align: right;">39.4</td> <td style="width: 12px; text-align: left;">%</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Risk-free interest rate</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1.26</td> <td style="text-align: left;">%</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Dividend yield</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1.30</td> <td style="text-align: left;">%</td> </tr> </table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 65%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap">&#160;</td><td nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid;" colspan="2" nowrap="nowrap">Shares</td><td style="border-bottom: black 2px solid;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid;" nowrap="nowrap">&#160;</td><td style="border-bottom: black 2px solid;" colspan="2" nowrap="nowrap">Weighted&#160;<br />average grant&#160;<br />date fair value</td><td style="border-bottom: black 2px solid;" nowrap="nowrap">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; width: 754px;">Non-vested at beginning of year</td><td style="width: 11px;">&#160;</td><td style="text-align: left; width: 11px;">&#160;</td><td style="text-align: right; width: 101px;">795</td><td style="text-align: left; width: 10px;">&#160;</td><td style="width: 10px;">&#160;</td><td style="text-align: left; width: 10px;">$</td><td style="text-align: right; width: 101px;">20.73</td><td style="text-align: left; width: 10px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Granted</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">501</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">18.92</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Vested</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(396</td><td style="text-align: left;">)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">17.26</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 2px;">Forfeited</td><td>&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">(103</td><td style="border-bottom: black 2px solid; text-align: left;">)</td><td style="border-bottom: black 2px solid;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">21.33</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td>Non-vested at June 30, 2017</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">797</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">21.24</td><td style="text-align: left;">&#160;</td></tr></table> <table style="font: 10pt/normal 'times new roman', times, serif; width: 85%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: center; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="width: 614px;">Dividends</td> <td style="width: 13px;">&#160;</td> <td style="width: 13px; text-align: left;">$</td> <td style="width: 176px; text-align: right;">277</td> <td style="width: 13px; text-align: left;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="width: 13px; text-align: left;">$</td> <td style="width: 175px; text-align: right;">222</td> <td style="width: 12px; text-align: left;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="width: 12px; text-align: left;">$</td> <td style="width: 175px; text-align: right;">233</td> <td style="width: 12px; text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td>Interest</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">264</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">313</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">282</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Foreign government subsidies received</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">64</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">25</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">22</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Joint venture equity earnings</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,336</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,060</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,761</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Foreign currency (losses) gains</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(298</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">56</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(1,065</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Deferred compensation plan losses</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(257</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(35</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(96</td> <td style="text-align: left;">)</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Rental income</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">158</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">154</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">151</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 2px;">Miscellaneous income</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">33</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">28</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">&#160;</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;">198</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">2,577</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">2,823</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 4px; border-bottom-style: double;">1,486</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 534px;">Domestic operations</td> <td style="width: 11px;">&#160;</td> <td style="text-align: left; width: 11px;">$</td> <td style="text-align: right; width: 153px;">9,555</td> <td style="text-align: left; width: 11px;">&#160;</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">$</td> <td style="text-align: right; width: 152px;">43,906</td> <td style="text-align: left; width: 10px;">&#160;</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">$</td> <td style="text-align: right; width: 152px;">48,276</td> <td style="text-align: left; width: 10px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2px;">Foreign operations</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">7,806</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">9,948</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">5,589</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">17,361</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">53,854</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">53,865</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center; text-decoration: none;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px; text-decoration: none;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; text-decoration: none;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px; text-decoration: none;">&#160;</td> <td style="padding-bottom: 2px; text-decoration: none;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; text-decoration: none;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px; text-decoration: none;">&#160;</td> <td style="padding-bottom: 2px; text-decoration: none;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; text-decoration: none;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 2px; text-decoration: none;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Federal:</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 9pt; width: 522px;">Current</td> <td style="width: 11px;">&#160;</td> <td style="text-align: left; width: 11px;">$</td> <td style="text-align: right; width: 153px;">3,713</td> <td style="text-align: left; width: 11px;">&#160;</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">$</td> <td style="text-align: right; width: 152px;">15,129</td> <td style="text-align: left; width: 10px;">&#160;</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">$</td> <td style="text-align: right; width: 152px;">18,393</td> <td style="text-align: left; width: 10px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 9pt;">Deferred</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(585</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(204</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(1,357</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">State and local:</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 9pt;">Current</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">555</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">755</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,526</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 9pt;">Deferred</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(110</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">173</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">189</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Foreign:</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 9pt;">Current</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,221</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">3,222</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,337</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2px; padding-left: 9pt;">Deferred</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">191</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">13</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(706</td> <td style="text-align: left; padding-bottom: 2px;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">5,985</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">19,088</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">20,382</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Deferred tax assets:</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt; width: 796px;">Accrued deferred compensation</td> <td style="width: 11px;">&#160;</td> <td style="text-align: left; width: 11px;">$</td> <td style="text-align: right; width: 109px;">4,229</td> <td style="text-align: left; width: 10px;">&#160;</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">$</td> <td style="text-align: right; width: 109px;">4,122</td> <td style="text-align: left; width: 10px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Accrual for sales deductions not currently deductible</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5,796</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5,925</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Additional inventoried costs for tax purposes</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">697</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">389</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Allowance for doubtful accounts receivable</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">106</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">106</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Depreciation and amortization</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">11,957</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">7,784</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Debt issuance costs</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">7,611</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">9,462</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Foreign deferred tax assets</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">983</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,121</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Domestic net operating loss carryforwards</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">81</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">109</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Foreign net operating loss carryforwards</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">692</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">685</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 0.25in;">Total gross deferred tax assets</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">32,152</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">29,703</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 0.25in;">Valuation allowances</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(773</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(794</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 0.25in;">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">31,379</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">28,909</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Deferred tax liabilities:</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Foreign deferred tax liabilities</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(65</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(27</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 9pt;">Goodwill</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(10,244</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(7,586</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 9pt;">Original issue discount &#8211; convertible senior notes</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(7,260</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(9,115</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2px; padding-left: 9pt;">Other</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(1,136</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(26</td> <td style="text-align: left; padding-bottom: 2px;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2px; padding-left: 0.25in;">Total gross deferred tax liabilities</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(18,705</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(16,754</td> <td style="text-align: left; padding-bottom: 2px;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-left: 0.25in;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 4px;">Net deferred tax assets</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">12,674</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">12,155</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 70%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td> <td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 668px;">Current deferred tax assets, net</td> <td style="width: 9px;">&#160;</td> <td style="text-align: left; width: 9px;">$</td> <td style="text-align: right; width: 115px;">546</td> <td style="text-align: left; width: 9px;">&#160;</td> <td style="width: 9px;">&#160;</td> <td style="text-align: left; width: 9px;">$</td> <td style="text-align: right; width: 114px;">3,244</td> <td style="text-align: left; width: 8px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Non-current deferred tax assets, net</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">19,453</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">18,053</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Non-current deferred tax liabilities</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(7,325</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(9,142</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 4px; padding-left: 9pt;">Net deferred tax assets</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">12,674</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">12,155</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 95%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 665px;">Federal statutory tax rate</td> <td style="width: 11px;">&#160;</td> <td style="text-align: left; width: 10px;">&#160;</td> <td style="text-align: right; width: 109px;">35.0</td> <td style="text-align: left; width: 11px;">%</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">&#160;</td> <td style="text-align: right; width: 109px;">35.0</td> <td style="text-align: left; width: 11px;">%</td> <td style="width: 10px;">&#160;</td> <td style="text-align: left; width: 10px;">&#160;</td> <td style="text-align: right; width: 109px;">35.0</td> <td style="text-align: left; width: 11px;">%</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-indent: -0.25in; padding-left: 0.25in;">State and local taxes, net of federal income tax benefit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1.2</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1.7</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2.4</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Decrease (increase) in valuation allowance</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">0.1</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">0.4</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Foreign tax rate differential</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(1.8</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(0.4</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(0.9</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2px;">Other</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(0.9</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">0.9</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 4px;">Effective tax rate</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">&#160;</td> <td style="border-bottom: black 4px double; text-align: right;">34.5</td> <td style="text-align: left; padding-bottom: 4px;">%</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">&#160;</td> <td style="border-bottom: black 4px double; text-align: right;">35.4</td> <td style="text-align: left; padding-bottom: 4px;">%</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">&#160;</td> <td style="border-bottom: black 4px double; text-align: right;">37.8</td> <td style="text-align: left; padding-bottom: 4px;">%</td> </tr> </table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;" nowrap="nowrap">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td><td style="padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td><td style="padding-bottom: 2px;">&#160;</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2015</td><td style="padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="width: 765px;">Interest</td><td style="width: 13px;">&#160;</td><td style="text-align: left; width: 13px;">$</td><td style="text-align: right; width: 126px;">7,794</td><td style="text-align: left; width: 13px;">&#160;</td><td style="width: 13px;">&#160;</td><td style="text-align: left; width: 12px;">$</td><td style="text-align: right; width: 125px;">2,970</td><td style="text-align: left; width: 12px;">&#160;</td><td style="width: 12px;">&#160;</td><td style="text-align: left; width: 12px;">$</td><td style="text-align: right; width: 125px;">3,954</td><td style="text-align: left; width: 12px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Income taxes, net of refunds</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">7,912</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">16,076</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">25,459</td><td style="text-align: left;">&#160;</td></tr></table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 50%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; margin-left: 0.5in; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="border-bottom: black 2px solid; text-align: center;" nowrap="nowrap">Fiscal year</td><td style="border-bottom: black 2px solid;">&#160;</td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">Amount</td><td style="padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; width: 619px;">2018</td><td style="width: 8px;">&#160;</td><td style="text-align: left; width: 8px;">$</td><td style="text-align: right; width: 141px;">1,673</td><td style="text-align: left; width: 7px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">2019</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,327</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">2020</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,766</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">2021</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,327</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify;">2022</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,031</td><td style="text-align: left;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 2px;">Thereafter</td><td style="padding-bottom: 2px;">&#160;</td><td style="border-bottom: black 2px solid; text-align: left;">&#160;</td><td style="border-bottom: black 2px solid; text-align: right;">6,744</td><td style="text-align: left; padding-bottom: 2px;">&#160;</td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: justify; padding-bottom: 4px;">&#160;</td><td style="padding-bottom: 4px;">&#160;</td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">14,868</td><td style="text-align: left; padding-bottom: 4px;">&#160;</td></tr></table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom; text-decoration: none;"> <td style="text-align: center; text-decoration: none;" nowrap="nowrap">&#160;</td> <td style="text-decoration: none;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; text-decoration: none;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Human</font><br /><font style="font-size: 10pt;">Health</font></td> <td style="text-decoration: none;">&#160;</td> <td style="text-decoration: none;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; text-decoration: none;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Pharmaceutical</font><br /><font style="font-size: 10pt;">Ingredients</font></td> <td style="text-decoration: none;">&#160;</td> <td style="font-weight: normal; text-decoration: none;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: normal; text-decoration: none;" colspan="2" nowrap="nowrap"><font style="font-family: 'times new roman', times, serif; font-weight: normal;">Performance</font><br /><font style="font-family: 'times new roman', times, serif; font-weight: normal;">Chemicals</font></td> <td style="font-weight: normal; text-decoration: none;">&#160;</td> <td style="text-decoration: none;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; text-decoration: none;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Unallocated</font><br /><font style="font-size: 10pt;">Corporate</font></td> <td style="text-decoration: none;">&#160;</td> <td style="text-decoration: none;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; text-decoration: none;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Consolidated</font><br /><font style="font-size: 10pt;">Totals</font></td> <td style="text-decoration: none;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify; text-decoration: underline;">2017</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 478px;">Net sales</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 137px;">315,395</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 137px;">157,445</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 136px;">165,478</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 136px;">-</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 136px;">638,318</td> <td style="text-align: left; width: 13px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Gross profit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">78,109</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">25,474</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">37,209</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">140,792</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Income before income taxes</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">15,434</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">9,322</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">18,829</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(26,224</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">17,361</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-decoration: underline;">2016</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Net sales</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">228,035</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">161,011</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">169,478</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">558,524</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Gross profit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">77,880</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">28,752</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">36,153</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">142,785</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Income before income taxes</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">36,362</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">11,856</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">17,799</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(12,163</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">53,854</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; text-decoration: underline;">2015</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Net sales</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">225,263</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">149,296</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">172,392</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">546,951</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Gross profit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">75,749</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">26,683</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">33,002</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">-</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">135,434</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Income before income taxes</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">35,152</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">8,697</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">14,289</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(4,273</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">53,865</td> <td style="text-align: left;">&#160;</td> </tr> </table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 90%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="10" nowrap="nowrap">Net Sales</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="10" nowrap="nowrap">Gross Profit</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">2015</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 270px;">United States</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 123px;">483,678</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">400,883</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">407,101</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">116,792</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">117,180</td> <td style="text-align: left; width: 12px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 122px;">111,734</td> <td style="text-align: left; width: 12px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Germany</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">79,105</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">76,666</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">69,889</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">13,609</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">15,154</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">14,660</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Netherlands</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">9,949</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">16,217</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">14,656</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,231</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,598</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,325</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>France</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">35,796</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">30,177</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">27,976</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">4,651</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">4,043</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">3,634</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2px;">Asia-Pacific</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">29,790</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">34,581</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">27,329</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">4,509</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">4,810</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">4,081</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 4px;">Total</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">638,318</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">558,524</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">546,951</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">140,792</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">142,785</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">135,434</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <table style="widows: 2; text-transform: none; text-indent: 0px; width: 50%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;" colspan="6" nowrap="nowrap">Long-lived assets</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 477px;">United States</td> <td style="width: 6px;">&#160;</td> <td style="text-align: left; width: 7px;">$</td> <td style="text-align: right; width: 82px;">528,359</td> <td style="text-align: left; width: 6px;">&#160;</td> <td style="width: 6px;">&#160;</td> <td style="text-align: left; width: 6px;">$</td> <td style="text-align: right; width: 81px;">152,701</td> <td style="text-align: left; width: 6px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Europe</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,538</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,504</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2px;">Asia-Pacific</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">1,582</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">1,781</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 4px;">Total</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">532,479</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">156,986</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="14" nowrap="nowrap">For&#160;the&#160;quarter&#160;ended</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-weight: bold;" nowrap="nowrap">Fiscal&#160;year&#160;ended&#160;June&#160;30,&#160;2017</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">September&#160;30,<br />2016&#160;(1)</td> <td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">December&#160;31,<br />2016(2)</td> <td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">March&#160;31,<br />2017(2)(3)</td> <td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">June&#160;30,<br />2017&#160;(2)(4)</td> <td style="padding-bottom: 2px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 622px;">Net sales</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 130px;">128,018</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 130px;">125,552</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 130px;">190,128</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 129px;">194,620</td> <td style="text-align: left; width: 12px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Gross profit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">30,839</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">30,805</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">42,319</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">36,829</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Net income (loss)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">4,385</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(564</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5,588</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,967</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Net income (loss) per diluted share</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.15</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">(0.02</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.16</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.06</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="14" nowrap="nowrap">For&#160;the&#160;quarter&#160;ended</td> <td style="border-bottom: black 2px solid;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-weight: bold;" nowrap="nowrap">Fiscal&#160;year&#160;ended&#160;June&#160;30,&#160;2016</td> <td>&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">September&#160;30,<br />2015</td> <td style="border-bottom: black 2px solid;">&#160;</td> <td style="border-bottom: black 2px solid;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">December&#160;31,<br />2015</td> <td style="border-bottom: black 2px solid;">&#160;</td> <td style="border-bottom: black 2px solid;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">March&#160;31,<br />2016(5)</td> <td style="border-bottom: black 2px solid;">&#160;</td> <td style="border-bottom: black 2px solid;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap">June&#160;30,<br />2016(6)</td> <td style="border-bottom: black 2px solid;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 622px;">Net sales</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 130px;">133,500</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 130px;">131,674</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 13px;">&#160;</td> <td style="text-align: left; width: 13px;">$</td> <td style="text-align: right; width: 130px;">157,926</td> <td style="text-align: left; width: 13px;">&#160;</td> <td style="width: 12px;">&#160;</td> <td style="text-align: left; width: 12px;">$</td> <td style="text-align: right; width: 129px;">135,424</td> <td style="text-align: left; width: 12px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Gross profit</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">34,581</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">35,868</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">38,289</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">34,047</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Net income</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">9,298</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">8,270</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">10,424</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">6,774</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Net income per diluted share</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.32</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.28</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.35</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">0.23</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The net income per common share calculation for each of the quarters is based on the weighted average number of shares outstanding in each period. Therefore, the sum of the quarters in a year does not necessarily equal the year&#8217;s net income per common share.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">&#160;</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">(1) Includes pretax item of $170 environmental remediation charge in connection with Arsynco.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">(2) Results for the last nine days of the quarter ended December 31, 2016 and for the subsequent two quarters reflect the acquisition of certain generic products and related assets from Citron and Lucid on December 21, 2016.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">(3) Includes pretax item of $733 environmental remediation charge in connection with Arsynco.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">(4) Includes pretax item of $3,139 representing immaterial correction of an error associated with certain accrued expenses.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">(5) Includes pretax items consisting of $833 reversal of contingent consideration related to the PACK acquisition and $241 reversal of contingent consideration related to the acquisition of a company in France.</p> <p style="text-align: justify; widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">(6) Includes pretax item of $1,313 environmental remediation charge in connection with Arsynco.</p> 18 P5Y 50000000 50000000 0.05 5122000 5122 P5Y 50000000 2622000 132000 132000 2580000 2952000 2952000 2807000 145000 224850000 135700000 88800000 350000 P10Y P11Y P6M 2 122118000 7437000 10278000 11176000 21000000 22234000 21000000 13200000 13200000 4502000 8818000 78937000 38995000 1425000 513278000 46840000 53458000 360400000 731100000 739318000 30469000 24166000 0.89 0.70 0.88 0.69 -6120000 -4340000 -581000 205000 191000 10986000 20249000 1005000 3630000 690000 517000 32167000 30692000 938000 4335000 2682000 691000 22715000 22828000 1312000 7202000 2423000 513000 59919000 32359000 8864000 39333000 6037000 485000 23526000 1496000 4500000 28944000 2360000 208965000 21403000 4259000 36923000 9381000 247186000 7618000 5124000 90915000 10267000 431606000 19666000 7694000 162023000 20129000 187784000 10960000 4326000 36218000 7389000 310000 256638000 15482000 4750000 88048000 10526000 254000 417928000 11631000 4642000 158836000 18875000 25000 516000 471000 349000 20708000 1056000 8690000 184000 405000 6048000 2365000 1960000 21555000 979000 8678000 184000 398000 7255000 2094000 1967000 10664000 11127000 P20Y P3Y P5Y P10Y P3Y P5Y P3Y P7Y Shorter of asset life or lease term 104000 220000 May 2020 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.065 0.065 0.065 0.065 2017-08-24 2017-09-21 2017-09-08 3497000 51352000 41036000 54454000 33.215 33.215 1571000 1522000 1520000 100000000 62187000 2021-12-21 881000 2046000 2580000 2580000 1500000 85000 237000 1000 -3000 6249000 6249000 5781000 5781000 881000 881000 2046000 2046000 160000 160000 486000 486000 169000 169000 137000 137000 581000 581000 132000 132000 2952000 2952000 2807000 145000 -703000 -10000 -515000 143750000 125000000 0.065 13489000 134400000 133000000 1578000 169071000 169071000 1000 1000 28000 23000 5000 127034000 13591000 1868000 155000 83048000 21761000 6611000 355184000 14307000 2218000 221335000 110787000 6537000 48724000 9927000 1800000 140000 23511000 7815000 5531000 70886000 11011000 2195000 37677000 13968000 6035000 78310000 3664000 68000 15000 59537000 13946000 1080000 284298000 3296000 23000 183658000 96819000 502000 P10Y P14Y P3Y P11Y P7Y P11Y P6Y P3Y P4Y 761000 783000 16747000 32431000 31880000 31819000 31782000 139639000 6880000 5793000 9180000 6112000 31342000 80556000 16068000 5273000 9799000 1700000 21500000 23300000 12532000 8451000 550000 550000 1200000 5639000 3803000 150 3947000 2960000 2763000 118789000 115829000 150000000 353666000 90000000 121676000 139227000 90000000 143750000 143750000 142500000 24267000 19255000 3654000 2819000 1788000 2867000 2974000 5012000 522000 835000 5284000 8714000 14466000 14466000 14466000 138115000 172153000 18750000 0.0200 0.0492 0.0330 0.0345 0.0321 4328000 1000000 20 30 P5D 1.30 0.9800 150000000 225000000 1758000 1737000 7397000 7351000 0.050 0.045 0.045 0 232500000 155639000 140613000 11 Maturity Date shall mean the date that is 91 days prior to the 2015 Convertible Maturity Date 100000000 19 Quarterly 3750000 15000000 P20Y 551000 397000 302000 260000 28000 28000 8000 232000 7.72 7.28 7.19 8.36 20.03 20.03 8.74 7.56 7.90 10.94 6.98 1968000 1968000 28000 5.44 5.44 P4Y10M24D 0.3940 0.0126 0.0130 795000 797000 116000 12000 165000 67000 142000 14000 221000 46000 501000 160000 22000 277000 42000 396000 103000 20.73 21.24 18.92 17.26 21.33 700000 5250000 4250000 0 255000 3144000 1713000 1700000 865000 P4Y 22000 22000 26000 21000 4494000 0 6697000 55000 6875000 203000 248000 280000 1.00 1.00 1.00 P3Y P1Y P3Y P3Y P1Y P3Y P3Y P1Y P3Y 95000 8382000 P1Y9M18D 40 P20D P1Y 2021-06-30 P10Y 233000 222000 277000 282000 313000 264000 22000 25000 64000 -1065000 56000 -298000 -96000 -35000 -257000 151000 154000 158000 198000 28000 33000 1486000 2823000 2577000 6000 0.30 48276000 43906000 9555000 5589000 9948000 7806000 18393000 15129000 3713000 -1357000 -204000 -585000 1526000 755000 555000 189000 173000 -110000 2337000 3222000 2221000 -706000 13000 191000 4122000 4229000 5925000 5796000 389000 697000 106000 106000 7784000 11957000 9462000 7611000 1121000 983000 109000 8100081000 685000 692000 29703000 32152000 794000 773000 28909000 31379000 27000 65000 7586000 10244000 9115000 7260000 26000 1136000 16754000 18705000 12155000 12674000 0.35 0.35 0.35 0.024 0.017 0.012 0.004 0.001 0.009 0.004 0.018 0.009 -0.009 0.378 0.354 0.345 2119000 64000 16000 21000 34638000 111569000 3954000 2970000 7794000 25459000 16076000 7912000 90400000 726000 294000 284000 1849000 1957000 1794000 853000 883000 53000 28000 30000 0.016 0.019 0.020 0.000 0.000 0.000 3046000 3551000 3028000 3337000 18000 214000 2693000 3087000 1 0 1 0 3 1 0 3 0.34 0.20 0.11 0.31 0.21 0.15 0.10 0.10 0.10 0.13 0.14 0.12 0.65 0.12 0.56 0.22 0.62 0.17 48846000 62399000 50641000 68235000 1673000 2327000 1766000 1327000 1031000 6744000 14868000 61381000 2357000 0 0 1567000 1265000 1301000 3204000 2831000 3236000 165000 1865000 125000 156986000 152701000 1781000 2504000 532479000 528359000 1582000 2538000 38295000 23810000 21750000 3 484000 76000 -3000 Specific accounts written off as uncollectible. Included in "Other receivables" in the accompanying Consolidated Balance Sheet as of June 30, 2016. Included in "Other receivables" in the accompanying Consolidated Balance Sheet as of June 30, 2017. Included in "Accrued expenses" in the accompanying Consolidated Balance Sheet as of June 30, 2016. Included in "Accrued expenses" in the accompanying Consolidated Balance Sheet as of June 30, 2017. Included in "Long-term liabilities" in the accompanying Consolidated Balance Sheet as of June 30, 2017. Included in "Long-term liabilities" in the accompanying Consolidated Balance Sheet as of June 30, 2016. $145 included in "Accrued expenses" and $2,807 included in "Long-term liabilities" in the accompanying Consolidated Balance Sheet as of June 30, 2017. Includes pretax item of $170 environmental remediation charge in connection with Arsynco. Results for the last nine days of the quarter ended December 31, 2016 and for the subsequent two quarters reflect the acquisition of certain generic products and related assets from Citron and Lucid on December 21, 2016. Includes pretax item of $733 environmental remediation charge in connection with Arsynco. Includes pretax item of $3,139 representing immaterial correction of an error associated with certain accrued expenses. Includes pretax items consisting of $833 reversal of contingent consideration related to the PACK acquisition and $241 reversal of contingent consideration related to the acquisition of a company in France. Includes pretax item of $1,313 environmental remediation charge in connection with Arsynco. 95000000 5000000 0000002034us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberacet:ExpirationDateDecember212021Member2017-06-30 acet:Principal_Segment 0.02005 straight-line method 0000002034us-gaap:AcquisitionRelatedCostsMemberacet:CitronPharmaLimitedLiabilityCompanyAndLucidPharmaLimitedLiabilityCompanyMember2017-06-30 8818000 3659000 1748000 0000002034us-gaap:RestrictedStockUnitsRSUMember2016-07-012017-06-30 0000002034us-gaap:SalesRevenueNetMemberacet:CustomerTwoMember2016-07-012017-06-30 0.11 0000002034acet:CustomerTwoMemberus-gaap:SalesRevenueNetMember2015-07-012016-06-30 0.07 0000002034acet:CustomerTwoMemberus-gaap:SalesRevenueNetMember2014-07-012015-06-30 0.06 0000002034acet:CronusResearchLabsPrivateLimitedMemberacet:DevelopmentAgreementIMember2016-11-012016-11-02 Under the terms of Development Agreement I, Cronus has agreed to pay the first $3,500 of the development costs incurred after December 21, 2016, and 50% of any development costs incurred above that threshold in exchange for obtaining reimbursement for its costs funded out of the profits earned, if any, from the pipeline products that are commercially launched, and a specified portion of the profits from those products thereafter. 0000002034acet:CronusResearchLabsPrivateLimitedMemberacet:DevelopmentAgreementIIMember2016-11-012016-11-02 Under the terms of Development Agreement II, Cronus has agreed to pay the development costs for the products covered thereby in exchange for obtaining reimbursement for its costs funded out of the profits earned, if any, from such products that are commercially launched (subject to a $1,445 maximum), and a specified portion of the profits from those products thereafter. 0000002034acet:CronusResearchLabsPrivateLimitedMemberacet:DevelopmentAgreementIMember2015-10-012015-12-31 3500000 1445000 0.50 3139000 0 EX-101.SCH 9 acet-20170630.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONSOLIDATED STATEMENTS OF INCOME link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:definitionLink link:calculationLink 006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 008 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 009 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Description of Business link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Business Combinations link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Investments link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Environmental Remediation link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Debt link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Stock Based Compensation Plans link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Interest and Other Income link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Supplemental Cash Flow Information link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Retirement Plans link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Financial Instruments link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Commitments, Contingencies and Other Matters link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Segment Information link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Unaudited Quarterly Financial Data link:presentationLink link:definitionLink link:calculationLink 030 - Schedule - Valuation and Qualifying Accounts link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Business Combinations (Tables) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Investments (Tables) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Debt (Tables) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Stock Based Compensation Plans (Tables) link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Interest and Other Income (Tables) link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Supplemental Cash Flow Information (Tables) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Commitments, Contingencies and Other Matters (Tables) link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Segment Information (Tables) link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Unaudited Quarterly Financial Data (Tables) link:presentationLink link:definitionLink link:calculationLink 046 - Disclosure - Summary of Significant Accounting Policies (Components of accumulated other comprehensive loss (Detail) link:presentationLink link:definitionLink link:calculationLink 047 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 048 - Disclosure - Summary of Significant Accounting Policies (Schedule of Reconciliation of Weighted Average Shares Outstanding and Diluted Weighted Average Shares Outstanding) (Detail) link:presentationLink link:definitionLink link:calculationLink 049 - Disclosure - Summary of Significant Accounting Policies (Schedule of Components of Property and Equipment) (Detail) link:presentationLink link:definitionLink link:calculationLink 050 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 051 - Disclosure - Business Combinations (Details) link:presentationLink link:definitionLink link:calculationLink 052 - Disclosure - Business Combinations (Details 1) link:presentationLink link:definitionLink link:calculationLink 053 - Disclosure - Business Combinations (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 054 - Disclosure - Business Combinations (Narrative) (Detail 1) link:presentationLink link:definitionLink link:calculationLink 055 - Disclosure - Investments (Schedule of Summary of Short-Term Investments) (Detail) link:presentationLink link:definitionLink link:calculationLink 056 - Disclosure - Fair Value Measurements (Schedule Changes in contingent consideration) (Details) link:presentationLink link:definitionLink link:calculationLink 057 - Disclosure - Fair Value Measurements (Schedule of Valuation of Financial Assets and Liabilities) (Detail) link:presentationLink link:definitionLink link:calculationLink 058 - Disclosure - Fair Value Measurements (Schedule of Valuation of Financial Assets and Liabilities) (Parentheticals) (Detail) link:presentationLink link:definitionLink link:calculationLink 059 - Disclosure - Fair Value Measurements (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 060 - Disclosure - Goodwill and Other Intangible Assets - Summary of changes in goodwill (Details) link:presentationLink link:definitionLink link:calculationLink 061 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets Subject to Amortization) (Detail) link:presentationLink link:definitionLink link:calculationLink 062 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 063 - Disclosure - Accrued Expenses (Schedule of Components of Accrued Expenses) (Detail) link:presentationLink link:definitionLink link:calculationLink 064 - Disclosure - Environmental Remediation (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 065 - Disclosure - Debt (Schedule of Long-term Debt) (Detail) link:presentationLink link:definitionLink link:calculationLink 066 - Disclosure - Debt (Summary carrying value of Notes) (Detail 1) link:presentationLink link:definitionLink link:calculationLink 067 - Disclosure - Debt (Summary interest expense related to notes recognized) (Detail 2) link:presentationLink link:definitionLink link:calculationLink 068 - Disclosure - Debt (Maturity of Long-term Debt) (Detail 3) link:presentationLink link:definitionLink link:calculationLink 069 - Disclosure - Debt (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 070 - Disclosure - Debt (Narrative) (Detail 1) link:presentationLink link:definitionLink link:calculationLink 071 - Disclosure - Debt (Narrative) (Detail 2) link:presentationLink link:definitionLink link:calculationLink 072 - Disclosure - Stock Based Compensation Plans (Schedule of Shares of Common Stock under Options for All Plans) (Detail) link:presentationLink link:definitionLink link:calculationLink 073 - Disclosure - Stock Based Compensation Plans (Summary of non-vested stock options) (Detail) link:presentationLink link:definitionLink link:calculationLink 074 - Disclosure - Stock Based Compensation Plans (Per-share fair value of stock options granted using Monte Carlo simulation option-pricing model) (Detail) link:presentationLink link:definitionLink link:calculationLink 075 - Disclosure - Stock Based Compensation Plans (Schedule of Restricted Stock Awards Including Restricted Stock Units) (Detail) link:presentationLink link:definitionLink link:calculationLink 076 - Disclosure - Stock Based Compensation (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 077 - Disclosure - Interest and Other Income (Schedule of Interest and other income) (Detail) link:presentationLink link:definitionLink link:calculationLink 078 - Disclosure - Interest and Other Income (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 079 - Disclosure - Income Taxes (Schedule of Provision for Income Taxes) (Detail) link:presentationLink link:definitionLink link:calculationLink 080 - Disclosure - Income Taxes (Schedule of Tax Effects of Temporary Differences that Give Rise to the Deferred Tax Assets and Liabilities) (Detail) link:presentationLink link:definitionLink link:calculationLink 081 - Disclosure - Income Taxes (Schedule of Current and Non-Current Deferred Tax Assets (Liabilities)) (Detail) link:presentationLink link:definitionLink link:calculationLink 082 - Disclosure - Income Taxes (Schedule of Reconciliation of Statutory Federal Income Tax Rate and Effective Tax Rate for Continuing Operations) (Detail) link:presentationLink link:definitionLink link:calculationLink 083 - Disclosure - Income Taxes (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 084 - Disclosure - Supplemental Cash Flow Information (Schedule of Cash Paid for Interest and Income Taxes) (Detail) link:presentationLink link:definitionLink link:calculationLink 085 - Disclosure - Supplemental Cash Flow Information (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 086 - Disclosure - Retirement Plans (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 087 - Disclosure - Financial Instruments (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 088 - Disclosure - Commitments, Contingencies and Other Matters (Schedule of Future Minimum Lease Payments) (Detail) link:presentationLink link:definitionLink link:calculationLink 089 - Disclosure - Commitments, Contingencies and Other Matters (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 090 - Disclosure - Related Party Transactions (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 092 - Disclosure - Segment Information (Schedule of Segment Perfomance Measures by Segment) (Detail) link:presentationLink link:definitionLink link:calculationLink 093 - Disclosure - Segment Information (Schedule of Net Sales and Gross Profit by Source Country) (Detail) link:presentationLink link:definitionLink link:calculationLink 094 - Disclosure - Segment Information (Schedule of Long-Lived Assets by Geographic Region) (Detail) link:presentationLink link:definitionLink link:calculationLink 095 - Disclosure - Segment Information (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 096 - Disclosure - Unaudited Quarterly Financial Data (Detail) link:presentationLink link:definitionLink link:calculationLink 097 - Disclosure - Unaudited Quarterly Financial Data (Narrative) (Detail) link:presentationLink link:definitionLink link:calculationLink 098 - Disclosure - Valuation and Qualifying Accounts (Detail) link:presentationLink link:definitionLink link:calculationLink 091 - Disclosure - Related Party Transactions (Narrative) (Detail 1) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 10 acet-20170630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 11 acet-20170630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 acet-20170630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 13 acet-20170630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 14 v472462_img1.jpg GRAPHIC begin 644 v472462_img1.jpg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�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end XML 15 R1.htm IDEA: XBRL DOCUMENT v3.7.0.1
Document and Entity Information - USD ($)
 12 Months Ended
Jun. 30, 2017
Aug. 21, 2017
Dec. 31, 2016
Document And Entity Information [Abstract]      
Entity Registrant Name ACETO CORP    
Entity Central Index Key 0000002034    
Trading Symbol acet    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Current Fiscal Year End Date --06-30    
Entity Filer Category Large Accelerated Filer    
Entity Well-known Seasoned Issuer No    
Entity Common Stock Shares Outstanding   30,109,417  
Entity Public Float     $ 564,677,707
Document Type 10-K    
Document Period End Date Jun. 30, 2017    
Amendment Flag false    
Document Fiscal Year Focus 2017    
Document Fiscal Period Focus FY    

XML 16 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2017
Jun. 30, 2016
Current assets:    
Cash and cash equivalents $ 55,680 $ 66,828
Investments 2,046 881
Trade receivables: less allowance for doubtful accounts (2017, $485; 2016, $513) 264,896 167,612
Other receivables 10,664 12,650
Inventory 136,387 98,107
Prepaid expenses and other current assets 3,941 3,339
Deferred income tax asset, net 546 3,244
Total current assets 474,160 352,661
Property and equipment, net 10,428 10,044
Property held for sale 7,152 6,868
Goodwill 236,970 67,871
Intangible assets, net 285,081 79,071
Deferred income tax asset, net 19,453 18,053
Other assets 7,546 6,210
TOTAL ASSETS 1,040,790 540,778
Current liabilities:    
Current portion of long-term debt 14,466 197
Accounts payable 90,011 46,034
Accrued expenses 118,328 52,675
Total current liabilities 222,805 98,906
Long-term debt 339,200 118,592
Long-term liabilities 61,449 6,344
Environmental remediation liability 2,339 3,352
Deferred income tax liability 7,325 9,142
Total liabilities 633,118 236,336
Commitments and contingencies (Note 16)
Shareholders' equity:    
Preferred stock, 2,000 shares authorized; no shares issued and outstanding
Common stock, $.01 par value, 75,000 shares authorized at June 30, 2017 and June 30, 2016; 30,094 and 29,595 shares issued and outstanding at June 30, 2017 and 2016, respectively 301 296
Capital in excess of par value 214,198 115,667
Retained earnings 198,285 194,804
Accumulated other comprehensive loss (5,112) (6,325)
Total shareholders' equity 407,672 304,442
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 1,040,790 $ 540,778
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)
shares in Thousands, $ in Thousands
Jun. 30, 2017
Jun. 30, 2016
Statement Of Financial Position [Abstract]    
Trade receivables, allowance for doubtful accounts (in dollars) $ 485 $ 513
Preferred stock, shares authorized 2,000 2,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized 75,000 75,000
Common stock, shares issued 30,094 29,595
Common stock, shares outstanding 30,094 29,595
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Income Statement [Abstract]      
Net sales $ 638,318 $ 558,524 $ 546,951
Cost of sales 497,526 415,739 411,517
Gross profit 140,792 142,785 135,434
Selling, general and administrative expenses 102,340 76,820 73,159
Research and development expenses 7,898 7,937 5,942
Operating income 30,554 58,028 56,333
Other (expense) income:      
Interest expense (15,770) (6,997) (3,954)
Interest and other income, net 2,577 2,823 1,486
Other (expense) income, Total (13,193) (4,174) (2,468)
Income before income taxes 17,361 53,854 53,865
Provision for income taxes 5,985 19,088 20,382
Net income $ 11,376 $ 34,766 $ 33,483
Basic income per common share (in dollars per share) $ 0.35 $ 1.19 $ 1.17
Diluted income per common share (in dollars per share) $ 0.35 $ 1.18 $ 1.14
Weighted average shares outstanding:      
Basic (in shares) 32,283 29,110 28,731
Diluted (in shares) 32,632 29,581 29,247
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Statement of Comprehensive Income [Abstract]      
Net income $ 11,376 $ 34,766 $ 33,483
Other comprehensive income (loss):      
Foreign currency translation adjustments 1,780 368 (12,354)
Change in fair value of interest rate swaps (581) (149) 99
Reclassification for realized loss on interest rate swap included in interest expense   487  
Defined benefit plans, net of tax of $7, $31 and $100 respectively 14 65 (213)
Total other comprehensive income (loss) 1,213 771 (12,468)
Comprehensive income $ 12,589 $ 35,537 $ 21,015
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parentheticals) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Statement of Comprehensive Income [Abstract]      
Defined benefit plans, tax $ 7 $ 31 $ 100
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Operating activities:      
Net income $ 11,376 $ 34,766 $ 33,483
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 23,754 12,698 11,849
Amortization of debt issuance costs and debt discount 5,847 3,496  
Amortization of deferred financing costs 570    
Provision for doubtful accounts (3) 76 484
Non-cash stock compensation 6,956 6,719 4,537
Deferred income taxes (504) (18) (1,874)
Earnings on equity investment in joint venture (2,336) (2,060) (1,761)
Contingent consideration   (1,074) (3,468)
Amortization of inventory step-up 4,502    
Environmental remediation charge 903 1,313 1,618
Changes in assets and liabilities:      
Trade accounts receivable (17,598) (6,149) (44,181)
Other receivables 185 136 (5,644)
Inventory (2,958) (2,489) (229)
Prepaid expenses and other current assets 1,209 (243) 304
Other assets (157) (557) 1,254
Accounts payable (3,097) (8,937) 8,133
Accrued expenses and other liabilities 14,010 (7,689) 1,816
Distributions from joint venture 1,908 1,843 2,022
Net cash provided by operating activities 44,567 31,831 8,343
Investing activities:      
Payment for net assets acquired (270,000)    
Purchases of investments (2,035) (34) (2,720)
Sales of investments 909 2,517  
Payments for intangible assets (3,359) (11,249) (1,564)
Purchases of property and equipment, net (1,893) (1,128) (617)
Net cash used in investing activities (276,378) (9,894) (4,901)
Financing activities:      
Proceeds from exercise of stock options 551 729 1,273
Excess income tax benefit on stock option exercises and restricted stock 546 1,219 790
Payment of cash dividends (7,831) (7,084) (6,964)
Payment of deferred consideration     (3,500)
Payment of contingent consideration   (1,500) (4,500)
Proceeds from convertible senior notes   143,750  
Payment for debt issuance costs   (5,153)  
Proceeds from sold warrants   13,685  
Purchase of call option (hedge)   (27,174)  
Termination payment for interest rate swap   (420)  
Borrowings of bank loans 275,000 15,500 19,000
Payment for deferred financing costs (5,407)    
Repayment of bank loans (42,697) (122,697) (14,344)
Net cash provided by (used in) financing activities 220,162 10,855 (8,245)
Effect of foreign exchange rate changes on cash 501 16 (4,074)
Net (decrease) increase in cash and cash equivalents (11,148) 32,808 (8,877)
Cash and cash equivalents at beginning of period 66,828 34,020 42,897
Cash and cash equivalents at end of period $ 55,680 $ 66,828 $ 34,020
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Common Stock
Capital in Excess of Par Value
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Total
Balance at Jun. 30, 2014 $ 288 $ 87,156 $ 140,768 $ 5,372 $ 233,584
Balance (in shares) at Jun. 30, 2014 28,772        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income     33,483   33,483
Other comprehensive income (loss)       (12,468) (12,468)
Stock issued pursuant to employee stock incentive plans   77     77
Stock issued pursuant to employee stock incentive plans (in shares) 5        
Issuance of restricted stock, net of forfeitures $ 2 (2)      
Issuance of restricted stock, net of forfeitures (in shares) 224        
Dividends declared $0.24 per share for June 30, 2015, 2016 and $0.26 for 2017, respectively     (7,043)   (7,043)
Share-based compensation   4,515     4,515
Exercise of stock options $ 2 1,271     1,273
Exercise of stock options (in shares) 146        
Tax benefit from employee stock incentive plans   790     790
Balance at Jun. 30, 2015 $ 292 93,807 167,208 (7,096) 254,211
Balance (in shares) at Jun. 30, 2015 29,147        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income     34,766   34,766
Other comprehensive income (loss)       771 771
Stock issued pursuant to employee stock incentive plans   113     113
Stock issued pursuant to employee stock incentive plans (in shares) 7        
Issuance of restricted stock, net of forfeitures $ 3 (3)      
Issuance of restricted stock, net of forfeitures (in shares) 346        
Sale of warrants   13,685     13,685
Dividends declared $0.24 per share for June 30, 2015, 2016 and $0.26 for 2017, respectively     (7,170)   (7,170)
Share-based compensation   6,697     6,697
Exercise of stock options $ 1 728     729
Exercise of stock options (in shares) 95        
Tax benefit from employee stock incentive plans   1,219     1,219
Purchase of call option (hedge)   (27,174)     (27,174)
Allocation of proceeds from convertible senior notes   27,241     27,241
Equity component of debt issuance costs   (976)     (976)
Deferred taxes related to convertible senior notes   330     330
Balance at Jun. 30, 2016 $ 296 115,667 194,804 (6,325) 304,442
Balance (in shares) at Jun. 30, 2016 29,595        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income     11,376   11,376
Other comprehensive income (loss)       1,213 1,213
Stock issued pursuant to employee stock incentive plans 109     109
Stock issued pursuant to employee stock incentive plans (in shares) 5        
Issuance of restricted stock, net of forfeitures $ 4 (4)      
Issuance of restricted stock, net of forfeitures (in shares) 424        
Stock to be issued in connection with acquisition of assets of Citron and Lucid   90,400     90,400
Dividends declared $0.24 per share for June 30, 2015, 2016 and $0.26 for 2017, respectively     (7,895)   (7,895)
Share-based compensation   6,930     6,930
Exercise of stock options $ 1 550     551
Exercise of stock options (in shares) 70        
Tax benefit from employee stock incentive plans   546     546
Balance at Jun. 30, 2017 $ 301 $ 214,198 $ 198,285 $ (5,112) $ 407,672
Balance (in shares) at Jun. 30, 2017 30,094        
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Parentheticals) - $ / shares
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Statement of Stockholders' Equity [Abstract]      
Dividends declared, per share $ 0.26 $ 0.24 $ 0.24
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.7.0.1
Description of Business
 12 Months Ended
Jun. 30, 2017
Accounting Policies [Abstract]  
Description of Business

(1) Description of Business

 

Aceto Corporation and subsidiaries (“Aceto” or the “Company”) is primarily engaged in the sourcing, regulatory support, quality assurance, development, marketing, sales and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical intermediates and active ingredients, agricultural protection products and specialty chemicals used principally as finished products or raw materials in the pharmaceutical, nutraceutical, agricultural, coatings and industrial chemical consuming industries.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.7.0.1
Summary of Significant Accounting Policies
 12 Months Ended
Jun. 30, 2017
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

(2) Summary of Significant Accounting Policies

 

Principles of Consolidation

 

The consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries. All significant inter-company balances and transactions are eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses reported in those financial statements and the disclosure of contingent assets and liabilities at the date of the financial statements. These judgments can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company’s most critical accounting policies relate to revenue recognition; allowance for doubtful accounts; inventory; goodwill and other indefinite-life intangible assets; long-lived assets; environmental matters and other contingencies; income taxes; stock-based compensation; and purchase price allocation.

 

Cash Equivalents

 

The Company considers all highly liquid debt instruments with original maturities at the time of purchase of three months or less to be cash equivalents. Included in cash equivalents as of June 30, 2017 and June 30, 2016 is $220 and $104, respectively, of restricted cash.

 

Investments

 

The Company classifies investments in marketable securities as trading, available-for-sale or held-to-maturity at the time of purchase and periodically re-evaluates such classifications. Trading securities are carried at fair value, with unrealized holding gains and losses included in earnings. Held-to-maturity securities are recorded at cost and are adjusted for the amortization or accretion of premiums or discounts over the life of the related security. Unrealized holding gains and losses on available-for-sale securities are excluded from earnings and are reported as a separate component of accumulated other comprehensive income (loss) until realized. In determining realized gains and losses, the cost of securities sold is based on the specific identification method. Interest and dividends on the investments are accrued at the balance sheet date.

 

Inventory

 

Inventory, which consists principally of finished goods, are stated at the lower of cost (first-in first-out method) and net realizable value. The Company writes down its inventory for estimated excess and obsolete goods by an amount equal to the difference between the carrying cost of the inventory and net realizable value based upon assumptions about future demand and market conditions.

 

Environmental and Other Contingencies

 

The Company establishes accrued liabilities for environmental matters and other contingencies when it is probable that a liability has been incurred and the amount of the liability is reasonably estimable. If the contingency is resolved for an amount greater or less than the accrual, or the Company’s share of the contingency increases or decreases, or other assumptions relevant to the development of the estimate were to change, the Company would recognize an additional expense or benefit in the consolidated statements of income in the period such determination was made.

  

Pension Benefits

 

In connection with certain historical acquisitions in Germany, the Company assumed defined benefit pension plans covering certain employees who meet certain eligibility requirements. The net pension benefit obligations recorded and the related periodic costs are based on, among other things, assumptions of the discount rate, estimated return on plan assets, salary increases and the mortality of participants. The obligation for these claims and the related periodic costs are measured using actuarial techniques and assumptions. Actuarial gains and losses are deferred and amortized over future periods. The Company’s plans are funded in conformity with the funding requirements of applicable government regulations.

 

Accumulated Other Comprehensive Loss

 

The components of accumulated other comprehensive loss as of June 30, 2017 and 2016 are as follows:

 

    2017     2016  
Cumulative foreign currency translation adjustments   $ (4,340 )   $ (6,120 )
Fair value of interest rate swaps     (581 )     -  
Defined benefit plans, net of tax     (191 )     (205 )
Total   $ (5,112 )   $ (6,325 )

 

The foreign currency translation adjustments for the years ended June 30, 2017 and 2016 primarily relate to the fluctuation of the conversion rate of the Euro. The currency translation adjustments are not adjusted for income taxes as they relate to indefinite investments in non-US subsidiaries.

 

Common Stock

 

At the annual meeting of shareholders of the Company, held on December 15, 2015, the Company’s shareholders approved the proposal to amend Aceto’s Certificate of Incorporation to increase the total number of authorized shares of common stock from 40,000 shares to 75,000 shares.

 

Cash dividends of $0.065 per common share were paid in September, December, March and June of fiscal year 2017. Cash dividends of $0.06 per common share were paid in September, December, March and June of fiscal years 2016 and 2015. On August 24, 2017, the Company's board of directors declared a regular quarterly dividend of $0.065 per share to be distributed on September 21, 2017 to shareholders of record as of September 8, 2017.

 

On May 4, 2017, the Board of Directors of the Company authorized the continuation of the Company’s stock repurchase program, expiring in May 2020. Under the stock repurchase program, the Company is authorized to purchase up to 5,000 shares of common stock in open market or private transactions, at prices not to exceed the market value of the common stock at the time of such purchase. The Company did not repurchase shares in fiscal 2017 or fiscal 2016.

 

The Board of Directors has authority under the Company’s Restated Certificate of Incorporation to issue shares of preferred stock with voting and other relative rights to be determined by the Board of Directors.

  

Stock-based Compensation

 

GAAP requires that all stock-based compensation be recognized as an expense in the financial statements and that such costs be measured at the fair value of the award. GAAP also requires that excess tax benefits related to stock option exercises be reflected as financing cash inflows.

 

All restricted stock grants include a service requirement for vesting. The Company has also granted restricted stock units that include either a performance or market condition. The fair value of restricted stock unit with either solely a service requirement or with the combination of service and performance requirements is based on the closing fair market value of Aceto’s common stock on the date of grant. The fair value of market condition-based awards is estimated at the date of grant using a binomial lattice model or Monte Carlo Simulation. All models incorporate various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the awards. Stock-based compensation expense is recognized on a straight-line basis over the service period or over our best estimate of the period over which the performance condition will be met, as applicable.

 

Revenue Recognition

 

The Company recognizes revenue from product sales at the time of shipment and passage of title and risk of loss to the customer. The Company has no acceptance or other post-shipment obligations and does not offer product warranties or services to its customers.

 

Sales are recorded net of estimated returns of damaged goods from customers, which historically have been immaterial, and sales incentives offered to customers. Sales incentives include volume incentive rebates. The Company records volume incentive rebates based on the underlying revenue transactions that result in progress by the customer in earning the rebate.

 

The Company has arrangements with various third parties, such as drug store chains and managed care organizations, establishing prices for its finished dosage form generics. While these arrangements are made between Aceto and its customers, the customers independently select a wholesaler from which they purchase the products. Alternatively, certain wholesalers may enter into agreements with the customers, with the Company’s concurrence, which establishes the pricing for certain products which the wholesalers provide. Upon each sale of finished dosage form generics, estimates of chargebacks, rebates, returns, government reimbursed rebates, sales discounts and other adjustments are made. These estimates are based on historical experience, future expectations, contractual arrangements with wholesalers and indirect customers, and other factors known to management at the time of accrual. These estimates are recorded as reductions to gross revenues, with corresponding adjustments either as a reduction of accounts receivable or as a liability for price concessions.

 

Under certain arrangements, Rising will issue a credit (referred to as a “chargeback”) to the wholesaler for the difference between the invoice price to the wholesaler and the customer’s contract price. As sales to the large wholesale customers increase or decrease, the reserve for chargebacks will also generally increase or decrease. The provision for chargebacks varies in relation to changes in sales volume, product mix, pricing and the level of inventory at the wholesalers. The Company continually monitors the reserve for chargebacks and makes adjustments when management believes that expected chargebacks may differ from the actual chargeback reserve.

 

The Company estimates its provision for returns of finished dosage generics based on historical experience, product expiration dates, changes to business practices, credit terms and any extenuating circumstances known to management. While historical experience has allowed for reasonable estimations in the past, future returns may or may not follow historical trends. The Company continually monitors the reserve for returns and makes adjustments when management believes that actual product returns may differ from the established reserve. Generally, the reserve for returns increases as net sales increase.

 

Government rebate accruals are based on estimated payments due to governmental agencies for purchases made by third parties under various governmental programs. Other rebates are offered to the Company’s key chain drug store, distributor and wholesaler customers to promote customer loyalty and increase product sales. These rebate programs provide customers with credits upon attainment of pre-established volumes or attainment of net sales milestones for a specified period. Other promotional programs are incentive programs offered to the customers. The Company provides a provision for government reimbursed rebates and other rebates at the time of sale based on contracted rates and historical redemption rates. Assumptions used to establish the provision include level of customer inventories, contract sales mix and average contract pricing. Aceto regularly reviews the information related to these estimates and adjusts the provision accordingly.

  

Sales discount accruals are based on payment terms extended to customers.

 

The following table summarizes activity in the consolidated balance sheet for contra assets and liability for price concessions for the years ended June 30, 2017, 2016 and 2015:

 

    Accruals for Chargebacks, Rebates, Returns and Other Allowances        
            Government     Other     Sales  
    Chargebacks     Returns     Reimbursed Rebates     Rebates     Discounts  
Balance at June 30, 2014   $ 10,986     $ 20,249     $ 1,005     $ 3,630     $ 690  
Current year provision     208,965       21,403       4,259       36,923       9,381  
Credits issued during the year     (187,784 )     (10,960 )     (4,326 )     (36,218 )     (7,389 )
Balance at June 30, 2015   $ 32,167     $ 30,692     $ 938     $ 4,335     $ 2,682  
Current year provision     247,186       7,618       5,124       90,915       10,267  
Credits issued during the year     (256,638 )     (15,482 )     (4,750 )     (88,048 )     (10,526 )
Balance at June 30, 2016   $ 22,715     $ 22,828     $ 1,312     $ 7,202     $ 2,423  
 Acquisitions     23,526       1,496       4,500       28,944       2,360  
Current year provision     431,606       19,666       7,694       162,023       20,129  
Credits issued during the year     (417,928 )     (11,631 )     (4,642 )     (158,836 )     (18,875 )
Balance at June 30, 2017   $ 59,919     $ 32,359     $ 8,864     $ 39,333     $ 6,037  

 

Credits issued during a given period represent cash payments or credit memos issued to the Company’s customers as settlement for the related reserve. Management has the experience and access to relevant information that it believes is necessary to reasonably estimate the amounts of such deductions from gross revenues. The Company regularly reviews the information related to these estimates and adjusts its reserves accordingly, if and when actual experience differs from previous estimates. The Company has not experienced any significant changes in its estimates as it relates to its chargebacks, rebates or sales discounts in each of the years in the three year period ended June 30, 2017. During the year ended June 30, 2015, the Company recorded $3,497 in additional gross profit related to a change in estimate for product returns due to the most recent returns experience. The Company had not experienced any significant changes in its estimates as it relates to its product returns during the years ended June 30, 2017 and June 30, 2016.

 

Partnered Products

 

The Company has various products that are subject to one of two types of collaborative arrangements with certain pharmaceutical companies. One type of arrangement relates to the Company’s finished dosage form generics business acting strictly as a distributor and purchasing products at arm’s length; in that type of arrangement, there is no profit sharing element. The second type of collaborative arrangement results in a profit sharing agreement between the Company and a developer and/or manufacturer of a finished dosage form generic drug. Both types of collaborative arrangements are conducted in the ordinary course of Rising’s business. The nature and purpose of both of these arrangements is for the Company to act as a distributor of finished dose products to its customers.  Under these arrangements, the Company maintains distribution rights with respect to specific drugs within the U.S. marketplace.  Generally, the distribution rights are exclusive rights in the territory.  In certain arrangements, the Company is required to maintain service level minimums including, but not limited to, market share and purchase levels, in order to preserve the exclusive rights.  The Company’s accounting policy with respect to these collaborative arrangements calls for the Company to present the sales and associated costs on a gross basis, with the amounts of the shared profits earned by the pharmaceutical companies on sales of these products, if applicable, included in cost of sales in the consolidated statements of income. The shared profits are settled on a quarterly basis. For each of the fiscal years 2017, 2016 and 2015, there was approximately $54,454, $41,036 and $51,352 respectively, of shared profits included in cost of sales, related to these types of collaborative arrangements. In the case of a collaborative arrangement where the Company solely acts as a distributor and purchases product at arm’s length, the costs of those purchases are included as a cost of sales similar to any other purchase arrangement.

  

Shipping and Handling Fees and Costs

 

All amounts billed to a customer in a sales transaction related to shipping and handling represent revenues earned and are included in net sales. The costs incurred by the Company for shipping and handling are reported as a component of cost of sales. Cost of sales also includes inbound freight, receiving, inspection, warehousing, distribution network, and customs and duty costs.

 

Net Income Per Common Share

 

Basic income per common share is based on the weighted average number of common shares outstanding during the period. Diluted income per common share includes the dilutive effect of potential common shares outstanding. The following table sets forth the reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding for the fiscal years ended June 30, 2017, 2016 and 2015:

 

    2017     2016     2015  
                   
Weighted average shares outstanding     32,283       29,110       28,731  
                         
Dilutive effect of stock options and restricted stock awards and units     349       471       516  
                         
Diluted weighted average shares outstanding     32,632       29,581       29,247  

 

The Convertible Senior Notes (see Note 9) will only be included in the dilutive net income per share calculations using the treasury stock method during periods in which the average market price of Aceto’s common stock is above the applicable conversion price of the Convertible Senior Notes, or $33.215 per share, and the impact would not be anti-dilutive.

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

 

Property and Equipment

 

Property and equipment are stated at cost and are depreciated using the straight line method over the estimated useful lives of the related asset. The Company allocates depreciation and amortization to cost of sales. Expenditures for improvements that extend the useful life of an asset are capitalized. Ordinary repairs and maintenance are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any related gains or losses are included in income.

  

The components of property and equipment were as follows:

 

    June 30, 2017     June 30, 2016     Estimated useful
life (years)
Machinery and equipment   $ 398     $ 405     3-7
Leasehold improvements     979       1,056     Shorter of asset life or lease term
Computer equipment and software     7,255       6,048     3-5
Furniture and fixtures     2,094       2,365     5-10
Automobiles     184       184     3
Building     8,678       8,690     20
Land     1,967       1,960     -
      21,555       20,708      
Accumulated depreciation and amortization     11,127       10,664      
    $ 10,428     $ 10,044      

 

Property held for sale represents land and land improvements of $7,152 and $6,868 at June 30, 2017 and 2016, respectively. See Note 8, “Environmental Remediation” for further discussion on property held for sale.

 

Depreciation and amortization of property and equipment amounted to $1,520, $1,522 and $1,571 for the years ended June 30, 2017, 2016, and 2015 respectively.

 

Goodwill and Other Intangibles

 

Goodwill is calculated as the excess of the cost of purchased businesses over the fair value of their underlying net assets. Other intangible assets principally consist of customer relationships, license agreements, technology-based intangibles, EPA registrations and related data, trademarks and product rights and related intangibles. Goodwill and other intangible assets that have an indefinite life are not amortized.

 

In accordance with GAAP, the Company tests goodwill and other indefinite life intangible assets for impairment on at least an annual basis. Goodwill impairment exists if the net book value of a reporting unit exceeds its estimated fair value. Initially, an assessment of qualitative factors is conducted in order to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company determines that it is more likely than not that its carrying amount is greater than its fair value for a reporting unit, then it proceeds with the subsequent two-step process: (i) the Company determines impairment by comparing the fair value of a reporting unit with its carrying value, and (ii) if there is an impairment, the Company measures the amount of impairment loss by comparing the implied fair value of goodwill with the carrying amount of that goodwill. To determine the fair value of these intangible assets, the Company uses many assumptions and estimates using a market participant approach that directly impact the results of the testing. In making these assumptions and estimates, the Company uses industry accepted valuation models and set criteria that are reviewed and approved by various levels of management. The Company has the option to bypass the initial qualitative assessment stage and proceed directly to perform step one of the two-step process. In fiscal 2017, the Company performed step one of the two-step process and in fiscal 2016 the Company performed a qualitative assessment. There was no impairment of goodwill and other intangible assets in fiscal 2017 and fiscal 2016.

  

Impairment of Long-Lived Assets and Long-Lived Assets to be Disposed of

 

Long-lived assets and certain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability of assets held for sale is measured by comparing the carrying amount of the assets to their estimated fair value. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceed the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.

 

Accounting for Derivatives and Hedging Activities

 

The Company accounts for derivatives and hedging activities under the provisions of GAAP which establishes accounting and reporting guidelines for derivative instruments and hedging activities. GAAP requires the recognition of all derivative financial instruments as either assets or liabilities in the statement of financial condition and measurement of those instruments at fair value. Changes in the fair values of those derivatives are reported in earnings or other comprehensive income depending on the designation of the derivative and whether it qualifies for hedge accounting. The accounting for gains and losses associated with changes in the fair value of a derivative and the effect on the consolidated financial statements depends on its hedge designation and whether the hedge is highly effective in achieving offsetting changes in the fair value or cash flows of the asset or liability hedged. The method that is used for assessing the effectiveness of a hedging derivative, as well as the measurement approach for determining the ineffective aspects of the hedge, is established at the inception of the hedged instrument.

 

The Company operates internationally, therefore its earnings, cash flows and financial positions are exposed to foreign currency risk from foreign-currency-denominated receivables and payables, which, in the U.S., have been denominated in various foreign currencies, including, among others, Euros, British Pounds, Japanese Yen, Singapore Dollars and Chinese Renminbi and at certain foreign subsidiaries in U.S. dollars and other non-local currencies.

 

Management believes it is prudent to minimize the risk caused by foreign currency fluctuation. Management minimizes the currency risk on its foreign currency receivables and payables by purchasing foreign currency contracts (futures) with one of its financial institutions. Futures are traded on regulated U.S. and international exchanges and represent commitments to purchase or sell a particular foreign currency at a future date and at a specific price. Since futures are purchased for the amount of the foreign currency receivable or for the amount of foreign currency needed to pay for specific purchase orders, and the futures mature on the due date of the related foreign currency vendor invoices or customer receivables, the Company believes that it eliminates risks relating to foreign currency fluctuation. The Company takes delivery of all futures to pay suppliers in the appropriate currency. The gains or losses for the changes in the fair value of the foreign currency contracts are recorded in cost of sales (sales) and offset the gains or losses associated with the impact of changes in foreign exchange rates on trade payables (receivables) denominated in foreign currencies. Senior management and members of the financial department continually monitor foreign currency risks and the use of this derivative instrument.

 

In conjunction with its existing credit agreement (see Note 9), the Company entered into an interest rate swap on March 21, 2017 for an additional interest cost of 2.005% on a notional amount of $100,000, which has been designated as a cash flow hedge. The expiration date of this interest rate swap is December 21, 2021.

 

Foreign Currency

 

The financial statements of the Company’s foreign subsidiaries are translated into U.S. dollars in accordance with GAAP. Where the functional currency of a foreign subsidiary is its local currency, balance sheet accounts are translated at the current exchange rate and income statement items are translated at the average exchange rate for the period. Exchange gains or losses resulting from the translation of financial statements of foreign operations are accumulated in other comprehensive income. Where the local currency of a foreign subsidiary is not its functional currency, financial statements are translated at either current or historical exchange rates, as appropriate.
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business Combinations
 12 Months Ended
Jun. 30, 2017
Business Combinations [Abstract]  
Business Combinations

(3) Business Combinations

 

On December 21, 2016, wholly owned subsidiaries of Rising Pharmaceuticals, Inc. (“Rising”), a wholly owned subsidiary of Aceto, completed the acquisition of certain generic products and related assets of entities formerly known as Citron Pharma LLC (“Citron”) and its affiliate Lucid Pharma LLC (“Lucid”). Rising formed two subsidiaries to consummate the product acquisition – Rising Health, LLC (“Rising Health”) (which acquired certain products and related assets of Citron) and Acetris Health, LLC (“Acetris Health”) (which acquired certain products and related assets of Lucid). Citron is a privately-held New Jersey-based pharmaceutical company focused on developing and marketing generic pharmaceutical products in partnership with leading generic pharmaceutical manufacturers based in India and the United States. Lucid is a privately-held New Jersey-based generic pharmaceutical distributor specializing in providing cost-effective products to various agencies of the U.S. Federal Government including the Veterans Administration and the Defense Logistics Agency. Lucid services 18 national contracts with the Federal Government, nearly all of which have 5-year terms.

 

Aceto and Rising Health possess complementary asset-light business models, drug development and manufacturing partnerships and product portfolios. The Company believes, consistent with its strategy of expanding Rising’s portfolio of finished dosage form generic products through product development partnerships and acquisitions of late stage assets, abbreviated new drug applications (“ANDAs”) and complementary generic drug businesses, this transaction significantly expanded its roster of commercialized products and pipeline of products under development. The Company believes the acquired assets meet the definition of a business. In addition, the Company believes that this product acquisition greatly enhances its size and stature within the generic pharmaceutical industry, expands its partnership network and offers the Company opportunities to realize meaningful cost and tax efficiencies.

 

At closing, Aceto paid the sellers $270,000 in cash, committed to make a $50,000 unsecured deferred payment that will bear interest at a rate of 5% per annum to the sellers on December 21, 2021 and agreed to issue 5,122 shares of Aceto common stock beginning on December 21, 2019. The product purchase agreement also provides the sellers with a 5-year potential earn-out of up to an additional $50,000 in cash, based on the financial performance of four pre-specified pipeline products that are currently in development. As of June 30, 2017, the Company accrued $2,807 related to this contingent consideration.

 

The product acquisition was accounted for using the purchase method of accounting. The following table summarizes the allocation of the preliminary purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of December 21, 2016:

 

Trade receivables   $ 78,937  
Inventory     38,995  
Prepaid expenses and other current assets     1,425  
Goodwill     169,071  
Intangible assets     224,850  
Total assets acquired     513,278  
         
Accounts payable     46,840  
Accrued expenses     53,458  
Deferred payment     50,000  
Contingent consideration     2,580  
         
Net assets acquired   $ 360,400  

  

The fair values of the net assets acquired were determined using discounted cash flow analyses and estimates made by management. The preliminary purchase price was allocated to intangible assets as follows: approximately $169,071 to goodwill, which is nonamortizable under generally accepted accounting principles and is deductible for income tax purposes; approximately $135,700 of product rights, amortizable over a period of approximately ten years; approximately $88,800 of customer relationships, amortizable over approximately eleven years; and approximately $350 of trademarks, amortizable over a period of approximately six months. Amortization of the acquired intangible assets is deductible for income tax purposes. Goodwill represents the excess of the preliminary purchase price paid over the fair value of the underlying net assets acquired and was allocated to the Human Health Segment.

 

As part of the product acquisition, the Company entered into an Administrative Services Agreement with the sellers in which excess cash payments may be made by either of the parties in connection with certain liabilities assumed upon the closing of the transaction related to rebates, chargebacks, commercial rebates and Medicaid and other government rebates. As of the closing date, the Company is responsible for the processing and administration of these related adjustments to sales completed prior to the closing date. In general, (i) if the amounts reserved for these liabilities underestimate the amounts that the Company is required to pay with respect to these items, the sellers will be required to reimburse the Company for the difference and (ii) if the amounts reserved for these liabilities overestimate the amounts that the Company is required to pay, the Company will be required to reimburse the sellers for the difference. Settlement is to be made two years after the closing date of December 21, 2016.

 

For the period from December 22, 2016 to June 30, 2017, net sales and income before income taxes from the product acquisition was approximately $122,118 and $7,437, respectively, which have been included in the Consolidated Statement of Income for the year ended June 30, 2017. The following represents unaudited pro forma operating results as if the operations of Rising Health and Acetris Health had been included in the Company’s consolidated statements of operations as of July 1, 2015.

 

    Year ended  
    June 30,  
    2017     2016  
             
Net sales   $ 739,318     $ 731,100  
Net income     24,166       30,469  
Net income per common share   $ 0.70     $ 0.89  
Diluted net income per common share   $ 0.69     $ 0.88  

 

The pro forma financial information includes business combination accounting effects from the product acquisition including amortization charges from acquired intangible assets of approximately $21,000 for both periods presented, increase in interest expense of approximately $13,200 for both periods presented associated with bank borrowings to fund the product acquisition and interest expense associated with the deferred payment to the sellers, $4,502 step-up in the fair value of the acquired inventory in the year ended June 30, 2016, reversal of acquisition related transaction costs of $8,818 and tax related effects in both periods. The unaudited pro forma information as presented above is for informational purposes only and is not indicative of the results of operations that would have been achieved if the product acquisition had taken place at the beginning of fiscal 2016.
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.7.0.1
Investments
 12 Months Ended
Jun. 30, 2017
Investments Debt And Equity Securities [Abstract]  
Investments

(4) Investments

 

A summary of short-term investments was as follows:

 

    June 30, 2017     June 30, 2016  
Held to Maturity Investments            
Time deposits   $ 2,046     $ 881  

 

Short-term investments consist of time deposits that the Company classifies as held-to- maturity and are recorded at cost plus accumulated interest. The Company has classified all investments with maturity dates of greater than three months as current since it has the ability to redeem them within the year and amounts are available for current operations.
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.7.0.1
Fair Value Measurements
 12 Months Ended
Jun. 30, 2017
Fair Value Disclosures [Abstract]  
Fair Value Measurements

(5) Fair Value Measurements

 

GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly fashion between market participants at the measurement date. GAAP establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s assumptions (unobservable inputs). The hierarchy consists of three levels:

 

Level 1 – Quoted market prices in active markets for identical assets or liabilities;

 

Level 2 – Inputs other than Level 1 inputs that are either directly or indirectly observable; and

 

Level 3 – Unobservable inputs that are not corroborated by market data.

 

On a recurring basis, Aceto measures at fair value certain financial assets and liabilities, which consist of cash equivalents, investments and foreign currency contracts. The Company classifies cash equivalents and investments within Level 1 if quoted prices are available in active markets. Level 1 assets include instruments valued based on quoted market prices in active markets which generally include corporate equity securities publicly traded on major exchanges. Time deposits are very short-term in nature and are accordingly valued at cost plus accrued interest, which approximates fair value, and are classified within Level 2 of the valuation hierarchy. The Company uses foreign currency futures contracts to minimize the risk caused by foreign currency fluctuation on its foreign currency receivables and payables by purchasing futures with one of its financial institutions. Futures are traded on regulated U.S. and international exchanges and represent commitments to purchase or sell a particular foreign currency at a future date and at a specific price. Aceto’s foreign currency derivative contracts are classified within Level 2 as the fair value of these hedges is primarily based on observable futures foreign exchange rates. At June 30, 2017, the Company had foreign currency contracts outstanding that had a notional amount of $62,187. Unrealized losses on hedging activities for the years ended June 30, 2017, 2016, and 2015, amounted to $515, $10 and $703, respectively, and are included in interest and other income, net, in the consolidated statements of income. The contracts have varying maturities of less than one year.

 

In conjunction with its existing credit agreement (see Note 9), the Company entered into an interest rate swap on March 21, 2017 for an additional interest cost of 2.005% on a notional amount of $100,000, which has been designated as a cash flow hedge. The expiration date of this interest rate swap is December 21, 2021. The remaining balance of this derivative as of June 30, 2017 is $95,000. The unrealized loss to date associated with this derivative, which is recorded in accumulated other comprehensive loss in the consolidated balance sheet at June 30, 2017, is $581. Aceto’s interest rate swaps are classified within Level 2 as the fair value of this hedge is primarily based on observable interest rates.

 

At June 30, 2017, the Company had $2,952 of contingent consideration, $2,807 of which related to the acquisition of certain products and related assets of Citron and Lucid, which was completed in December 2016 (see Note 3) and $145 of contingent consideration related to a previously acquired company in France. At June 30, 2016, the Company had $132 of contingent consideration related to a previously acquired company in France. The contingent consideration was calculated using the present value of a probability weighted income approach.

 

During the fourth quarter of each year, the Company evaluates goodwill for impairment at the reporting unit level using a market participant approach using Level 3 inputs. Additionally, on a nonrecurring basis, the Company uses fair value measures when analyzing asset impairment.

 

Changes in contingent consideration during 2017 and 2016 are as follows:

 

Balance as of June 30, 2015   $ 2,622  
Reversal of fair value of liability-PACK     (833 )
Reversal of fair value of liability-France     (241 )
Payments     (1,500 )
Accrued interest expense     85  
Change in foreign currency exchange rate     (1 )
Balance as of June 30, 2016   $ 132  
Acquisitions     2,580  
Accrued interest expense     237  
Change in foreign currency exchange rate     3  
Balance as of June 30, 2017   $ 2,952  

 

Long-lived assets and certain identifiable intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  If it is determined such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization periods, their carrying values are reduced to estimated fair value.  Measurements based on undiscounted cash flows are considered to be Level 3 inputs.

 

In November 2015, the Company issued $143,750 aggregate principal amount of Notes (see Note 9). Since Aceto has the option to settle the potential conversion of the Notes in cash, the Company separated the embedded conversion option feature from the debt feature and accounts for each component separately, based on the fair value of the debt component assuming no conversion option. The calculation of the fair value of the debt component required the use of Level 3 inputs, and was determined by calculating the fair value of similar non-convertible debt, using a theoretical borrowing rate of 6.5%. The value of the embedded conversion option was determined using an expected present value technique (income approach) to estimate the fair value of similar non-convertible debt and included utilization of convertible investors’ credit assumptions and high yield bond indices. The carrying amount of the Notes approximate a fair value of $133,000 at June 30, 2017 and $134,400 at June 30, 2016 giving effect for certain factors, including the term of the Notes, current stock price of Aceto stock and effective interest rate. A portion of the offering proceeds was used to simultaneously enter into privately negotiated convertible note hedge transactions with option counterparties, which are affiliates of certain of the initial purchasers in the offering of the Notes and privately negotiated warrant transactions with the option counterparties (see Note 9). The Company calculated the fair value of the bond hedge based on the price that was paid to purchase the call. The Company also calculated the fair value of the warrant based on the price at which the affiliate purchased the warrants from the Company. Since the convertible note hedge and warrant are both indexed to the Company’s common stock and otherwise would be classified as equity, Aceto recorded both elements as equity, resulting in a net reduction to capital in excess of par value of $13,489.

 

The carrying values of all financial instruments classified as a current asset or current liability are deemed to approximate fair value because of the short maturity of these instruments. The fair values of the Company’s notes receivable and short-term and long-term bank loans were based upon current rates offered for similar financial instruments to the Company.

 

The following tables summarize the valuation of the Company’s financial assets and liabilities which were determined by using the following inputs at June 30, 2017 and 2016:

 

    Fair Value Measurements at June 30, 2017 Using  
    Quoted Prices
in Active
Markets
(Level 1)		     Significant
Other
Observable
Inputs
(Level 2)		     Significant
Unobservable
Inputs
(Level 3)		     Total  
Cash equivalents:                                
Time deposits     -     $ 5,781       -     $ 5,781  
Investments:                                
Time deposits     -       2,046       -       2,046  
                                 
Foreign currency contracts-assets (1)     -       486       -       486  
Foreign currency contracts-liabilities (2)     -       137       -       137  
Derivative liability for interest rate swap(3)             581               581  
Contingent consideration (4)     -       -     $ 2,952       2,952  

 

(1) Included in “Other receivables” in the accompanying Consolidated Balance Sheet as of June 30, 2017.
(2) Included in “Accrued expenses” in the accompanying Consolidated Balance Sheet as of June 30, 2017.
(3) Included in “Long-term liabilities” in the accompanying Consolidated Balance Sheet as of June 30, 2017.
(4) $145 included in “Accrued expenses” and $2,807 included in “Long-term liabilities” in the accompanying Consolidated Balance Sheet as of June 30, 2017.

 

    Fair Value Measurements at June 30, 2016 Using  
    Quoted Prices
in Active
Markets
(Level 1)		     Significant
Other
Observable
Inputs
(Level 2)		     Significant
Unobservable
Inputs
(Level 3)		     Total  
Cash equivalents:                                
Time deposits     -     $ 6,249       -     $ 6,249  
Investments:                                
Time deposits     -       881       -       881  
                                 
Foreign currency contracts-assets (5)     -       160       -       160  
Foreign currency contracts-liabilities (6)     -       169       -       169  
Contingent consideration (7)     -       -     $ 132       132  

 

(5) Included in “Other receivables” in the accompanying Consolidated Balance Sheet as of June 30, 2016.
(6) Included in “Accrued expenses” in the accompanying Consolidated Balance Sheet as of June 30, 2016.
(7) Included in “Long-term liabilities” in the accompanying Consolidated Balance Sheet as of June 30, 2016.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.7.0.1
Goodwill and Other Intangible Assets
 12 Months Ended
Jun. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets

(6) Goodwill and Other Intangible Assets

 

As of June 30, 2017 and June 30, 2016, there was goodwill of $236,970 and $67,871, respectively.

 

Changes in the Company's goodwill during 2017 and 2016 are as follows:

 

    Human
Health
Segment		     Pharmaceutical
Ingredients
Segment		     Performance
Chemicals
Segment		     Total
Goodwill		  
Balance as of June 30, 2015   $ 66,039     $ 1,650     $ 181     $ 67,870  
Changes in foreign currency exchange rates     -       1       -       1  
Balance as of June 30, 2016     66,039       1,651       181       67,871  
Acquisitions     169,071       -       -       169,071  
Changes in foreign currency exchange rates     -       23       5       28  
Balance as of June 30, 2017   $ 235,110     $ 1,674     $ 186     $ 236,970  

 

Intangible assets subject to amortization as of June 30, 2017 and 2016 were as follows:

 

    Gross
Carrying
Value		     Accumulated
Amortization		     Net Book
Value		  
June 30, 2017                        
Customer relationships   $ 110,787     $ 13,968     $ 96,819  
Trademarks     2,218       2,195       23  
Product rights and related intangibles     221,335       37,677       183,658  
License agreements     6,537       6,035       502  
EPA registrations and related data     14,307       11,011       3,296  
    $ 355,184     $ 70,886     $ 284,298  

 

    Gross
Carrying
Value		     Accumulated
Amortization		     Net Book
Value		  
June 30, 2016                        
Customer relationships   $ 21,761     $ 7,815     $ 13,946  
Trademarks     1,868       1,800       68  
Product rights and related intangibles     83,048       23,511       59,537  
License agreements     6,611       5,531       1,080  
EPA registrations and related data     13,591       9,927       3,664  
Technology-based intangibles     155       140       15  
    $ 127,034     $ 48,724     $ 78,310  

 

Intangible assets with definitive useful lives are amortized using the straight-line method over their estimated useful lives. The straight-line method is utilized as it best reflects the use of the asset. The estimated useful lives of customer relationships, trademarks, product rights and related intangibles, license agreements and EPA registrations are 7-11 years, 3-4 years, 3-14 years, 6-11 years and 10 years respectively.

 

As of June 30, 2017 and June 30, 2016, the Company also had $783 and $761, respectively, of intangible assets pertaining to trademarks which have indefinite lives and are not subject to amortization. The change in trademarks with indefinite lives is attributable to foreign currency exchange rates used to translate the financial statements of foreign subsidiaries.

  

Amortization expense for intangible assets subject to amortization amounted to $22,234, $11,176 and $10,278 for the years ended June 30, 2017, 2016 and 2015, respectively. The estimated aggregate amortization expense for intangible assets subject to amortization for each of the succeeding years ending June 30, 2018 through June 30, 2023 are as follows: 2018: $16,747; 2019: $32,431; 2020: $31,880; 2021: $31,819; 2022: $31,782 and 2023 and thereafter: $139,639.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.7.0.1
Accrued Expenses
 12 Months Ended
Jun. 30, 2017
Payables And Accruals [Abstract]  
Accrued Expenses

(7) Accrued Expenses

 

The components of accrued expenses as of June 30, 2017 and 2016 were as follows:

 

    2017     2016  
Accrued compensation   $ 5,793     $ 6,880  
Accrued environmental remediation costs-current portion     6,112       9,180  
Reserve for price concessions     80,556       31,342  
Partnered product liabilities     16,068       -  
Other accrued expenses     9,799       5,273  
    $ 118,328     $ 52,675  
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.7.0.1
Environmental Remediation
 12 Months Ended
Jun. 30, 2017
Environmental Remediation Obligations [Abstract]  
Environmental Remediation

(8) Environmental Remediation

 

In fiscal years 2011, 2009, 2008 and 2007, the Company received letters from the Pulvair Site Group, a group of potentially responsible parties (PRP Group) who are working with the State of Tennessee (the State) to remediate a contaminated property in Tennessee called the Pulvair site. The PRP Group has alleged that Aceto shipped hazardous substances to the site which were released into the environment. The State had begun administrative proceedings against the members of the PRP Group and Aceto with respect to the cleanup of the Pulvair site and the PRP Group has begun to undertake cleanup. The PRP Group is seeking a settlement of approximately $1,700 from the Company for its share to remediate the site contamination. Although the Company acknowledges that it shipped materials to the site for formulation over twenty years ago, the Company believes that the evidence does not show that the hazardous materials sent by Aceto to the site have significantly contributed to the contamination of the environment and thus believes that, at most, it is a de minimis contributor to the site contamination. Accordingly, the Company believes that the settlement offer is unreasonable. Management believes that the ultimate outcome of this matter will not have a material adverse effect on the Company's financial condition or liquidity.

 

The Company has environmental remediation obligations in connection with Arsynco, Inc. (“Arsynco”), a subsidiary formerly involved in manufacturing chemicals located in Carlstadt, New Jersey, which was closed in 1993 and is currently held for sale. Based on continued monitoring of the contamination at the site and the approved plan of remediation, Arsynco received an estimate from an environmental consultant stating that the costs of remediation could be between $21,500 and $23,300. Remediation commenced in fiscal 2010, and as of June 30, 2017 and June 30, 2016, a liability of $8,451 and $12,532, respectively, is included in the accompanying consolidated balance sheets for this matter. For the year ended June 30, 2017, the Company recorded environmental remediation charges of $903, which is included in selling, general and administrative expenses in the accompanying consolidated statements of income for the year ended June 30, 2017. In accordance with GAAP, management believes that the majority of costs incurred to remediate the site will be capitalized in preparing the property which is currently classified as held for sale. An appraisal of the fair value of the property by a third-party appraiser supports the assumption that the expected fair value after the remediation is in excess of the amount required to be capitalized. However, these matters, if resolved in a manner different from those assumed in current estimates, could have a material adverse effect on the Company’s financial condition, operating results and cash flows when resolved in a future reporting period.

 

In connection with the environmental remediation obligation for Arsynco, in July 2009, Arsynco entered into a settlement agreement with BASF Corporation (“BASF”), the former owners of the Arsynco property. In accordance with the settlement agreement, BASF paid for a portion of the prior remediation costs and going forward, will co-remediate the property with the Company. The contract requires that BASF pay $550 related to past response costs and pay a proportionate share of the future remediation costs. Accordingly, the Company had recorded a gain of $550 in fiscal 2009. This $550 gain relates to the partial reimbursement of costs of approximately $1,200 that the Company had previously expensed. The Company also recorded an additional receivable from BASF, with an offset against property held for sale, representing its estimated portion of the future remediation costs. The balance of this receivable for future remediation costs as of June 30, 2017 and June 30, 2016 is $3,803 and $5,639, respectively, which is included in the accompanying consolidated balance sheets.

 

In March 2006, Arsynco received notice from the EPA of its status as a PRP under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) for a site described as the Berry’s Creek Study Area (“BCSA”). Arsynco is one of over 150 PRPs which have potential liability for the required investigation and remediation of the site. The estimate of the potential liability is not quantifiable for a number of reasons, including the difficulty in determining the extent of contamination and the length of time remediation may require. In addition, any estimate of liability must also consider the number of other PRPs and their financial strength. In July 2014, Arsynco received notice from the U.S. Department of Interior (“USDOI”) regarding the USDOI’s intent to perform a Natural Resource Damage (NRD) Assessment at the BCSA. Arsynco has to date declined to participate in the development and performance of the NRD assessment process. Based on prior practice in similar situations, it is possible that the State may assert a claim for natural resource damages with respect to the Arsynco site itself, and either the federal government or the State (or both) may assert claims against Arsynco for natural resource damages in connection with Berry's Creek; any such claim with respect to Berry's Creek could also be asserted against the approximately 150 PRPs which the EPA has identified in connection with that site. Any claim for natural resource damages with respect to the Arsynco site itself may also be asserted against BASF, the former owners of the Arsynco property. In September 2012, Arsynco entered into an agreement with three of the other PRPs that had previously been impleaded into New Jersey Department of Environmental Protection, et al. v. Occidental Chemical Corporation, et al., Docket No. ESX-L-9868-05 (the "NJDEP Litigation") and were considering impleading Arsynco into the same proceeding. Arsynco entered into an agreement to avoid impleader. Pursuant to the agreement, Arsynco agreed to (1) a tolling period that would not be included when computing the running of any statute of limitations that might provide a defense to the NJDEP Litigation; (2) the waiver of certain issue preclusion defenses in the NJDEP Litigation; and (3) arbitration of certain potential future liability allocation claims if the other parties to the agreement are barred by a court of competent jurisdiction from proceeding against Arsynco. In July 2015, Arsynco was contacted by an allocation consultant retained by a group of the named PRPs, inviting Arsynco to participate in the allocation among the PRPs’ investigation and remediation costs relating to the BCSA. Arsynco declined that invitation. Since an amount of the liability cannot be reasonably estimated at this time, no accrual is recorded for these potential future costs. The impact of the resolution of this matter on the Company’s results of operations in a particular reporting period is not currently known.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.7.0.1
Debt
 12 Months Ended
Jun. 30, 2017
Debt Disclosure [Abstract]  
Debt

(9) Debt

 

Long-term debt

 

    June 30,  
    2017     2016  
             
Convertible Senior Notes, net   $ 121,676     $ 115,829  
Revolving bank loans     90,000       -  
Term bank loans     139,227       -  
Mortgage     2,763       2,960  
      353,666       118,789  
Less current portion     14,466       197  
    $ 339,200     $ 118,592  

 

Convertible Senior Notes

 

In November 2015, Aceto offered $125,000 aggregate principal amount of Convertible Senior Notes due 2020 (the "Notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In addition, Aceto granted the initial purchasers for the offering an option to purchase up to an additional $18,750 aggregate principal amount pursuant to the initial purchasers’ option to purchase additional Notes, which was exercised in November 2015. Therefore the total offering was $143,750 aggregate principal amount. The Notes are unsecured obligations of Aceto and rank senior in right of payment to any of Aceto’s subordinated indebtedness, equal in right of payment to all of Aceto’s unsecured indebtedness that is not subordinated, effectively junior in right of payment to any of Aceto’s secured indebtedness to the extent of the value of the assets securing such indebtedness and structurally junior in right of payment to all indebtedness and other liabilities (including trade payables) of Aceto’s subsidiaries. The Notes will be convertible into cash, shares of Aceto common stock or a combination thereof, at Aceto’s election, upon the satisfaction of specified conditions and during certain periods. The Notes will mature in November 2020. The Notes pay 2.0% interest semi-annually in arrears on May 1 and November 1 of each year, which commenced on May 1, 2016. The Notes are convertible into 4,328 shares of common stock, based on an initial conversion price of $33.215 per share.

  

Holders may convert all or any portion of their notes, in multiples of one thousand dollar principal amount, at their option at any time prior to the close of business on the business day immediately preceding May 1, 2020 only under the following circumstances: (i) during any calendar quarter (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, (ii) during the five consecutive business day period after any five consecutive trading day period (which is referred to as the “measurement period”) in which the trading price per one thousand dollar principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of Aceto’s common stock and the conversion rate on each such trading day; or (iii) upon the occurrence of specified corporate events.

 

Upon conversion by the holders, the Company may elect to settle such conversion in shares of its common stock, cash, or a combination thereof. As a result of its cash conversion option, the Company separately accounted for the value of the embedded conversion option as a debt discount (with an offset to capital in excess of par value). The debt discount is being amortized as additional non-cash interest expense using the effective interest method over the term of the Notes. Debt issuance costs are being amortized as additional non-cash interest expense. The Company presents debt issuance costs as a direct deduction from the carrying value of the debt liability rather than showing the debt issuance costs as a deferred charge on the balance sheet.

 

In connection with the offering of the Notes, Aceto entered into privately negotiated convertible note hedge transactions with option counterparties, which are affiliates of certain of the initial purchasers. The convertible note hedge transactions are expected generally to reduce the potential dilution to Aceto’s common stock and/or offset any cash payments Aceto is required to make in excess of the principal amount of converted Notes upon any conversion of Notes. Aceto also entered into privately negotiated warrant transactions with the option counterparties. The warrant transactions could separately have a dilutive effect to the extent that the market price per share of Aceto’s common stock as measured over the applicable valuation period at the maturity of the warrants exceeds the applicable strike price of the warrants. By entering into these transactions with the option counterparties, the Company issued convertible debt and a freestanding “call-spread.”

 

The carrying value of the Notes is as follows:

 

    June 30,
2017		     June 30,
2016		  
             
Principal amount   $ 143,750     $ 143,750  
Unamortized debt discount     (19,255 )     (24,267 )
Unamortized debt issuance costs     (2,819 )     (3,654 )
Net carrying value   $ 121,676     $ 115,829  

  

The following table sets forth the components of total “interest expense” related to the Notes recognized in the accompanying consolidated statements of income for the year ended June 30:

 

    2017     2016  
             
Contractual coupon   $ 2,867     $ 1,788  
Amortization of debt discount     5,012       2,974  
Amortization of debt issuance costs     835       522  
    $ 8,714     $ 5,284  

 

Credit Facilities

 

On December 21, 2016 the Company entered into a Second Amended and Restated Credit Agreement (the “A&R Credit Agreement”), with eleven banks, which amended and restated in its entirety the Amended and Restated Credit Agreement, dated as of October 28, 2015, as amended by Amendment No. 1 to Amended and Restated Credit Agreement, dated as of November 10, 2015, and Amendment No. 2 to Amended and Restated Credit Agreement, dated as of August 26, 2016 (collectively, the “First Amended Credit Agreement”). The A&R Credit Agreement increases the aggregate available revolving commitment under the First Amended Credit Agreement from $150,000 to an initial aggregate available revolving commitment of $225,000 (the “Initial Revolving Commitment”). Under the A&R Credit Agreement, the Company may borrow, repay and reborrow from and as of December 21, 2016, to but excluding December 21, 2021 (the “Maturity Date”) provided, that if any of the Notes remain outstanding on the date that is 91 days prior to the maturity date of the Notes (the “2015 Convertible Maturity Date”), then the Maturity Date shall mean the date that is 91 days prior to the 2015 Convertible Maturity Date. The A&R Credit Agreement provides for (i) Eurodollar Loans (as such terms are defined in the A&R Credit Agreement), (ii) ABR Loans (as such terms are defined in the A&R Credit Agreement) or (iii) a combination thereof. As of June 30, 2017, the Company borrowed Revolving Loans aggregating $90,000 which loans are Eurodollar Loans at interest rates ranging from 3.21% to 3.45 % at June 30, 2017. The applicable interest rate margin percentage is subject to adjustment quarterly based upon the Company’s senior secured net leverage ratio.

 

Under the A&R Credit Agreement, the Company also borrowed $150,000 in term loans (the “Initial Term Loan). Subject to certain conditions, including obtaining commitments from existing or prospective lenders, the Company will have the right to increase the amount of the Initial Revolving Commitment (each, a “Revolving Facility Increase” and, together with the Initial Revolving Commitment, the “Revolving Commitment”) and/or the Initial Term Loan in an aggregate amount not to exceed $100,000 pursuant to an incremental loan feature in the A&R Credit Agreement. As of June 30, 2017, the remaining amount outstanding under the Initial Term Loan is $142,500 and is payable as a Eurodollar Loan at an interest rate of 3.30%. The proceeds of the Initial Revolving Commitment and Initial Term Loan have been used to partially finance the acquisition of generic products and related assets of Citron and its affiliate Lucid, and pay fees and expenses related thereto. The applicable interest rate margin percentage is subject to adjustment quarterly based upon the Company’s senior secured net leverage ratio.

 

The Initial Term Loan is payable as to principal in nineteen consecutive, equal quarterly installments of $3,750, which commenced on March 31, 2017 and will continue on each March 31, June 30, September 30 and December 31 thereafter. To the extent not previously paid, the final payment on the Term Loan Maturity Date (as defined in the A&R Credit Agreement) shall be in an amount equal to the then outstanding unpaid principal amount of the Initial Term Loan.

 

As such, the Company has classified $15,000 of the Initial Term Loan as short-term in the consolidated balance sheet at June 30, 2017. The A&R Credit Agreement, similar to the First Amended Credit Agreement, provides that commercial letters of credit shall be issued to provide the primary payment mechanism in connection with the purchase of any materials, goods or services in the ordinary course of business. The Company had no open letters of credit at June 30, 2017 and June 30, 2016.

 

In accordance with generally accepted accounting principles, $3,659 of deferred financing costs associated with the Initial Term Loan are presented as a direct deduction from the carrying value of the debt liability rather than showing the deferred financing costs as a deferred charge on the balance sheet. In addition, deferred financing costs of $1,748 associated with the Revolving Commitment have been recorded as a deferred charge on the balance sheet.

  

The A&R Credit Agreement, like the First Amended Credit Agreement, provides for a security interest in substantially all of the personal property of the Company and certain of its subsidiaries. The A&R Credit Agreement contains several financial covenants including, among other things, maintaining a minimum level of debt service and certain leverage ratios. Under the A&R Credit Agreement, the Company and its subsidiaries are also subject to certain restrictive covenants, including, among other things, covenants governing liens, limitations on indebtedness, limitations on guarantees, limitations on sales of assets and sales of receivables, and limitations on loans and investments. The Company was in compliance with all covenants at June 30, 2017.

 

The Company has available lines of credit with foreign financial institutions. At June 30, 2017, the Company had available lines of credit with foreign financial institutions totaling $7,351. At June 30, 2016, the Company had available lines of credit with foreign financial institutions totaling $7,397. The Company has issued a cross corporate guarantee to the foreign banks. Short term loans under these agreements bear interest at a fixed rate of 4.5% at June 30, 2017 and June 30, 2016 and 5.0% at June 30, 2015. The Company is not subject to any financial covenants under these arrangements.

 

Under the above financing arrangements, the Company had $232,500 in bank loans and $1,737 in standby letters of credit, leaving an unused facility of $140,613 at June 30, 2017. At June 30, 2016 the Company had $0 in bank loans and $1,758 in standby letters of credit leaving an unused facility of $155,639.

 

Mortgage

 

On June 30, 2011, the Company entered into a mortgage payable for $3,947 on its new corporate headquarters, in Port Washington, New York. This mortgage payable is secured by the land and building and is being amortized over a period of 20 years. The mortgage payable, which was modified in October 2013, bears interest at 4.92% as of June 30, 2017 and matures on June 30, 2021.

 

Maturity of Long-term Debt

 

Long-term debt matures by fiscal year as follows:

 

2018   $ 14,466  
2019     14,466  
2020     14,466  
2021     138,115  
2022     172,153  
Thereafter     -  
    $ 353,666  
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock Based Compensation Plans
 12 Months Ended
Jun. 30, 2017
Disclosure Of Compensation Related Costs Share based Payments [Abstract]  
Stock Based Compensation Plans

(10) Stock Based Compensation Plans

 

At the annual meeting of shareholders of the Company, held on December 15, 2015, the Company’s shareholders approved the Aceto Corporation 2015 Equity Participation Plan (the “2015 Plan”). Under the 2015 Plan, grants of stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards (“Stock Awards”) may be offered to employees, non-employee directors, consultants and advisors of the Company, including the chief executive officer, chief financial officer and other named executive officers. The maximum number of shares of common stock of the Company that may be issued pursuant to Stock Awards granted under the 2015 Plan will not exceed, in the aggregate, 4,250 shares. Stock Awards that are intended to qualify as “performance-based compensation” for purposes of Section 162(m) of the Internal Revenue Code of 1986, as amended, may be granted.  Performance-based awards may be granted, vested and paid based on the attainment of specified performance goals.

 

At the annual meeting of shareholders of the Company, held on December 6, 2012, the Company’s shareholders approved the amended and restated Aceto Corporation 2010 Equity Participation Plan (the “2010 Plan”). Under the 2010 Plan, grants of stock options, restricted stock, restricted stock units, stock appreciation rights, and stock bonuses may be made to employees, non-employee directors and consultants of the Company. The maximum number of shares of common stock of the Company that may be issued pursuant to awards granted under the 2010 Plan will not exceed, in the aggregate, 5,250 shares. In addition, restricted stock may be granted to an eligible participant in lieu of a portion of any annual cash bonus earned by such participant. Such award may include additional shares of restricted stock (premium shares) greater than the portion of bonus paid in restricted stock. The restricted stock award is vested at issuance and the restrictions lapse ratably over a period of years as determined by the Board of Directors, generally three years. The premium shares vest when all the restrictions lapse, provided that the participant remains employed by the Company at that time.

 

At the annual meeting of shareholders of the Company held December 6, 2007, the shareholders approved the Aceto Corporation 2007 Long-Term Performance Incentive Plan (the “2007 Plan”). The Company has reserved 700 shares of common stock for issuance under the 2007 Plan to the Company’s employees and non-employee directors. There are five types of awards that may be granted under the 2007 Plan-options to purchase common stock, stock appreciation rights, restricted stock, restricted stock units and performance incentive units.

 

In September 2016, the Company granted 28 performance stock options to an executive officer at an exercise price of $20.03 per share. The performance options vest if the closing stock price meets or exceeds the target price of $40 for 20 consecutive trading days prior to June 30, 2021 and the explicit service period of 1 year has been met. The options will expire June 30, 2021, if the stock price target is not achieved. If it is achieved, the options will expire ten years from the date of grant. There were no stock options granted in fiscal years 2016 or 2015.

 

As of June 30, 2017, there were 3,144, 255 and 0 shares of common stock available for grant under the 2015, 2010 and 2007 Plans, respectively.

 

In December 1998, the Company adopted the Aceto Corporation 1998 Omnibus Equity Award Plan (1998 Plan). The 1998 Plan expired in December 2008. Outstanding options survive the expiration of the 1998 Plan.

 

The following summarizes the shares of common stock under options for all plans at June 30, 2017, 2016 and 2015, and the activity with respect to options for the respective years then ended:

 

    Shares subject to
option		     Weighted average
exercise price per
share		     Aggregate
Intrinsic
Value		  
Balance at June 30, 2014     551     $ 7.72          
Granted     -       -          
Exercised     (146 )     8.74          
Forfeited (including cancelled options)     (8 )     10.94          
Balance at June 30, 2015     397     $ 7.28          
Granted     -       -          
Exercised     (95 )     7.56          
Forfeited (including cancelled options)     -       -          
Balance at June 30, 2016     302     $ 7.19          
Granted     28       20.03          
Exercised     (70 )     7.90          
Forfeited (including cancelled options)     -       -          
Balance at June 30, 2017     260     $ 8.36     $ 1,968  
Options exercisable at June 30, 2017     232     $ 6.98     $ 1,968  

 

The total intrinsic value of stock options exercised during the years ended June 30, 2017, 2016 and 2015 was approximately $865, $1,700 and $1,713, respectively. The weighted average remaining contractual life of options outstanding at June 30, 2017 was approximately 4 years. At June 30, 2017, outstanding options had expiration dates ranging from December 2017 to June 2021.

 

Under the 2015 Plan, 2010 Plan, 2002 Plan and the 1998 Plan, compensation expense is recorded for the fair value of the restricted stock awards in the year the related bonus is earned and over the vesting period for the market value at the date of grant of the premium shares granted. In fiscal 2017, 2016 and 2015, restricted stock awarded and premium shares vested of 5, 7 and 5 common shares, respectively, were issued under employee incentive plans, which increased stockholders’ equity by $109, $113 and $77, respectively. The related non-cash compensation expense related to the vesting of premium shares during the year was $26, $22 and $22 in fiscal 2017, 2016 and 2015, respectively. Additionally, non-cash compensation expense of $55, $0 and $21 was recorded in fiscal 2017, 2016 and 2015, respectively, relating to stock option grants, which is included in selling, general and administrative expenses. As of June 30, 2017, the total unrecognized compensation cost related to option awards is $95.

 

The following summarizes the non-vested stock options at June 30, 2017 and the activity with respect to non-vested options for the year ended June 30, 2017:

 

    Shares
subject to
option		     Weighted
average grant
date fair value		  
Non-vested at June 30, 2016     -       -  
Granted     28     $ 5.44  
Vested     -       -  
Forfeited     -       -  
Non-vested at June 30, 2017     28     $ 5.44  

 

The per-share fair value of stock options granted during 2017 was $5.44 on the date of the grant using a Monte Carlo simulation option-pricing model with the following assumptions:

 

    2017  
       
Expected life     4.9 years  
Expected volatility     39.4 %
Risk-free interest rate     1.26 %
Dividend yield     1.30 %

 

During the year ended June 30, 2017, the Company granted 277 shares of restricted common stock to its employees that vest over three years and 22 shares of restricted common stock to its non-employee directors, which vest over approximately one year as well as 42 restricted stock units that have varying vest dates through July 2017. In addition, the Company also issued a target grant of 160 performance-vested restricted stock units, which grant could be as much as 280 restricted stock units if certain performance criteria and market conditions are met. Performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant.

 

During the year ended June 30, 2016, the Company granted 221 shares of restricted common stock to its employees that vest over three years and 14 shares of restricted common stock to its non-employee directors, which vest over approximately one year as well as 46 restricted stock units that have varying vest dates through July 2017. In addition, the Company also issued a target grant of 142 performance-vested restricted stock units, which grant could be as much as 248 if certain performance criteria and market conditions are met. Performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant.

 

During the year ended June 30, 2015, the Company granted 165 shares of restricted common stock to its employees that vest over three years and 12 shares of restricted common stock to its non-employee directors, which vest over approximately one year as well as 67 restricted stock units that have varying vest dates through August 2016. In addition, the Company also issued a target grant of 116 performance-vested restricted stock units, which grant could be as much as 203 if certain performance criteria and market conditions are met. Performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant.

 

For the years ended June 30, 2017, 2016 and 2015, the Company recorded stock-based compensation expense of approximately $6,875, $6,697, and $4,494, respectively, which is included in selling, general and administrative expenses, for shares of restricted common stock and restricted stock units.

 

The remaining stock-based compensation expense for restricted stock awards and units is approximately $8,382 at June 30, 2017 and the related weighted average period over which it is expected that such unrecognized compensation cost will be recognized is approximately 1.8 years.

 

A summary of restricted stock awards including restricted stock units as of June 30, 2017, is presented below:

 

    Shares     Weighted
average grant
date fair value		  
Non-vested at beginning of year     795     $ 20.73  
Granted     501       18.92  
Vested     (396 )     17.26  
Forfeited     (103 )     21.33  
Non-vested at June 30, 2017     797     $ 21.24  
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.7.0.1
Interest and Other Income
 12 Months Ended
Jun. 30, 2017
Other Income And Expenses [Abstract]  
Interest and Other Income

(11) Interest and Other Income

 

Interest and other income during fiscal 2017, 2016 and 2015 was comprised of the following:

 

    2017     2016     2015  
Dividends   $ 277     $ 222     $ 233  
Interest     264       313       282  
Foreign government subsidies received     64       25       22  
Joint venture equity earnings     2,336       2,060       1,761  
Foreign currency (losses) gains     (298 )     56       (1,065 )
Deferred compensation plan losses     (257 )     (35 )     (96 )
Rental income     158       154       151  
Miscellaneous income     33       28       198  
    $ 2,577     $ 2,823     $ 1,486  

 

The Company’s joint venture earnings represent the Company’s investment in a corporate joint venture established for the purpose of selling a particular agricultural protection product. The Company’s initial investment was $6 in fiscal 2009, representing a 30% ownership and the Company accounts for this joint venture using the equity method of accounting.
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.7.0.1
Income Taxes
 12 Months Ended
Jun. 30, 2017
Income Tax Disclosure [Abstract]  
Income Taxes

(12) Income Taxes

 

The components of income before the provision for income taxes are as follows:

 

    2017     2016     2015  
Domestic operations   $ 9,555     $ 43,906     $ 48,276  
Foreign operations     7,806       9,948       5,589  
    $ 17,361     $ 53,854     $ 53,865  

  

The components of the provision for income taxes are as follows:

 

    2017     2016     2015  
Federal:                        
Current   $ 3,713     $ 15,129     $ 18,393  
Deferred     (585 )     (204 )     (1,357 )
State and local:                        
Current     555       755       1,526  
Deferred     (110 )     173       189  
Foreign:                        
Current     2,221       3,222       2,337  
Deferred     191       13       (706 )
    $ 5,985     $ 19,088     $ 20,382  

 

Income taxes payable, which is included in accrued expenses, was $64 and $2,119 at June 30, 2017 and 2016, respectively.

 

The tax effects of temporary differences that give rise to the deferred tax assets and liabilities at June 30, 2017 and 2016 are presented below:

 

    2017     2016  
Deferred tax assets:                
Accrued deferred compensation   $ 4,229     $ 4,122  
Accrual for sales deductions not currently deductible     5,796       5,925  
Additional inventoried costs for tax purposes     697       389  
Allowance for doubtful accounts receivable     106       106  
Depreciation and amortization     11,957       7,784  
Debt issuance costs     7,611       9,462  
Foreign deferred tax assets     983       1,121  
Domestic net operating loss carryforwards     81       109  
Foreign net operating loss carryforwards     692       685  
Total gross deferred tax assets     32,152       29,703  
Valuation allowances     (773 )     (794 )
      31,379       28,909  
                 
Deferred tax liabilities:                
Foreign deferred tax liabilities     (65 )     (27 )
Goodwill     (10,244 )     (7,586 )
Original issue discount – convertible senior notes     (7,260 )     (9,115 )
Other     (1,136 )     (26 )
Total gross deferred tax liabilities     (18,705 )     (16,754 )
                 
Net deferred tax assets   $ 12,674     $ 12,155  

 

The following table shows the current and non-current deferred tax assets (liabilities) at June 30, 2017 and 2016:

 

    2017     2016  
Current deferred tax assets, net   $ 546     $ 3,244  
Non-current deferred tax assets, net     19,453       18,053  
Non-current deferred tax liabilities     (7,325 )     (9,142 )
Net deferred tax assets   $ 12,674     $ 12,155  

  

The net change in the total valuation allowance for the years ended June 30, 2017 and June 30, 2016 was a decrease of $21 and $16, respectively. A valuation allowance is provided when it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The Company has established valuation allowances primarily for net operating loss carryforwards in certain foreign countries. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets are not expected to be realized. The assessment of the amount of value assigned to the Company’s deferred tax assets under the applicable accounting rules is judgmental. Management is required to consider all available positive and negative evidence in evaluating the likelihood that the Company will be able to realize the benefit of its deferred tax assets in the future. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which net operating loss carryforwards are utilizable and temporary differences become deductible. The Company has federal and state net operating loss carryforwards of $0 and $81, respectively, which will expire in fiscal year 2018. The Company has foreign net operating loss carryforwards of $692 which do not have any expiry dates. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, taxable income in carryback years if carryback is permitted and tax planning strategies in making this assessment. In order to fully realize the net deferred tax assets recognized at June 30, 2017, the Company will need to generate future taxable income of approximately $34,638.

 

Based upon the level of historical taxable income and projections for taxable income over the periods which the deferred tax assets are deductible, management believes it is more likely than not the Company will realize the benefits of these deductible differences. There can be no assurance, however, that the Company will generate any earnings or any specific level of continuing earnings in the future. The amount of the deferred tax asset considered realizable, however, could be reduced in the near term if estimates of future taxable income during the carryforward period are reduced.

 

Deferred taxes have not been provided for undistributed earnings of foreign subsidiaries amounting to approximately $111,569 at June 30, 2017 since substantially all of these earnings are expected to be indefinitely reinvested in foreign operations. A deferred tax liability will be recognized when the Company expects that it will recover these undistributed earnings in a taxable manner, such as through the receipt of dividends or sale of the investments. The Company intends to indefinitely reinvest the remaining undistributed earnings and has no plan for further repatriation. Determination of the amount of unrecognized deferred U.S. income tax liabilities, net of unrecognized foreign tax credits, is not practical to calculate because of the complexity of this hypothetical calculation resulting in various methods available, each with different U.S. tax consequences.

 

A reconciliation of the statutory federal income tax rate and the effective tax rate for continuing operations for the fiscal years ended June 30, 2017, 2016 and 2015 follows:

 

    2017     2016     2015  
Federal statutory tax rate     35.0 %     35.0 %     35.0 %
State and local taxes, net of federal income tax benefit     1.2       1.7       2.4  
Decrease (increase) in valuation allowance     0.1       -       0.4  
Foreign tax rate differential     (1.8 )     (0.4 )     (0.9 )
Other     -       (0.9 )     0.9  
Effective tax rate     34.5 %     35.4 %     37.8 %

 

The Company operates in various tax jurisdictions, and although it believes that it has provided for income and other taxes in accordance with the relevant regulations, if the applicable regulations were ultimately interpreted differently by a taxing authority, the Company may be exposed to additional tax liabilities.

 

There are no material unrecognized tax benefits included in the consolidated balance sheet that would, if recognized, have a material effect on the Company’s effective tax rate. The Company is continuing its practice of recognizing interest and penalties related to income tax matters in income tax expense. The Company did not recognize interest and penalties during the years ended June 30, 2017 and June 30, 2016. The Company files U.S. federal, U.S. state, and foreign tax returns, and is generally no longer subject to tax examinations for fiscal years prior to 2013 (in the case of certain foreign tax returns, fiscal year 2012).
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.7.0.1
Supplemental Cash Flow Information
 12 Months Ended
Jun. 30, 2017
Supplemental Cash Flow Elements [Abstract]  
Supplemental Cash Flow Information

(13) Supplemental Cash Flow Information

 

Cash paid for interest and income taxes during fiscal 2017, 2016 and 2015 was as follows:

 

    2017     2016     2015  
Interest   $ 7,794     $ 2,970     $ 3,954  
Income taxes, net of refunds   $ 7,912     $ 16,076     $ 25,459  

 

In connection with the acquisition of certain products and related assets of Citron and Lucid, approximately 5,122 shares of Aceto common stock with a fair value of $90,400, to be issued beginning on December 21, 2019, a $50,000 unsecured deferred payment payable on December 21, 2021 and a contingent earn out liability of $2,580 are non-cash items and are excluded from the Consolidated Statement of Cash Flows during the year ended June 30, 2017. In addition, the Company had non-cash items excluded from the Consolidated Statements of Cash Flows during the years ended June 30, 2017, 2016 and 2015 of $284, $294 and $726, respectively related to capitalized environmental remediation costs and property held for sale and $1,578 measurement period adjustments to goodwill during the year ended June 30, 2015.
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1
Retirement Plans
 12 Months Ended
Jun. 30, 2017
Compensation And Retirement Disclosure [Abstract]  
Retirement Plans

(14) Retirement Plans

 

Defined Contribution Plans

 

The Company has defined contribution retirement plans in which certain employees are eligible to participate, including deferred compensation plans (see below). The Company's annual contribution per employee, which is at management's discretion, is based on a percentage of the employee’s compensation. The Company's provision for these defined contribution plans amounted to $1,794, $1,957 and $1,849 in fiscal 2017, 2016 and 2015, respectively.

 

Defined Benefit Plans

 

The Company sponsors certain defined benefit pension plans covering certain employees of its German subsidiaries who meet the plan’s eligibility requirements. The accrued pension liability as of June 30, 2017 was $883. The accrued pension liability as of June 30, 2016 was $853. Net periodic pension costs, which consists principally of interest cost and service cost was $30 in fiscal 2017, $28 in fiscal 2016 and $53 in fiscal 2015. The Company’s plans are funded in conformity with the funding requirements of the applicable government regulations. An assumed weighted average discount rate of 2.0%, 1.9% and 1.6% and a compensation increase rate of 0.0% were used in determining the actuarial present value of benefit obligations as of June 30, 2017, 2016 and 2015, respectively.

 

Deferred Compensation Plans

 

To comply with the requirements of the American Jobs Creation Act of 2004, as of December 2004, the Company froze its non-qualified Supplemental Executive Retirement Plan (the Frozen Plan) and has not allowed any further deferrals or contributions to the Frozen Plan after December 31, 2004. All of the earned benefits of the participants in the Frozen Plan as of December 31, 2004, will be preserved under the existing plan provisions.

 

On March 14, 2005, the Company’s Board of Directors adopted the Aceto Corporation Supplemental Executive Deferred Compensation Plan (the Plan). The Plan is a non-qualified deferred compensation plan intended to provide certain qualified executives with supplemental benefits beyond the Company’s 401(k) plan, as well as to permit additional deferrals of a portion of their compensation. The Plan is intended to comply with the provisions of section 409A of the Internal Revenue Code of 1986, as amended, and is designed to provide comparable benefits to those under the Frozen Plan. Substantially all compensation deferred under the Plan, as well as Company contributions, is held by the Company in a grantor trust, which is considered an asset of the Company. The assets held by the grantor trust are in life insurance policies. Effective July 1, 2013, the Plan was frozen and a new plan, entitled “Aceto Corporation 2013 Senior Executive Retirement Plan” was adopted by the Company’s Board of Directors.

 

As of June 30, 2017, the Company recorded a liability under the Plans of $3,551 (of which $3,337 is included in long-term liabilities and $214 is included in accrued expenses) and an asset (included in other assets) of $3,087, primarily representing mutual fund investments owned by the Company. As of June 30, 2016, the Company recorded a liability under the Plans of $3,046 (of which $3,028 is included in long-term liabilities and $18 is included in accrued expenses) and an asset (included in other assets) of $2,693, primarily representing the cash surrender value of policies owned by the Company.
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.7.0.1
Financial Instruments
 12 Months Ended
Jun. 30, 2017
Investments All Other Investments [Abstract]  
Financial Instruments

(15) Financial Instruments

 

Derivative Financial Instruments

 

The Company is exposed to credit losses in the event of non-performance by the financial institutions, who are the counterparties, on its future foreign currency contracts. The Company anticipates, however, that the financial institutions will be able to fully satisfy their obligations under the contracts. The Company does not obtain collateral to support financial instruments, but monitors the credit standing of the financial institutions.

 

Fair Value of Financial Instruments

 

The carrying values of all financial instruments classified as a current asset or current liability are deemed to approximate fair value because of the short maturity of these instruments. The fair value of the Company’s notes receivable and accrued expenses was based upon current rates offered for similar financial instruments to the Company. The Company believes that borrowings outstanding under its long-term bank loans and mortgage approximate fair value because such borrowings bear interest at current variable market rates.

 

Business and Credit Concentration

 

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of trade receivables. The Company’s customers are dispersed across many industries and are located throughout the United States as well as in Canada, France, Germany, Malaysia, The Netherlands, Switzerland, the United Kingdom, and other countries. The Company estimates an allowance for doubtful accounts based upon the creditworthiness of its customers as well as general economic conditions. Consequently, an adverse change in those factors could affect the Company’s estimate of this allowance. At June 30, 2017, three customers approximated 31%, 21% and 15%, respectively, of net trade accounts receivable. At June 30, 2016, three customers approximated 34%, 20% and 11%, respectively, of net trade accounts receivable.

 

One customer accounted for 12% of net sales in fiscal 2017, 14% of net sales in fiscal 2016 and 13% of net sales in fiscal 2015. Another customer accounted for 11% of net sales in fiscal 2017, 7% of net sales in 2016 and 6% of net sales in 2015. No single product accounted for as much as 10% of net sales in fiscal 2017, 2016 or 2015.

 

During the fiscal years ended June 30, 2017, 2016 and 2015, approximately 62%, 56% and 65%, respectively, of the Company’s purchases came from Asia and approximately 17%, 22% and 12%, respectively, came from Europe.

 

The Company maintains operations located outside of the United States. Net assets located in Europe and Asia approximated $68,235 and $50,641, respectively at June 30, 2017. Net assets located in Europe and Asia approximated $62,399 and $48,846, respectively at June 30, 2016.
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.7.0.1
Commitments, Contingencies and Other Matters
 12 Months Ended
Jun. 30, 2017
Commitments And Contingencies Disclosure [Abstract]  
Commitments, Contingencies and Other Matters

(16) Commitments, Contingencies and Other Matters

 

As of June 30, 2017, the Company has outstanding purchase obligations totaling $61,381 with suppliers to the Company’s domestic and foreign operations to acquire certain products for resale to third party customers.

 

The Company and its subsidiaries are subject to various claims which have arisen in the normal course of business. The Company provides for costs related to contingencies when a loss from such claims is probable and the amount is reasonably determinable. In determining whether it is possible to provide an estimate of loss, or range of possible loss, the Company reviews and evaluates its litigation and regulatory matters on a quarterly basis in light of potentially relevant factual and legal developments. If the Company determines an unfavorable outcome is not probable or reasonably estimable, the Company does not accrue for a potential litigation loss. While the Company has determined that there is a reasonable possibility that a loss has been incurred, no amounts have been recognized in the financial statements, other than what has been discussed below, because the amount of the liability cannot be reasonably estimated at this time.

 

In fiscal years 2011, 2009, 2008 and 2007, the Company received letters from the Pulvair Site Group, a group of potentially responsible parties (PRP Group) who are working with the State of Tennessee (the State) to remediate a contaminated property in Tennessee called the Pulvair site. The PRP Group has alleged that Aceto shipped hazardous substances to the site which were released into the environment. The State had begun administrative proceedings against the members of the PRP Group and Aceto with respect to the cleanup of the Pulvair site and the PRP Group has begun to undertake cleanup. The PRP Group is seeking a settlement of approximately $1,700 from the Company for its share to remediate the site contamination. Although the Company acknowledges that it shipped materials to the site for formulation over twenty years ago, the Company believes that the evidence does not show that the hazardous materials sent by Aceto to the site have significantly contributed to the contamination of the environment and thus believes that, at most, it is a de minimis contributor to the site contamination. Accordingly, the Company believes that the settlement offer is unreasonable. Management believes that the ultimate outcome of this matter will not have a material adverse effect on the Company's financial condition or liquidity.

 

The Company has environmental remediation obligations in connection with Arsynco, Inc. (“Arsynco”), a subsidiary formerly involved in manufacturing chemicals located in Carlstadt, New Jersey, which was closed in 1993 and is currently held for sale. Based on continued monitoring of the contamination at the site and the approved plan of remediation, Arsynco received an estimate from an environmental consultant stating that the costs of remediation could be between $21,500 and $23,300. Remediation commenced in fiscal 2010, and as of June 30, 2017 and June 30, 2016, a liability of $8,451 and $12,532, respectively, is included in the accompanying consolidated balance sheets for this matter. For the year ended June 30, 2017, the Company recorded environmental remediation charges of $903 which is included in selling, general and administrative expenses in the accompanying consolidated statements of income for the year ended June 30, 2017. In accordance with GAAP, management believes that the majority of costs incurred to remediate the site will be capitalized in preparing the property which is currently classified as held for sale. An appraisal of the fair value of the property by a third-party appraiser supports the assumption that the expected fair value after the remediation is in excess of the amount required to be capitalized. However, these matters, if resolved in a manner different from those assumed in current estimates, could have a material adverse effect on the Company’s financial condition, operating results and cash flows when resolved in a future reporting period.

 

In connection with the environmental remediation obligation for Arsynco, in July 2009, Arsynco entered into a settlement agreement with BASF Corporation (“BASF”), the former owners of the Arsynco property. In accordance with the settlement agreement, BASF paid for a portion of the prior remediation costs and going forward, will co-remediate the property with the Company. The contract requires that BASF pay $550 related to past response costs and pay a proportionate share of the future remediation costs. Accordingly, the Company had recorded a gain of $550 in fiscal 2009. This $550 gain relates to the partial reimbursement of costs of approximately $1,200 that the Company had previously expensed. The Company also recorded an additional receivable from BASF, with an offset against property held for sale, representing its estimated portion of the future remediation costs. The balance of this receivable for future remediation costs as of June 30, 2017 and June 30, 2016 is $3,803 and $5,639, respectively, which is included in the accompanying consolidated balance sheets.

 

In March 2006, Arsynco received notice from the EPA of its status as a PRP under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) for a site described as the Berry’s Creek Study Area (“BCSA”). Arsynco is one of over 150 PRPs which have potential liability for the required investigation and remediation of the site. The estimate of the potential liability is not quantifiable for a number of reasons, including the difficulty in determining the extent of contamination and the length of time remediation may require. In addition, any estimate of liability must also consider the number of other PRPs and their financial strength. In July 2014, Arsynco received notice from the U.S. Department of Interior (“USDOI”) regarding the USDOI’s intent to perform a Natural Resource Damage (NRD) Assessment at the BCSA. Arsynco has to date declined to participate in the development and performance of the NRD assessment process. Based on prior practice in similar situations, it is possible that the State may assert a claim for natural resource damages with respect to the Arsynco site itself, and either the federal government or the State (or both) may assert claims against Arsynco for natural resource damages in connection with Berry's Creek; any such claim with respect to Berry's Creek could also be asserted against the approximately 150 PRPs which the EPA has identified in connection with that site. Any claim for natural resource damages with respect to the Arsynco site itself may also be asserted against BASF, the former owners of the Arsynco property. In September 2012, Arsynco entered into an agreement with three of the other PRPs that had previously been impleaded into New Jersey Department of Environmental Protection, et al. v. Occidental Chemical Corporation, et al., Docket No. ESX-L-9868-05 (the "NJDEP Litigation") and were considering impleading Arsynco into the same proceeding. Arsynco entered into an agreement to avoid impleader. Pursuant to the agreement, Arsynco agreed to (1) a tolling period that would not be included when computing the running of any statute of limitations that might provide a defense to the NJDEP Litigation; (2) the waiver of certain issue preclusion defenses in the NJDEP Litigation; and (3) arbitration of certain potential future liability allocation claims if the other parties to the agreement are barred by a court of competent jurisdiction from proceeding against Arsynco. In July 2015, Arsynco was contacted by an allocation consultant retained by a group of the named PRPs, inviting Arsynco to participate in the allocation among the PRPs’ investigation and remediation costs relating to the BCSA. Arsynco declined that invitation. Since an amount of the liability cannot be reasonably estimated at this time, no accrual is recorded for these potential future costs. The impact of the resolution of this matter on the Company’s results of operations in a particular reporting period is not currently known.

 

A subsidiary of the Company markets certain agricultural protection products which are subject to the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA). FIFRA requires that test data be provided to the EPA to register, obtain and maintain approved labels for pesticide products. The EPA requires that follow-on registrants of these products compensate the initial registrant for the cost of producing the necessary test data on a basis prescribed in the FIFRA regulations. Follow-on registrants do not themselves generate or contract for the data. However, when FIFRA requirements mandate that new test data be generated to enable all registrants to continue marketing a pesticide product, often both the initial and follow-on registrants establish a task force to jointly undertake the testing effort. The Company is presently a member of several such task force groups, which requires payments for such memberships. In addition, in connection with our agricultural protection business, the Company plans to acquire product registrations and related data filed with the United States Environmental Protection Agency to support such registrations and other supporting data for several products. The acquisition of these product registrations and related data filed with the United States Environmental Protection Agency as well as payments to various task force groups could approximate $2,357 through fiscal 2018, of which $0 has been accrued as of June 30, 2017 and June 30, 2016.

 

The Company leases office facilities in the United States, The Netherlands, Germany, France, Singapore and the Philippines expiring at various dates between October 2017 and June 2021.

 

At June 30, 2017, the future minimum lease payments for office facilities and equipment for each of the five succeeding years and in the aggregate are as follows:

 

Fiscal year Amount 
2018 $1,673 
2019  2,327 
2020  1,766 
2021  1,327 
2022  1,031 
Thereafter  6,744 
  $14,868 

 

Total rental expense amounted to $1,301, $1,265 and $1,567 for fiscal 2017, 2016 and 2015, respectively.
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.7.0.1
Related Party Transactions
 12 Months Ended
Jun. 30, 2017
Related Party Transactions [Abstract]  
Related Party Transactions

(17) Related Party Transactions

 

During fiscal 2017, 2016 and 2015, the Company purchased inventory from its corporate joint venture in the amount of $3,236, $2,831 and $3,204, respectively.

  

During fiscal 2017, Rising Health and Acetris Health incurred costs of $1,865 and $165, respectively, related to consulting services provided by former Citron and Lucid employees, in connection with a transition services agreement entered into at the time of the Company’s 2016 product purchase agreement. Citron and Lucid are affiliates of Vimal Kavuru, a member of the Company’s Board of Directors.

 

In October 2017, Rising will commence leasing approximately 125,000 gross square feet of warehouse space in Somerset, New Jersey. This building is owned by an affiliate of Mr. Kavuru.

 

On November 2, 2016, the Company, Citron and Cronus Research Labs Private Limited, a research and development company headquartered in India that is affiliated with Vimal Kavuru (“Cronus”), entered into two amended and restated joint development agreements pursuant to which Cronus has been engaged to develop a portfolio of nine pipeline products (“Development Agreement I”) and certain other products (“Development Agreement II” and together with Development Agreement I, the “Development Agreements”) on behalf of Citron. Under the terms of Development Agreement I, Cronus has agreed to pay the first $3,500 of the development costs incurred after December 21, 2016, and 50% of any development costs incurred above that threshold in exchange for obtaining reimbursement for its costs funded out of the profits earned, if any, from the pipeline products that are commercially launched, and a specified portion of the profits from those products thereafter. Under the terms of Development Agreement II, Cronus has agreed to pay the development costs for the products covered thereby in exchange for obtaining reimbursement for its costs funded out of the profits earned, if any, from such products that are commercially launched (subject to a $1,445 maximum), and a specified portion of the profits from those products thereafter.

 

Mr. Kavuru was not a member of the Company’s Board at the time that the above-mentioned transition services agreement, lease or Development Agreements were executed.
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.7.0.1
Recent Accounting Pronouncements
 12 Months Ended
Jun. 30, 2017
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]  
Recent Accounting Pronouncements

(18) Recent Accounting Pronouncements

 

In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting, which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. ASU 2017-09 is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. The Company does not believe this new accounting standard update will have a material impact on its consolidated financial statements.

 

In January 2017, the FASB issued ASU 2017-04 Intangibles - Goodwill and Other (Topic 350) which would eliminate the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. Instead, the amount of an impairment charge would be recognized if the carrying amount of a reporting unit is greater than its fair value. ASU 2017-04 is effective for public companies for fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company does not believe this new accounting pronouncement will have a material impact on its consolidated financial statements.

 

In January 2017, the FASB issued ASU 2017-01 Business Combinations (Topic 805): Clarifying the Definition of a Business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. ASU 2017-01 is effective for public companies for annual periods beginning after December 15, 2017, including interim periods within those periods. The Company does not believe this new accounting pronouncement will have a material impact on its consolidated financial statements.

 

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which addresses eight specific cash flow issues with the objective of reducing diversity in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact of the provisions of ASU 2016-15.

  

In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which will change certain aspects of accounting for share-based payments to employees. ASU 2016-09 is effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2016. ASU 2019-09 requires that all tax benefits and deficiencies related to share-based payments be recognized and recorded through the statement of income for all awards settled or expiring after the adoption of ASU 2016-09. Under prior guidance, tax benefits in excess of compensation costs ("windfalls") were recorded in equity, and any tax deficiencies ("shortfalls") were recorded in equity to the extent of previous windfalls and then to the statement of income. ASU 2016-09 also requires, either prospectively or retrospectively, that all tax-related cash flows resulting from share-based payments be reported as operating activities on the statement of cash flows, a change from prior guidance that required windfall tax benefits to be presented as an inflow from financing activities and an outflow from operating activities on the statement of cash flows. Additionally, ASU 2016-09 allows entities to make an accounting policy election for the impact of most types of forfeitures on the recognition of expense for share-based payment awards by allowing the forfeitures to be either estimated, as was required under prior guidance, or recognized when they actually occur. Under ASU 2016-09, it is possible for equity awards to have a more dilutive effect on earnings per share (EPS). Under prior guidance, anticipated income tax windfalls and shortfalls were included in the calculation of assumed proceeds when applying the treasury stock method for computing the dilutive effect of share-based awards in the calculation of diluted EPS. Because there is no longer any excess tax benefits recognized in additional paid capital under ASU 2016-09, when applying the treasury stock method for computing diluted EPS, the assumed proceeds do not include any windfall tax benefits. As a result, fewer hypothetical shares can be repurchased under the treasury stock method, resulting in an assumption of more incremental shares being issued upon the exercise of shared-based awards. Therefore, equity awards have a more dilutive effect on EPS for any period where the average market price of an entity's underlying stock exceeds the average fair value of outstanding dilutive equity awards for the period.  The provisions of ASU 2016-09 are effective for the Company at the beginning of fiscal 2018. The impact of ASU 2016-09 on the Company's income tax expense or benefit and related cash flows during and after the period of adoption are dependent in part upon future grants and vesting of stock-based compensation awards and other factors that are not fully controllable or predicable by the Company such as the future market price of the Company's common stock, the timing of employee exercises of vested stock options, and the future achievement of performance criteria that affect performance-based awards. Under ASU 2016-09, the Company will recognize forfeitures when they actually occur.

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) that replaces existing lease guidance. The new standard is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet. The new guidance will continue to classify leases as either finance or operating, with classification affecting the pattern of expense recognition in the statement of income. ASU 2016-02 is effective for fiscal years (and interim reporting periods within those years) beginning after December 15, 2018. The Company is currently evaluating the impact of the provisions of ASU 2016-02.

 

In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740) Balance Sheet Classification of Deferred Assets. This ASU is intended to simplify the presentation of deferred taxes on the balance sheet and will require an entity to present all deferred tax assets and deferred tax liabilities as non-current on the balance sheet. Under the current guidance, entities are required to separately present deferred taxes as current or non-current. Netting deferred tax assets and deferred tax liabilities by tax jurisdiction will still be required under the new guidance. This guidance will be effective for Aceto beginning in the first quarter of fiscal 2018. The Company does not believe this new accounting standard update will have a material impact on its consolidated financial statements.

 

In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330) – Simplifying the Measurement of Inventory. This ASU requires that an entity measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The adoption of this standard will not have any impact on the consolidated financial statements of the Company.

  

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which is the new comprehensive revenue recognition standard that will supersede all existing revenue recognition guidance under U.S. GAAP. The standard's core principle is that a company will recognize revenue when it transfers promised goods or services to a customer in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB subsequently issued ASU 2015-14, Revenue from Contracts with Customers - Deferral of the Effective Date, which approved a one year deferral of ASU 2014-09 for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. In March 2016 and April 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers - Principal versus Agent Considerations (Reporting Revenue Gross versus Net), and ASU 2016-10, Revenue from Contracts with Customers - Identifying Performance Obligations and Licensing, respectively, which further clarify the guidance related to those specific topics within ASU 2014-09. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients, to reduce the risk of diversity in practice for certain aspects in ASU 2014-09, including collectibility, noncash consideration, presentation of sales tax and transition. Additionally, in December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers. ASU 2016-20 makes minor corrections or minor improvements to the standard that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. The Company has made progress in its evaluation of the amended guidance, including identification of revenue streams. The Company recognizes revenue from product sales at the time of shipment and passage of title and risk of loss and control of the goods is transferred to the customer. The Company has no acceptance or other post-shipment obligations and does not offer product warranties or services to its customers. Although the Company is continuing to assess the impact of the amended guidance, Aceto generally anticipates that the timing of recognition of revenue will be substantially unchanged under the amended guidance. The Company is continuing to evaluate the impact on certain other transactions including third-party collaborations and other arrangements. The amended guidance will be effective for Aceto in the first quarter of fiscal 2019 and permits adoption under either the full retrospective approach (recognize effects of the amended guidance in each prior reporting period presented) or the modified retrospective approach (recognize the cumulative effect of adoption as an adjustment to retained earnings at the date of initial application). The Company anticipates adopting this amended standard on a modified retrospective basis.
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information
 12 Months Ended
Jun. 30, 2017
Segment Reporting [Abstract]  
Segment Information

(19) Segment Information

 

The Company's business is organized along product lines into three principal segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals.

 

Human Health - includes finished dosage form generic drugs and nutraceutical products.

 

Pharmaceutical Ingredients – includes pharmaceutical intermediates and active pharmaceutical ingredients (“APIs”).

 

Performance Chemicals - The Performance Chemicals segment is made up of two product groups: Specialty Chemicals and Agricultural Protection Products. Specialty Chemicals include a variety of chemicals used in the manufacture of plastics, surface coatings, cosmetics and personal care, textiles, fuels and lubricants, perform to their designed capabilities. Dye and pigment intermediates are used in the color-producing industries such as textiles, inks, paper, and coatings. Organic intermediates are used in the production of agrochemicals.

 

Agricultural Protection Products include herbicides, fungicides and insecticides that control weed growth as well as control the spread of insects and other microorganisms that can severely damage plant growth.

 

The Company's chief operating decision maker evaluates performance of the segments based on net sales, gross profit and income before income taxes. Unallocated corporate amounts are deemed by the Company as administrative, oversight costs, not managed by the segment managers. The Company does not allocate assets by segment because the chief operating decision maker does not review the assets by segment to assess the segments' performance, as the assets are managed on an entity-wide basis. During all periods presented, our chief operating decision maker has been the Chief Executive Officer of the Company. In accordance with GAAP, the Company has aggregated certain operating segments into reportable segments because they have similar economic characteristics, and the operating segments are similar in all of the following areas: (a) the nature of the products and services; (b) the nature of the production processes; (c) the type or class of customer for their products and services; (d) the methods used to distribute their products or provide their services; and (e) the nature of the regulatory environment.

  

    Human
Health		     Pharmaceutical
Ingredients		     Performance
Chemicals		     Unallocated
Corporate		     Consolidated
Totals		  
2017                                        
Net sales   $ 315,395     $ 157,445     $ 165,478     $ -     $ 638,318  
Gross profit     78,109       25,474       37,209       -       140,792  
Income before income taxes     15,434       9,322       18,829       (26,224 )     17,361  
                                         
2016                                        
Net sales   $ 228,035     $ 161,011     $ 169,478     $ -     $ 558,524  
Gross profit     77,880       28,752       36,153       -       142,785  
Income before income taxes     36,362       11,856       17,799       (12,163 )     53,854  
                                         
2015                                        
Net sales   $ 225,263     $ 149,296     $ 172,392     $ -     $ 546,951  
Gross profit     75,749       26,683       33,002       -       135,434  
Income before income taxes     35,152       8,697       14,289       (4,273 )     53,865  

 

Net sales and gross profit by source country for the years ended June 30, 2017, 2016 and 2015 were as follows:

 

    Net Sales     Gross Profit  
    2017     2016     2015     2017     2016     2015  
United States   $ 483,678     $ 400,883     $ 407,101     $ 116,792     $ 117,180     $ 111,734  
Germany     79,105       76,666       69,889       13,609       15,154       14,660  
Netherlands     9,949       16,217       14,656       1,231       1,598       1,325  
France     35,796       30,177       27,976       4,651       4,043       3,634  
Asia-Pacific     29,790       34,581       27,329       4,509       4,810       4,081  
Total   $ 638,318     $ 558,524     $ 546,951     $ 140,792     $ 142,785     $ 135,434  

 

Sales generated from the United States to foreign countries amounted to $21,750, $23,810 and $38,295 for the fiscal years ended June 30, 2017, 2016 and 2015, respectively.

 

Long-lived assets by geographic region as of June 30, 2017 and June 30, 2016 were as follows:

 

    Long-lived assets  
    2017     2016  
United States   $ 528,359     $ 152,701  
Europe     2,538       2,504  
Asia-Pacific     1,582       1,781  
Total   $ 532,479     $ 156,986  
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1
Unaudited Quarterly Financial Data
 12 Months Ended
Jun. 30, 2017
Quarterly Financial Information Disclosure [Abstract]  
Unaudited Quarterly Financial Data

(20) Unaudited Quarterly Financial Data

 

The following is a summary of the unaudited quarterly results of operations for the years ended June 30, 2017 and 2016.

 

    For the quarter ended  
Fiscal year ended June 30, 2017   September 30,
2016 (1)		     December 31,
2016(2)		     March 31,
2017(2)(3)		     June 30,
2017 (2)(4)		  
Net sales   $ 128,018     $ 125,552     $ 190,128     $ 194,620  
Gross profit     30,839       30,805       42,319       36,829  
Net income (loss)     4,385       (564 )     5,588       1,967  
                                 
Net income (loss) per diluted share   $ 0.15     $ (0.02 )   $ 0.16     $ 0.06  

 

    For the quarter ended  
Fiscal year ended June 30, 2016   September 30,
2015		     December 31,
2015		     March 31,
2016(5)		     June 30,
2016(6)		  
Net sales   $ 133,500     $ 131,674     $ 157,926     $ 135,424  
Gross profit     34,581       35,868       38,289       34,047  
Net income     9,298       8,270       10,424       6,774  
                                 
Net income per diluted share   $ 0.32     $ 0.28     $ 0.35     $ 0.23  

 

The net income per common share calculation for each of the quarters is based on the weighted average number of shares outstanding in each period. Therefore, the sum of the quarters in a year does not necessarily equal the year’s net income per common share.

 

(1) Includes pretax item of $170 environmental remediation charge in connection with Arsynco.

(2) Results for the last nine days of the quarter ended December 31, 2016 and for the subsequent two quarters reflect the acquisition of certain generic products and related assets from Citron and Lucid on December 21, 2016.

(3) Includes pretax item of $733 environmental remediation charge in connection with Arsynco.

(4) Includes pretax item of $3,139 representing immaterial correction of an error associated with certain accrued expenses.

(5) Includes pretax items consisting of $833 reversal of contingent consideration related to the PACK acquisition and $241 reversal of contingent consideration related to the acquisition of a company in France.

(6) Includes pretax item of $1,313 environmental remediation charge in connection with Arsynco.
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.7.0.1
Valuation and Qualifying Accounts
 12 Months Ended
Jun. 30, 2017
Valuation And Qualifying Accounts [Abstract]  
Valuation and Qualifying Accounts

Valuation and Qualifying Accounts

 

For the years ended June 30, 2017, 2016 and 2015

(dollars in thousands)

 

Description Balance at 
beginning of 
year		  Charged to 
costs and 
expenses		  Charged to 
other 
accounts		  Deductions  Balance at 
end of year		 
Year ended June 30, 2017                    
Allowance for doubtful accounts $513  $(3)  -  $25(a) $485 
Year ended June 30, 2016                    
Allowance for doubtful accounts $691  $76   -  $254(a) $513 
Year ended June 30, 2015                    
Allowance for doubtful accounts $517  $484   -  $310(a) $691 

 

(a) Specific accounts written off as uncollectible.
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.7.0.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Jun. 30, 2017
Accounting Policies [Abstract]  
Principles of Consolidation

Principles of Consolidation

 

The consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries. All significant inter-company balances and transactions are eliminated in consolidation.
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses reported in those financial statements and the disclosure of contingent assets and liabilities at the date of the financial statements. These judgments can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company’s most critical accounting policies relate to revenue recognition; allowance for doubtful accounts; inventory; goodwill and other indefinite-life intangible assets; long-lived assets; environmental matters and other contingencies; income taxes; stock-based compensation; and purchase price allocation.
Cash Equivalents

Cash Equivalents

 

The Company considers all highly liquid debt instruments with original maturities at the time of purchase of three months or less to be cash equivalents. Included in cash equivalents as of June 30, 2017 and June 30, 2016 is $220 and $104, respectively, of restricted cash.
Investments

Investments

 

The Company classifies investments in marketable securities as trading, available-for-sale or held-to-maturity at the time of purchase and periodically re-evaluates such classifications. Trading securities are carried at fair value, with unrealized holding gains and losses included in earnings. Held-to-maturity securities are recorded at cost and are adjusted for the amortization or accretion of premiums or discounts over the life of the related security. Unrealized holding gains and losses on available-for-sale securities are excluded from earnings and are reported as a separate component of accumulated other comprehensive income (loss) until realized. In determining realized gains and losses, the cost of securities sold is based on the specific identification method. Interest and dividends on the investments are accrued at the balance sheet date.
Inventory

Inventory

 

Inventory, which consists principally of finished goods, are stated at the lower of cost (first-in first-out method) and net realizable value. The Company writes down its inventory for estimated excess and obsolete goods by an amount equal to the difference between the carrying cost of the inventory and net realizable value based upon assumptions about future demand and market conditions.
Environmental and Other Contingencies

Environmental and Other Contingencies

 

The Company establishes accrued liabilities for environmental matters and other contingencies when it is probable that a liability has been incurred and the amount of the liability is reasonably estimable. If the contingency is resolved for an amount greater or less than the accrual, or the Company’s share of the contingency increases or decreases, or other assumptions relevant to the development of the estimate were to change, the Company would recognize an additional expense or benefit in the consolidated statements of income in the period such determination was made.
Pension Benefits

Pension Benefits

 

In connection with certain historical acquisitions in Germany, the Company assumed defined benefit pension plans covering certain employees who meet certain eligibility requirements. The net pension benefit obligations recorded and the related periodic costs are based on, among other things, assumptions of the discount rate, estimated return on plan assets, salary increases and the mortality of participants. The obligation for these claims and the related periodic costs are measured using actuarial techniques and assumptions. Actuarial gains and losses are deferred and amortized over future periods. The Company’s plans are funded in conformity with the funding requirements of applicable government regulations.
Accumulated Other Comprehensive Loss

Accumulated Other Comprehensive Loss

 

The components of accumulated other comprehensive loss as of June 30, 2017 and 2016 are as follows:

 

    2017     2016  
Cumulative foreign currency translation adjustments   $ (4,340 )   $ (6,120 )
Fair value of interest rate swaps     (581 )     -  
Defined benefit plans, net of tax     (191 )     (205 )
Total   $ (5,112 )   $ (6,325 )

 

The foreign currency translation adjustments for the years ended June 30, 2017 and 2016 primarily relate to the fluctuation of the conversion rate of the Euro. The currency translation adjustments are not adjusted for income taxes as they relate to indefinite investments in non-US subsidiaries.
Common Stock

Common Stock

 

At the annual meeting of shareholders of the Company, held on December 15, 2015, the Company’s shareholders approved the proposal to amend Aceto’s Certificate of Incorporation to increase the total number of authorized shares of common stock from 40,000 shares to 75,000 shares.

 

Cash dividends of $0.065 per common share were paid in September, December, March and June of fiscal year 2017. Cash dividends of $0.06 per common share were paid in September, December, March and June of fiscal years 2016 and 2015. On August 24, 2017, the Company's board of directors declared a regular quarterly dividend of $0.065 per share to be distributed on September 21, 2017 to shareholders of record as of September 8, 2017.

 

On May 4, 2017, the Board of Directors of the Company authorized the continuation of the Company’s stock repurchase program, expiring in May 2020. Under the stock repurchase program, the Company is authorized to purchase up to 5,000 shares of common stock in open market or private transactions, at prices not to exceed the market value of the common stock at the time of such purchase. The Company did not repurchase shares in fiscal 2017 or fiscal 2016.

 

The Board of Directors has authority under the Company’s Restated Certificate of Incorporation to issue shares of preferred stock with voting and other relative rights to be determined by the Board of Directors.
Stock-based Compensation

Stock-based Compensation

 

GAAP requires that all stock-based compensation be recognized as an expense in the financial statements and that such costs be measured at the fair value of the award. GAAP also requires that excess tax benefits related to stock option exercises be reflected as financing cash inflows.

 

All restricted stock grants include a service requirement for vesting. The Company has also granted restricted stock units that include either a performance or market condition. The fair value of restricted stock unit with either solely a service requirement or with the combination of service and performance requirements is based on the closing fair market value of Aceto’s common stock on the date of grant. The fair value of market condition-based awards is estimated at the date of grant using a binomial lattice model or Monte Carlo Simulation. All models incorporate various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the awards. Stock-based compensation expense is recognized on a straight-line basis over the service period or over our best estimate of the period over which the performance condition will be met, as applicable.
Revenue Recognition

Revenue Recognition

 

The Company recognizes revenue from product sales at the time of shipment and passage of title and risk of loss to the customer. The Company has no acceptance or other post-shipment obligations and does not offer product warranties or services to its customers.

 

Sales are recorded net of estimated returns of damaged goods from customers, which historically have been immaterial, and sales incentives offered to customers. Sales incentives include volume incentive rebates. The Company records volume incentive rebates based on the underlying revenue transactions that result in progress by the customer in earning the rebate.

 

The Company has arrangements with various third parties, such as drug store chains and managed care organizations, establishing prices for its finished dosage form generics. While these arrangements are made between Aceto and its customers, the customers independently select a wholesaler from which they purchase the products. Alternatively, certain wholesalers may enter into agreements with the customers, with the Company’s concurrence, which establishes the pricing for certain products which the wholesalers provide. Upon each sale of finished dosage form generics, estimates of chargebacks, rebates, returns, government reimbursed rebates, sales discounts and other adjustments are made. These estimates are based on historical experience, future expectations, contractual arrangements with wholesalers and indirect customers, and other factors known to management at the time of accrual. These estimates are recorded as reductions to gross revenues, with corresponding adjustments either as a reduction of accounts receivable or as a liability for price concessions.

 

Under certain arrangements, Rising will issue a credit (referred to as a “chargeback”) to the wholesaler for the difference between the invoice price to the wholesaler and the customer’s contract price. As sales to the large wholesale customers increase or decrease, the reserve for chargebacks will also generally increase or decrease. The provision for chargebacks varies in relation to changes in sales volume, product mix, pricing and the level of inventory at the wholesalers. The Company continually monitors the reserve for chargebacks and makes adjustments when management believes that expected chargebacks may differ from the actual chargeback reserve.

 

The Company estimates its provision for returns of finished dosage generics based on historical experience, product expiration dates, changes to business practices, credit terms and any extenuating circumstances known to management. While historical experience has allowed for reasonable estimations in the past, future returns may or may not follow historical trends. The Company continually monitors the reserve for returns and makes adjustments when management believes that actual product returns may differ from the established reserve. Generally, the reserve for returns increases as net sales increase.

 

Government rebate accruals are based on estimated payments due to governmental agencies for purchases made by third parties under various governmental programs. Other rebates are offered to the Company’s key chain drug store, distributor and wholesaler customers to promote customer loyalty and increase product sales. These rebate programs provide customers with credits upon attainment of pre-established volumes or attainment of net sales milestones for a specified period. Other promotional programs are incentive programs offered to the customers. The Company provides a provision for government reimbursed rebates and other rebates at the time of sale based on contracted rates and historical redemption rates. Assumptions used to establish the provision include level of customer inventories, contract sales mix and average contract pricing. Aceto regularly reviews the information related to these estimates and adjusts the provision accordingly.

  

Sales discount accruals are based on payment terms extended to customers.

 

The following table summarizes activity in the consolidated balance sheet for contra assets and liability for price concessions for the years ended June 30, 2017, 2016 and 2015:

 

    Accruals for Chargebacks, Rebates, Returns and Other Allowances        
            Government     Other     Sales  
    Chargebacks     Returns     Reimbursed Rebates     Rebates     Discounts  
Balance at June 30, 2014   $ 10,986     $ 20,249     $ 1,005     $ 3,630     $ 690  
Current year provision     208,965       21,403       4,259       36,923       9,381  
Credits issued during the year     (187,784 )     (10,960 )     (4,326 )     (36,218 )     (7,389 )
Balance at June 30, 2015   $ 32,167     $ 30,692     $ 938     $ 4,335     $ 2,682  
Current year provision     247,186       7,618       5,124       90,915       10,267  
Credits issued during the year     (256,638 )     (15,482 )     (4,750 )     (88,048 )     (10,526 )
Balance at June 30, 2016   $ 22,715     $ 22,828     $ 1,312     $ 7,202     $ 2,423  
 Acquisitions     23,526       1,496       4,500       28,944       2,360  
Current year provision     431,606       19,666       7,694       162,023       20,129  
Credits issued during the year     (417,928 )     (11,631 )     (4,642 )     (158,836 )     (18,875 )
Balance at June 30, 2017   $ 59,919     $ 32,359     $ 8,864     $ 39,333     $ 6,037  

 

Credits issued during a given period represent cash payments or credit memos issued to the Company’s customers as settlement for the related reserve. Management has the experience and access to relevant information that it believes is necessary to reasonably estimate the amounts of such deductions from gross revenues. The Company regularly reviews the information related to these estimates and adjusts its reserves accordingly, if and when actual experience differs from previous estimates. The Company has not experienced any significant changes in its estimates as it relates to its chargebacks, rebates or sales discounts in each of the years in the three year period ended June 30, 2017. During the year ended June 30, 2015, the Company recorded $3,497 in additional gross profit related to a change in estimate for product returns due to the most recent returns experience. The Company had not experienced any significant changes in its estimates as it relates to its product returns during the years ended June 30, 2017 and June 30, 2016.
Partnered Products

Partnered Products

 

The Company has various products that are subject to one of two types of collaborative arrangements with certain pharmaceutical companies. One type of arrangement relates to the Company’s finished dosage form generics business acting strictly as a distributor and purchasing products at arm’s length; in that type of arrangement, there is no profit sharing element. The second type of collaborative arrangement results in a profit sharing agreement between the Company and a developer and/or manufacturer of a finished dosage form generic drug. Both types of collaborative arrangements are conducted in the ordinary course of Rising’s business. The nature and purpose of both of these arrangements is for the Company to act as a distributor of finished dose products to its customers.  Under these arrangements, the Company maintains distribution rights with respect to specific drugs within the U.S. marketplace.  Generally, the distribution rights are exclusive rights in the territory.  In certain arrangements, the Company is required to maintain service level minimums including, but not limited to, market share and purchase levels, in order to preserve the exclusive rights.  The Company’s accounting policy with respect to these collaborative arrangements calls for the Company to present the sales and associated costs on a gross basis, with the amounts of the shared profits earned by the pharmaceutical companies on sales of these products, if applicable, included in cost of sales in the consolidated statements of income. The shared profits are settled on a quarterly basis. For each of the fiscal years 2017, 2016 and 2015, there was approximately $54,454, $41,036 and $51,352 respectively, of shared profits included in cost of sales, related to these types of collaborative arrangements. In the case of a collaborative arrangement where the Company solely acts as a distributor and purchases product at arm’s length, the costs of those purchases are included as a cost of sales similar to any other purchase arrangement.
Shipping and Handling Fees and Costs

Shipping and Handling Fees and Costs

 

All amounts billed to a customer in a sales transaction related to shipping and handling represent revenues earned and are included in net sales. The costs incurred by the Company for shipping and handling are reported as a component of cost of sales. Cost of sales also includes inbound freight, receiving, inspection, warehousing, distribution network, and customs and duty costs.
Net Income Per Common Share

Net Income Per Common Share

 

Basic income per common share is based on the weighted average number of common shares outstanding during the period. Diluted income per common share includes the dilutive effect of potential common shares outstanding. The following table sets forth the reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding for the fiscal years ended June 30, 2017, 2016 and 2015:

 

  2017  2016       2015 
          
Weighted average shares outstanding  32,283   29,110   28,731 
             
Dilutive effect of stock options and restricted stock awards and units  349   471   516 
             
Diluted weighted average shares outstanding  32,632   29,581   29,247 

 

The Convertible Senior Notes (see Note 9) will only be included in the dilutive net income per share calculations using the treasury stock method during periods in which the average market price of Aceto’s common stock is above the applicable conversion price of the Convertible Senior Notes, or $33.215 per share, and the impact would not be anti-dilutive.
Income Taxes

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
Property and Equipment

Property and Equipment

 

Property and equipment are stated at cost and are depreciated using the straight line method over the estimated useful lives of the related asset. The Company allocates depreciation and amortization to cost of sales. Expenditures for improvements that extend the useful life of an asset are capitalized. Ordinary repairs and maintenance are expensed as incurred. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any related gains or losses are included in income.

 

The components of property and equipment were as follows:

 

  

 

June 30, 2017

  

 

June 30, 2016

  Estimated useful 
life (years)
Machinery and equipment $398  $405  3-7
           
Leasehold improvements  979   1,056  Shorter of asset life or lease term
Computer equipment and software  7,255   6,048  3-5
Furniture and fixtures  2,094   2,365  5-10
Automobiles  184   184  3
Building  8,678   8,690  20
Land  1,967   1,960  -
   21,555   20,708   
Accumulated depreciation and amortization  11,127   10,664   
  $10,428  $10,044  

 

Property held for sale represents land and land improvements of $7,152 and $6,868 at June 30, 2017 and 2016, respectively. See Note 8, “Environmental Remediation” for further discussion on property held for sale.

 

Depreciation and amortization of property and equipment amounted to $1,520, $1,522 and $1,571 for the years ended June 30, 2017, 2016, and 2015 respectively.
Goodwill and Other Intangibles

Goodwill and Other Intangibles

 

Goodwill is calculated as the excess of the cost of purchased businesses over the fair value of their underlying net assets. Other intangible assets principally consist of customer relationships, license agreements, technology-based intangibles, EPA registrations and related data, trademarks and product rights and related intangibles. Goodwill and other intangible assets that have an indefinite life are not amortized.

 

In accordance with GAAP, the Company tests goodwill and other indefinite life intangible assets for impairment on at least an annual basis. Goodwill impairment exists if the net book value of a reporting unit exceeds its estimated fair value. Initially, an assessment of qualitative factors is conducted in order to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company determines that it is more likely than not that its carrying amount is greater than its fair value for a reporting unit, then it proceeds with the subsequent two-step process: (i) the Company determines impairment by comparing the fair value of a reporting unit with its carrying value, and (ii) if there is an impairment, the Company measures the amount of impairment loss by comparing the implied fair value of goodwill with the carrying amount of that goodwill. To determine the fair value of these intangible assets, the Company uses many assumptions and estimates using a market participant approach that directly impact the results of the testing. In making these assumptions and estimates, the Company uses industry accepted valuation models and set criteria that are reviewed and approved by various levels of management. The Company has the option to bypass the initial qualitative assessment stage and proceed directly to perform step one of the two-step process. In fiscal 2017, the Company performed step one of the two-step process and in fiscal 2016 the Company performed a qualitative assessment. There was no impairment of goodwill and other intangible assets in fiscal 2017 and fiscal 2016.
Impairment of Long-Lived Assets and Long-Lived Assets to be Disposed of

Impairment of Long-Lived Assets and Long-Lived Assets to be Disposed of

 

Long-lived assets and certain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability of assets held for sale is measured by comparing the carrying amount of the assets to their estimated fair value. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceed the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
Accounting for Derivatives and Hedging Activities

Accounting for Derivatives and Hedging Activities

 

The Company accounts for derivatives and hedging activities under the provisions of GAAP which establishes accounting and reporting guidelines for derivative instruments and hedging activities. GAAP requires the recognition of all derivative financial instruments as either assets or liabilities in the statement of financial condition and measurement of those instruments at fair value. Changes in the fair values of those derivatives are reported in earnings or other comprehensive income depending on the designation of the derivative and whether it qualifies for hedge accounting. The accounting for gains and losses associated with changes in the fair value of a derivative and the effect on the consolidated financial statements depends on its hedge designation and whether the hedge is highly effective in achieving offsetting changes in the fair value or cash flows of the asset or liability hedged. The method that is used for assessing the effectiveness of a hedging derivative, as well as the measurement approach for determining the ineffective aspects of the hedge, is established at the inception of the hedged instrument.

 

The Company operates internationally, therefore its earnings, cash flows and financial positions are exposed to foreign currency risk from foreign-currency-denominated receivables and payables, which, in the U.S., have been denominated in various foreign currencies, including, among others, Euros, British Pounds, Japanese Yen, Singapore Dollars and Chinese Renminbi and at certain foreign subsidiaries in U.S. dollars and other non-local currencies.

 

Management believes it is prudent to minimize the risk caused by foreign currency fluctuation. Management minimizes the currency risk on its foreign currency receivables and payables by purchasing foreign currency contracts (futures) with one of its financial institutions. Futures are traded on regulated U.S. and international exchanges and represent commitments to purchase or sell a particular foreign currency at a future date and at a specific price. Since futures are purchased for the amount of the foreign currency receivable or for the amount of foreign currency needed to pay for specific purchase orders, and the futures mature on the due date of the related foreign currency vendor invoices or customer receivables, the Company believes that it eliminates risks relating to foreign currency fluctuation. The Company takes delivery of all futures to pay suppliers in the appropriate currency. The gains or losses for the changes in the fair value of the foreign currency contracts are recorded in cost of sales (sales) and offset the gains or losses associated with the impact of changes in foreign exchange rates on trade payables (receivables) denominated in foreign currencies. Senior management and members of the financial department continually monitor foreign currency risks and the use of this derivative instrument.

 

In conjunction with its existing credit agreement (see Note 9), the Company entered into an interest rate swap on March 21, 2017 for an additional interest cost of 2.005% on a notional amount of $100,000, which has been designated as a cash flow hedge. The expiration date of this interest rate swap is December 21, 2021.
Foreign Currency

Foreign Currency

 

The financial statements of the Company’s foreign subsidiaries are translated into U.S. dollars in accordance with GAAP. Where the functional currency of a foreign subsidiary is its local currency, balance sheet accounts are translated at the current exchange rate and income statement items are translated at the average exchange rate for the period. Exchange gains or losses resulting from the translation of financial statements of foreign operations are accumulated in other comprehensive income. Where the local currency of a foreign subsidiary is not its functional currency, financial statements are translated at either current or historical exchange rates, as appropriate.
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.7.0.1
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Jun. 30, 2017
Accounting Policies [Abstract]  
Schedule of components of accumulated other comprehensive income
  2017  2016 
Cumulative foreign currency translation adjustments $(4,340) $(6,120)
Fair value of interest rate swaps  (581)  - 
Defined benefit plans, net of tax  (191)  (205)
Total $(5,112) $(6,325)
Schedule of contra assets and liability for price concessions
    Accruals for Chargebacks, Rebates, Returns and Other Allowances        
                Government     Other     Sales  
    Chargebacks     Returns     Reimbursed Rebates     Rebates     Discounts  
Balance at June 30, 2014   $ 10,986     $ 20,249     $ 1,005     $ 3,630     $ 690  
Current year provision     208,965       21,403       4,259       36,923       9,381  
Credits issued during the year     (187,784 )     (10,960 )     (4,326 )     (36,218 )     (7,389 )
Balance at June 30, 2015   $ 32,167     $ 30,692     $ 938     $ 4,335     $ 2,682  
Current year provision     247,186       7,618       5,124       90,915       10,267  
Credits issued during the year     (256,638 )     (15,482 )     (4,750 )     (88,048 )     (10,526 )
Balance at June 30, 2016   $ 22,715     $ 22,828     $ 1,312     $ 7,202     $ 2,423  
Acquisitions            23,526       1,496       4,500       28,944       2,360  
Current year provision     431,606       19,666       7,694       162,023       20,129  
Credits issued during the year     (417,928 )     (11,631 )     (4,642 )     (158,836 )     (18,875 )
Balance at June 30, 2017   $ 59,919     $ 32,359     $ 8,864     $ 39,333     $ 6,037  
Schedule of reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding
  2017  2016       2015 
          
Weighted average shares outstanding  32,283   29,110   28,731 
             
Dilutive effect of stock options and restricted stock awards and units  349   471   516 
             
Diluted weighted average shares outstanding  32,632   29,581   29,247 
Schedule of components of property and equipment
  

 

June 30, 2017

  

 

June 30, 2016

  Estimated useful 
life (years)
Machinery and equipment $398  $405  3-7
           
Leasehold improvements  979   1,056  Shorter of asset life or lease term
Computer equipment and software  7,255   6,048  3-5
Furniture and fixtures  2,094   2,365  5-10
Automobiles  184   184  3
Building  8,678   8,690  20
Land  1,967   1,960  -
   21,555   20,708   
Accumulated depreciation and amortization  11,127   10,664   
  $10,428  $10,044  
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business Combinations (Tables)
 12 Months Ended
Jun. 30, 2017
Business Combinations [Abstract]  
Schedule of purchase price to the estimated fair values of the assets acquired and liabilities assumed
Trade receivables $78,937 
Inventory  38,995 
Prepaid expenses and other current assets  1,425 
Goodwill  169,071 
Intangible assets  224,850 
Total assets acquired  513,278 
     
Accounts payable  46,840 
Accrued expenses  53,458 
Deferred payment  50,000 
Contingent consideration  2,580 
     
Net assets acquired $360,400 
Schedule of unaudited pro forma operating results
  Year ended 
  June 30, 
    
  2017  2016 
       
Net sales $739,318  $731,100 
Net income  24,166   30,469 
Net income per common share $0.70  $0.89 
Diluted net income per common share $0.69  $0.88 
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.7.0.1
Investments (Tables)
 12 Months Ended
Jun. 30, 2017
Investments Debt And Equity Securities [Abstract]  
Schedule of Summary of short-term investments
    June 30, 2017     June 30, 2016  
Held to Maturity Investments            
Time deposits   $ 2,046     $ 881  
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.7.0.1
Fair Value Measurements (Tables)
 12 Months Ended
Jun. 30, 2017
Fair Value Disclosures [Abstract]  
Schedule of changes in contingent consideration
Balance as of June 30, 2015   $ 2,622  
Reversal of fair value of liability-PACK     (833 )
Reversal of fair value of liability-France     (241 )
Payments     (1,500 )
Accrued interest expense     85  
Change in foreign currency exchange rate     (1 )
Balance as of June 30, 2016   $ 132  
Acquisitions     2,580  
Accrued interest expense     237  
Change in foreign currency exchange rate     3  
Balance as of June 30, 2017   $ 2,952  
Summary of valuation of the Company's financial assets and liabilities
  Fair Value Measurements at June 30, 2017 Using 
  Quoted Prices 
in Active 
Markets 
(Level 1)		  Significant 
Other 
Observable 
Inputs 
(Level 2)		  Significant 
Unobservable 
Inputs 
(Level 3)		  Total 
Cash equivalents:                
Time deposits  -  $5,781   -  $5,781 
Investments:                
    Time deposits  -   2,046   -   2,046 
                 
Foreign currency contracts-assets (1)  -   486   -   486 
Foreign currency contracts-liabilities (2)  -   137   -   137 
Derivative liability for interest rate swap(3)      581       581 
Contingent consideration (4)  -   -  $2,952   2,952 

 

(1)Included in “Other receivables” in the accompanying Consolidated Balance Sheet as of June 30, 2017.
(2)Included in “Accrued expenses” in the accompanying Consolidated Balance Sheet as of June 30, 2017.
(3)Included in “Long-term liabilities” in the accompanying Consolidated Balance Sheet as of June 30, 2017.
(4)$145 included in “Accrued expenses” and $2,807 included in “Long-term liabilities” in the accompanying Consolidated Balance Sheet as of June 30, 2017.

 

  Fair Value Measurements at June 30, 2016 Using 
  Quoted Prices 
in Active 
Markets 
(Level 1)		  Significant 
Other 
Observable 
Inputs 
(Level 2)		  Significant 
Unobservable 
Inputs 
(Level 3)		  Total 
Cash equivalents:                
    Time deposits  -  $6,249   -  $6,249 
Investments:                
    Time deposits  -   881   -   881 
                 
Foreign currency contracts-assets (5)  -   160   -   160 
Foreign currency contracts-liabilities (6)  -   169   -   169 
Contingent consideration (7)  -   -  $132   132 

 

(5)Included in “Other receivables” in the accompanying Consolidated Balance Sheet as of June 30, 2016.
(6)Included in “Accrued expenses” in the accompanying Consolidated Balance Sheet as of June 30, 2016.
(7)Included in “Long-term liabilities” in the accompanying Consolidated Balance Sheet as of June 30, 2016.
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.7.0.1
Goodwill and Other Intangible Assets (Tables)
 12 Months Ended
Jun. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]  
Schedule of goodwill
    Human
Health
Segment		     Pharmaceutical
Ingredients
Segment		     Performance
Chemicals
Segment		     Total
Goodwill		  
Balance as of June 30, 2015   $ 66,039     $ 1,650     $ 181     $ 67,870  
Changes in foreign currency exchange rates     -       1       -       1  
Balance as of June 30, 2016     66,039       1,651       181       67,871  
Acquisitions     169,071       -       -       169,071  
Changes in foreign currency exchange rates     -       23       5       28  
Balance as of June 30, 2017   $ 235,110     $ 1,674     $ 186     $ 236,970  
Schedule of Intangible assets subject to amortization
  

Gross 
Carrying

Value

  

Accumulated
Amortization

  

Net Book
Value

 
June 30, 2017            
Customer relationships $110,787  $13,968  $96,819 
Trademarks  2,218   2,195   23 
Product rights and related intangibles  221,335   37,677   183,658 
License agreements  6,537   6,035   502 
EPA registrations and related data  14,307   11,011   3,296 
  $355,184  $70,886  $284,298 

 

  

Gross 
Carrying
Value

  

Accumulated
Amortization

  

Net Book
Value

 
June 30, 2016            
Customer relationships $21,761  $7,815  $13,946 
Trademarks  1,868   1,800   68 
Product rights and related intangibles  83,048   23,511   59,537 
License agreements  6,611   5,531   1,080 
EPA registrations and related data  13,591   9,927   3,664 
Technology-based intangibles  155   140   15 
  $127,034  $48,724  $78,310 
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.7.0.1
Accrued Expenses (Tables)
 12 Months Ended
Jun. 30, 2017
Payables And Accruals [Abstract]  
Schedule of components of accrued expenses
    2017     2016  
Accrued compensation   $ 5,793     $ 6,880  
Accrued environmental remediation costs-current portion     6,112       9,180  
Reserve for price concessions     80,556       31,342  
Partnered product liabilities     16,068       -  
Other accrued expenses     9,799       5,273  
    $ 118,328     $ 52,675  
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.7.0.1
Debt (Tables)
 12 Months Ended
Jun. 30, 2017
Debt Disclosure [Abstract]  
Schedule of long-term debt
  June 30, 
  2017  2016 
       
Convertible Senior Notes, net $121,676  $115,829 
Revolving bank loans  90,000   - 
Term bank loans  139,227   - 
Mortgage  2,763   2,960 
   353,666   118,789 
Less current portion  14,466   197 
  $339,200  $118,592 
Schedule of carrying value of the notes
  

June 30,

2017

  

June 30,

2016

 
       
Principal amount $143,750  $143,750 
Unamortized debt discount  (19,255)  (24,267)
Unamortized debt issuance costs  (2,819)  (3,654)
Net carrying value $121,676  $115,829 
Schedule of components of total interest expense related to the notes
  2017  2016 
       
Contractual coupon $2,867  $1,788 
Amortization of debt discount  5,012   2,974 
Amortization of debt issuance costs  835   522 
  $8,714  $5,284 
Schedule of maturities of long-term debt
2018 $14,466 
2019  14,466 
2020  14,466 
2021  138,115 
2022  172,153 
Thereafter  - 
  $353,666 
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock Based Compensation Plans (Tables)
 12 Months Ended
Jun. 30, 2017
Disclosure Of Compensation Related Costs Share based Payments [Abstract]  
Schedule of shares of common stock under options for all plans
  Shares subject to 
option		  Weighted average 
exercise price per 
share		  Aggregate 
Intrinsic 
Value		 
Balance at June 30, 2014  551  $7.72     
Granted  -   -     
Exercised  (146)  8.74     
Forfeited (including cancelled options)  (8)  10.94     
Balance at June 30, 2015  397  $7.28     
Granted  -   -     
Exercised  (95)  7.56     
Forfeited (including cancelled options)  -   -     
Balance at June 30, 2016  302  $7.19     
Granted  28   20.03     
Exercised  (70)  7.90     
Forfeited (including cancelled options)  -   -     
Balance at June 30, 2017  260  $8.36  $1,968 
Options exercisable at June 30, 2017  232  $6.98  $1,968 
Schedule of non-vested stock options activity
    Shares
subject to
option		     Weighted
average grant
date fair value		  
Non-vested at June 30, 2016     -       -  
Granted     28     $ 5.44  
Vested     -       -  
Forfeited     -       -  
Non-vested at June 30, 2017     28     $ 5.44  

 
Schedule of per-share fair value of stock options granted using Monte Carlo simulation option-pricing model
    2017  
       
Expected life     4.9 years  
Expected volatility     39.4 %
Risk-free interest rate     1.26 %
Dividend yield     1.30 %
Schedule of restricted stock awards including restricted stock units
  Shares  Weighted 
average grant 
date fair value		 
Non-vested at beginning of year  795  $20.73 
Granted  501   18.92 
Vested  (396)  17.26 
Forfeited  (103)  21.33 
Non-vested at June 30, 2017  797  $21.24 
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.7.0.1
Interest and Other Income (Tables)
 12 Months Ended
Jun. 30, 2017
Other Income And Expenses [Abstract]  
Schedule of interest and other income
    2017     2016     2015  
Dividends   $ 277     $ 222     $ 233  
Interest     264       313       282  
Foreign government subsidies received     64       25       22  
Joint venture equity earnings     2,336       2,060       1,761  
Foreign currency (losses) gains     (298 )     56       (1,065 )
Deferred compensation plan losses     (257 )     (35 )     (96 )
Rental income     158       154       151  
Miscellaneous income     33       28       198  
    $ 2,577     $ 2,823     $ 1,486  
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.7.0.1
Income Taxes (Tables)
 12 Months Ended
Jun. 30, 2017
Income Tax Disclosure [Abstract]  
Schedule of income before income tax, domestic and foreign
    2017     2016     2015  
Domestic operations   $ 9,555     $ 43,906     $ 48,276  
Foreign operations     7,806       9,948       5,589  
    $ 17,361     $ 53,854     $ 53,865  
Schedule of components of provision for income taxes
    2017     2016     2015  
Federal:                        
Current   $ 3,713     $ 15,129     $ 18,393  
Deferred     (585 )     (204 )     (1,357 )
State and local:                        
Current     555       755       1,526  
Deferred     (110 )     173       189  
Foreign:                        
Current     2,221       3,222       2,337  
Deferred     191       13       (706 )
    $ 5,985     $ 19,088     $ 20,382  
Schedule of tax effects of temporary differences that give rise to the deferred tax assets and liabilities
    2017     2016  
Deferred tax assets:                
Accrued deferred compensation   $ 4,229     $ 4,122  
Accrual for sales deductions not currently deductible     5,796       5,925  
Additional inventoried costs for tax purposes     697       389  
Allowance for doubtful accounts receivable     106       106  
Depreciation and amortization     11,957       7,784  
Debt issuance costs     7,611       9,462  
Foreign deferred tax assets     983       1,121  
Domestic net operating loss carryforwards     81       109  
Foreign net operating loss carryforwards     692       685  
Total gross deferred tax assets     32,152       29,703  
Valuation allowances     (773 )     (794 )
      31,379       28,909  
                 
Deferred tax liabilities:                
Foreign deferred tax liabilities     (65 )     (27 )
Goodwill     (10,244 )     (7,586 )
Original issue discount – convertible senior notes     (7,260 )     (9,115 )
Other     (1,136 )     (26 )
Total gross deferred tax liabilities     (18,705 )     (16,754 )
                 
Net deferred tax assets   $ 12,674     $ 12,155  
Schedule of current and non-current deferred tax assets (liabilities)
    2017     2016  
Current deferred tax assets, net   $ 546     $ 3,244  
Non-current deferred tax assets, net     19,453       18,053  
Non-current deferred tax liabilities     (7,325 )     (9,142 )
Net deferred tax assets   $ 12,674     $ 12,155  
Schedule of reconciliation of the statutory federal income tax rate and the effective tax rate for continuing operation
    2017     2016     2015  
Federal statutory tax rate     35.0 %     35.0 %     35.0 %
State and local taxes, net of federal income tax benefit     1.2       1.7       2.4  
Decrease (increase) in valuation allowance     0.1       -       0.4  
Foreign tax rate differential     (1.8 )     (0.4 )     (0.9 )
Other     -       (0.9 )     0.9  
Effective tax rate     34.5 %     35.4 %     37.8 %
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.7.0.1
Supplemental Cash Flow Information (Tables)
 12 Months Ended
Jun. 30, 2017
Supplemental Cash Flow Elements [Abstract]  
Schedule of cash paid for interest and income taxes
  2017  2016  2015 
Interest $7,794  $2,970  $3,954 
Income taxes, net of refunds $7,912  $16,076  $25,459 
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.7.0.1
Commitments, Contingencies and Other Matters (Tables)
 12 Months Ended
Jun. 30, 2017
Commitments And Contingencies Disclosure [Abstract]  
Schedule of future minimum lease payments for office facilities and equipment
Fiscal year Amount 
2018 $1,673 
2019  2,327 
2020  1,766 
2021  1,327 
2022  1,031 
Thereafter  6,744 
  $14,868 
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information (Tables)
 12 Months Ended
Jun. 30, 2017
Segment Reporting [Abstract]  
Schedule of segment performance measures
    Human
Health		     Pharmaceutical
Ingredients		     Performance
Chemicals		     Unallocated
Corporate		     Consolidated
Totals		  
2017                                        
Net sales   $ 315,395     $ 157,445     $ 165,478     $ -     $ 638,318  
Gross profit     78,109       25,474       37,209       -       140,792  
Income before income taxes     15,434       9,322       18,829       (26,224 )     17,361  
                                         
2016                                        
Net sales   $ 228,035     $ 161,011     $ 169,478     $ -     $ 558,524  
Gross profit     77,880       28,752       36,153       -       142,785  
Income before income taxes     36,362       11,856       17,799       (12,163 )     53,854  
                                         
2015                                        
Net sales   $ 225,263     $ 149,296     $ 172,392     $ -     $ 546,951  
Gross profit     75,749       26,683       33,002       -       135,434  
Income before income taxes     35,152       8,697       14,289       (4,273 )     53,865  
Schedule of net sales and gross profit by source country
    Net Sales     Gross Profit  
    2017     2016     2015     2017     2016     2015  
United States   $ 483,678     $ 400,883     $ 407,101     $ 116,792     $ 117,180     $ 111,734  
Germany     79,105       76,666       69,889       13,609       15,154       14,660  
Netherlands     9,949       16,217       14,656       1,231       1,598       1,325  
France     35,796       30,177       27,976       4,651       4,043       3,634  
Asia-Pacific     29,790       34,581       27,329       4,509       4,810       4,081  
Total   $ 638,318     $ 558,524     $ 546,951     $ 140,792     $ 142,785     $ 135,434  
Schedule of long-lived assets by geographic region
    Long-lived assets  
    2017     2016  
United States   $ 528,359     $ 152,701  
Europe     2,538       2,504  
Asia-Pacific     1,582       1,781  
Total   $ 532,479     $ 156,986  
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.7.0.1
Unaudited Quarterly Financial Data (Tables)
 12 Months Ended
Jun. 30, 2017
Quarterly Financial Information Disclosure [Abstract]  
Schedule of unaudited quarterly financial data
    For the quarter ended  
Fiscal year ended June 30, 2017   September 30,
2016 (1)		     December 31,
2016(2)		     March 31,
2017(2)(3)		     June 30,
2017 (2)(4)		  
Net sales   $ 128,018     $ 125,552     $ 190,128     $ 194,620  
Gross profit     30,839       30,805       42,319       36,829  
Net income (loss)     4,385       (564 )     5,588       1,967  
                                 
Net income (loss) per diluted share   $ 0.15     $ (0.02 )   $ 0.16     $ 0.06  

 

    For the quarter ended  
Fiscal year ended June 30, 2016   September 30,
2015		     December 31,
2015		     March 31,
2016(5)		     June 30,
2016(6)		  
Net sales   $ 133,500     $ 131,674     $ 157,926     $ 135,424  
Gross profit     34,581       35,868       38,289       34,047  
Net income     9,298       8,270       10,424       6,774  
                                 
Net income per diluted share   $ 0.32     $ 0.28     $ 0.35     $ 0.23  

 

The net income per common share calculation for each of the quarters is based on the weighted average number of shares outstanding in each period. Therefore, the sum of the quarters in a year does not necessarily equal the year’s net income per common share.

 

(1) Includes pretax item of $170 environmental remediation charge in connection with Arsynco.

(2) Results for the last nine days of the quarter ended December 31, 2016 and for the subsequent two quarters reflect the acquisition of certain generic products and related assets from Citron and Lucid on December 21, 2016.

(3) Includes pretax item of $733 environmental remediation charge in connection with Arsynco.

(4) Includes pretax item of $3,139 representing immaterial correction of an error associated with certain accrued expenses.

(5) Includes pretax items consisting of $833 reversal of contingent consideration related to the PACK acquisition and $241 reversal of contingent consideration related to the acquisition of a company in France.

(6) Includes pretax item of $1,313 environmental remediation charge in connection with Arsynco.
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.7.0.1
Summary of Significant Accounting Policies (Components of accumulated other comprehensive loss (Detail) - USD ($)
$ in Thousands
Jun. 30, 2017
Jun. 30, 2016
Accounting Policies [Abstract]    
Cumulative foreign currency translation adjustments $ (4,340) $ (6,120)
Fair value of interest rate swaps (581)
Defined benefit plans, net of tax (191) (205)
Total $ (5,112) $ (6,325)
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.7.0.1
Summary of Significant Accounting Policies (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Chargebacks      
Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at beginning of year $ 22,715 $ 32,167 $ 10,986
Acquisitions 23,526    
Current year provision 431,606 247,186 208,965
Credits issued during the year (417,928) (256,638) (187,784)
Balance at end of year 59,919 22,715 32,167
Returns      
Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at beginning of year 22,828 30,692 20,249
Acquisitions 1,496    
Current year provision 19,666 7,618 21,403
Credits issued during the year (11,631) (15,482) (10,960)
Balance at end of year 32,359 22,828 30,692
Government Reimbursed Rebates      
Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at beginning of year 1,312 938 1,005
Acquisitions 4,500    
Current year provision 7,694 5,124 4,259
Credits issued during the year (4,642) (4,750) (4,326)
Balance at end of year 8,864 1,312 938
Other Rebates      
Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at beginning of year 7,202 4,335 3,630
Acquisitions 28,944    
Current year provision 162,023 90,915 36,923
Credits issued during the year (158,836) (88,048) (36,218)
Balance at end of year 39,333 7,202 4,335
Sales Discounts      
Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at beginning of year 2,423 2,682 690
Acquisitions 2,360    
Current year provision 20,129 10,267 9,381
Credits issued during the year (18,875) (10,526) (7,389)
Balance at end of year $ 6,037 $ 2,423 $ 2,682
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.7.0.1
Summary of Significant Accounting Policies (Schedule of Reconciliation of Weighted Average Shares Outstanding and Diluted Weighted Average Shares Outstanding) (Detail) - shares
shares in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Accounting Policies [Abstract]      
Weighted average shares outstanding 32,283 29,110 28,731
Dilutive effect of stock options and restricted stock awards and units 349 471 516
Diluted weighted average shares outstanding 32,632 29,581 29,247
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.7.0.1
Summary of Significant Accounting Policies (Schedule of Components of Property and Equipment) (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Significant Accounting Policies [Line Items]    
Property plant and equipment, gross $ 21,555 $ 20,708
Accumulated depreciation and amortization 11,127 10,664
Property plant and equipment, net 10,428 10,044
Machinery and equipment    
Significant Accounting Policies [Line Items]    
Property plant and equipment, gross $ 398 405
Machinery and equipment | Minimum    
Significant Accounting Policies [Line Items]    
Property, plant and equipment, estimated useful life 3 years  
Machinery and equipment | Maximum    
Significant Accounting Policies [Line Items]    
Property, plant and equipment, estimated useful life 7 years  
Leasehold improvements    
Significant Accounting Policies [Line Items]    
Property plant and equipment, gross $ 979 1,056
Property, plant and equipment, estimated useful life Shorter of asset life or lease term  
Computer equipment and software    
Significant Accounting Policies [Line Items]    
Property plant and equipment, gross $ 7,255 6,048
Computer equipment and software | Minimum    
Significant Accounting Policies [Line Items]    
Property, plant and equipment, estimated useful life 3 years  
Computer equipment and software | Maximum    
Significant Accounting Policies [Line Items]    
Property, plant and equipment, estimated useful life 5 years  
Furniture and fixtures    
Significant Accounting Policies [Line Items]    
Property plant and equipment, gross $ 2,094 2,365
Furniture and fixtures | Minimum    
Significant Accounting Policies [Line Items]    
Property, plant and equipment, estimated useful life 5 years  
Furniture and fixtures | Maximum    
Significant Accounting Policies [Line Items]    
Property, plant and equipment, estimated useful life 10 years  
Automobiles    
Significant Accounting Policies [Line Items]    
Property plant and equipment, gross $ 184 184
Property, plant and equipment, estimated useful life 3 years  
Building    
Significant Accounting Policies [Line Items]    
Property plant and equipment, gross $ 8,678 8,690
Property, plant and equipment, estimated useful life 20 years  
Land    
Significant Accounting Policies [Line Items]    
Property plant and equipment, gross $ 1,967 $ 1,960
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.7.0.1
Summary of Significant Accounting Policies (Narrative) (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
May 04, 2017
Aug. 24, 2017
Mar. 21, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Dec. 14, 2015
Summary Of Significant Accounting Policies [Line Items]                                      
Restricted cash       $ 220       $ 104               $ 220 $ 104    
Common stock, shares authorized       75,000       75,000               75,000 75,000   40,000
Stock repurchase program, expiration date May 2020                                    
Stock repurchase program, shares authorized 5,000                                    
Cash dividends paid       $ 0.065 $ 0.065 $ 0.065 $ 0.065 $ 0.06 $ 0.06 $ 0.06 $ 0.06 $ 0.06 $ 0.06 $ 0.06 $ 0.06        
Dividends declared, per share                               $ 0.26 $ 0.24 $ 0.24  
Additional gross profit related to a change in estimate for product returns                                   $ 3,497  
Shared profits included in cost of sales related to collaborative arrangements                               $ 54,454 $ 41,036 51,352  
Property held for sale       $ 7,152       $ 6,868               7,152 6,868    
Depreciation and amortization                               $ 1,520 $ 1,522 $ 1,571  
Senior Notes                                      
Summary Of Significant Accounting Policies [Line Items]                                      
Conversion price       $ 33.215                       $ 33.215      
Interest rate swap | Cash flow hedging | December 21, 2021                                      
Summary Of Significant Accounting Policies [Line Items]                                      
Derivative, notional amount     $ 100,000                                
Derivative, expiration date     Dec. 21, 2021                                
Additional interest cost rate of derivative     2.005%                                
Subsequent Event                                      
Summary Of Significant Accounting Policies [Line Items]                                      
Dividends declared, per share   $ 0.065                                  
Dividends declared, date of declaration   Aug. 24, 2017                                  
Dividends declared, date of distribution   Sep. 21, 2017                                  
Dividends declared, date of record   Sep. 08, 2017                                  
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business Combinations (Details) - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 21, 2016
Jun. 30, 2016
Jun. 30, 2015
Business Acquisition [Line Items]        
Goodwill $ 236,970   $ 67,871 $ 67,870
Contingent consideration 2,952      
Citron and Lucid        
Business Acquisition [Line Items]        
Trade receivables   $ 78,937    
Inventory   38,995    
Prepaid expenses and other current assets   1,425    
Goodwill   169,071    
Intangible assets   224,850    
Total assets acquired   513,278    
Accounts payable   46,840    
Accrued expenses   53,458    
Deferred payment   50,000    
Contingent consideration $ 2,807 2,580    
Net assets acquired   $ 360,400    
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business Combinations (Details 1) - Citron and Lucid - Pro forma operating results as of July 1, 2015 - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Business Acquisition [Line Items]    
Net sales $ 739,318 $ 731,100
Net income $ 24,166 $ 30,469
Net income per common share $ 0.70 $ 0.89
Diluted net income per common share $ 0.69 $ 0.88
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business Combinations (Narrative) (Detail)
shares in Thousands, $ in Thousands
 1 Months Ended 12 Months Ended
Dec. 21, 2016
USD ($)
Contract
Subsidiary
shares
Jun. 30, 2017
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
Business Acquisition [Line Items]        
Cash paid   $ 270,000    
Contingent consideration   2,952    
Goodwill   236,970 $ 67,871 $ 67,870
Citron and Lucid        
Business Acquisition [Line Items]        
Number of national contracts with the Federal Government | Contract 18      
Term of national contracts 5 years      
Cash paid $ 270,000      
Deferred payment $ 50,000      
Interest rate 5.00%      
Number of shares to be issued | shares 5,122      
Purchase price, earn-out period 5 years      
Purchase price, earn-out amount $ 50,000      
Contingent consideration 2,580 $ 2,807    
Goodwill 169,071      
Intangible assets 224,850      
Citron and Lucid | Product Rights        
Business Acquisition [Line Items]        
Intangible assets $ 135,700      
Amortizable period of intangible assets 10 years      
Citron and Lucid | Customer relationships        
Business Acquisition [Line Items]        
Intangible assets $ 88,800      
Amortizable period of intangible assets 11 years      
Citron and Lucid | Trademarks        
Business Acquisition [Line Items]        
Intangible assets $ 350      
Amortizable period of intangible assets 6 months      
Rising Pharmaceuticals, Inc.        
Business Acquisition [Line Items]        
Number of subsidiary | Subsidiary 2      
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business Combinations (Narrative) (Detail 1) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]      
Amortization charges from acquired intangible assets $ 22,234 $ 11,176 $ 10,278
Citron and Lucid      
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]      
Net sales 122,118    
Income before income taxes 7,437    
Citron and Lucid | Acquisition of intangible assets      
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]      
Amortization charges from acquired intangible assets 21,000 21,000  
Citron and Lucid | Acquisition related interest expense      
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]      
Increase in interest expense 13,200 13,200  
Citron and Lucid | Step-up in fair value of acquired inventory      
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]      
Step up in fair value of acquired inventory   4,502  
Citron and Lucid | Acquisition related transaction costs      
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]      
Acquisition related transaction costs $ 8,818 $ 8,818  
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.7.0.1
Investments (Schedule of Summary of Short-Term Investments) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2017
Jun. 30, 2016
Time deposits    
Schedule of Investments [Line Items]    
Held to Maturity Investments $ 2,046 $ 881
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.7.0.1
Fair Value Measurements (Schedule Changes in contingent consideration) (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2016
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Changes In Contingent Consideration [Roll Forward]        
Acquisitions   $ 2,580    
Reversal of fair value of liability     $ (1,074) $ (3,468)
Ending Balance   2,952    
Rising Pharmaceuticals Inc. , France Company and PACK Pharmaceuticals, LLC        
Changes In Contingent Consideration [Roll Forward]        
Beginning Balance   132 2,622  
Acquisitions   2,580    
Payments     (1,500)  
Accrued interest expense   237 85  
Change in foreign currency exchange rate   3 (1)  
Ending Balance   $ 2,952 132 $ 2,622
Pack Pharmaceuticals Llc        
Changes In Contingent Consideration [Roll Forward]        
Reversal of fair value of liability $ (833)   (833)  
France        
Changes In Contingent Consideration [Roll Forward]        
Reversal of fair value of liability     $ (241)  
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.7.0.1
Fair Value Measurements (Schedule of Valuation of Financial Assets and Liabilities) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2017
Jun. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign currency contracts-assets $ 486 [1] $ 160 [2]
Foreign currency contracts-liabilities 137 [3] 169 [4]
Derivative liability for interest rate swap [5] 581  
Contingent consideration 2,952 [6] 132 [7]
Time deposits    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 5,781 6,249
Investments 2,046 881
Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign currency contracts-assets [1] [2]
Foreign currency contracts-liabilities [3] [4]
Derivative liability for interest rate swap [5]  
Contingent consideration [6] [7]
Quoted Prices in Active Markets (Level 1) | Time deposits    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents
Investments
Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign currency contracts-assets 486 [1] 160 [2]
Foreign currency contracts-liabilities 137 [3] 169 [4]
Derivative liability for interest rate swap [5] 581  
Contingent consideration [6] [7]
Significant Other Observable Inputs (Level 2) | Time deposits    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents 5,781 6,249
Investments 2,046 881
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Foreign currency contracts-assets [1] [2]
Foreign currency contracts-liabilities [3] [4]
Derivative liability for interest rate swap [5]  
Contingent consideration 2,952 [6] 132 [7]
Significant Unobservable Inputs (Level 3) | Time deposits    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents
Investments
[1] Included in "Other receivables" in the accompanying Consolidated Balance Sheet as of June 30, 2017.
[2] Included in "Other receivables" in the accompanying Consolidated Balance Sheet as of June 30, 2016.
[3] Included in "Accrued expenses" in the accompanying Consolidated Balance Sheet as of June 30, 2017.
[4] Included in "Accrued expenses" in the accompanying Consolidated Balance Sheet as of June 30, 2016.
[5] Included in "Long-term liabilities" in the accompanying Consolidated Balance Sheet as of June 30, 2017.
[6] $145 included in "Accrued expenses" and $2,807 included in "Long-term liabilities" in the accompanying Consolidated Balance Sheet as of June 30, 2017.
[7] Included in "Long-term liabilities" in the accompanying Consolidated Balance Sheet as of June 30, 2016.
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.7.0.1
Fair Value Measurements (Schedule of Valuation of Financial Assets and Liabilities) (Parentheticals) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2017
Jun. 30, 2016
 [2]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration $ 2,952 [1] $ 132
Accrued expenses    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration 145  
Long-term liabilities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration $ 2,807  
[1] $145 included in "Accrued expenses" and $2,807 included in "Long-term liabilities" in the accompanying Consolidated Balance Sheet as of June 30, 2017.
[2] Included in "Long-term liabilities" in the accompanying Consolidated Balance Sheet as of June 30, 2016.
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.7.0.1
Fair Value Measurements (Narrative) (Detail) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Mar. 21, 2017
Nov. 30, 2015
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Dec. 21, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Unrealized gain (loss) recorded in accumulated other comprehensive income     $ (581)    
Accrued contingent consideration     2,952      
Aggregate principal amount   $ 143,750        
Theoretical borrowing rate used to calculate fair value of debt   6.50%        
Fair value of the notes     133,000 134,400    
Net reduction to capital in excess of par value   $ 13,489        
Foreign exchange contract            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Derivative, notional amount     62,187      
Unrealized gains (losses) on hedging activities     515 10 $ 703  
Interest rate swap | Cash flow hedging | December 21, 2021            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Derivative, notional amount $ 100,000          
Derivative, expiration date Dec. 21, 2021          
Remaining balance of derivative     95,000      
Additional interest cost rate of derivative 2.005%          
France Company            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Accrued contingent consideration     145 $ 132    
Citron and Lucid            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Accrued contingent consideration     $ 2,807     $ 2,580
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.7.0.1
Goodwill and Other Intangible Assets - Summary of changes in goodwill (Details) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Goodwill [Roll Forward]    
Beginning balance $ 67,871 $ 67,870
Acquisitions 169,071  
Changes in foreign currency exchange rates 28 1
Ending balance 236,970 67,871
Human Health Segment    
Goodwill [Roll Forward]    
Beginning balance 66,039 66,039
Acquisitions 169,071  
Changes in foreign currency exchange rates  
Ending balance 235,110 66,039
Pharmaceutical Ingredients Segment    
Goodwill [Roll Forward]    
Beginning balance 1,651 1,650
Acquisitions  
Changes in foreign currency exchange rates 23 1
Ending balance 1,674 1,651
Performance Chemicals Segment    
Goodwill [Roll Forward]    
Beginning balance 181 181
Acquisitions  
Changes in foreign currency exchange rates 5  
Ending balance $ 186 $ 181
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.7.0.1
Goodwill and Other Intangible Assets (Schedule of Intangible Assets Subject to Amortization) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2017
Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Line Items]    
Gross Carrying Value $ 355,184 $ 127,034
Accumulated Amortization 70,886 48,724
Net Book Value 284,298 78,310
Customer relationships    
Goodwill and Intangible Assets Disclosure [Line Items]    
Gross Carrying Value 110,787 21,761
Accumulated Amortization 13,968 7,815
Net Book Value 96,819 13,946
Trademarks    
Goodwill and Intangible Assets Disclosure [Line Items]    
Gross Carrying Value 2,218 1,868
Accumulated Amortization 2,195 1,800
Net Book Value 23 68
Product rights and related intangibles    
Goodwill and Intangible Assets Disclosure [Line Items]    
Gross Carrying Value 221,335 83,048
Accumulated Amortization 37,677 23,511
Net Book Value 183,658 59,537
License agreements    
Goodwill and Intangible Assets Disclosure [Line Items]    
Gross Carrying Value 6,537 6,611
Accumulated Amortization 6,035 5,531
Net Book Value 502 1,080
EPA registrations and related data    
Goodwill and Intangible Assets Disclosure [Line Items]    
Gross Carrying Value 14,307 13,591
Accumulated Amortization 11,011 9,927
Net Book Value $ 3,296 3,664
Technology-based intangibles    
Goodwill and Intangible Assets Disclosure [Line Items]    
Gross Carrying Value   155
Accumulated Amortization   140
Net Book Value   $ 15
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.7.0.1
Goodwill and Other Intangible Assets (Narrative) (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Line Items]      
Goodwill $ 236,970 $ 67,871 $ 67,870
Intangible assets amortization method straight-line method    
Indefinite-lived trademarks $ 783 761  
Amortization charges from acquired intangible assets 22,234 $ 11,176 $ 10,278
Estimated aggregate amortization expense for 2018 16,747    
Estimated aggregate amortization expense for 2019 32,431    
Estimated aggregate amortization expense for 2020 31,880    
Estimated aggregate amortization expense for 2021 31,819    
Estimated aggregate amortization expense for 2022 31,782    
Estimated aggregate amortization expense after 2023 $ 139,639    
Customer relationships | Minimum      
Goodwill and Intangible Assets Disclosure [Line Items]      
Finite-lived intangible assets, estimated useful life 7 years    
Customer relationships | Maximum      
Goodwill and Intangible Assets Disclosure [Line Items]      
Finite-lived intangible assets, estimated useful life 11 years    
Trademarks | Minimum      
Goodwill and Intangible Assets Disclosure [Line Items]      
Finite-lived intangible assets, estimated useful life 3 years    
Trademarks | Maximum      
Goodwill and Intangible Assets Disclosure [Line Items]      
Finite-lived intangible assets, estimated useful life 4 years    
Product rights and related intangibles | Minimum      
Goodwill and Intangible Assets Disclosure [Line Items]      
Finite-lived intangible assets, estimated useful life 3 years    
Product rights and related intangibles | Maximum      
Goodwill and Intangible Assets Disclosure [Line Items]      
Finite-lived intangible assets, estimated useful life 14 years    
License agreements | Minimum      
Goodwill and Intangible Assets Disclosure [Line Items]      
Finite-lived intangible assets, estimated useful life 6 years    
License agreements | Maximum      
Goodwill and Intangible Assets Disclosure [Line Items]      
Finite-lived intangible assets, estimated useful life 11 years    
EPA registrations and related data      
Goodwill and Intangible Assets Disclosure [Line Items]      
Finite-lived intangible assets, estimated useful life 10 years    
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.7.0.1
Accrued Expenses (Schedule of Components of Accrued Expenses) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2017
Jun. 30, 2016
Payables And Accruals [Abstract]    
Accrued compensation $ 5,793 $ 6,880
Accrued environmental remediation costs-current portion 6,112 9,180
Reserve for price concessions 80,556 31,342
Partnered product liabilities 16,068  
Other accrued expenses 9,799 5,273
Accrued expenses $ 118,328 $ 52,675
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.7.0.1
Environmental Remediation (Narrative) (Detail)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
USD ($)
Entity
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
Jun. 30, 2009
USD ($)
Site Contingency [Line Items]        
Environmental remediation charge included in selling, general and administrative expenses $ 903 $ 1,313 $ 1,618  
Pulvair Site Group        
Site Contingency [Line Items]        
Loss contingency, damages sought value 1,700      
Arsynco, Inc        
Site Contingency [Line Items]        
Accrual for environmental loss contingencies 8,451 12,532    
Environmental remediation charge included in selling, general and administrative expenses 903      
Arsynco, Inc | Minimum        
Site Contingency [Line Items]        
Site contingency loss exposure not accrued 21,500      
Arsynco, Inc | Maximum        
Site Contingency [Line Items]        
Site contingency loss exposure not accrued $ 23,300      
Arsynco, Inc | Berry's Creek Study Area        
Site Contingency [Line Items]        
Number of potentially responsible parties | Entity 150      
BASF Corporation        
Site Contingency [Line Items]        
Partial reimbursement of environmental remediation costs previously expensed       $ 550
Gain related to partial reimbursement       550
Environmental remediation costs expensed in prior years       $ 1,200
Future remediation costs receivable $ 3,803 $ 5,639    
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.7.0.1
Debt (Schedule of Long-term Debt) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2017
Jun. 30, 2016
Debt Instrument [Line Items]    
Mortgage $ 2,763 $ 2,960
Long-term debt including current portion 353,666 118,789
Less current portion 14,466 197
Long-term debt 339,200 118,592
Convertible Senior Notes, net    
Debt Instrument [Line Items]    
Long-term debt including current portion 121,676 115,829
Revolving Bank Loans    
Debt Instrument [Line Items]    
Long-term debt including current portion 90,000
Term bank loans    
Debt Instrument [Line Items]    
Long-term debt including current portion $ 139,227
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.7.0.1
Debt (Summary carrying value of Notes) (Detail 1) - USD ($)
$ in Thousands
Jun. 30, 2017
Jun. 30, 2016
Debt Instrument [Line Items]    
Net carrying value $ 353,666 $ 118,789
Convertible Senior Notes, net    
Debt Instrument [Line Items]    
Principal amount 143,750 143,750
Unamortized debt discount (19,255) (24,267)
Unamortized debt issuance costs (2,819) (3,654)
Net carrying value $ 121,676 $ 115,829
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.7.0.1
Debt (Summary interest expense related to notes recognized) (Detail 2) - Interest expense - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Debt Instrument [Line Items]    
Contractual coupon $ 2,867 $ 1,788
Amortization of debt discount 5,012 2,974
Amortization of debt issuance costs 835 522
Interest expense, total $ 8,714 $ 5,284
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.7.0.1
Debt (Maturity of Long-term Debt) (Detail 3) - USD ($)
$ in Thousands
Jun. 30, 2017
Jun. 30, 2016
Debt Disclosure [Abstract]    
2018 $ 14,466  
2019 14,466  
2020 14,466  
2021 138,115  
2022 172,153  
Thereafter  
Long-term Debt $ 353,666 $ 118,789
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.7.0.1
Debt (Narrative) (Detail)
$ / shares in Units, Share in Thousands, $ in Thousands
 1 Months Ended 12 Months Ended
Nov. 30, 2015
USD ($)
Share
$ / shares
Jun. 30, 2017
USD ($)
Day
Jun. 30, 2016
USD ($)
Debt Instrument [Line Items]      
Aggregate principal amount $ 143,750    
Aggregate proceeds from convertible senior notes     $ 143,750
Convertible Senior Notes due 2020      
Debt Instrument [Line Items]      
Aggregate principal amount 125,000    
Aggregate principal amount of additional convertible debt 18,750    
Aggregate proceeds from convertible senior notes $ 143,750    
Debt interest rate 2.00%    
Number of common stock issue in conversion debt | Share 4,328    
Senior notes, initial conversion price per share | $ / shares $ 33.215    
Threshold multiple for debt conversion of notes   $ 1,000  
Threshold trading days for convertible debt | Day   20  
Threshold consecutive trading days for convertible debt | Day   30  
Measurement period   5 days  
Percentage of minimum stock price trigger for conversion   130.00%  
Maximum calculated percentage to which trading price of notes is compared in order to trigger conversion feature of notes   98.00%  
XML 84 R70.htm IDEA: XBRL DOCUMENT v3.7.0.1
Debt (Narrative) (Detail 1)
$ in Thousands
 1 Months Ended
Dec. 21, 2016
USD ($)
Bank
Installment
Jun. 30, 2017
USD ($)
Aug. 26, 2016
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2015
Debt Instrument [Line Items]          
Available lines of credit with foreign financial institutions   $ 7,351   $ 7,397  
Short term loans, fixed interest rate   4.50%   4.50% 5.00%
Bank loans outstanding   $ 232,500   $ 0  
Bank loans, unused borrowing capacity   140,613   155,639  
Number of banks | Bank 11        
Borrowed loans   353,666   118,789  
Revolving Bank Loans          
Debt Instrument [Line Items]          
Borrowed loans   90,000    
Deferred financing costs   1,748      
Revolving Bank Loans | Amended and Restated Credit Agreement          
Debt Instrument [Line Items]          
Aggregate revolving commitment $ 225,000   $ 150,000    
Borrowed loans   $ 90,000      
Maturity date description Maturity Date shall mean the date that is 91 days prior to the 2015 Convertible Maturity Date        
Revolving Bank Loans | Amended and Restated Credit Agreement | Eurodollar | Minimum          
Debt Instrument [Line Items]          
Marginal rate added   3.21%      
Revolving Bank Loans | Amended and Restated Credit Agreement | Eurodollar | Maximum          
Debt Instrument [Line Items]          
Marginal rate added   3.45%      
Standby letters of credit          
Debt Instrument [Line Items]          
Letters of credit   $ 1,737   1,758  
Initial Term Loan          
Debt Instrument [Line Items]          
Borrowed loans   139,227    
Number of installments | Installment 19        
Frequency of periodic payment Quarterly        
Principal payment $ 3,750        
Short-term debt   15,000      
Deferred financing costs   3,659      
Initial Term Loan | Amended and Restated Credit Agreement          
Debt Instrument [Line Items]          
Borrowed loans 150,000        
Aggregate amount increase $ 100,000        
Remaining amount outstanding   $ 142,500      
Initial Term Loan | Amended and Restated Credit Agreement | Eurodollar          
Debt Instrument [Line Items]          
Marginal rate added   3.30%      
XML 85 R71.htm IDEA: XBRL DOCUMENT v3.7.0.1
Debt (Narrative) (Detail 2) - USD ($)
$ in Thousands
 1 Months Ended
Jun. 30, 2011
Jun. 30, 2017
Jun. 30, 2016
Debt Instrument [Line Items]      
Mortgage payable   $ 2,763 $ 2,960
Mortgage      
Debt Instrument [Line Items]      
Mortgage payable $ 3,947    
Mortgage payable, amortization period 20 years    
Debt interest rate   4.92%  
XML 86 R72.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock Based Compensation Plans (Schedule of Shares of Common Stock under Options for All Plans) (Detail) - Common stock under option - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Shares subject to option      
Beginning balance 302 397 551
Shares, Granted 28    
Shares subject to option, Exercised (70) (95) (146)
Shares subject to option, Forfeited (including cancelled options) (8)
Ending balance 260 302 397
Shares subject to option, options exercisable at June 30, 2017 232    
Weighted average exercise price per share      
Weighted average exercise price per share, beginning balance $ 7.19 $ 7.28 $ 7.72
Weighted average exercise price per share, granted 20.03
Weighted average exercise price per share, exercised 7.90 7.56 8.74
Weighted average exercise price per share, forfeited (including canceled options) 10.94
Weighted average exercise price per share, ending balance 8.36 $ 7.19 $ 7.28
Weighted average exercise price per share, options exercisable at June 30, 2017 $ 6.98    
Aggregate Intrinsic Value, Balance at June 30, 2017 $ 1,968    
Aggregate Intrinsic Value, Options exercisable at June 30, 2017 $ 1,968    
XML 87 R73.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock Based Compensation Plans (Summary of non-vested stock options) (Detail) - Stock Option
shares in Thousands
 12 Months Ended
Jun. 30, 2017
$ / shares
shares
Shares subject to option  
Shares subject to option, Non-vested at June 30, 2016 | shares
Shares subject to option, Granted | shares 28
Shares subject to option, Vested | shares
Shares subject to option, Forfeited | shares
Shares subject to option, Non-vested at June 30, 2017 | shares 28
Weighted average grant date fair value  
Weighted average grant date fair value, Non-vested at June 30, 2016 | $ / shares
Weighted average grant date fair value, Granted | $ / shares 5.44
Weighted average grant date fair value, Vested | $ / shares
Weighted average grant date fair value, Forfeited | $ / shares
Weighted average grant date fair value, Non-vested at June 30, 2017 | $ / shares $ 5.44
XML 88 R74.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock Based Compensation Plans (Per-share fair value of stock options granted using Monte Carlo simulation option-pricing model) (Detail) - Stock Option
 12 Months Ended
Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expected life 4 years 10 months 24 days
Expected volatility 39.40%
Risk-free interest rate 1.26%
Dividend yield 1.30%
XML 89 R75.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock Based Compensation Plans (Schedule of Restricted Stock Awards Including Restricted Stock Units) (Detail) - Restricted stock awards and restricted stock units
shares in Thousands
 12 Months Ended
Jun. 30, 2017
$ / shares
shares
Non-vested, Shares  
Non-vested at beginning of year | shares 795
Granted | shares 501
Vested | shares (396)
Forfeited | shares (103)
Non-vested at June 30, 2017 | shares 797
Non-vested, Weighted average grant date fair value  
Non-vested at beginning of year | $ / shares $ 20.73
Granted | $ / shares 18.92
Vested | $ / shares 17.26
Forfeited | $ / shares 21.33
Non-vested at June 30, 2017 | $ / shares $ 21.24
XML 90 R76.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock Based Compensation (Narrative) (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 1 Months Ended 12 Months Ended
Sep. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Dec. 15, 2015
Dec. 06, 2012
Dec. 06, 2007
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Stock options exercised, total intrinsic value   $ 865 $ 1,700 $ 1,713      
Weighted average remaining contractual term   4 years          
Stock issued pursuant to employee stock incentive plans   $ 109 113 77      
Non-cash restricted stock expense   26 22 22      
Non-cash stock option plan expense is included in selling, general and administrative expenses   55 0 21      
Non-cash stock compensation included in selling, general and administrative expenses   6,956 $ 6,719 $ 4,537      
Unrecognized compensation of stock options   $ 95          
Common Stock              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Restricted stock awarded and premium shares vested, common shares   5 7 5      
Stock issued pursuant to employee stock incentive plans            
Restricted Stock | Employees              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Common stock granted, shares   277 221 165      
Restricted stock units, vesting period   3 years 3 years 3 years      
Restricted Stock | Non Employee Directors              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Common stock granted, shares   22 14 12      
Restricted stock units, vesting period   1 year 1 year 1 year      
Performance-vested restricted stock units              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Common stock granted, shares   160 142 116      
Upper limit of target grant, shares     248 203      
Performance-vested restricted stock units, vesting percentage   100.00% 100.00% 100.00%      
Restricted stock units, vesting period   3 years 3 years 3 years      
Restricted stock awards and restricted stock units              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Non-cash stock option plan expense is included in selling, general and administrative expenses   $ 6,875 $ 6,697 $ 4,494      
Common stock granted, shares   501          
Remaining stock-based compensation expense   $ 8,382          
Remaining stock-based compensation expense, period for recognition   1 year 9 months 18 days          
Restricted stock units              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Upper limit of target grant, shares   280          
Restricted stock units | Employees              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Common stock granted, shares   42 46 67      
Performance Stock Options | Executive Officer              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of shares granted 28            
Exercise price of performance options granted $ 20.03            
Target price performance stock options $ 40            
Number of trading days 20 days            
Explicit service period 1 year            
Expiration date of stock options Jun. 30, 2021            
Expiration period of option if target price achieved 10 years            
Stock Option              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of shares granted   28          
Exercise price of performance options granted   $ 20.03      
Weighted average grant date fair value, Granted   $ 5.44          
2015 Plan              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Maximum number of shares of common stock that may be issued         4,250    
Shares of common stock available for grant   3,144          
2010 Plan              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Maximum number of shares of common stock that may be issued           5,250  
Shares of common stock available for grant   255          
2007 Plan              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Maximum number of shares of common stock that may be issued             700
Shares of common stock available for grant   0          
XML 91 R77.htm IDEA: XBRL DOCUMENT v3.7.0.1
Interest and Other Income (Schedule of Interest and other income) (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Other Income And Expenses [Abstract]      
Dividends $ 277 $ 222 $ 233
Interest 264 313 282
Foreign government subsidies received 64 25 22
Joint venture equity earnings 2,336 2,060 1,761
Foreign currency (losses) gains (298) 56 (1,065)
Deferred compensation plan losses (257) (35) (96)
Rental income 158 154 151
Miscellaneous income 33 28 198
Interest and other income $ 2,577 $ 2,823 $ 1,486
XML 92 R78.htm IDEA: XBRL DOCUMENT v3.7.0.1
Interest and Other Income (Narrative) (Detail)
$ in Thousands
Jun. 30, 2009
USD ($)
Other Income And Expenses [Abstract]  
Initial investment in joint venture, cost $ 6
Initial investment in joint venture, percentage 30.00%
XML 93 R79.htm IDEA: XBRL DOCUMENT v3.7.0.1
Income Taxes (Schedule of Provision for Income Taxes) (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Income Tax Disclosure [Abstract]      
Domestic operations $ 9,555 $ 43,906 $ 48,276
Foreign operations 7,806 9,948 5,589
Income before income taxes 17,361 53,854 53,865
Federal:      
Current 3,713 15,129 18,393
Deferred (585) (204) (1,357)
State and local:      
Current 555 755 1,526
Deferred (110) 173 189
Foreign:      
Current 2,221 3,222 2,337
Deferred 191 13 (706)
Provision for income taxes $ 5,985 $ 19,088 $ 20,382
XML 94 R80.htm IDEA: XBRL DOCUMENT v3.7.0.1
Income Taxes (Schedule of Tax Effects of Temporary Differences that Give Rise to the Deferred Tax Assets and Liabilities) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2017
Jun. 30, 2016
Deferred tax assets:    
Accrued deferred compensation $ 4,229 $ 4,122
Accrual for sales deductions not currently deductible 5,796 5,925
Additional inventoried costs for tax purposes 697 389
Allowance for doubtful accounts receivable 106 106
Depreciation and amortization 11,957 7,784
Debt issuance costs 7,611 9,462
Foreign deferred tax assets 983 1,121
Domestic net operating loss carryforwards 81 109
Foreign net operating loss carryforwards 692 685
Total gross deferred tax assets 32,152 29,703
Valuation allowances (773) (794)
Deferred tax assets, net 31,379 28,909
Deferred tax liabilities:    
Foreign deferred tax liabilities (65) (27)
Goodwill (10,244) (7,586)
Original issue discount - convertible senior notes (7,260) (9,115)
Other (1,136) (26)
Total gross deferred tax liabilities (18,705) (16,754)
Net deferred tax assets $ 12,674 $ 12,155
XML 95 R81.htm IDEA: XBRL DOCUMENT v3.7.0.1
Income Taxes (Schedule of Current and Non-Current Deferred Tax Assets (Liabilities)) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2017
Jun. 30, 2016
Income Tax Disclosure [Abstract]    
Current deferred tax assets, net $ 546 $ 3,244
Non-current deferred tax assets, net 19,453 18,053
Non-current deferred tax liabilities (7,325) (9,142)
Net deferred tax assets $ 12,674 $ 12,155
XML 96 R82.htm IDEA: XBRL DOCUMENT v3.7.0.1
Income Taxes (Schedule of Reconciliation of Statutory Federal Income Tax Rate and Effective Tax Rate for Continuing Operations) (Detail)
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Income Tax Disclosure [Abstract]      
Federal statutory tax rate 35.00% 35.00% 35.00%
State and local taxes, net of federal income tax benefit 1.20% 1.70% 2.40%
Decrease (increase) in valuation allowance 0.10% 0.40%
Foreign tax rate differential (1.80%) (0.40%) (0.90%)
Other (0.90%) 0.90%
Effective tax rate 34.50% 35.40% 37.80%
XML 97 R83.htm IDEA: XBRL DOCUMENT v3.7.0.1
Income Taxes (Narrative) (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Income Tax Disclosure [Abstract]    
Income taxes payable included in accrued expenses $ 64 $ 2,119
Net change in total valuation allowance 21 16
Future taxable income required to fully realize the net deferred tax assets 34,638  
Undistributed earnings of foreign subsidiaries 111,569  
Federal net operating loss carryforwards 0  
State net operating loss carryforwards 81  
Foreign net operating loss carryforwards $ 692 $ 685
XML 98 R84.htm IDEA: XBRL DOCUMENT v3.7.0.1
Supplemental Cash Flow Information (Schedule of Cash Paid for Interest and Income Taxes) (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Supplemental Cash Flow Elements [Abstract]      
Interest $ 7,794 $ 2,970 $ 3,954
Income taxes, net of refunds $ 7,912 $ 16,076 $ 25,459
XML 99 R85.htm IDEA: XBRL DOCUMENT v3.7.0.1
Supplemental Cash Flow Information (Narrative) (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Supplemental Cash Flow Information [Line Items]      
Environmental remediation costs and property held for sale $ 284 $ 294 $ 726
Measurement period adjustments to goodwill     $ 1,578
Contingent earn out liability $ 2,580    
Citron and Lucid | December 21, 2019      
Supplemental Cash Flow Information [Line Items]      
Number of shares to be issued 5,122    
Fair market value of shares of common stock issued in acquisition $ 90,400    
Citron and Lucid | December 21, 2021      
Supplemental Cash Flow Information [Line Items]      
Unsecured deferred payment payable $ 50,000    
XML 100 R86.htm IDEA: XBRL DOCUMENT v3.7.0.1
Retirement Plans (Narrative) (Detail) - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Compensation And Retirement Disclosure [Abstract]      
Provision for defined contribution plans $ 1,794 $ 1,957 $ 1,849
Accrued pension liability 883 853  
Net periodic pension costs, principally of interest cost and service cost $ 30 $ 28 $ 53
Actuarial present value of benefit obligations, assumed weighted average discount rate 2.00% 1.90% 1.60%
Actuarial present value of benefit obligations, assumed compensation increase rate 0.00% 0.00% 0.00%
Liability under the deferred compensation plans, total $ 3,551 $ 3,046  
Liability under deferred compensation plan included in long-term liabilities 3,337 3,028  
Liability under deferred compensation plan included in accrued expenses 214 18  
Deferred compensation plan assets $ 3,087 $ 2,693  
XML 101 R87.htm IDEA: XBRL DOCUMENT v3.7.0.1
Financial Instruments (Narrative) (Detail)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
USD ($)
Customer
Product
Jun. 30, 2016
USD ($)
Customer
Product
Jun. 30, 2015
Customer
Product
Accounts Receivable      
Financial Instruments Owned and Pledged as Collateral [Line Items]      
Concentration Risk, Number | Customer 3 3  
Accounts Receivable | Customer One      
Financial Instruments Owned and Pledged as Collateral [Line Items]      
Percentage of net trade accounts receivable attributable to single customer 31.00% 34.00%  
Accounts Receivable | Customer Two      
Financial Instruments Owned and Pledged as Collateral [Line Items]      
Percentage of net trade accounts receivable attributable to single customer 21.00% 20.00%  
Accounts Receivable | Customer three      
Financial Instruments Owned and Pledged as Collateral [Line Items]      
Percentage of net trade accounts receivable attributable to single customer 15.00% 11.00%  
Net sales | Customer One      
Financial Instruments Owned and Pledged as Collateral [Line Items]      
Concentration Risk, Number | Customer 1 1 1
Percentage of net sales attributable to single customer 12.00% 14.00% 13.00%
Net sales | Customer Two      
Financial Instruments Owned and Pledged as Collateral [Line Items]      
Percentage of net sales attributable to single customer 11.00% 7.00% 6.00%
Product Concentration | Net sales      
Financial Instruments Owned and Pledged as Collateral [Line Items]      
Concentration Risk, Number | Product 0 0 0
Minimum percentage of net sales for separate disclosure 10.00% 10.00% 10.00%
Geographic Concentration | Purchases | Europe      
Financial Instruments Owned and Pledged as Collateral [Line Items]      
Percentage of purchases for a single geographic area 17.00% 22.00% 12.00%
Net assets by geographic area | $ $ 68,235 $ 62,399  
Geographic Concentration | Purchases | Asia      
Financial Instruments Owned and Pledged as Collateral [Line Items]      
Percentage of purchases for a single geographic area 62.00% 56.00% 65.00%
Net assets by geographic area | $ $ 50,641 $ 48,846  
XML 102 R88.htm IDEA: XBRL DOCUMENT v3.7.0.1
Commitments, Contingencies and Other Matters (Schedule of Future Minimum Lease Payments) (Detail)
$ in Thousands
Jun. 30, 2017
USD ($)
Commitments And Contingencies Disclosure [Abstract]  
2018 $ 1,673
2019 2,327
2020 1,766
2021 1,327
2022 1,031
Thereafter 6,744
Total future minimum lease payments $ 14,868
XML 103 R89.htm IDEA: XBRL DOCUMENT v3.7.0.1
Commitments, Contingencies and Other Matters (Narrative) (Detail)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
USD ($)
Entity
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
Jun. 30, 2009
USD ($)
Commitments and Contingencies Disclosure [Line Items]        
Outstanding purchase obligations $ 61,381      
Environmental remediation charge included in selling, general and administrative expenses 903 $ 1,313 $ 1,618  
Total rental expense 1,301 1,265 $ 1,567  
Subsidiary        
Commitments and Contingencies Disclosure [Line Items]        
Amount expected to be paid for product registrations and various task force groups 2,357      
Amount accrued for product registrations and various task force groups 0 0    
Pulvair Site Group        
Commitments and Contingencies Disclosure [Line Items]        
Loss contingency, damages sought 1,700      
Arsynco, Inc        
Commitments and Contingencies Disclosure [Line Items]        
Environmental remediation charge included in selling, general and administrative expenses 903      
Accrual for environmental loss contingencies 8,451 12,532    
Arsynco, Inc | Minimum        
Commitments and Contingencies Disclosure [Line Items]        
Site contingency loss exposure not accrued 21,500      
Arsynco, Inc | Maximum        
Commitments and Contingencies Disclosure [Line Items]        
Site contingency loss exposure not accrued 23,300      
BASF Corporation        
Commitments and Contingencies Disclosure [Line Items]        
Gain related to partial reimbursement       $ 550
Partial reimbursement of environmental remediation costs previously expensed       550
Environmental remediation costs expensed in prior years       $ 1,200
Future remediation costs receivable $ 3,803 $ 5,639    
Berry's Creek Study Area | Arsynco, Inc        
Commitments and Contingencies Disclosure [Line Items]        
Number of potentially responsible parties | Entity 150      
XML 104 R90.htm IDEA: XBRL DOCUMENT v3.7.0.1
Related Party Transactions (Narrative) (Detail)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
Oct. 31, 2017
ft²
Joint Venture        
Related Party Transaction [Line Items]        
Inventory purchases $ 3,236 $ 2,831 $ 3,204  
Rising Health        
Related Party Transaction [Line Items]        
Amount of cost incurred 1,865      
Rising Health | Subsequent Event        
Related Party Transaction [Line Items]        
Gross area of warehouse space expected to lease | ft²       125,000
Acetris Health        
Related Party Transaction [Line Items]        
Amount of cost incurred $ 165      
XML 105 R91.htm IDEA: XBRL DOCUMENT v3.7.0.1
Related Party Transactions (Narrative) (Detail 1) - Cronus Research Labs Private Limited - USD ($)
$ in Thousands
 3 Months Ended
Nov. 02, 2016
Dec. 31, 2015
Development Agreement I    
Related Party Transaction [Line Items]    
Amount of cost incurred   $ 3,500
Two amended and restated joint development agreements, description Under the terms of Development Agreement I, Cronus has agreed to pay the first $3,500 of the development costs incurred after December 21, 2016, and 50% of any development costs incurred above that threshold in exchange for obtaining reimbursement for its costs funded out of the profits earned, if any, from the pipeline products that are commercially launched, and a specified portion of the profits from those products thereafter.  
Percentage of development costs incurred above threshold   50.00%
Development Agreement II    
Related Party Transaction [Line Items]    
Amount of cost incurred $ 1,445  
Two amended and restated joint development agreements, description Under the terms of Development Agreement II, Cronus has agreed to pay the development costs for the products covered thereby in exchange for obtaining reimbursement for its costs funded out of the profits earned, if any, from such products that are commercially launched (subject to a $1,445 maximum), and a specified portion of the profits from those products thereafter.  
XML 106 R92.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information (Schedule of Segment Perfomance Measures by Segment) (Detail) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Jun. 30, 2017
 [1],[2]
Mar. 31, 2017
 [2],[3]
Dec. 31, 2016
 [2]
Sep. 30, 2016
 [4]
Jun. 30, 2016
 [5]
Mar. 31, 2016
 [6]
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Segment Reporting Information [Line Items]                      
Net sales $ 194,620 $ 190,128 $ 125,552 $ 128,018 $ 135,424 $ 157,926 $ 131,674 $ 133,500 $ 638,318 $ 558,524 $ 546,951
Gross profit $ 36,829 $ 42,319 $ 30,805 $ 30,839 $ 34,047 $ 38,289 $ 35,868 $ 34,581 140,792 142,785 135,434
Income before income taxes                 17,361 53,854 53,865
Operating Segments | Human Health                      
Segment Reporting Information [Line Items]                      
Net sales                 315,395 228,035 225,263
Gross profit                 78,109 77,880 75,749
Income before income taxes                 15,434 36,362 35,152
Operating Segments | Pharmaceutical Ingredients                      
Segment Reporting Information [Line Items]                      
Net sales                 157,445 161,011 149,296
Gross profit                 25,474 28,752 26,683
Income before income taxes                 9,322 11,856 8,697
Operating Segments | Performance Chemicals                      
Segment Reporting Information [Line Items]                      
Net sales                 165,478 169,478 172,392
Gross profit                 37,209 36,153 33,002
Income before income taxes                 18,829 17,799 14,289
Unallocated Corporate                      
Segment Reporting Information [Line Items]                      
Net sales                
Gross profit                
Income before income taxes                 $ (26,224) $ (12,163) $ (4,273)
[1] Includes pretax item of $3,139 representing immaterial correction of an error associated with certain accrued expenses.
[2] Results for the last nine days of the quarter ended December 31, 2016 and for the subsequent two quarters reflect the acquisition of certain generic products and related assets from Citron and Lucid on December 21, 2016.
[3] Includes pretax item of $733 environmental remediation charge in connection with Arsynco.
[4] Includes pretax item of $170 environmental remediation charge in connection with Arsynco.
[5] Includes pretax item of $1,313 environmental remediation charge in connection with Arsynco.
[6] Includes pretax items consisting of $833 reversal of contingent consideration related to the PACK acquisition and $241 reversal of contingent consideration related to the acquisition of a company in France.
XML 107 R93.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information (Schedule of Net Sales and Gross Profit by Source Country) (Detail) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Jun. 30, 2017
 [1],[2]
Mar. 31, 2017
 [2],[3]
Dec. 31, 2016
 [2]
Sep. 30, 2016
 [4]
Jun. 30, 2016
 [5]
Mar. 31, 2016
 [6]
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Segment Reporting Information [Line Items]                      
Net Sales $ 194,620 $ 190,128 $ 125,552 $ 128,018 $ 135,424 $ 157,926 $ 131,674 $ 133,500 $ 638,318 $ 558,524 $ 546,951
Gross Profit $ 36,829 $ 42,319 $ 30,805 $ 30,839 $ 34,047 $ 38,289 $ 35,868 $ 34,581 140,792 142,785 135,434
Geographic region | United States                      
Segment Reporting Information [Line Items]                      
Net Sales                 483,678 400,883 407,101
Gross Profit                 116,792 117,180 111,734
Geographic region | Germany                      
Segment Reporting Information [Line Items]                      
Net Sales                 79,105 76,666 69,889
Gross Profit                 13,609 15,154 14,660
Geographic region | Netherlands                      
Segment Reporting Information [Line Items]                      
Net Sales                 9,949 16,217 14,656
Gross Profit                 1,231 1,598 1,325
Geographic region | France                      
Segment Reporting Information [Line Items]                      
Net Sales                 35,796 30,177 27,976
Gross Profit                 4,651 4,043 3,634
Geographic region | Asia-Pacific                      
Segment Reporting Information [Line Items]                      
Net Sales                 29,790 34,581 27,329
Gross Profit                 $ 4,509 $ 4,810 $ 4,081
[1] Includes pretax item of $3,139 representing immaterial correction of an error associated with certain accrued expenses.
[2] Results for the last nine days of the quarter ended December 31, 2016 and for the subsequent two quarters reflect the acquisition of certain generic products and related assets from Citron and Lucid on December 21, 2016.
[3] Includes pretax item of $733 environmental remediation charge in connection with Arsynco.
[4] Includes pretax item of $170 environmental remediation charge in connection with Arsynco.
[5] Includes pretax item of $1,313 environmental remediation charge in connection with Arsynco.
[6] Includes pretax items consisting of $833 reversal of contingent consideration related to the PACK acquisition and $241 reversal of contingent consideration related to the acquisition of a company in France.
XML 108 R94.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information (Schedule of Long-Lived Assets by Geographic Region) (Detail) - USD ($)
$ in Thousands
Jun. 30, 2017
Jun. 30, 2016
Segment Reporting Information [Line Items]    
Long-lived assets $ 532,479 $ 156,986
Geographic region | United States    
Segment Reporting Information [Line Items]    
Long-lived assets 528,359 152,701
Geographic region | Europe    
Segment Reporting Information [Line Items]    
Long-lived assets 2,538 2,504
Geographic region | Asia-Pacific    
Segment Reporting Information [Line Items]    
Long-lived assets $ 1,582 $ 1,781
XML 109 R95.htm IDEA: XBRL DOCUMENT v3.7.0.1
Segment Information (Narrative) (Detail)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
USD ($)
Principal_Segment
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
Segment Reporting Information [Line Items]      
Number of operating segments | Principal_Segment 3    
Foreign Segments | United States      
Segment Reporting Information [Line Items]      
Sales generated from the United States to foreign countries | $ $ 21,750 $ 23,810 $ 38,295
XML 110 R96.htm IDEA: XBRL DOCUMENT v3.7.0.1
Unaudited Quarterly Financial Data (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Jun. 30, 2017
 [1],[2]
Mar. 31, 2017
 [2],[3]
Dec. 31, 2016
 [2]
Sep. 30, 2016
 [4]
Jun. 30, 2016
 [5]
Mar. 31, 2016
 [6]
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Quarterly Financial Information Disclosure [Abstract]                      
Net sales $ 194,620 $ 190,128 $ 125,552 $ 128,018 $ 135,424 $ 157,926 $ 131,674 $ 133,500 $ 638,318 $ 558,524 $ 546,951
Gross profit 36,829 42,319 30,805 30,839 34,047 38,289 35,868 34,581 140,792 142,785 135,434
Net income (loss) $ 1,967 $ 5,588 $ (564) $ 4,385 $ 6,774 $ 10,424 $ 8,270 $ 9,298 $ 11,376 $ 34,766 $ 33,483
Net income (loss) per diluted share (in dollars per share) $ 0.06 $ 0.16 $ (0.02) $ 0.15 $ 0.23 $ 0.35 $ 0.28 $ 0.32 $ 0.35 $ 1.18 $ 1.14
[1] Includes pretax item of $3,139 representing immaterial correction of an error associated with certain accrued expenses.
[2] Results for the last nine days of the quarter ended December 31, 2016 and for the subsequent two quarters reflect the acquisition of certain generic products and related assets from Citron and Lucid on December 21, 2016.
[3] Includes pretax item of $733 environmental remediation charge in connection with Arsynco.
[4] Includes pretax item of $170 environmental remediation charge in connection with Arsynco.
[5] Includes pretax item of $1,313 environmental remediation charge in connection with Arsynco.
[6] Includes pretax items consisting of $833 reversal of contingent consideration related to the PACK acquisition and $241 reversal of contingent consideration related to the acquisition of a company in France.
XML 111 R97.htm IDEA: XBRL DOCUMENT v3.7.0.1
Unaudited Quarterly Financial Data (Narrative) (Detail) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Jun. 30, 2017
Mar. 31, 2017
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Effect of Fourth Quarter Events [Line Items]                
Environmental remediation charge           $ 903 $ 1,313 $ 1,618
Contingent consideration             (1,074) $ (3,468)
Immaterial Correction Of Error $ 3,139              
Pack Pharmaceuticals Llc                
Effect of Fourth Quarter Events [Line Items]                
Contingent consideration         $ (833)   (833)  
Arsynco, Inc                
Effect of Fourth Quarter Events [Line Items]                
Environmental remediation charge   $ 733 $ 170 $ 1,313        
France                
Effect of Fourth Quarter Events [Line Items]                
Contingent consideration             $ (241)  
XML 112 R98.htm IDEA: XBRL DOCUMENT v3.7.0.1
Valuation and Qualifying Accounts (Detail) - Allowance for Doubtful Accounts - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2015
Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at beginning of year $ 513 $ 691 $ 517
Charged to costs and expenses (3) 76 484
Charged to other accounts
Deductions [1] 25 254 310
Balance at end of year $ 485 $ 513 $ 691
[1] Specific accounts written off as uncollectible.
EXCEL 113 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
  •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�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

    C6.T][>3$V(L^?#GO_5 + @*-U Q8+7>H M@1!-I&3\FCG]I:1.7._?V#\9[\K+"0NH&?G9G66[]PO?.\,%WXA\8N-GF/VD MOC>;_PIW( JNE:@:#2/"/+WF)B2C,XN20O'KM':]6<>9_RW-G8#F!+0D1-E_ M$^(Y(7Y/2(SY29FQ^A%+7)6_,.^56J.B]RA J M@[LFFC&'"8-6F&A!!(I]*8%<)0YHDVX5J+>(&+DKQ$X3LZK]T%5TFV2/2=\^*']2$FP;2.\TT'K]A?NUZX9V8 M5#?;W+\+8Q*4QO!!-:I5$WDY$+A(O&PO=V]R:W-H965T*VAE[.^9RHY MD"9SW[^Y?;.VZE@.5L./L M=WU2U<;/?.\$9WIEZH7W7V&L)_:]L?CO< .FY283S3AR)NVO=[Q*Q9O11:?2 MT/>AK5O;]L-*>@]S!X1C0#@%X.AA !D#R"( #9G94C]31'C<0DF7V=X>:L91AG:;9,!\WNLWE??U!Q MJ5OI';C23X.]P&?.%6C+X$EO8*6?]&G X*Q,-]5],3QLPT#Q;GRST?3'4?X# M4$L#!!0 ( &I8&4O5X+_MQP( (T* 9 >&PO=V]R:W-H965TJT[;.;. DJ8&8[ M2??O9QM"J3FZ[@O8YKGGN3MS]BTN4CWKHQ F>JG*6B_CHS'-;9+H[5%47-_( M1M3VRUZJBAL[58=$-TKPG3>JR@2G*4LJ7M3Q:N'7'M1J(4^F+&KQH")]JBJN M_JQ%*2_+&,77A%P?&7_Y(.WP3QQ+3:R_%7LS'$9S^)H)_;\5)I'>?DLNH"R..JB_RK.HK1P MYXG5V,I2^V>T/6DCJX[%NE+QE_9=U/Y]Z?BO9K ![@QP;T#8NP:D,R"] :;O M&M#.@+X:M-EJ0_&YN>>&KQ9*7B+5;F_#W5^$;JG-_M8M^F3[;S8]VJZ>5XRD MB^3LB#K,NL7@ 89F["UF,\:@'I%8#WHW,.3&&H_,&4&!!(3!;S'W8PS-YK C M!,P'\01D*()2F(""!-03T %!1FB0T!;#/*9NDT5)GDWH9*!.-M)AA 39R/Y+ MAX$Z#-"A,$$.$N0?S^@,))A](*,M)AM&BK,TG="9@SIS(-(LT)F/=6:3"44I M7'+IO[=NW8$^NG=HHKH1(,5"*0B43^B Y7N',$ Q"W7P*'F4X-F$$%R>B !" M\U"H!DH$+ M&0&53'$HPT8R9$H&+G>4 S(DE(% $Z<*@D\%-#X6&,U"'0C$)G3@4P$!QP+- M0QT(%/[9R>!.KH0Z^'Y'1UMYJHV[LP:K?4]UA]V='JQO7*_E[_I7FK91^\;5 MH:AU]"2-[1C\O;Z7T@CK8WIC-_5H>\-^4HJ]<794C"SQ??C_M#T[V(5HM3MM=_Z.;/TUO5/D63E^VQT&5] M-&50Z=TR?"0/KYQU!CWBKZ.^U%??@RZ5=V-^= ^_;I=AW#'2N=XTG8NL_?C0 MSSK/.T\MCW]&I^$4LS.\_O[I_;5/ODWF/:OUL\G_/FZ;PS),PF"K=]DY;[Z; MRR]Z3$B$P9C];_I#YRV\8]+&V)B\[O\&FW/=F&+TTE(ILI_#Y['L/R^C_T\S M;$!' WJK 1L-V&1 R9<&?#3@MQJ(T4#<:B!' SD9$-ZOQU"LOOHO69.M%I6Y M!-6P@4Y9MT_)@VS7=].][)>S_U^[ '7[]F,E>;J(/CI'(^9IP- K#!=RPD2M M_RD(14&>J.- BG@>Y-G%<)',,2_(#YECULB/E="KBU$ISH?!HK'>GEWS(#%V MP*$#WCO@LT2H59 !(WM,.9!D3K8(E"I,14 J E!A%A6$X1:3&S"O+H9+@]DCH#6490=<)IW'L[$G@2_AJ@CL388!-:K-A;OD53SR!< 4CMY!&*>.%CW! A?N9 M CU+ST2E6(3TCO,!Q?*B2%Y.M@CDD3'%&J1@;$M/RZ%8@U3>D2W6# 6:449E11KAJ:W%X5AS3 PWIQ&,H)FZ;*44KLL MP)EOLC"L/P:DI>QN,X)F='QAL/P8D)]B=A@$\G0DYCG"@T&IA!V'.5N.*>%; M1JQD!D2J[)/B"!+VZ/%$PEIFZ ANS_X1-#NA2>]6P(IG8.HJ3XMD6/%,W:$/ MK%*&SKR)O8+@T/O%3&=8S0Q,0.6$2MW^%/M#<:QZ#E2O[$4<0;-0?/8;9QX* M*YH#12<^%UBMG-[Q2Q@+D0,A.I,.@1*[(T=7=QZ%KO;]C54=;,RY[*_+KMY. MMV*/M+\S^1\^7*G]GE7[8UD'[Z9I3-'?C^R,:73+)?[6;J:#SK;30ZYW3?=5 MM=^KX2IK>&C,:;RFBZ:[PM5_4$L#!!0 ( &I8&4O&IZQB(P( %4& 9 M >&PO=V]R:W-H965T0FBN&[<(C>Q R]R M=I6D;N# '7&E%/,_6R"LV[B^^QIXK"^5U %4Y"V^P ^0/]L#5RLTJIQJ"HVH M6>-P.&_<>W^]7VF\ ?RJH1.3N:,K.3+VI!=?3QO7TPD!@5)J!:R&&^R $"VD MTG@>--W14A.G\U?U!U.[JN6(!>P8^5V?9+5Q,]MWXG"@V0G!0 A&@O+^C! . MA/"-$'U*B 9"-".@OA1S-GLL<9%SUCF\O]T6ZX_(7T?J]$L=-(=M]M3Q"!6] M%4D6Y.BFA0;,ML<$$TP4)R,&*?W1)+"9;(.%0)*%[TUV2\PLC?T2$0;V+$)K MJ:'AA],L?,\N$%D%(B,0O2LCFI718Q*#:?HRTF16Z]X"6B4?I!);4XF7J?B^ M72"Q"B3_?QBI52#]]V%LTT6=X2I*[2Z9U26SN,0SER4F\C[X/%=6D]72)$QF M]VK!9',3-'ET%/C%-#3AE.S:F&8ZB8X]\SXPC_8-WC?<[YA?ZD8X1R;5TS&UL MC5=M;YLP$/XKB.\#S(O!51*I"9HV:9.J3=L^T\1)4 %GQDFZ?S_;N)381]M\ M"-@\=_?<@WT^%E?&G_HCI<)[;INN7_I'(4YW8=AOC[2M^H"=:">?[!EO*R&' M_!#V)TZKG39JFS".(ARV5=WYJX6>>^"K!3N+IN[H _?Z<]M6_-^:-NRZ])'_ M,O&C/AR%F@A7BU-UH#^I^'5ZX'(4CEYV=4N[OF:=Q^E^Z=^CNQ(5RD C?M?T MVD_N/97*(V-/:O!UM_0CQ8@V="N4BTI>+G1#FT9YDCS^&J?^&%,93N]?O'_6 MR;ECSI]Z)X](O?&]']]6Y$3_8]0LU"66^9[+_1B^TD7#%1,;8LJ;7 M_][VW O6&B^22EL]#]>ZT]>K\?]B!AO$QB >#1!^TR Q!LFK0?JF06H,4LL@ M'%+1VI25J%8+SJX>'U[OJ5*K"-VE4OVMFM1BZV=2GE[.7E:XR!?A13DRF/6 MB2<8-")"Z7T,$4,AUK%C'M\&V+B(Q(*4+B0G,(D$S#/1]LE-G@7L( 4=I-I! M.G&0I9DEU(#)-*8;\HCL7 $,L00O74R6S4B>@60SARPNB$4V@&4#ZAF@?(7@,@:K)W!FE!5#Z7-U@Y[U$,D+:+C@$IC5X% MCH(HL6F[SIRU^S;FEC)<9U$"4,8VY<2EG >.SB JPS9G %8$>3I#&Z[NR"WO MV"[+:P#D%(@/8$J#N6&,HH#,489K/ **/"ELRADD3I*1Z<].(?O +BA!U-P) M@N C!$%GB'U.&= T$ [(7""X^B.W;N>1?5@9$)Z^%8+G L'%&[G5.X_L<\: MW@D43EJXEO*#;H][;\O.G5"=T&1V;,'O8]4"6O-KU9KKUO#5S=#7?Z_XH>YZ M[Y$)V6#J-G#/F*"29!3(]WN4GQ+CH*%[H6YS><^'?GH8"'8RWPKA^,&R^@]0 M2P,$% @ :E@92PM,],Q+ @ K0< !D !X;"]W;W)K&ULC95MCYLP#,>_"N(#'(2'0BN*U-XT;=(F53?M]CJE;D$7"$O2 M]O;MEP3*&)AI;TH2_O;/=G&BHLG6P'T9(UJY@6^O_)J6C5NGMFS@\@S?E6L:N @''FM:RI^[8'Q M^]8E[N/@I;J4RAQX>=;2"WP#];T]"+WS!B^GJH9&5KQQ!)RW[HYL]B0R!E;Q M6L%=CM:.2>7(^9O9?#YM7=]$! P*95Q0_;C!,S!F/.DX?O9.W8%I#,?KA_>/ M-GF=S)%*>.;L1W52Y=9-7><$9WIEZH7?/T&?4.PZ??9?X 9,RTTDFE%P)NVO M4UREXG7O18=2T_?N637V>>_]/\QP@Z W" :#T!IX'"WQW1%;^E MYC\FFT#7IC"'MA3VG0Y>ZM-;GOA!YMV,HUZS[S3!2$,&A:>]#X@ 0^R#F7GB MA[B#$(TQM ["D8-5FN(.(M1!9!U$?T4039*<:^(USHA11HPPX@FCT\16TUA- ML)#'"F6L$,9JPIAKEO)(4$:",)()8ZY98J0H(T48Z821_G>MUBAC/?MH$G\A M2.+CK>'/PR3^M#?FHJ5:D(4.) B&3#%]G_JC>L1/4;1 0AMQ1P*$-&OVN6@Q M(;Q=28A@PBEF+EK$X$U-D*XFTZ[N1D4_-K8(34Z'6;1 M+K"W[1]Y-\B^4G&I&ND&UL=53;;IPP$/T5BP^(P;L+Z0J0LHFB5FJE M5:JFSUX8+HJ-J6V6].]K&Y82ZKY@S_C,.3.#Q^DHY)MJ #1ZYZQ36=!HW1\Q M5D4#G*H[T4-G3BHA.=7&E#56O01:NB#., G#&'/:=D&>.M]9YJD8-&L[.$ND M!LZI_'T")L8LB(*;XZ6M&VT=.$][6L-WT#_ZLS067EC*ED.G6M$A"546/$3' M4V+Q#O#:PJA6>V0KN0CQ9HTO91:$-B%@4&C+0,URA4=@S!*9-'[-G,$B:0/7 M^QO[LZO=U'*A"AX%^]F6NLF"^P"54-&!Z1$>P_$"2;$GV8>[_(P2MR\!!\VHAX,"3TB\1> MD=A#$&U$?)C_]#OQBB0>@MU&Q(?9;T3PZ@IRD+4;/H4*,71N\%?>9;X?B+O" M?^'3X_"-RKKM%+H(;0;!7==*" TFE?#.=+4Q[]%B,*BTW29F+Z>IG PM^OG! MP&PO=V]R:W-H M965T-U(^2[NC*FO8^25VKC7[6N5V&HCE=6 M4A6(FE7FS5G(DFJSE9=0U9+1DW,J>8BC:!&6M*C\?.W.]C)?BYOF1<7VTE.W MLJ3R[XYQT6Q\Y#\.7HO+5=N#,%_7],)^,OU6[Z79A;W*J2A9I0I1>9*=-_X6 MK78HM@[.XE?!&C58>S:5@Q#O=O/MM/$C&Q'C[*BM!#6/.WMAG%LE$\>?3M3O MF=9QN'ZH?W')FV0.5+$7P7\7)WW=^)GOG=B9WKA^%\::T*#L5$TI)/]IG4;EGT^D_W& 'W#G@WH$XA[ %N<@_4TWS MM12-)]OBU]1^8[3"IC9'>^A*X=Z9X)4YO> M@2'$#D_036<[4*P4IZ91"HA$EG5+0W&?-0$H&4-"( MD@%?)84A2Q"RG/YW"(8%4 1W2 3$2<8MTAJE@T!Q%*0S]4 SO8@ 4CPF=1T; M#5 H"Y9S28$]N4480$WZ'@.H-)CK/01W+R( :C%&D2D*HX#,%1#NF>4/I-P/"*%@QNT9/+B9H?RCN)6N<$U..WGTQ:[&_B_>3O=IO.#MKNTS-6K9#I=UH47<#,^RG=OX/4$L#!!0 M ( &I8&4N$(OF_E04 &,@ 9 >&PO=V]R:W-H965TBS)/Z^9G^194^]*FZ\XHSP(>ACK(T^UN.I]USY[+^:QXK[/MSCZ7D^H] MS]/ROP>;%8>[*9M^/OB^?=O4[8-@/MNG;_9/6_^U?RZ;7\'1RWJ;VUVU+7:3 MTK[>3>_9[9/6K4&'^'MK#]7)]TD[E)>B^-'^^&U]-PW;C&QF5W7K(FT^/NS" M9EGKJ-9"#@?P5X;R!&@S4I09Z,-"7&IC!P%QJ$ T& M$3$(^G)T]5VF=3J?E<5A4O8MND];)K#;J.F@5?NP:YCN;TV)J^;IQ]R(:!9\ MM(X&S$./X2<8J?08LW Q[(@(F@R.:7"4Q@-W0S!!0K@8/D8L780@D,2%F'@, M>00003#? $:&8\P3PG@F1<#:B,Z!.'7 -'8@H0/9.9"C#,B$+'J,[C"[#A-I M1>;5Q3 3DN$F"'12PU&Z"J:K0+JT"5R,,@8'T3"(=APP+4D0[0XE)!VP[#'J M%$,[-G$QOEP-S-6 ":&Y&B<&)]Q< @BEQ5G(*-,(9AJ!3$D7+2(GAJ*-YD)H ME[D([N%4#!.-0:)4RV(GAHZIX"UCIT>T8:1)$A\)@461(%7TNL.0Q?45AL!(Q($4JI(,%*F(,+0V2&D:+XX*8]I4' M*Q(#DJ08S=@%B9C1C"\ )5^ QAEC:6) FY1'A3D6"QY>7FF.A8"[0N!6>@"= M6U*6 ,,(/1*$\8T8BP[G%Y09@@3-]P)0\@5HG#'6. XT3DF/"RP]7%Y19BPK M',B*6V8%:!C2>0,@NLM,$,B;,58Q[N[7@)*O@"-,\9ZR)$>1MB%P'HHKM!#@?50 M #UTMK8#:+0;C QM3H32,:TU0$D9>P1"8%442*8HNP?0: <4^@ZHGA,JTK*8 MQA'N$5-$'ID76/$$.,I2)5I D&] 6!8%D$7M2Q7KE+ABMR6PN@A$=Z?GP$8J M"CUQL"8(H G:(X0"DU3$5[RDP"25X(3C-.L .ATM7626"$,T.0$8[1%2B05! M D'0'GI*3$]YQ4E)8N9)P#SZWN9!NF<<[A%0Z7F#A"BE:9@>9$;KZ8UO1968 M>1(QS]!(RM5&3\M+S$X)=A&:OO"$(,^92V(*2T!A$](XB.>^:<,4EH#"AM$X M".11-8EY+L%B; 2-XX*DKPT4%@,%Q,!XV*4P016[G%T*$U2!]9.R:Z'<]=/' M+H5)K!")Z2YR /G9U8L?\$57XN0\9IPQU@,%](#NE3N0BRY\LB2PC16B*'TQ9=R7WX*YIU7S&.%>.SI M 8TIJJ_85&M,40W64#JOW[3[-2"R[]VGQDS6@,F^S9C& MU-)7'.HU)HU&I"'3^J3=H_CI93 M5?&^J]N;LY.GQYOR>][>-+EM;+H^_LCL:]U^-&UL?99M;YLP$,>_"N+]"K9YK))(I=&T29M4;=KVVDV8UG#^_N;] MLTO>)//,>_$HFS_U5A^681$&6['CIT;_D)RW;T8E!:_CH\Z\X]+Z/_-S/<@(X&=#(@V8<&;#1@[P;)AP;):) M@VA(Q=5FS35?+92\!&KX>X_(< M)%>% I#5H,F-^"%QEN*X)8I;(KA@^U0E@IO" M/8:(&%P+B*:\<2"0&#\Z8X2W@&=G[/^+*2PO*@+K>XV*;BP'-2Q]LY*G3]HZ:S4[-T8/KCNN#YZE-E>_ MNZ!W4FIA(.,[4]*#:?*F02-VVK[FYET-G@%T&L 0 O0, !D !X;"]W;W)K&UL=5/MCILP$'P5Y W $JSS![6=<'W[KFT. MT8C^P=[U[,SL8I>CL:^N!_#9FY+:5:3W?MA3ZIH>%'=W9@"-)YVQBGL,[9FZ MP0)O8Y&2E&TV.ZJXT*0N8^YHZ])Y)-S7^#*TB$!R>HT1CIXC=K+LX;-;&@%<7?TBIT7,=T MLF-3V7H!FPK87,!2+TDH.O_$/:]+:\;,IMD///SB?,]P-DU(QE'$,S3O,'NM M'Q[SDEX#T80Y) Q;8.X?V8RAR#^+L%41%@FV"P*6[]8)MJL$VTA0_..2W;A, MF%W$Z(CYCT2Q*E&L2&QO)-8PQ8T(74P^7.SOW)Z%=MG)>/R)<=2=,1Z0;W.' MMZ7'MS0'$CH?M@^XM^E&I<";87HL='ZQ]5]02P,$% @ :E@92Y7KW\@5 M P [PL !D !X;"]W;W)K&ULC99M;YLP$,>_ M"N)]BQ\PV%42J4DT;=(F59NVO::)DZ "SL!)NF\_VU":V,?4-P$[OSO_[VP? M-[NH]J4[2*FCU[IJNGE\T/KXD"3=YB#KHKM71]F8?W:JK0MMANT^Z8ZM++;. MJ*X2@E"6U$79Q(N9FWMJ%S-UTE79R*)[^7^H.U$ MLI@=B[W\(?7/XU-K1LGH95O6LNE*U42MW,WC1_RPQIDU<,2O4EZZJ_?(AO*L MU(L=?-G.8V05R4INM'51F,=9KF1564]&QY_!:3RN:0VOW]^\?W+!FV">BTZN M5/6[W.K#/.9QM)6[XE3I[^KR60X!L3@:HO\JS[(RN%5BUMBHJG._T>;4:54/ M7HR4NGCMGV7CGI?!_YL9;$ & S(:],F9-*"# 7TW2/]KD X&J6>0]*&XW*P+ M72QFK;I$;;^]Q\*>(OR0FNQO[*1+MOO/I*P1 F+(<%HP17.%0L$L<310P/%$D\0?V:8!N;X ?-0#E/K0&(,S(Q-W'8-%] MQ.0#&S5 M_G%R-<<4N;6^9H!:.KZ8[A$X[!& M_-)VLZZ;>G?3M\+?BG9?-EWTK+3IR5SGM%-*2Z,2W9ND'DSW/0XJN=/V-3?O M;=^"]@.MCD-[G8P]_N(?4$L#!!0 ( &I8&4L&PO=V]R:W-H965TWE6W7-_D%)[KTW= M]BO_H/7Q/@CZS4$V97^GCK(U_^Q4UY3:#+M]T!\[66ZM45,'&(9IT)15ZZ^7 M=NZQ6R_52==5*Q\[KS\U3=G]?9"U.J]\\-\FOE?[@QXF@O7R6.[E#ZE_'A\[ M,PHN7K95(]N^4JW7R=W*_P#W!5H#B_A5R7-_]>X-J3PI]3P,OFQ7?C@PDK7< MZ,%%:1XOLI!U/7@R//Y,3OU+S,'P^OW-^R>;O$GFJ>QEH>K?U58?5G[F>UNY M*T^U_J[.G^644.)[4_9?Y8NL#7Q@8F)L5-W;7V]SZK5J)B^&2E.^CL^JM<_S MY/_-C#? R0 O!A"_:Q!-!A$Q"$9F-M6/I2[7RTZ=O6[\6L=R: JXCTPQ-\.D MK9W]SV3;F]F7=19&R^!E<#1A'D8,7F'P%E&XB.@_)# $+BR098'6/KIA$?,. M(M9!9!W$-PX2DL:(22VFM9@8,2>9,"# F5QBEDK,4$D)E1&37$5)1$Y !0/* M,>&I)"R5A*$B")7$B9+F!%.XF"C+>2(I2R1EB&2$2.H$ 5JWXGW,#1'!$A$. M$0#:[L(- GE":^*BA,AF>C9CN61,44@[/F1NE!2 4'%!>9S.]&S.4LE=*A 2 M*KD;)2.E*UP, +/!$)>D$*&"U!%"IU &:T*@X%PIFMA1AR!X8*4"S KR!%( M!I3-K&7@-1*0(>-(-;I+%2%QZ+@PS,65\-\2XC47&-&%F!**G$@+(6C?L*A\ M9C4!K[O ""_0/0!<48T@$G078&"8Y;/=PZLO).ZN!C-J!;QN B.<0!4<7%5< MI G-B &AF"'#:R>XXAD[G]N5Q06$2'$%AQ-)-E<=7D"!45"@VPJXZK@0F(:4 M$ /+ >:6*"^CP.DHE71P17)A-B&ZU7$PG*D/\E**C)0BE75T97(!F:"GIX+% MI2*96:3(*RHRBHI4W2?0]2$,,!6TAU@8)/23!5='X>%N\JWL]E7;>T]*FU.U M/?ONE-+2N SO3'H'"<8!UH=I_M.<+ETK?\!4$L#!!0 M ( &I8&4O 46/E_0$ '@% 9 >&PO=V]R:W-H965T^(5$-^ M1F+@0"I3U%$4!4&*.M+V?I&9N0,O,G:1M.WAP#UQZ3K"?S\!96/NA_YMXJ4] M-U)/H"(;R!F^@?P^'+@:H<6E:COH1K!YRKW PT$%$Y2.Q#57*$$2K61PO@U>_K+DKIPW;^Y?S39598C$5 R^K.M M9)/[6]^KH"87*E_8^ GF/(GOS>&_P!6HDFL2M<:)46&>WNDB).MF%X72D;>I M;7O3CK/_KGCS40_4^$^UAM MYDE/FKTS[U1:H6:OQ3:*,G351K/F:=)$*XVE*.\5\5\)4@ +1>2DB$Q]O%XA MW+D-8J=!; SPNQBQ%6/2I$;3&TV"4RO(O2:.,':38"<)=I!@BV32)*M5PAU. M+-[2H=H&*]4[F,0)DSA@$@LFN5OFPR:V5:5#M0OQ/SYRZH1)'3"A!9/>[7\8 MI1MK_TJ7*DP2"P:MSH"^D[X2?FY[X1V95,?)_/0U8Q*48_"@DC7J&EP&%&JI MNQO5Y]-E, TD&^9[#BV7;?$'4$L#!!0 ( &I8&4OR?-+460( #D( 9 M >&PO=V]R:W-H965T* MUF+C%E(V:\\3>0$5$4^L@5I]J'OS[V*E+6;)B:V MYVG"+I*6->RY(RY51?C?+5#6;MS O05>RG,A=JYTWJ!S+ M"FI1LMKA<-JXS\$Z6VF\ ;R6T(K1VM&9'!A[TYMOQXWK:T- (9=:@:C'%79 MJ192-O[TFNYPI":.US?U+R9WE$I]."+$CMB&$WIX?\!NBH@L2#:%+%:XB0C- M,S+\:&PB^$0@1@5B(Q#?%6IA%0K#+*U<_P.3/<;(P,HRBV BWS*+ M80+++(8)<;-SU.P<$8@LLQ@FMLQ.,3,KYPR3F>%>%ZC7!2)@ORX8QNJ4'8:Q MNP##?-*R2]3LKE0JUY-\VZC61-/ZB]X=]"^@]0 M2P,$% @ :E@92RW3:49* @ #0< !D !X;"]W;W)K&UL?57MCILP$'P5Q ,W;BU$O_$\7M708OY$>^CDFS-E M+19RR2X>[QG@DTYJB1?X?N*UN.GA6DZ># ''YM6\S^[H#08>LB M]SWPTEQJH0)>6?3X C] _.P/3*Z\F>74M-#QAG8.@_/6?4:;/?)5@D;\:F#@ MB[FC2CE2^JH67T];UU>.@$ E% 66PPWV0(ABDC[^3*3NK*D2E_-W]L^Z>%G, M$7/84_*[.8EZZV:NX 9%PY41J5)1P_72J*Q>T MG5BDE1:_C6/3Z7$8WZ3)E&9/"*:$8$Y _T\(IX3P(R'2Q8_.=*F?L,!EP>C@ ML/%K]5C]%&@3RLVL5%#OG7XGJ^4R>BNS*"Z\FR*:,+L1$RPP:$9XDGV6"&P2 MNV"5'MP+[->(,+ KA-8B0IT?+A50;B>(K 21)HCN=B$Q=F'$)!K3:4P2&76L M(0%Z9"2V&HDM1E+#R(B)[U0,(VL(2NPV$JN-Q&(C,VPD*XTP2L+,+I-:95*+ M3&[(I.M2$(J3![N:676RM4[L&SK92L>W2^16B=PB87R57;Z2R!X<)-D8K8?5 M7ZN@P#RM_OI'S;;\#R'U!+ P04 " !J6!E+_B-#_1 " "/!0 &0 'AL+W=O MX9SC,[Y,UG'Q)BL Y7TPVLB=7RG5;A&2 M106,R"?>0J/_7+E@1.E0E$BV LC%DAA%. A2Q$C=^'EF19_RF:-W 27CR MQA@1__9 >;?S0_^1>*W+2ID$RK.6E/ +U._V)'2$1I5+S:"1-6\\ =>=_QQN MCXG!6\"?&CHYF7NFDC/G;R;X?MGY@3$$% IE%(@>[G 2HV0MO$^:/KCDH8X MG3_47VSMNI8SD7#@]&]]4=7.7_O>!:[D1M4K[[[!4$_B>T/Q/^ .5,.-$[U& MP:FT7Z^X2<79H**M,/+1CW5CQV[0?]"6"7@@X)$0IE\2HH$0?1+B+PGQ0(@= M NI+L7MS)(KDF>"=)_K3;8FY1.$VUKM?F*3=;/M/;X_4V7N^3G"&[D9HP.Q[ M#)Y@PA&!M/JX!%Y:8H]G=&>!PQP1.9#C'++:+)N(%NN,+#^:FL!X62!>%(BM M0#PUL(ZHQJ<4T/6:UB9UBYR"\605.N7-0M$GB9;_)HM]DYG>=N'Z3N=]- MZ![.'!2FP2IU#,]1.(D3]XC0Y%HR$*5]\M(K^*U1YG0GV;&K/&-SK9W\7G>; MOCE\RO2MZB<19=U([\R5?C3V:E\Y5Z!-!D_:9:6[XQA0N"HS7>FYZ'M$'RC> M#NT/C3TX_P]02P,$% @ :E@92P41<#5G @ Z0< !D !X;"]W;W)K M&ULC57;CILP$/T5Q >L;>Y9D4BYJ&JE5HJV:OOL M$">@!4QM)VS_OK8A+('):E_B"V?.F3../6G+Q:O,&5/.6U76IW=N+5. MO%05%?\VK.3MTB7N;>.E..?*;*!5VM S^\G4KV8O] H-+,>B8K4L>.T(=EJZ M:_*\([X)L(C?!6OE:.X8*P?.7\WBVW'I8I,1*UFF# 75PY5M65D:)IW'WY[4 M'31-X'A^8_]BS6LS!RK9EI=_BJ/*EV[B.D=VHI=2O?#V*^L-A:[3N__.KJS4 M<).)ULAX*>VODUVDXE7/HE.IZ%LW%K4=VY[_%@8'>'V -P20Z,, OP_PWP." M#P."/B"8!*#.BJW-CBJZ2@5O'=$=;T/-OX@\![KZF=FTQ;;?='FDWKVNDC!( MT=40]9A-A_%&&#(@D&8?)#Q(8N/-PKU[@>TQ&<; @F&P+)QA.1<"9" MPCB!52)0)0)4DDE)HKG=,,&P2@RJQ(#*@Z-/0(+D\T>_ D6\PPB//'98<*1 MSY!X'JQ",'P5,:!#IG<1SPJZP %^4%'RX-(30.E1LN"E7A/O\U4E\)4D/I"% M/_7KS_R&&,_\HM%[5S%QMKU$.AF_U,H\&Z/=H5^M/?->3O8WIH_9=_2=IFN" M/Z@X%[5T#ESIU]B^F2?.%=-9XB=]\+GNN\.B9"=EIK&>BZ[Y= O%F[ZQHJ&[ MK_X#4$L#!!0 ( &I8&4OCS19=J@( * ) 9 >&PO=V]R:W-H965T M,X+UV:FH/^7[B-;AJW46A;1NV*.A9U%5+-LSAYZ;! M[&]):GJ=NX%[,[Q6QY-0!F]1=/A(?A+QJ]LPN?-&EGW5D)97M'48.R(G6MF*2./P.I.\94 MCM/UC?V+3EXFL\6&-";&'I[3#R) MDF6A(1? Q"$L) &%)( 0(]TRL=(-?4.'#4&9430;\DAI"BI- :5&C-+&)*&1 MS0KBR0VM ";U8;$9*#8#" )#+(0QO[W_P*R?8^[$YJ#8'" P#EJ9VV<@CHV, M5@#(CQ)82N##'<\'Q%@MS[>.?1A:+QI"^9-C>2_G00,. #EF8QE TT H,!L+ M H>:0$[]3) @!:S:0R@^W>06:6Q42C)S<_1FUQ3#6%'/0)P9T?/K5#=?F(= MQXREGC(,>ZG&#WW]?=+TL\L/S(Y5RYTM%?(2U5?=@5)!I$C_1=;J),>E<5.3 M@U#+5*Y9/S/T&T&[81[RQJ%L\0]02P,$% @ :E@92T)J12!X P N1 M !D !X;"]W;W)K&ULE5CM;ILP%'T5Q ,,?Q# M51*I331MTB95G;;]IHF3H +.P&FZMY_Y* -S2),_ *+-;FLMA[Y;&0\;8.RE*/$1)X M69SD[G)>CST6R[DZZ33)Y6/AE*!IV1_T-6 MYP?X[W\ M(?7/XV-AKKR.99MD,B\3E3N%W"W<>WJWYKP*J!&_$GDN>^=.-95GI5ZJBZ_; MA4NJC&0J-[JBB,WA5:YDFE9,)H\_+:G;/;,*[)^_LW^N)V\F\QR7 MJ+-3-,M[C*NWB-[YIOJ;:K N=GW/E*&@SK86B'\ Q[ M]PB&'O' 1N%1& T?L4(8,<2L 28B.!$.Y\IK G] ,#$3'Q+X-0$?$#!,,(,$ M,Y !MZK=8&8U)J\Q%F)U"3%((H!)!" )'Q.$D""\O@P1)(A !C.K# @36(5 MF! G(F B A!$F( 2K!]R?3'HA 3I%>6 ($LA*P02$Q*A4*SWE &*"9%0+#/* M;R@)%AKUKRD) EFEP2!)N1"L6@I4*V8$ S%DJ/!#27!HJ/A%=[1@OK60.V" M? A97X0,<\7ZID"88K1\"&0K'()".U\$FI(Q-@(*G$ (3,&P$[ ;G(!A)V!( MOW;=(,C^1 "0(,2J&P1-?=JQ7;"Q70@R-6EL%^P&NV#8+MA8Y(+8VFA!_;>: MV%7[$+*^"!GFBMV$C=U$$-_.%8%F=K97@-8?@(898_-BXPV#(,$$!38O=L.6 M@6%/86.1"V+O5"%HM-=$H-%F\[([#3/&GL+&GB(HL3-N0$'O?0HBQD=K#6", M3SD4QP[%"4AH0N\<.Q2GUR\DQY;!D678"XE U/ZV0Y E^S4$37R]^43?,&X< MQ@O9@OHK-".!;W]^ A M.2^:9KJYT.K8_E'@=?]6+/\!4$L#!!0 ( &I8&4OM*P[U @( ,4% 9 M >&PO=V]R:W-H965TN!AV(0X?"Z_-M=9V 55ESZ[P$_2O_B!-A&:7<]-" MIQK1!1(NN_ 3?MX75N\$OQL8U&(>V$Z.0KS9X-MY%T:V(.!PTM:!F>$.+\"Y M-3)E_)T\PQEI$Y?SA_L7U[OIY<@4O C^ISGK>A?F87"&"[MQ_2J&KS#UDX;! MU/QWN ,W9/(%,"F1/(V,L( M][YG]B_$S,7MSLHMN*]PW4[PRJ_>JP&F)[M9HTNQ'#5EH MDC2?-8;8B_&$WF1>3^3!DA=F* MU#G@<-%VFIFY'%^6,="BGQY--+_< MU7]02P,$% @ :E@92PR@ATET P 1P\ !D !X;"]W;W)K&ULE5?M;MHP%'V5* _0V->QDU2 5-I.F[1)5:=MOU,P$#6) M66)*]_9S/DJ)?5W1/Y"8<\_]L,\U=W94S7.[DU('KU59M_-PI_7^.HK:U4Y6 M>7NE]K(VOVQ44^7:O#;;J-TW,E_W1E49 2$BJO*B#A>S?NVA68M.+.NBDG5;J#IH MY&8>WM#K>P:=08_X7_8<=*D\*?7\E;>J_%.L]6X>IF&PEIO\4.I'=?PJQX1X M&(S9?YOP7=3]]W'D?S/##6 T@),! M)!\:L-& O1O0#PWBT2"^U("/!MPRB(;<^V+>Y3I?S!IU#)KA/.SS[MC1:VZV M:]4M]KO3_V;JV9K5ET5&DUGTTA&-F.6 @3,,/2$BPWYR 9B+)3CF/*-3%[J1X@0Q2A#W!/&$P,ID.6!$CZE[C* L M]125HVZXXX9GL>5FP/ S-QEA5N&Y$PIEU +=(2#AJXI PQ5N5<#:NZ5PPJ6, MV <% 8'@5KS"C9>+!(\W0>--D'@]^Y.B!.GEYRA#"3(D K JECG% ,8]>5*" MZY\@?IC= (CCR-J\VP\ATT \C8@B)YI[*-!&6P=36")H

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end XML 114 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 115 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 117 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 362 484 1 true 109 0 false 15 false false R1.htm 001 - Document - Document and Entity Information Sheet http://imetrix.edgar-online.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://imetrix.edgar-online.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://imetrix.edgar-online.com/role/ConsolidatedBalanceSheetsParentheticals CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 3 false false R4.htm 004 - Statement - CONSOLIDATED STATEMENTS OF INCOME Sheet http://imetrix.edgar-online.com/role/ConsolidatedStatementsOfIncome CONSOLIDATED STATEMENTS OF INCOME Statements 4 false false R5.htm 005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://imetrix.edgar-online.com/role/ConsolidatedStatementsOfComprehensiveIncome CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 5 false false R6.htm 006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parentheticals) Sheet http://imetrix.edgar-online.com/role/ConsolidatedStatementsOfComprehensiveIncomeParentheticals CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parentheticals) Statements 6 false false R7.htm 007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://imetrix.edgar-online.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 008 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Sheet http://imetrix.edgar-online.com/role/ConsolidatedStatementsOfShareholdersEquity CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Statements 8 false false R9.htm 009 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Parentheticals) Sheet http://imetrix.edgar-online.com/role/ConsolidatedStatementsOfShareholdersEquityParentheticals CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Parentheticals) Statements 9 false false R10.htm 010 - Disclosure - Description of Business Sheet http://imetrix.edgar-online.com/role/DescriptionOfBusiness Description of Business Notes 10 false false R11.htm 011 - Disclosure - Summary of Significant Accounting Policies Sheet http://imetrix.edgar-online.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 012 - Disclosure - Business Combinations Sheet http://imetrix.edgar-online.com/role/BusinessCombinations Business Combinations Notes 12 false false R13.htm 013 - Disclosure - Investments Sheet http://imetrix.edgar-online.com/role/Investments Investments Notes 13 false false R14.htm 014 - Disclosure - Fair Value Measurements Sheet http://imetrix.edgar-online.com/role/FairValueMeasurements Fair Value Measurements Notes 14 false false R15.htm 015 - Disclosure - Goodwill and Other Intangible Assets Sheet http://imetrix.edgar-online.com/role/GoodwillAndOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 15 false false R16.htm 016 - Disclosure - Accrued Expenses Sheet http://imetrix.edgar-online.com/role/AccruedExpenses Accrued Expenses Notes 16 false false R17.htm 017 - Disclosure - Environmental Remediation Sheet http://imetrix.edgar-online.com/role/EnvironmentalRemediation Environmental Remediation Notes 17 false false R18.htm 018 - Disclosure - Debt Sheet http://imetrix.edgar-online.com/role/Debt Debt Notes 18 false false R19.htm 019 - Disclosure - Stock Based Compensation Plans Sheet http://imetrix.edgar-online.com/role/StockBasedCompensationPlans Stock Based Compensation Plans Notes 19 false false R20.htm 020 - Disclosure - Interest and Other Income Sheet http://imetrix.edgar-online.com/role/InterestAndOtherIncome Interest and Other Income Notes 20 false false R21.htm 021 - Disclosure - Income Taxes Sheet http://imetrix.edgar-online.com/role/IncomeTaxes Income Taxes Notes 21 false false R22.htm 022 - Disclosure - Supplemental Cash Flow Information Sheet http://imetrix.edgar-online.com/role/SupplementalCashFlowInformation Supplemental Cash Flow Information Notes 22 false false R23.htm 023 - Disclosure - Retirement Plans Sheet http://imetrix.edgar-online.com/role/RetirementPlans Retirement Plans Notes 23 false false R24.htm 024 - Disclosure - Financial Instruments Sheet http://imetrix.edgar-online.com/role/FinancialInstruments Financial Instruments Notes 24 false false R25.htm 025 - Disclosure - Commitments, Contingencies and Other Matters Sheet http://imetrix.edgar-online.com/role/CommitmentsContingenciesAndOtherMatters Commitments, Contingencies and Other Matters Notes 25 false false R26.htm 026 - Disclosure - Related Party Transactions Sheet http://imetrix.edgar-online.com/role/RelatedPartyTransactions Related Party Transactions Notes 26 false false R27.htm 027 - Disclosure - Recent Accounting Pronouncements Sheet http://imetrix.edgar-online.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 27 false false R28.htm 028 - Disclosure - Segment Information Sheet http://imetrix.edgar-online.com/role/SegmentInformation Segment Information Notes 28 false false R29.htm 029 - Disclosure - Unaudited Quarterly Financial Data Sheet http://imetrix.edgar-online.com/role/UnauditedQuarterlyFinancialData Unaudited Quarterly Financial Data Notes 29 false false R30.htm 030 - Schedule - Valuation and Qualifying Accounts Sheet http://imetrix.edgar-online.com/role/ValuationAndQualifyingAccounts Valuation and Qualifying Accounts Uncategorized 30 false false R31.htm 031 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://imetrix.edgar-online.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Uncategorized 31 false false R32.htm 032 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://imetrix.edgar-online.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Uncategorized 32 false false R33.htm 033 - Disclosure - Business Combinations (Tables) Sheet http://imetrix.edgar-online.com/role/BusinessCombinationsTables Business Combinations (Tables) Uncategorized 33 false false R34.htm 034 - Disclosure - Investments (Tables) Sheet http://imetrix.edgar-online.com/role/NotesToFinancialStatementsInvestmentTextBlockTables Investments (Tables) Uncategorized 34 false false R35.htm 035 - Disclosure - Fair Value Measurements (Tables) Sheet http://imetrix.edgar-online.com/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value Measurements (Tables) Uncategorized 35 false false R36.htm 036 - Disclosure - Goodwill and Other Intangible Assets (Tables) Sheet http://imetrix.edgar-online.com/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlockTables Goodwill and Other Intangible Assets (Tables) Uncategorized 36 false false R37.htm 037 - Disclosure - Accrued Expenses (Tables) Sheet http://imetrix.edgar-online.com/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables Accrued Expenses (Tables) Uncategorized 37 false false R38.htm 038 - Disclosure - Debt (Tables) Sheet http://imetrix.edgar-online.com/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables Debt (Tables) Uncategorized 38 false false R39.htm 039 - Disclosure - Stock Based Compensation Plans (Tables) Sheet http://imetrix.edgar-online.com/role/StockBasedCompensationPlansTables Stock Based Compensation Plans (Tables) Uncategorized 39 false false R40.htm 040 - Disclosure - Interest and Other Income (Tables) Sheet http://imetrix.edgar-online.com/role/NotesToFinancialStatementsInterestAndOtherIncomeTextBlockTables Interest and Other Income (Tables) Uncategorized 40 false false R41.htm 041 - Disclosure - Income Taxes (Tables) Sheet http://imetrix.edgar-online.com/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables Income Taxes (Tables) Uncategorized 41 false false R42.htm 042 - Disclosure - Supplemental Cash Flow Information (Tables) Sheet http://imetrix.edgar-online.com/role/NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlockTables Supplemental Cash Flow Information (Tables) Uncategorized 42 false false R43.htm 043 - Disclosure - Commitments, Contingencies and Other Matters (Tables) Sheet http://imetrix.edgar-online.com/role/CommitmentsContingenciesandOtherMattersTables Commitments, Contingencies and Other Matters (Tables) Uncategorized 43 false false R44.htm 044 - Disclosure - Segment Information (Tables) Sheet http://imetrix.edgar-online.com/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables Segment Information (Tables) Uncategorized 44 false false R45.htm 045 - Disclosure - Unaudited Quarterly Financial Data (Tables) Sheet http://imetrix.edgar-online.com/role/NotesToFinancialStatementsQuarterlyFinancialInformationTextBlockTables Unaudited Quarterly Financial Data (Tables) Uncategorized 45 false false R46.htm 046 - Disclosure - Summary of Significant Accounting Policies (Components of accumulated other comprehensive loss (Detail) Sheet http://imetrix.edgar-online.com/role/SummaryOfSignificantAccountingPoliciesComponentsOfAccumulatedOtherComprehensiveIncomeDetail Summary of Significant Accounting Policies (Components of accumulated other comprehensive loss (Detail) Uncategorized 46 false false R47.htm 047 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://imetrix.edgar-online.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Uncategorized 47 false false R48.htm 048 - Disclosure - Summary of Significant Accounting Policies (Schedule of Reconciliation of Weighted Average Shares Outstanding and Diluted Weighted Average Shares Outstanding) (Detail) Sheet http://imetrix.edgar-online.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfWeightedAverageSharesOutstandingAndDilutedWeightedAverageSharesOutstanding Summary of Significant Accounting Policies (Schedule of Reconciliation of Weighted Average Shares Outstanding and Diluted Weighted Average Shares Outstanding) (Detail) Uncategorized 48 false false R49.htm 049 - Disclosure - Summary of Significant Accounting Policies (Schedule of Components of Property and Equipment) (Detail) Sheet http://imetrix.edgar-online.com/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfComponentsOfPropertyAndEquipment Summary of Significant Accounting Policies (Schedule of Components of Property and Equipment) (Detail) Uncategorized 49 false false R50.htm 050 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Detail) Sheet http://imetrix.edgar-online.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrative Summary of Significant Accounting Policies (Narrative) (Detail) Uncategorized 50 false false R51.htm 051 - Disclosure - Business Combinations (Details) Sheet http://imetrix.edgar-online.com/role/BusinessCombinationsDetails Business Combinations (Details) Uncategorized 51 false false R52.htm 052 - Disclosure - Business Combinations (Details 1) Sheet http://imetrix.edgar-online.com/role/BusinessCombinationsDetails1 Business Combinations (Details 1) Uncategorized 52 false false R53.htm 053 - Disclosure - Business Combinations (Narrative) (Detail) Sheet http://imetrix.edgar-online.com/role/BusinessCombinationsNarrativeDetail Business Combinations (Narrative) (Detail) Uncategorized 53 false false R54.htm 054 - Disclosure - Business Combinations (Narrative) (Detail 1) Sheet http://imetrix.edgar-online.com/role/BusinessCombinationsNarrativeDetail1 Business Combinations (Narrative) (Detail 1) Uncategorized 54 false false R55.htm 055 - Disclosure - Investments (Schedule of Summary of Short-Term Investments) (Detail) Sheet http://imetrix.edgar-online.com/role/DisclosureInvestmentsScheduleOfSummaryOfShortTermInvestments Investments (Schedule of Summary of Short-Term Investments) (Detail) Uncategorized 55 false false R56.htm 056 - Disclosure - Fair Value Measurements (Schedule Changes in contingent consideration) (Details) Sheet http://imetrix.edgar-online.com/role/FairValueMeasurementsScheduleChangesInContingentConsiderationDetails Fair Value Measurements (Schedule Changes in contingent consideration) (Details) Uncategorized 56 false false R57.htm 057 - Disclosure - Fair Value Measurements (Schedule of Valuation of Financial Assets and Liabilities) (Detail) Sheet http://imetrix.edgar-online.com/role/FairValueMeasurementsScheduleOfValuationOfFinancialAssetsAndLiabilitiesDetail Fair Value Measurements (Schedule of Valuation of Financial Assets and Liabilities) (Detail) Uncategorized 57 false false R58.htm 058 - Disclosure - Fair Value Measurements (Schedule of Valuation of Financial Assets and Liabilities) (Parentheticals) (Detail) Sheet http://imetrix.edgar-online.com/role/FairValueMeasurementsScheduleOfValuationOfFinancialAssetsAndLiabilitiesParentheticalsDetail Fair Value Measurements (Schedule of Valuation of Financial Assets and Liabilities) (Parentheticals) (Detail) Uncategorized 58 false false R59.htm 059 - Disclosure - Fair Value Measurements (Narrative) (Detail) Sheet http://imetrix.edgar-online.com/role/FairValueMeasurementsNarrativeDetail Fair Value Measurements (Narrative) (Detail) Uncategorized 59 false false R60.htm 060 - Disclosure - Goodwill and Other Intangible Assets - Summary of changes in goodwill (Details) Sheet http://imetrix.edgar-online.com/role/GoodwillAndOtherIntangibleAssetsSummaryOfChangesInGoodwillDetails Goodwill and Other Intangible Assets - Summary of changes in goodwill (Details) Uncategorized 60 false false R61.htm 061 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets Subject to Amortization) (Detail) Sheet http://imetrix.edgar-online.com/role/GoodwillAndOtherIntangibleAssetsScheduleOfIntangibleAssetsSubjectToAmortizationDetail Goodwill and Other Intangible Assets (Schedule of Intangible Assets Subject to Amortization) (Detail) Uncategorized 61 false false R62.htm 062 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Detail) Sheet http://imetrix.edgar-online.com/role/GoodwillAndOtherIntangibleAssetsNarrativeDetail Goodwill and Other Intangible Assets (Narrative) (Detail) Uncategorized 62 false false R63.htm 063 - Disclosure - Accrued Expenses (Schedule of Components of Accrued Expenses) (Detail) Sheet http://imetrix.edgar-online.com/role/AccruedExpensesScheduleOfComponentsOfAccruedExpensesDetail Accrued Expenses (Schedule of Components of Accrued Expenses) (Detail) Uncategorized 63 false false R64.htm 064 - Disclosure - Environmental Remediation (Narrative) (Detail) Sheet http://imetrix.edgar-online.com/role/EnvironmentalRemediationNarrativeDetail Environmental Remediation (Narrative) (Detail) Uncategorized 64 false false R65.htm 065 - Disclosure - Debt (Schedule of Long-term Debt) (Detail) Sheet http://imetrix.edgar-online.com/role/DebtScheduleOfLongTermDebtDetail Debt (Schedule of Long-term Debt) (Detail) Uncategorized 65 false false R66.htm 066 - Disclosure - Debt (Summary carrying value of Notes) (Detail 1) Notes http://imetrix.edgar-online.com/role/DebtSummaryCarryingValueOfNotesDetail1 Debt (Summary carrying value of Notes) (Detail 1) Uncategorized 66 false false R67.htm 067 - Disclosure - Debt (Summary interest expense related to notes recognized) (Detail 2) Notes http://imetrix.edgar-online.com/role/DebtSummaryInterestExpenseRelatedToNotesRecognizedDetail2 Debt (Summary interest expense related to notes recognized) (Detail 2) Uncategorized 67 false false R68.htm 068 - Disclosure - Debt (Maturity of Long-term Debt) (Detail 3) Sheet http://imetrix.edgar-online.com/role/DebtMaturityOfLongTermDebtDetail3 Debt (Maturity of Long-term Debt) (Detail 3) Uncategorized 68 false false R69.htm 069 - Disclosure - Debt (Narrative) (Detail) Sheet http://imetrix.edgar-online.com/role/DebtNarrativeDetail Debt (Narrative) (Detail) Uncategorized 69 false false R70.htm 070 - Disclosure - Debt (Narrative) (Detail 1) Sheet http://imetrix.edgar-online.com/role/DebtNarrativeDetail1 Debt (Narrative) (Detail 1) Uncategorized 70 false false R71.htm 071 - Disclosure - Debt (Narrative) (Detail 2) Sheet http://imetrix.edgar-online.com/role/DebtNarrativeDetail2 Debt (Narrative) (Detail 2) Uncategorized 71 false false R72.htm 072 - Disclosure - Stock Based Compensation Plans (Schedule of Shares of Common Stock under Options for All Plans) (Detail) Sheet http://imetrix.edgar-online.com/role/StockBasedCompensationPlansScheduleOfSharesOfCommonStockUnderOptionsForAllPlansDetail Stock Based Compensation Plans (Schedule of Shares of Common Stock under Options for All Plans) (Detail) Uncategorized 72 false false R73.htm 073 - Disclosure - Stock Based Compensation Plans (Summary of non-vested stock options) (Detail) Sheet http://imetrix.edgar-online.com/role/StockBasedCompensationPlansDetails Stock Based Compensation Plans (Summary of non-vested stock options) (Detail) Uncategorized 73 false false R74.htm 074 - Disclosure - Stock Based Compensation Plans (Per-share fair value of stock options granted using Monte Carlo simulation option-pricing model) (Detail) Sheet http://imetrix.edgar-online.com/role/StockBasedCompensationPlansDetails1 Stock Based Compensation Plans (Per-share fair value of stock options granted using Monte Carlo simulation option-pricing model) (Detail) Uncategorized 74 false false R75.htm 075 - Disclosure - Stock Based Compensation Plans (Schedule of Restricted Stock Awards Including Restricted Stock Units) (Detail) Sheet http://imetrix.edgar-online.com/role/StockBasedCompensationPlansScheduleOfRestrictedStockAwardsIncludingRestrictedStockUnitsDetail Stock Based Compensation Plans (Schedule of Restricted Stock Awards Including Restricted Stock Units) (Detail) Uncategorized 75 false false R76.htm 076 - Disclosure - Stock Based Compensation (Narrative) (Detail) Sheet http://imetrix.edgar-online.com/role/StockBasedCompensationNarrativeDetail Stock Based Compensation (Narrative) (Detail) Uncategorized 76 false false R77.htm 077 - Disclosure - Interest and Other Income (Schedule of Interest and other income) (Detail) Sheet http://imetrix.edgar-online.com/role/InterestAndOtherIncomeScheduleOfInterestAndOtherIncomeDetail Interest and Other Income (Schedule of Interest and other income) (Detail) Uncategorized 77 false false R78.htm 078 - Disclosure - Interest and Other Income (Narrative) (Detail) Sheet http://imetrix.edgar-online.com/role/InterestAndOtherIncomeNarrativeDetail Interest and Other Income (Narrative) (Detail) Uncategorized 78 false false R79.htm 079 - Disclosure - Income Taxes (Schedule of Provision for Income Taxes) (Detail) Sheet http://imetrix.edgar-online.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetail Income Taxes (Schedule of Provision for Income Taxes) (Detail) Uncategorized 79 false false R80.htm 080 - Disclosure - Income Taxes (Schedule of Tax Effects of Temporary Differences that Give Rise to the Deferred Tax Assets and Liabilities) (Detail) Sheet http://imetrix.edgar-online.com/role/IncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToDeferredTaxAssetsAndLiabilitiesDetail Income Taxes (Schedule of Tax Effects of Temporary Differences that Give Rise to the Deferred Tax Assets and Liabilities) (Detail) Uncategorized 80 false false R81.htm 081 - Disclosure - Income Taxes (Schedule of Current and Non-Current Deferred Tax Assets (Liabilities)) (Detail) Sheet http://imetrix.edgar-online.com/role/IncomeTaxesScheduleOfCurrentAndNonCurrentDeferredTaxAssetsLiabilitiesDetail Income Taxes (Schedule of Current and Non-Current Deferred Tax Assets (Liabilities)) (Detail) Uncategorized 81 false false R82.htm 082 - Disclosure - Income Taxes (Schedule of Reconciliation of Statutory Federal Income Tax Rate and Effective Tax Rate for Continuing Operations) (Detail) Sheet http://imetrix.edgar-online.com/role/IncomeTaxesScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateAndEffectiveTaxRateForContinuingOperationsDetail Income Taxes (Schedule of Reconciliation of Statutory Federal Income Tax Rate and Effective Tax Rate for Continuing Operations) (Detail) Uncategorized 82 false false R83.htm 083 - Disclosure - Income Taxes (Narrative) (Detail) Sheet http://imetrix.edgar-online.com/role/IncomeTaxesNarrativeDetail Income Taxes (Narrative) (Detail) Uncategorized 83 false false R84.htm 084 - Disclosure - Supplemental Cash Flow Information (Schedule of Cash Paid for Interest and Income Taxes) (Detail) Sheet http://imetrix.edgar-online.com/role/SupplementalCashFlowInformationScheduleOfCashPaidForInterestAndIncomeTaxesDetail Supplemental Cash Flow Information (Schedule of Cash Paid for Interest and Income Taxes) (Detail) Uncategorized 84 false false R85.htm 085 - Disclosure - Supplemental Cash Flow Information (Narrative) (Detail) Sheet http://imetrix.edgar-online.com/role/SupplementalCashFlowInformationNarrativeDetail Supplemental Cash Flow Information (Narrative) (Detail) Uncategorized 85 false false R86.htm 086 - Disclosure - Retirement Plans (Narrative) (Detail) Sheet http://imetrix.edgar-online.com/role/RetirementPlansNarrativeDetail Retirement Plans (Narrative) (Detail) Uncategorized 86 false false R87.htm 087 - Disclosure - Financial Instruments (Narrative) (Detail) Sheet http://imetrix.edgar-online.com/role/FinancialInstrumentsNarrativeDetail Financial Instruments (Narrative) (Detail) Uncategorized 87 false false R88.htm 088 - Disclosure - Commitments, Contingencies and Other Matters (Schedule of Future Minimum Lease Payments) (Detail) Sheet http://imetrix.edgar-online.com/role/CommitmentsContingenciesAndOtherMattersScheduleOfFutureMinimumLeasePaymentsDetail Commitments, Contingencies and Other Matters (Schedule of Future Minimum Lease Payments) (Detail) Uncategorized 88 false false R89.htm 089 - Disclosure - Commitments, Contingencies and Other Matters (Narrative) (Detail) Sheet http://imetrix.edgar-online.com/role/DisclosureCommitmentsContingenciesAndOtherMattersNarrative Commitments, Contingencies and Other Matters (Narrative) (Detail) Uncategorized 89 false false R90.htm 090 - Disclosure - Related Party Transactions (Narrative) (Detail) Sheet http://imetrix.edgar-online.com/role/RelatedPartyTransactionsNarrativeDetail Related Party Transactions (Narrative) (Detail) Uncategorized 90 false false R91.htm 091 - Disclosure - Related Party Transactions (Narrative) (Detail 1) Sheet http://imetrix.edgar-online.com/role/RelatedPartyTransactionsNarrativeDetail1 Related Party Transactions (Narrative) (Detail 1) Uncategorized 91 false false R92.htm 092 - Disclosure - Segment Information (Schedule of Segment Perfomance Measures by Segment) (Detail) Sheet http://imetrix.edgar-online.com/role/DisclosureSegmentInformationScheduleOfSegmentPerfomanceMeasuresBySegment Segment Information (Schedule of Segment Perfomance Measures by Segment) (Detail) Uncategorized 92 false false R93.htm 093 - Disclosure - Segment Information (Schedule of Net Sales and Gross Profit by Source Country) (Detail) Sheet http://imetrix.edgar-online.com/role/DisclosureSegmentInformationScheduleOfNetSalesAndGrossProfitBySourceCountry Segment Information (Schedule of Net Sales and Gross Profit by Source Country) (Detail) Uncategorized 93 false false R94.htm 094 - Disclosure - Segment Information (Schedule of Long-Lived Assets by Geographic Region) (Detail) Sheet http://imetrix.edgar-online.com/role/DisclosureSegmentInformationScheduleOfLongLivedAssetsByGeographicRegion Segment Information (Schedule of Long-Lived Assets by Geographic Region) (Detail) Uncategorized 94 false false R95.htm 095 - Disclosure - Segment Information (Narrative) (Detail) Sheet http://imetrix.edgar-online.com/role/DisclosureSegmentInformationNarrative Segment Information (Narrative) (Detail) Uncategorized 95 false false R96.htm 096 - Disclosure - Unaudited Quarterly Financial Data (Detail) Sheet http://imetrix.edgar-online.com/role/DisclosureUnauditedQuarterlyFinancialData Unaudited Quarterly Financial Data (Detail) Uncategorized 96 false false R97.htm 097 - Disclosure - Unaudited Quarterly Financial Data (Narrative) (Detail) Sheet http://imetrix.edgar-online.com/role/UnauditedQuarterlyFinancialDataNarrativeDetail Unaudited Quarterly Financial Data (Narrative) (Detail) Uncategorized 97 false false R98.htm 098 - Disclosure - Valuation and Qualifying Accounts (Detail) Sheet http://imetrix.edgar-online.com/role/ValuationAndQualifyingAccountsDetail Valuation and Qualifying Accounts (Detail) Uncategorized 98 false false All Reports Book All Reports acet-20170630.xml acet-20170630.xsd acet-20170630_cal.xml acet-20170630_def.xml acet-20170630_lab.xml acet-20170630_pre.xml true true ZIP 119 0001144204-17-045100-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-17-045100-xbrl.zip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